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Cardiovascular diseases (CVD) are a group of diseases affecting the blood vessels and 
include coronary artery disease (CAD), ischaemic stroke and peripheral arterial disease 
(PAD).  
Coronary artery disease (CAD) is a progressive inflammation of the arterial wall caused 
by a passive build-up of cholesterol that could lead into myocardial infarction. 
Myocardial infarction (MI) is caused by a reduction in the blood flow in one part of the 
heart causing muscle damage and could be due to the formation of a blood clot. 
Acute coronary syndrome (ACS) are medical emergencies that group different types of 
MI. They include ST-segment elevation myocardial infarction (STEMI) which is 
characterised by a high increase in Troponins, non ST-segment elevation myocardial 
infarction (NSTEMI) which is characterised by a moderate increase in troponins and 
unstable angina (UA) with no increase in troponins. 
Cardiovascular risk is assessed by established risk factors such as cholesterol levels, 
blood pressure levels, smoking status and the presence of diabetes and family history. 
In Europe, cardiovascular risk is assessed based on the SCORE risk chart. 
Cardiovascular events are referred to within the literature as a group of events including 
ACS, strokes, the development of heart failure, cardiovascular deaths and the need for 
a coronary revascularisation. 
Major adverse cardiovascular events (MACE) have been referred to within this work as 
recurrent cardiovascular events in an individual with an established CVD. These were 
defined as cardiovascular deaths, strokes, recurrent ACS, recurrent angina, stent 
restenosis and the recurrent need for addition revascularisation procedures 
Revascularisation procedure aims to restore the blood flow to the heart by treating a 
blocked blood vessel. This can be achieved by stent implantation (known as 
percutaneous coronary intervention) or by placing new blood vessels around the 
existing blockage (also known as coronary artery bypass grafting).  
A biomarker is defined as a biological marker that reflects a certain disease state and 
guides clinical decision.  
Primary prevention is defined as a set of procedures that are put in place to control CVD 
risk factors to delay or prevent the onset of CVD. 
Secondary prevention is defined is defined as a set of procedures that are put in place 





Biomarker research in cardiovascular disease (CVD) is increasingly challenging with very 
few biomarkers being adopted into clinical practice. CVD risk assessment scores are in 
place to guide primary and secondary prevention however, they require considerable 
improvement. At present, there is no blood test that can predict who is at higher risk of 
first or recurrent cardiovascular events. Since CVD is a complex inflammatory disease 
with several underlying biological pathways, one biomarker is unlikely to define an 
individual’s cardiovascular risk. However, it is possible to improve the current risk 
assessment scores using a multimarker approach. To date no one has investigated the 
many known and potentially novel markers in individuals at various levels of CVD risk. 
Therefore, in this present work, 344 participants at various levels of CVD risk (according 
to the European Society of Cardiology risk score), were recruited to explore potential 
biomarkers for risk stratification.  
Proteins belonging to the tumour necrosis factor alpha (TNFα) inflammatory pathway, 
which has previously been shown to play a major role in CVD initiation and 
complications, as well as novel proteins associated with atherosclerosis, plaque rupture 
and thrombosis were explored using ELISA, multiplex proximity extension assays (PEA) 
developed by Olink Proteomics®, MSD® MULTI-SPOT Assay System and quantitative 
real-time PCR. Results reveal a complex panel of markers that were able to identify 
individuals at very high risk of CVD. Furthermore, more specific panels of markers were 
discovered that were able to further stratify patients at very high risk of CVD according 
to their cardiac history and co-morbidities. The present investigation overall 
demonstrates that a combination of proteins from several inflammatory pathways are 
necessary to evaluate an individual’s risk of first or recurrent cardiovascular events as 
well as the risk of developing CVD-associated co-morbidities and treatment response.  
The blood biomarker panels discovered in this present work can be used to establish a 
unique proteomic disease signature for each individual recruited to the study. This will 
aid future long term prospective longitudinal studies in evaluating the clinical utility of 
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AMBP: Protein Alpha-1-Microglobulin/Bikunin Precursor 
CTSD: Cathepsin D 
RAGE: Receptor For Advanced Glycosylation End Products 
GRN: Granulins 
CD93: Complement Component C1q Receptor 
PAR-1: Proteinase Activated Receptor 1 
SPON1: Spondin 1 
ST2: Interleukin 1 Receptor-Like 1 
FGF21: Fibroblast Growth Factor 21 
CPA1: Carboxypeptidase 1 
CCL15: C-C Motif Chemokine 15 
IGFBP7: Insulin Like Growth Factor Binding Protein 7 















Chapter 1  
Introduction to Cardiovascular 
Disease Risk Assessment and 





1.1 Introduction to Cardiovascular Disease  
Cardiovascular disease (CVD) due to atherosclerosis of the arterial vessel wall was the 
leading cause of noncommunicable disease deaths worldwide in 2012 being responsible 
for 17.5 million deaths (46% of noncommunicable disease deaths). Of these deaths, an 
estimated 7.4 million were due to heart attacks and 6.7 million were due to strokes (1). 
CVD is divided into coronary artery disease (CAD), ischaemic stroke and peripheral 
arterial disease (PAD).  
In Europe, CVD kills more than 4 million people each year. It kills more women [2.2 
million (55%)] than men [1.8 million (45%)], although cardiovascular (CV) deaths before 
the age of 65 years are more common in men (490 000 deaths vs. 193 000 deaths) (2).  
In the United Kingdom (UK), CVD was the second most common cause of death in 
2014 causing 27% of all deaths, while cancer caused 29%. The Global Burden of Disease 
study has shown that the burden of CVD is declining in the UK (3). Nevertheless, CVD 
still constitutes a huge economic burden with £4.3 billion spent on treatment within the 
NHS in England in 2014 (4). Between 1979 and 2013, Northern Ireland had a 75% 
decrease in CVD mortality and a reduction of 87% for premature CAD mortality. 
However, there was still a 6% increase  in hospital admissions for CAD in Northern 
Ireland between 2010/2011 and 2013/2014 (5). Despite large reductions in mortality 
from CVD, this condition has remained a substantial burden to the UK, with rises in 
hospital admissions for all CVD. The underlying pathological process behind the 
development and progression of CAD is atherosclerosis. The concept of atherosclerosis 
being a chronic inflammatory disease is being widely accepted nowadays, however 





Atherosclerosis is a progressive build-up of cholesterol in the arterial wall accompanied 
by an endothelial dysfunction and an increased inflammatory response. This causes 
the artery to become narrow which reduces the blood flow and increases the risk of 
heart attack and clot formation.  
1.1.1.1 Lipoprotein retention 
Atherosclerosis occurs in the intima of large and medium-sized arteries at regions of 
disturbed blood flow and is a result of an endothelial dysfunction, a subendothelial 
lipoprotein retention and a maladaptive immune response. Over time, atherosclerosis 
leads to a chronic inflammation in the arterial wall causing intimal destruction, arterial 
thrombosis and end-organ ischemia (6,7). 
Atherosclerosis starts with a subendothelial retention of apolipoprotein B – 
containing lipoproteins (LPs) in particular regions of the arteries where laminar flow is 
disturbed by bends or branch points in the arteries (7,8). 
1.1.1.2 Inflammatory response and fibrous cap formation 
Different modifications of the retained LPs likely mimic pathogen- and/or damage-
associated molecular patterns and subsequently trigger a low-grade inflammatory 
response. This response leads to activation of endothelial and vascular smooth muscle 
cells, recruitment of monocytes and accumulation of cellular, extracellular, and lipid 
material in the intima. The cells recruited to the inflammatory lesion include monocyte 
derived macrophages, T cells, B cells, dendritic cells, mast cells, and smooth muscle cells. 
In most of the cases, atherosclerotic lesions undergo a partial resolution process 




cap forms a protective barrier between platelets in the blood stream and prothrombotic 
material in the plaque. In addition, outer remodelling of the arterial wall, resulting in the 
preservation of luminal blood flow and collateral vessel formation, help prevent end 
organ ischemia (Figure 1).  
 
Figure 1: Atherosclerotic plaque formation and progression. 1. Atherosclerosis starts with a 
sub-endothelial retention of low density lipoprotein (LDL) particles in the arterial wall. 2. LDL 
particles undergo oxidation which 3. Triggers an inflammatory response with the recruitment 
of monocytes and foam cell formation. 4. This is followed by the recruitment of T cells, B cells, 
dendritic cells and smooth muscle cells. 5. This results in the formation of a fibrous cap in stable 
plaques. 6. Some plaques, known as vulnerable plaques, may undergo thinning of the fibrous 
cap and the subsequent formation of a necrotic core. 7. This leads to the exposition of 
thrombotic material to the blood circulation and the formation of thrombus. 
1.1.1.3 Progression of atherosclerotic lesions and vulnerable 
plaques 
Most atherosclerotic lesions do not cause acute vascular disease (11), nevertheless, 
certain types of atherosclerotic lesions develop features over time that can result in an 
acute thrombotic vascular disease. These are known as “vulnerable plaques” and are 
characterised by a large area of necrosis in the intima, called the necrotic or lipid core, 




likely caused by a combination of defective collagen synthesis by intimal smooth muscle 
cells and an increased degradation by matrix metalloproteinases which are secreted by 
inflammatory cells. Activation of innate and adaptive immune pathways contribute to 
the inflammatory response, (12) and this is amplified in advanced lesions by the 
increased production of damage-associated molecular patterns (DAMP) from necrotic 
cells. 
There are different ways that a vulnerable plaque can rupture. First, thinning of the 
fibrous cap leads to the exposure of thrombotic and proinflammatory material of the 
necrotic core to the circulating blood leading to thrombotic coronary occlusion. This 
type of plaque rupture is recognised to be the most common cause of myocardial 
infarction and death from cardiac causes (11). Second, the blood vessel can break 
leading to the formation of a thrombus on a cell-denuded endothelial layer of a non-
ruptured plaque. Finally, calcified nodules are also reported to lead to clinical events and 
are considered as another type of vulnerable plaques (13). 
To date, there is no reliable way to identify vulnerable plaques. Few techniques are 
currently used such as intravascular ultrasound (IVUS), which is an invasive coronary 
atherosclerotic plaque imaging technique, and optical coherence tomography. 
Nevertheless, apart from a proof of concept studies, none of them have successfully 
established criteria for assessing plaque vulnerability in a larger sense. 
1.1.2 Likelihood of recurrences of cardiac events after first event  
Nowadays, more patients are surviving their first heart attack but are nevertheless at 
high risk of recurrences. Recurrent events have also been referred to as major adverse 
cardiovascular events (MACE) in many studies and include death, myocardial infarction, 




Cardiovascular Intervention Society), (14,15). Even with access to the highest 
revascularisation strategy technology (Coronary Artery Bypass Grating (CABG) and 
Percutaneous Coronary Intervention (PCI)) as well as most recently available secondary 
prevention therapies, the burden of recurrent events after acute coronary syndromes 
remains unacceptable. The recurrences are of the order of 10% to 20% in the first 12 
months, despite optimal treatment with contemporary intervention and 
pharmacological agents (16–18). MACE can be due to a recurrence at the original 
treatment site, the presence of untreated lesions elsewhere, or progressive lesions. 
Moreover, retrospective studies have shown that most atherosclerotic plaques 
responsible for future acute coronary syndromes are angiographically mild and the 
lesion-related risk factors for MACE are poorly understood (19). 
After a heart attack, a number of measures are put in place in order to reduce the 
occurrence of MACE. As persistent high cholesterol levels (20) and high blood pressure 
(21) are known to be predictors of MACE, these factors are controlled using statins and 
anti-hypertensive therapy post infarction. Moreover, the patient is advised to modify his 
diet in order to control his body weight and practice regular exercise (22). Controlling 
diabetes when present has also proven to be a good way to avoid future MACE. 
However, despite these measures, MACE still occur (23).  
Other risk factors have also been shown to predict MACE. In 2000, aortic stiffness 
was proposed to be an independent risk factor for recurrent acute coronary events (24). 
However, measuring aortic stiffness has shown to be insufficient as it is also part of a 
normal process present in older patients, patients with diabetes mellitus, hypertension 
and renal disease and might therefore need to be combined to other clinical 
measurements for an accurate prediction of MACE (25,26). In 2001, leukocyte count was 




might contribute to recurrent cardiac events in post-infarction patients (27). However, 
this is confounded by the fact that lymphocyte count can be elevated in many other 
inflammatory conditions which complicates its interpretation. Measuring platelet 
reactivity in ex vivo assays has been shown to be potentially useful in predicting MACE, 
however, these tests haven’t made it into clinical routine practice (28). More recently, 
depression and anxiety have been linked to recurrent cardiac events (29). Since many 
variables can potentially influence risk, it seems unlikely that one mechanism is enough 
to effectively predict MACE. 
The prediction of cardiovascular events has always focused on the occurrence of 
primary events (30) as Framingham Heart Study data and similar observational study 
data as well as the developed risk scores are used to predict vascular disease risk in 
people with no established CAD. Cardiovascular prediction research on the risk of 
recurrent events in patients with an established CAD also exists, however, there is no 
clinical tests at present that can predict MACE (31–33). Moreover, the number of young 
individuals with coronary atherosclerosis is probably much larger than currently 
estimated (34) and this young population is often less represented in clinical studies 
(35). Multivariable analysis of MACE risk could provide an individualised risk scoring 
system and help identify individuals at higher risk for more intensive investigation, 
treatment, and follow-up. 
1.2 Acute coronary syndrome (ACS) and myocardial 
infarction (ESC guidelines 2015) 
1.2.1 Definition and diagnostic algorithm 
Acute coronary syndromes (ACS) are recognised as medical emergencies that include 




segment-elevation myocardial infarction (STEMI). A myocardial infarction is defined as 
a myocardial cell necrosis due to significant and sustained ischaemia (36) (WHO). It is 
the result of a reduction of blood flow to the heart usually caused by plaque rupture 
which can sometimes lead to the formation of blood clot (NICE guidelines).  According 
to the European Society of Cardiology (ESC) guidelines, diagnosing an ACS follows the 
algorithm below (Figure 2): 
1- Clinical symptoms include acute chest pain characterised by a retrosternal 
sensation of pressure or heaviness (‘angina’) radiating to the left arm (less 
frequently to both arms or to the right arm), neck or jaw, which may be 
intermittent (usually lasting several minutes) or persistent. Additional symptoms 
such as sweating, nausea, abdominal pain, dyspnoea and syncope may also be 
present. 
2- An emergency electrocardiogram (ECG) analysis is performed in order to 
identify: 
a. Patients with acute chest pain persistent ST -segment elevation 
generally reflecting a total coronary occlusion and could ultimately 
lead to the development of an ST-elevation myocardial infarction 
(STEMI) (37). 
b. Patients with acute chest pain but no persistent ST-segment 
elevation. At presentation, the working diagnosis of non-ST-elevation 
ACS (NSTE-ACS)  
c. Based on the measurement of cardiac troponins with at least one 




ACS will be further qualified as non-ST-elevation MI (NSTEMI) if 
cardiac troponins are elevated or unstable angina (UA) if they are not. 
 
Figure 2: Initial assessment of patients with suspected Acute Coronary Syndrome (ACS). The 
initial assessment of patients with suspected ACS is based on the features derived from 
clinical presentation. A 12-lead ECG is then performed to assess any changes in the heart 
rhythm and electrical activity. A cardiac troponin test is performed and levels are interpreted 
as a quantitative marker: the higher the level, the higher the likelihood for the presence of 
myocardial infarction. The presence of a severe thrombus is associated with a higher chance 
of having a STEMI. ECG changes and elevated cardiac markers can be present in other cardiac 
conditions such as Takotsubo cardiomyopathy, myocarditis, aortic dissection and heart 
failure. Adapted with minor modifications from 2015 ESC Guidelines for the management of acute coronary 
syndromes in patients resenting without persistent ST-segment elevation (38). 
In addition to the traditional CVD risk factors mentioned in section 1.3.3, many 
conditions are known to precipitate an ACS such as intense emotions, intense exercise, 
cold temperatures, anaemia, infection, fever, inflammation and metabolic disorders 
(38). In addition, imaging evidence of new or presumed new loss of viable myocardium 
or regional wall motion abnormality as well as intracoronary thrombus detected on 




1.2.2 STEMI versus NSTEMI 
A STEMI is considered to be more severe than a NSTEMI because mortality is generally 
higher in the STEMI group (39). A NSTEMI occurs by developing a complete occlusion of 
a minor coronary artery or a partial occlusion of a major coronary artery affected 
previously by atherosclerosis. This causes partial thickness damage of heart muscle 
historically referred to as a non-Q wave MI or a subendocardial MI. On the other hand, 
a STEMI occurs by developing a complete occlusion of a major coronary artery previously 
affected by atherosclerosis (Figure 2). This causes full thickness damage of heart muscle 
historically referred to as Q wave MI or transmural MI. Also, the elevation of cardiac 
markers is on average lower in a NSTEMI compared to a STEMI (40,41). The incidence of 
STEMI appears to be declining, while there is a concomitant increase in the incidence of 
NSTEMI (42). This is probably because the troponin measurement assays are increasing 
in sensitivity and specificity which makes it possible to detect a NSTEMI earlier leading 
to the initiation of a proper therapy before the development of a STEMI and other 
complications (43). 
1.2.3 Unstable angina  
Unstable angina (UA) is defined as myocardial ischaemia at rest or minimal exertion in 
the absence of myocardial cell necrosis. Compared with NSTEMI patients, individuals 
with UA do not experience myocardial necrosis that is currently detectable with the 
clinical available biomarkers, have a substantially lower risk of death and appear to have 





1.2.4 Cardiac troponins 
Troponin I (Tn I) and troponin T (Tn T) are cardiac proteins involved in the regulation of 
muscle contraction by controlling the calcium mediated interaction between actin and 
myosin. Tn I has not been identified outside the heart muscle (48) whereas Tn T can also 
be secreted by the skeletal muscle. Tn I and Tn T are detected in the serum using 
monoclonal antibodies which have high specificity to the cardiac troponins and 
negligible cross-reactivity with skeletal troponins (49). Cardiac troponins may not be 
detected for up to 4 hours after the onset of an ACS and are normally repeated after 12 
hours if levels were not elevated upon admission (50). Tn T assay is measured using a 
single assay so that levels can be compared across laboratories with a cut-off value of 
0.1 μg/litre. However, Tn I is measured using different assays with different sensitivities 
(51) and the European Society of Cardiology (ESC) and American College of Cardiology 
(ACC) consensus recommends that each laboratory should determine its cut-off values 
for each test at the 99th centile of normal with ≤ 10% coefficient of variation (52) (Refer 
to section 1.4.4). In line with these recommendations, serum Tn I values indicative of 
myocyte necrosis/myocardial damage range from 0.1 to 2 μg/litre (53) . The sensitivity 
of Tn T and Tn I assays improve with time following admission with a maximal sensitivity 
at 6 hours after the onset of an ACS (50). Serum levels can remain elevated for up to 4–
7 days for Tn I, and 10–14 days for Tn T (54). 
While troponin is helpful in the diagnosis of ACS, it lacks specificity and its clinical use is 
more effective in ruling out patients with no heart attack but, less effective in ruling in 










Critical illness (e.g. shock/ sepsis/ burns) 
Myocarditis 
Takotsubo cardiomyopathy 
Structural heart disease (e.g. aortic stenosis) 
Aortic dissection 
Pulmonary embolism, pulmonary hypertension 
Renal dysfunction and associated cardiac disease 
Coronary spasm 
Acute neurological event (e.g. stroke or subarachnoid haemorrhage) 
Cardiac contusion or cardiac procedures (CABG, PCI, ablation, pacing, cardioversion, or 
endomyocardial biopsy) 
Hypo- and hyperthyroidism 
Infiltrative disease (e.g. amyloidosis, haemochromatosis, sarcoidosis, scleroderma) 
Myocardial drug toxicity or poisoning (e.g. doxorubicin, 5-fluorouracil, herceptin, snake 
venoms) 
Extreme endurance efforts 
Rhabdomyolysis 
Adapted with courtesy of the 2015 ESC Guidelines for the management of acute coronary 
syndromes in patients presenting without persistent ST-segment elevation (38) 
1.3 Risk of cardiovascular disease 
1.3.1 Defining risk 
A risk factor is defined as a measurable characteristic associated with increased disease 
frequency (55). According to the European Society of Cardiology (ESC) guidelines, risk 
estimation in cardiovascular disease is defined as the ‘likelihood of a person developing 
an atherosclerotic cardiovascular event over a period of time’. Calculating and 
interpreting a patient’s cardiovascular risk is generally followed by several preventive 
lifestyle and medical measures where both the physician and the patient have a major 
role to play in. Clinical thresholds, which are based on the results of large clinical studies, 




1.3.2 History of risk 
A century of intensive research has shown that the presence of CVD is attributed to 
genetic, social, physiological, and environmental factors. Cardiovascular epidemiology 
began around the 1950’s when several epidemiological studies were set up with the aim 
of clarifying why patients get CVD. Four years after the Framingham Heart Study started, 
researchers had identified high cholesterol and high blood pressure levels as important 
factors in the development of CVD (55). In a follow up study that started in 1983, obesity 
was subsequently considered as an independent risk factor for CVD (56). Further down 
the line, other epidemiological studies have helped with identifying other CVD risk 
factors such as diabetes (57), dietary composition and fibre consumption (58) as well as 
kidney disease (59). 
1.3.3 Traditional risk factors 
The five major traditional risk factors known to be associated with CVD are total 
cholesterol levels, systolic blood pressure (SBP), tobacco smoking, diabetes and family 
history. These factors are included in most of the risk prediction scoring systems. 
Hypertension is defined as a systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic 
blood pressure (DBP) ≥ 90 mmHg. These cut-off blood pressure (BP) values are based on 
evidence from randomised control trials where treatment-induced BP reductions were 
beneficial in patients with these cut-off BP values (60). As for total cholesterol levels, the 
threshold for intervention is set at ≥ 4.9 mmol/L or 190 mg/dL as per the ESC guidelines 
for a patient with no other CVD risk factors. However, if the patient has a number of CVD 
risk factors (such as the presences of a family history, diabetes, or smoking) the 




Other risk factors known to contribute to cardiovascular risk include renal disease 
(62), lack of physical activity, dietary habits and obesity (63), (world health federation, 
risk factors, 2015). Nevertheless, it is well established that traditional risk factors 
account for only 50% of the incidence of CVD (64). In fact, many individuals who develop 
heart disease have normal cholesterol and blood pressure levels (64) which raises the 
point that these traditional risk factors do not fully explain CVD risk. Many physiological 
and social risk factors have recently been shown to contribute to CVD risk beyond the 
traditional CVD risk factors (Table 2). This highlights the need for a broader approach 






Table 2: Newly proposed risk factors for cardiovascular disease 
Risk Factor Association with CVD Studies 
Atrial fibrillation Risk factor for cardiovascular disease and death 
in women compared with men 
(65) 
Migraine Increased risk of cardiovascular disease in 
women 
(66) 
Ankylosing spondylitis Prevalent patients with ankylosing spondylitis 
are at a 30%–50% increased risk of incident CV 
events 
(67) 
Homelessness  Independent Risk Factor for Cardiovascular 
Disease Hospital Readmission 
(68) 
Anxiety Important risk factor for cardiovascular disease 
and increases the risk of major cardiac events in 
coronary heart disease 
(69) 
Depression Increased risk for CVD in middle-aged women in 
the general population 
(70) 
Loneliness and social 
isolation 
Deficiencies in social relationships are 
associated with an increased risk of developing 





Increases hypertension, inflammation, and 
cardiovascular disease risk through an increase 




Compared to those with daily bowel 
movements, women with more frequent bowel 
movements had a modestly increased risk of 
CAD incidence and total mortality 
(73) 
Sleep apnea Independent risk factor for cardiovascular 





corn syrup  
The risk of cardiovascular mortality is positively 
associated with consumption of increasing 
amounts of added sugars 
(75) 





1.3.4 Risk prevention 
Age-adjusted CVD mortality has declined since the 1980s, particularly in high-income 
regions (76) due to the implementation of preventive measures. CVD rates are now less 
than half what they were in the early 1980s in many countries in Europe. In fact, in the 
last three decades, more than half of the reduction in CV mortality has been attributed 
to modification of risk factors in the population, primarily by reducing cholesterol, BP 
and smoking. While CVD management is improving, the number of people affected by 
CVD is increasing due to the increase in other risk factors, mainly obesity and type 2 
diabetes mellitus (77,78). Changes in lifestyle behaviours such as smoking, physical 
activity and dietary habits would make it possible to prevent at least 80% of CVD and 
40% of cancers, thus providing added value for other chronic diseases (79,80). 
Ultimately, prevention is effective in reducing the impact of CVD but further work is 
needed to explore this. 
1.3.5 Risk scores 
Since CVD is the product of a multitude of risk factors, all current guidelines recommend 
the assessment of total CVD risk. Therefore, CVD prevention in an individual should be 
adapted to his/her total cardiovascular risk; the higher the risk, the more intense the 
action should be. Most guidelines use risk estimation systems based on the most 
popular risk estimation scores which are the Framingham Risk Score or the European 
SCORE projects and are highlighted below and in Table 3. Risk estimation can be 
determined either for primary or secondary prevention. Primary prevention is 
established to control CVD risk factors in patients with no prior CVD history in order to 




to control CVD risk factors in patients with established CVD in order to prevent the 
occurrence of further cardiovascular events (82). 
1.3.5.1 Risk Scores used in primary prevention 
1.3.5.1.1 EUROSCORE (European Systematic COronary Risk 
Evaluation (SCORE) algorithm) 
In Europe, the SCORE system is used in primary prevention to assess an individual’s 
cardiovascular risk. This SCORE system was established based on studies in different 
European cohorts and using other scoring systems won’t be as accurate to establish the 
cardiovascular risk of a European individual due to genetic background (Figure 3 and 
Table 3). The development of the SCORE system by the European Society of Cardiology 
was initiated between 1998 and 2001 using data from 12 European cohort studies 
(n=205,178) covering a wide geographic spread of countries with different levels of 
cardiovascular risk (83). This resulted in the generation of two SCORE charts depending 
on where an individual comes from which means they can fall into a low or high CVD risk 
region in Europe. The SCORE data contains more than 3-million person-years of 
observation and 7,934 fatal cardiovascular events. It estimates the 10-year risk of a first 
fatal atherosclerotic event, whether heart attack, stroke, or other occlusive arterial 
disease, including sudden cardiac death. 
In the case of primary prevention defined as the control of CVD risk factors to delay 
or prevent the onset of CVD, risk estimation is calculated using SCORE charts which are 
based on the following risk factors: gender, age, smoking, systolic blood pressure and 
total cholesterol. The threshold for high risk based on 10-year risk fatal cardiovascular 
events is defined as "higher than 5%”. To calculate risk the above variables are inputted 




easy with the development of the smart phone applications and online calculators. 
Patients with diabetes or moderate to severe chronic kidney disease are immediately 
classified as very high risk and so, SCORE charts do not apply. 
Subsequent work on the SCORE database has shown that high density lipoprotein 
cholesterol (HDL-C) can contribute greatly to risk estimation if entered as a separate 
variable and was shown to modify risk at all levels of risk as estimated from the SCORE 
with the same effect in both genders and in all age groups (84,85). That is the reason 
behind the development of the heartScore chart which takes into account the HDL-C 
level to score patients (http://www.heartscore.org/). 
On the other hand, fasting triglyceride (TG) levels related to risk in univariate analyses, 
but the effect is diminished by adjustment for other factors, especially HDL-C. Non-
fasting TG have been suggested to be more strongly related to risk independently of the 
effects of HDL-C (86). The effect of additional risk factors such as high sensitivity C-
reactive protein (hs-CRP) and homocysteine levels was also considered. However, the 
contribution of these risk factors to absolute cardiovascular risk estimations for 






Figure 3: EUROSCORE European low risk chart for the assessment the 10-year risk of 
fatal CVD in low risk regions of Europe. The use of the low risk chart is recommended in 
Andorra, Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Iceland, 
Ireland, Israel, Italy, Luxemburg, Malta, Monaco, The Netherlands, Norway, Portugal, 
San Marino, Slovenia, Spain, Sweden, Switzerland and the United Kingdom. The use of 





1.3.5.1.2 Other Risk Scores used in primary prevention 
There are several other scoring systems in place that assess cardiovascular risk. In the 
United States, the use of the Framingham risk score (FRS) is more common. This scoring 
system estimates the 10-year cardiovascular risk and was developed based on the data 
from the Framingham heart study, which recruited 5,209 men and women, to estimate 
the risk of developing coronary heart disease (Framingham study website.org). 
Moreover, the Prospective Cardiovascular Münster (PROCAM) study was initiated in 
1979 and its objectives were to determine the prevalence of CAD risk factors in the 
German population, improve the prediction and early detection of CAD, and derive 
recommendations for the primary prevention of vascular disease from the trial results. 
The PROCAM score resulting from this study is also used to assess cardiovascular risk. 
QRISK is another scoring system available to calculate the 10-year risk of CV events and 
it was established using a sample size of 1.28 (QRISK1) and 2.29 (QRISK2) million people. 
A study compared the FRS, PROCAM and SCORE ability to predict coronary 
atherosclerosis and cardiovascular events. The results showed that in a stable chest pain 
population, the ability of FRS and SCORE to predict CAD was similar and better compared 
to PROCAM. However, the number of low risk patients showing significant CAD or events 
was lower using FRS (87). However, more efforts should be done towards the 
encouragement of the use of any of those risk charts in clinical practice since many 
patients with high blood pressure or high cholesterol levels or any of the previously 
mentioned risk factors are not detected and treated on time before they develop an ACS 
(88).  
Recent work has proposed a new scoring system predicting cardiovascular risk 




of fatal CVD in low and middle income countries rather than in higher income countries 





Table 3: Current cardiovascular disease risk estimation systems for use in apparently healthy individuals. 
 
 
Data Population and size Outcome Variables Recommended in 
Guidelines 
Reference 














3969 men and 
4522 women 
10-year risk of CAD 
events originally. 
Latest version: 
10-year risk of CVD 
events 
NCEP ATP III version: 
10-year risk of hard 
coronary events 
Sex, age, total 
cholesterol, 
HDL-C, SBP, smoking 











SCORE 12 pooled 
prospective 
Studies from 11 
European countries 
(Europe) 
Mostly random samples 




117 098 men and 
88 080 women 
 
10-year risk of CVD 
mortality 
Sex, age, total 
cholesterol 
or total cholesterol/ 
HDL-C ratio, SBP, 
smoking status. 
Versions for use in high 
and low-risk countries 
European Guidelines 
on CVD Prevention 
(83) 
ASSIGN SCORE SHHEC prospective 
study 
(Scotland) 
Random sample from 
general population in 
Scotland, baseline: 
1984–1987 
10-year risk of CVD 
events 
Sex, age, total 
cholesterol, HDL-C, SBP, 








6540 men and 6757 
women 
 
cigs, DM, area based 








Health records of general 
practice attendees - not 
random, baseline: 1993–
2008 
1.28 million (QRISK1) 
2.29 million (QRISK2) 
10-year risk of CVD 
events. 
Lifetime risk 
QRISK1 - sex, age, total 
cholesterol to HDL-C 
ratio, SBP, smoking 
status, DM, area based 
index of deprivation, 
family history, BMI and 
BP treatment QRISK2—
also includes ethnicity 
and chronic diseases 












18 460 men and 
8515 women 
Two separate scores 
calculate 10-year 








Force for Prevention 
of Coronary Disease 
Guidelines 
(94) 
ATP = Adult Treatment Panel; BMI = body mass index; BP = blood pressure; CAD = coronary artery disease; CVD = cardiovascular disease; DM = diabetes mellitus; HDL-C = 
high-density lipoprotein cholesterol; JBS = Joint British Societies; LDL-C = low-density lipoprotein cholesterol; NCEP = National Cholesterol Education Program; NICE = 
National Institute for Health and Care Excellence; no. cigs = number of cigarettes; PROCAM = Prospective Cardiovascular Munster Study; SBP = systolic blood pressure; 




1.3.5.1.3 Weaknesses of the currently available scoring systems 
used in primary prevention 
Despite the advantages of having risk estimation tools in place to guide therapeutical 
strategy and patient management, they still hold many weaknesses and might need to 
be combined to other biological tests to improve cardiovascular risk estimation. Several 
highlighted problems with the current scoring systems are detailed below. 
1.3.5.1.3.1 Effect of one risk factor at different levels of other risk factors 
One limitation of all risk estimation systems is that they assume constant effects of the 
risk factors at differing ages and levels of the other risk factors. Certain combinations of 
risk factors may act synergistically to increase risk in a manner that is more than additive. 
The ideal solution for this problem would be to have an extremely large dataset (a whole 
country or even a continent) in which there were numerous persons with each 
combination of risk factors and to examine the actual risk within each combination. In 
this method, particularly dangerous combinations of risk factors could be identified. 
However, development of such a dataset would be practically impossible, especially in 
the modern era when many of the identified risk factors already have been treated (95), 
therefore, alternative methods should be investigated. 
1.3.5.1.3.2 Recalibration of the scoring systems according to the different 
regions 
Risk functions developed in one region will tend to overestimate or underestimate CVD 
risk in other populations with different baseline risks, either because of changes over 
time or regional differences. For example, the use of the high risk SCORE risk chart in 




Bulgaria, Latvia and Lithuania. This highlights the need to update the existing scoring 
systems based on recent prospective studies, the current CVD mortality rates and the 
different levels of risk factors in a population of a specific region (96). 
1.3.5.1.3.3 Evaluating the introduction of new risk factors to the scoring systems 
As mentioned above, traditional risk factors included in most of the scoring systems 
account for only 50% of the incidence of CVD (64). Adding “new” risk factors to the 
traditional CVD risk factors might help to appropriately reclassify some of the patients 
who are close to a treatment threshold to a more correct “treat/do not treat” category 
(95). Assessing the value of incorporating new risk factors into risk estimation systems 
has been traditionally evaluated by the Area Under the Receiving Operating 
Characteristic (AUROC) curve or Harrell's C statistic. However, AUROC was a technique 
developed for assessing the performance of a diagnostic test that has a straightforward 
yes/no answer, against that of a gold standard. A perfectly sensitive and specific test will 
result in an AUROC of 1. However, because risk estimation is just an estimate, a perfect 
AUROC could never be achieved and its use is more appropriate in diagnostic tests rather 
than in risk estimation. For this reason, there has been increasing interest in developing 
more appropriate methods to judge the improvement in performance induced by the 
incorporation of new risk factors (97). The method with most potential for clinical utility 
is patient reclassification and discrimination and calculation of measurements such as c 
statistics, the net reclassification improvement (NRI) index and the integrated 
discrimination improvement (IDI) index (98,99).  
It is noteworthy that when considering variables to include in a model for the 
generation of a risk score, selecting factors that report on orthogonal aspects of 




lipoprotein, myocardial stress, such as a natriuretic peptide, myocardial injury, such as 
troponin, inflammation, such as high sensitivity C-reactive protein, and glycemia, such 
as hemoglobin A1c, each report on different biological pathways (100–103). Inclusion of 
factors that lie in a common pathway (eg, low-density lipoprotein cholesterol, 
apolipoprotein B, and non–high-density lipoprotein cholesterol) would not be expected 
to add as much information to a risk assessment compared to factors that reflect 
orthogonal pathogenic pathways. 
1.3.5.1.3.4 Reassessing the risk in young and old individuals 
Younger individuals will always be at low absolute risk even when risk factor levels are 
very unfavourable, unless they suffer from a genetic defect that results in higher risk 
such as homozygous familial hypercholesterolemia. When looking at the 40-year age 
band of the SCORE chart for example, no combination of risk factors will place a person 
in the high-risk category (≥5% 10-year risk of fatal CVD). Even a 40-year-old man who is 
severely hypertensive, severely hypercholesterolemic, and a smoker will still only have 
a risk of 4%. The same situation occurs with use of the Framingham function. This 
represents a challenge when counselling these younger persons regarding the need for 
lifestyle modification to reduce their risk (104). This is an important issue since the 
modification of risk factors at this early stage has a great benefit on CVD prevention. The 
relative risk chart has been developed in the Fourth Joint Task Force ESC guidelines to 
counteract this problem which provides an estimate of the risk of a person with a certain 
combination of risk factors compared with a person of the same age and sex who has 
ideal risk factor levels. 
Similarly, the estimation of risk in the elderly remains a challenge. In some age 




an estimated cardiovascular death risk exceeding the 5– 10%, based on age (and gender) 
only, even when other cardiovascular risk factor levels are relatively low. This could lead 
to excessive usage of drugs in the elderly and should be evaluated carefully by the 
clinician. Furthermore, the SCORE function concentrates on the middle-aged group and 
is only recommended for use in the 40- to 65-year age range (83) which makes risk 
estimation between the ages of 65 and 75 years problematic as most of these systems 
were derived from cohorts of primarily middle-aged people. 
1.3.5.2 Risk Scores used in secondary prevention 
1.3.5.2.1 Current risk scores 
Patients who have had a clinical event such as an ACS or a stroke or a clinical intervention 
such as a PCI or a CABG fall into the category of secondary prevention. In this case, we 
estimate the risk of further cardiovascular events. The GRACE risk score was based on 
an international registry designed to track in-hospital and long-term outcomes of 
patients presenting with ACS (105–107). The GRACE 2.0 risk calculator (Figure 4) 
provides a direct estimation of mortality while in hospital, at 6 months, at 1 year and at 
3 years. The combined risk of death or MI at 1 year is also provided (108). Variables used 
in the GRACE 2.0 risk calculation include age, systolic blood pressure, pulse rate, serum 
creatinine, Killip class at presentation, cardiac arrest at admission, elevated cardiac 





Figure 4: GRACE 2.0 risk score calculator. 
Moreover, the TIMI risk score uses seven variables in an additive scoring system: age 
≥65 years, three or more CAD risk factors, known CAD, aspirin use in the past 7 days, 
severe angina (two or more episodes within 24 h), ST change ≥0.5 mm and positive 
cardiac marker (http://www.timi.org/index.php?page=calculators). TIMI risk score is 
known to be simple to use, but its discriminative accuracy is inferior to that of the GRACE 
risk score and the GRACE 2.0 risk calculation. PURSUIT and FRISC risk scores have also 
been developed and validated in patients with confirmed acute coronary syndrome 
(109). Further cardiovascular risk scores in specific disease conditions (diabetes, renal 
disease, rheumatoid arthritis, and obesity) also exist. However, ACS prediction models 
need to be re-evaluated in contemporary practice with evolving diagnostic and 
treatment options. 
1.3.5.2.2 Limitations of the Risk Scores used in Secondary Prevention 
Most of the available risk scores used in secondary prevention are only applicable to 
patients with an ACS and might not be as effective in patients with established CVD but 
with no previous cardiovascular events. In practice, it was shown that only a limited 
number of ACS patients actually have their GRACE score calculated (110) probably due 




the creatinine and the troponins measurements are required for the score calculation. 
In addition, GRACE score has been criticised because the age variable makes a major 
contribution to the score calculation and might lead to an underestimation of the risk in 
younger CVD patients.  
On the other hand, the TIMI risk score gives one point for every variable included in 
the model which assumes that all variables have the same impact on risk estimation. For 
example, the effect of using aspirin in the past 7 days is considered to have the same 
value as having more than 3 CVD risk factors or positive troponin levels. This is 
misleading as some variables might contribute more than others to the occurrence of 
secondary events. Ultimately, whether risk factor scores are used in primary or 
secondary prevention, it is essential to update them frequently according to the results 
of the latest clinical prospective studies and the discoveries in terms of novel CVD risk 
factors. 
1.3.5.4 The need for more effective risk estimation models 
Existing scoring systems should be improved given the weaknesses discussed previously. 
A significant proportion of individuals who have an MI are still categorised as low risk by 
many of the available methods. The current risk scoring systems for primary and 
secondary prevention need constant update and refinement based on current 
prospective cohort studies and any recent discoveries in relation to novel cardiac risk 
factors and biomarkers. In addition, risk estimation in a young or an old individual needs 
to be refined.  
Since it is well-established that atherosclerosis is an inflammatory disease, some 
inflammatory pathways are more important in the initiation of the lesion and others are 




inflammatory markers, specific for each pathway, will give a clearer image of the 
underlying state of the disease and the likelihood of the occurrence or recurrence of a 
cardiovascular event. Biomarkers are powerful tools that could improve the current CVD 
risk estimation models by looking at those different inflammatory pathways. By 
combining novel biomarkers to the traditional risk assessment scores, it would be 
possible to detect individuals which risk has been over or underestimated when using 
the traditional risk scores alone. Additionally, it will also be possible to identify 
individuals at high risk of recurrent events. 
1.4 Biomarkers 
Traditional risk assessment tools for primary or secondary prevention in CVD have 
several limitations. However, they can be improved by the addition of biomarkers that 
reflect the underlying inflammatory state of CVD. 
1.4.1 Biomarker definition 
A biomarker is defined as a characteristic that is objectively measured and evaluated as 
an indicator of normal biological processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention, a definition that was standardised in 2001 by 
the National Institutes of Health (NIH) working group. Biomarkers are indicators of 
disease trait (risk factor or risk marker), disease state (preclinical or clinical), or disease 
rate (progression) (111). A biomarker can be a gene mutation, a polymorphism, a 
protein, or other molecule or clinical measurement that indicates a given disease state. 
Therefore, biomarkers could be measured in a biosample such as a blood, urine, or 




monitor), or from an imaging test (echocardiogram or CT scan) (112). Biomarkers can be 
classified as:  
1- Antecedent biomarkers: Identify the risk of developing an illness 
2- Screening biomarkers: Screen for subclinical disease 
3- Diagnostic biomarkers: Recognise the presence of a disease 
4- Staging biomarkers: Categorise disease severity 
5- Prognostic biomarkers: Predict future disease course, including recurrence and 
response to therapy, and monitoring efficacy of therapy 
1.4.2 Ideal biomarker 
The ideal biomarker will increase the ability of the clinician to optimally manage the 
patient and will allow to distinguish between sub categories of patients that require a 
different type of management, a concept also known as personalised medicine (9). It is 
also important to examine the additional value of any novel biomarker to the existing 
and well-established risk factors. Ideally, a new biomarker should not only provide 
independent information on cardiovascular risk, but should also be easy to measure 
using inexpensive and standardised commercial assays with low variability that do not 
require specialised plasma collection or complicated assay techniques (9).  
1.4.2.1 Characteristics of a biomarker 
A novel biomarker would have added clinical value if it is: (113) 
1- Accurate, which refers to the degree of agreement with a reference standard for the 
analyte and is quantified in terms of percent bias (Clinical and Laboratory Standards 
Institute (CLSI), formerly National Committee for Clinical Laboratory Standards (NCCLS). 




2- Precise, which refers to consistent measurement on replicates (Clinical and 
Laboratory Standards Institute (CLSI), formerly National Committee for Clinical 
Laboratory Standards (NCCLS). Harmonized terminology database: 2005). One of the 
ways to evaluate precision is by measuring the coefficient of variation (CV) which is the 
standard deviation of a set of values divided by the average expressed in percentage. 
3- Acceptable to the patient 
4- Produces reproducible results in a standardised manner 
5- Highly sensitive and specific in relation to the outcome. Sensitivity is defined as the 
probability of getting a positive test result in subjects with the disease. Whereas 
specificity is defined as a proportion of subjects without the disease with negative test 
result in total of subjects without disease (114). These are normally expressed in terms 
of receiver operating characteristics (ROC) curve. Analytical sensitivity of an assay is 
related to two measurements. First, the limit of detection (LoD) which is the smallest 
amount or concentration of analyte that can be distinguished from background at a 
stated confidence level. Second, the limit of quantitation (LoQ) which is  the lowest 
amount of analyte in a sample that can be quantitatively determined with stated 
acceptable precision and accuracy, under stated experimental conditions (115). 
6- Easily interpreted by the clinicians 
7- It explains a reasonable proportion of the outcome independently of established 
predictors 
8- There is enough knowledge linking biomarker levels and changes in patient’s 
management 
9- Tested in a large spectrum of people with varying degrees of pathology 




However, these characteristics could change according to the intended use of each 
biomarker (116):  
- Screening biomarkers to identify “vulnerable patients”: High sensitivity, specificity, 
and predictive values, large likelihood ratios, and low costs are more important.  
- Diagnostic markers of acute cardiac disease identifying ischemia or injury (such as 
acute MI): In addition to the aforementioned characteristics, high tissue specificity 
(referring to a myocardial origin), rapid sustained elevation, proportional release to the 
extent of the disease, assay features applicable to point-of-care testing and diagnostic 
cut-off well defined and accepted are critical (117).  
- Biomarkers monitoring disease progression or response to therapy: In that case, 
sensitivity and specificity are less important features as each patient serves as his/her 
own control, but small intra-individual variation and changes in levels with disease 
outcome or treatment are important. 
Additionally, some biomarkers (eg, exercise stress test) may be used for both diagnostic 
and prognostic purposes. 
1.4.2.2 Assessing the value of a biomarker 
The prognostic utility of a biomarker is more challenging to establish because it requires 
a large number of patients and a prospective design, whereas demonstrating its value 
as a diagnostic test requires a smaller sample and a cross-sectional design (118) which 
is normally done in feasibility studies. The value of a new biomarker is demonstrated 
when elevated risk of an outcome is associated with higher levels of the new biomarker 
with adjustment for established risk factors. These results are typically presented as 
hazards ratios (relative risk estimates from a Cox model) and a probability value test of 




It is noteworthy to mention that biomarkers that do not change disease 
management cannot affect patient outcome and are less likely to be useful. Therefore, 
the biomarker needs to prove its clinical utility by providing evidence that a strategy 
reducing risk will change depending on the biomarker levels. In order to assess this, 
biomarker levels need to be measured over time and interpreted according to any 
adverse event that might occur. This suggests that biomarker levels should be directly 
or indirectly modifiable by therapy (119). In summary, using a biomarker-guided 
approach has to lead to better patient outcomes compared to an approach without the 
use of the biomarker.  
1.4.3 Single versus multiple biomarkers 
While the idea of using a single marker seems clinically appealing due to simplicity and 
low cost, it is becoming more and more apparent that CVD is so complex that one single 
biomarker is unlikely to capture the individual predisposition to disease development. 
The utility of adding multiple biomarkers from different disease pathways to predict the 
risk of death from cardiovascular cause has been explored in many studies and it is 
proving to be the only way to move forward (120–122). In their study, Halim et al 
associated a model combining 6 biomarkers (ICAM-1, MMP-3, NT-proBNP, IL-6, sCD40L, 
and IGFBP2) and 5 clinical variables (age, red-cell distribution width, diabetes, 
hemoglobin, and New York Heart Association class) with long term risk of cardiovascular 
events in terms of death and myocardial infarction (123).  
However, the generation of multimarker panels must take several factors into 
consideration. For example, comparisons of biomarkers measured on the same set of 
individuals must account for their inherent correlation (people with high values of one 




1.4.4 Defining abnormal biomarker values 
Before assessing the clinical use of a biomarker, it is important to define abnormal values 
(116). Therefore, the distribution of the markers in people from a certain community 
needs to be characterised and especially in patients who will eventually benefit from the 
use of the tested biomarkers. Variations in biomarker levels with sex, age, ethnicity, co-
morbidities and the disease itself must also be taken into account (125). There are 
different ways to define an abnormal biomarker level which are represented in Figure 
5. 
1- Reference limits: They are generally set with the use of cross-sectional analyses of a 
reference sample (usually a healthy sample free of the disease of interest), and an 
arbitrary percentile cutpoint (typically the 95th or 97.5th percentile) is chosen to define 
abnormality (126–128). Troponins cutpoint is 99th percentile (52). 
2-Discrimination limits: They are also used to indicate abnormal biomarker values. Such 
limits are generated by evaluating the degree of overlap between patients with and 
without disease in cross-sectional studies (129). As an example, when looking at the 
natriuretic peptides (NP) in a non-acute setting, a BNP plasma value >35 pg/mL and a 
NT-proBNP value of >125 pg/ml have been suggested as a threshold indicating heart 
failure and >125 pg/ml  (130). 
3-Threshold defining risk: A risk threshold identifies the level at which the risk of disease 
increases on follow-up. This method defines “undesirable” biomarker levels by 
associating values to the incidence of disease and seeking a threshold beyond which risk 








Figure 5: Three methods used to define abnormal values in biomarker development 
(Adapted from Vasan et al; 2006).  TN: True negative; TP: True positive; FN: False negative; 
FP: False positive 
 
1.4.5 Laboratory factors in biomarker evaluation 
In practice, biomarker performance needs to be assessed by analysing preanalytical, 
analytical, and postanalytical factors. 
1.4.5.1 Preanalytical variability 
Preanalytical variability refers to biomarker biological variability and stability over time 




- Sample related: Type of sample collected, sample processing (anticoagulant 
added, platelet activation, temperature, degrading enzymes, freeze-thaw 
cycles), sample storage, half-life of the analyte. 
- Assay related: Type of antibody used for the capture of the analyte, minimal 
detection limit, non-specific binding, false positive/false negative samples. 
- Biological: Intra-individual (time of the sample, circadian rhythm, fasting state) 
or inter-individual (age, gender, drugs, diet, co-morbidities). 
1.4.5.2 Analytical variability 
Analytical variability relates to the performance of the test in the laboratory. Low 
analytical variability is a fundamental requirement of all biomarkers (133–135) , (Clinical 
and Laboratory Standards Institute (CLSI), formerly National Committee for Clinical 
Laboratory Standards (NCCLS). Harmonized terminology database: 2005). Inter-
laboratory variability (reagents used, calibration and analytical platforms) and intra-
laboratory variability (staff-related) are important to consider. 
Analytical variability is a combination of good accuracy and precision. In practice, if 
analytical imprecision is greater than biological variability, samples should be assayed in 
replicate, and quality control procedures that improve assay methodology and/or 
operating procedures should be implemented. This is critical for biomarkers used for 
point-of-care testing because imprecision may be greater in this setting compared with 
standard laboratory measurements. On the other hand, if biological variability is greater 
than analytical imprecision, the patient should be sampled on more than one occasion 
to obtain a true estimate of a biomarker. In order to reduce variability, it is important to 
limit multiple lots, replicate measurements, avoid repeated freeze thaw cycles, use a lab 




1.4.5.3 Postanalytical variability 
Postanalytical factors that may affect biomarker performance, they include the 
processes of approval and transmission as well as the appropriate display of test results 
with the use of the laboratory’s information management systems and the use of the 
test (automated platform in a centralised laboratory or point of care testing) (136). 
1.4.6 Biomarker discovery 
Biomarker discovery in CVD is very challenging because the patient vulnerable to CVD is 
most likely subject to several abnormalities: vulnerable plaque, vulnerable blood and 
vulnerable myocardium. In terms of developing biomarkers, two of these three 
components (vulnerable plaque and myocardium) are less directly accessible relative to 
the third (vulnerable blood). It is noteworthy to mention that in the case of 
atherosclerotic cerebrovascular disease, biomarkers may not be detectable in the 
peripheral circulation after a brain injury due to the presence of the blood-brain barrier. 
Thus, identifying the onset of stroke is quite challenging using diagnostic biomarkers 
(137).  
There are two main strategies that are considered in CVD biomarker development which 
are complementary rather than mutually exclusive. 
- Deductive method or knowledge-based strategy relies on exploring the 
biological processes involved in atherosclerosis and its evolution. It could consist 
of designing new assays for potential new biomarkers that are proven to be part 
of the atherosclerosis process or improving already existing biomarkers to 




- Inductive strategy or unbiased strategy screens through a large number of 
molecules in order to characterise the ones that are more likely to be linked to 
the disease profile. 
Moreover, it is important to keep in mind that not every disease mediator is to be 
considered a biomarker. A particular analyte may participate clearly in a pathogenic 
pathway but not serve as an effective biomarker. As an example, soluble VCAM-1 does 
not predict the risk of future myocardial infarction in apparently healthy men (138). 
However, research has repeatedly and unequivocally demonstrated the essential role of 
VCAM-1 in experimental atherosclerotic lesion initiation and progression (139–143). 







Figure 6: Five phases of biomarker development. Adapted from Pepe et al, 2001 (144). Content validity refers to the degree to which the biomarker represents 
the biological phenomenon studied (eg, serum CRP represents systemic inflammation); construct validity refers to establishing that the biomarker is measuring 
the aspect of disease (some conceptual construct or theory) that we want to measure (eg, we want to measure plaque inflammation; therefore, we should 
establish whether serum CRP relates to atherogenesis and plaque inflammation); and criterion validity refers to the how well the biomarker identifies disease 




1.5 The need for new risk prediction tools: Exploring the 
TACE/TNFα pathway and new biomarkers using a proteomic 
approach 
Biomarkers are powerful tools that enable the understanding of the spectrum of CVD 
with applications in at least five areas: screening, diagnosis, prognostics, prediction of 
disease recurrence, and therapeutic monitoring. Although advances in functional 
genomics, proteomics, metabolomics, and bioinformatics have revolutionised the new 
era of personalised medicine, the translation of biomarker research into clinical practice 
is proving to be very difficult.  
The already available CVD biomarkers present many issues. High sensitivity C 
reactive protein lacks specificity and is known to be elevated in several inflammatory 
conditions (145). Troponins, on the other hand, give an idea of the extent of the 
myocardial damage, however, they are only elevated when the myocardial necrosis has 
already taken place and can also be elevated in other conditions highlighted in Table 2 
(146). Some characteristics revealed by the ECG hold a prognostic value, however, these 
changes are a result of an ACS and are ineffective when it comes to primary prevention 
(147). At present, there is no efficient blood test that allows the clinicians to know which 
patients are at higher risk of acute events before they have had their first or second 
event. In an ideal world, a coronary angiogram would be performed on everyone which 
wouldn’t be cost-effective. In addition, coronary angiograms are unable to detect any 
newly formed lesions that haven’t developed yet into a proper plaque (148). 
CVD risk factors such as family history, diabetes, blood pressure, chronic kidney 
disease, hypercholesterolemia, smoking and diet are among the characteristics that 




combined into risk scores. However, many people who are mistakenly considered at low 
risk eventually develop an ACS (149) and it was also shown that traditional risk factors 
only explain 50% of CVD risk (64,150). Recently, the concept of one ideal biomarker is 
becoming rather faint and the idea of multi-marker profiling is emerging. The 
development of a biomarker panel that explores a multitude of inflammatory pathways 
know to be involved in different stages of CVD initiation, progression and complications 
is the only way to improve current risk prediction models. 
The inflammatory pathway involving Tumour necrosis factor alpha converting enzyme 
(TACE) and tumour necrosis factor alpha (TNFα) has been previously investigated in CVD.  
As many studies have shown, TACE is responsible for the ectodomain shedding of a 
variety of inflammatory markers, including TNFα, most of which play role in the initiation 
and progression of CVD (151–156). The number of known TACE substrates continues to 
increase with mounting evidence that TACE is implicated in many cellular functions. 
Recent research indicates a particular role for TACE and the TNF family members in CAD 
and MACE, but none have really looked at this panel from a biomarker development 
point of view. Further investigations are however required to ascertain the exact role 
and mechanism of action of TACE in this disease area. Future prospective studies in 
clinical cohorts at varying degrees of MACE risk stratification are needed to fully assess 
TACE as a potential biomarker for CAD and MACE risk. This will be crucial for the future 
development of new personalised predictive tests and therapeutics that can improve 
patient clinical care pathways and prevent the high mortality rates associated with CAD 
(Figure 7). The rationale for investigating TACE inflammatory pathway is detailed in the 




On the other hand, recent advances in proteomics could enable the transition from the 
single marker to the multimarker approach. This will allow the identification of markers 
of CVD risk as well as markers to further stratify patients with established CVD (158).   
1.6 Hypothesis 
By exploring a large number of proteins from several inflammatory pathways involved 
in CVD in individuals at varying levels of CVD risk, it is hypothesised that it will be possible 
to discover multimarker panels that can identify individuals at risk of cardiovascular 
events and further stratify those people at very high risk of major adverse cardiovascular 
events. Specifically, this project hypothesises that by adding an increasing number of 
promising biomarkers to such a multimarker panel will improve the current CVD risk 
assessment tools. To test this hypothesis, first, the well-known inflammatory pathway 
involving tumour necrosis factor alpha converting enzyme (TACE) and tumour necrosis 
factor alpha (TNFα) is explored. Secondly, a proteomic approach is undertaken to 
uncover other known and novel markers of cardiovascular and MACE risk. 
1.7 Aims 
The aims of this present work are to: 
1.7.1 Evaluate the value of proteins from TNFα inflammatory 
pathway in cardiovascular disease (CVD) risk assessment and 
stratification  
By exploring a number of proteins that are part of the TNFα inflammatory pathway, it 




1.7.2 Investigate the value of a panel combining 10 inflammatory 
markers in CVD risk assessment 
Measuring circulating levels of 10 inflammatory proteins in participants at various levels 
of CVD risk could improve current CVD risk assessment. 
1.7.3 Determine whether a proteomic approach combining 184 
proteins could improve the current CVD risk assessment scores  
Exploring a large number of inflammatory proteins could highlight underlying biological 
and pathological CVD pathways that might be useful to include in multimarker panels 
for CVD risk assessment or might prove to be potential therapeutic targets.  
1.7.4 Explore whether potential proteins are useful in further 
stratifying very high risk CVD participants in terms of recurrent 
major adverse cardiovascular events (MACE) 
Since very high risk CVD individuals are at high risk of MACE, it could be useful to identify 




1.7.5 Assess whether candidate proteins for biomarker 
development are subject to experimental and technical 
variability  
In order to assess the value of a protein as a potential biomarker, levels could be 
evaluated in different experimental and technical conditions as a validation step before 
their validation in larger cohorts.  
 
 
Figure 7: TACE/TNFα pathway. TACE, once synthesised cleaves transmembrane TNFα 
(tmTNFα) releasing soluble TNFα (sTNFα). TACE is inhibited by Tissue Inhibitor of 
Metalloproteinase 3 (TIMP3). sTNFα binds to TNF receptor 1 (TNFR1) and 2 (TNFR2). TACE 
also cleaves TNFR1 and TNFR2 releasing their respective soluble forms, soluble TNFR1 
(sTNFR1) and soluble TNFR2 (sTNFR2). TACE: tumour necrosis factor alpha converting 
enzyme; TIMP3: Tissue Inhibitor of Metalloproteinase 3; tmTNFα: transmembrane tumour 
necrosis factor alfa; sTNFα: soluble tumour necrosis factor alfa; TNFR1: tumour necrosis 
factor alfa receptor 1; TNFR2: tumour necrosis factor alfa receptor; sTNFR1: soluble tumour 
necrosis factor alfa receptor 1; sTNFR2: soluble tumour necrosis factor alfa receptor 2; 



















Chapter 2  







2.1 Methods for participant recruitment  
The study was approved by the Office for Research Ethics Committees Northern Ireland 
(ORECNI). The ethics research reference number was 14/NI/0068. The study was 
conducted in accordance with the declaration of Helsinki and patients were recruited 
from November 2014 until March 2016. 
2.1.1 Participants recruited from Altnagelvin Area Hospital  
Participants were recruited consecutively from the catheterisation laboratory in 
Altnagelvin Area Hospital (cardiology unit (CCU) and day care unit (CDU)). Participants 
were consented prior to the blood sample collection and given the participant 
information sheet. A short questionnaire was completed which included the patient’s 
medical history, family history and lifestyle questions such as smoking, diet and exercise 
(Figure 1 and 2). Blood pressure was recorded at the time of consent. C reactive protein 
(CRP) and electrolytes levels were also measured on the day. Any missing information 
(such as medication history, blood test results and procedure outcome) was completed 
at a later stage by accessing the Northern Ireland Electronic Care Record (NIECR) with 
the help of cardiologists and cardiac research nurse (Figure 2). Recruited participants 
were identified as either acute coronary syndrome (ACS) or elective participants (ELEC) 
(Figure 1). ACS participants attended hospital either on the day or in the previous couple 
of days and were admitted for unstable angina (UA), non-ST segment elevation 
myocardial infarction (NSTEMI) or ST segment elevation myocardial infarction (STEMI) 
(Figure 1). ELEC participants attended the hospital for a scheduled cardiac angiogram to 
investigate a potential underlying coronary artery disease (CAD) behind their angina 




their medical history using the SCORE risk chart as per the European Society of 
Cardiology (ESC) guidelines. Refer to section 2.1.3. 
 
Figure 1: Participants with an Acute Coronary Syndrome (ACS) or admitted electively (ELEC) 
that took part in the study. ACS: Acute coronary syndrome; ECG: Electrocardiogram; PCI: 
percutaneous coronary intervention. 
 
 
Figure 2: Participants co-morbidities recorded in the questionnaire. ACS: Acute coronary 




2.1.2 Participants recruited among the Western Trust and Ulster 
University staff 
Participants were recruited via an email advertisement to the Western Trust and Ulster 
University staff across Northern Ireland. Interested participants were provided with 
participant information sheet and an appointment was arranged. After giving informed 
consent, a blood sample was collected followed by completion of the lifestyle 
questionnaire. Blood pressure was also recorded and CRP levels, total cholesterol and a 
full blood count were measured on the day. These participants were then stratified 
according to the ESC guidelines and a SCORE was assigned. 
2.1.3 Methods for scoring participants according to the SCORE 
risk chart (ESC guidelines) 
The European low risk Systematic COronary Risk Evaluation (SCORE) risk score chart was 
used to determine the 10-year risk of fatal CVD in low risk regions of Europe by gender, 
age, systolic blood pressure, total cholesterol and smoking status for all recruited 
individuals who were from Ireland. To include the effect of HDL cholesterol levels when 
calculating the SCORE risk, the online HeartScore system was used (heartscorre.org). 
Group1 were defined as very high risk participants (VHR) with a 10-year risk SCORE ≥10% 
risk of fatal CVD and had evidence of established CAD as per coronary angiography. VHR 
participants were subdivided in Acute Coronary Syndrome participants (ACS-VHR) and 
elective percutaneous coronary intervention participants (ELEC-VHR). Group 2 were 
identified as low, moderate and high risk participants referred to collectively as non-VHR 
with a 10-year risk SCORE <10% risk of fatal CVD.  Within the non-VHR category, low risk 




participants had a 10-year risk SCORE of ≥ 1% and <5% of fatal CVD and high risk (HR) 
participants had a SCORE of ≥5% and <10% of fatal CVD.  
The European low risk SCORE chart was used to determine the 10-year risk of fatal 
cardiovascular disease (CVD) in low risk regions of Europe by gender, age, systolic blood 
pressure, total cholesterol and smoking status for all recruited individuals who were 
from the UK and Ireland. To estimate a person’s 10-year risk of CVD death, the table 
corresponding to the individual’s gender, smoking status, and age was selected. Within 
this table the cell nearest to the individual’s blood pressure and total cholesterol was 
selected. In order to include the effect of HDL cholesterol and the effect of age when 
calculating the SCORE risk, the online HeartScore system was used (heartscorre.org). 
Participants with the following criteria were automatically considered at very high risk 
(VHR) (as per the ESC guidelines) (63) (Figure 3): 
 Documented CVD by invasive or non-invasive testing (such as coronary 
angiography, nuclear imaging, stress echocardiography, carotid plaque on 
ultrasound), previous myocardial infarction (MI), ACS, coronary revascularization 
[percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG)] 
and other arterial revascularization procedures, ischaemic stroke, peripheral 
artery disease (PAD). 
 Type 2 diabetes, participants with type 1 diabetes with target organ damage 
(such as microalbuminuria). 
 Moderate to severe chronic kidney disease [glomerular filtration rate (GFR) < 60 
mL/min/1.73 m2). 




High risk (HR) subjects were characterised with any of the following:  
 Markedly elevated single risk factors such as familial dyslipidaemias and severe 
hypertension.  
 A calculated SCORE ≥5% and <10% for 10-year risk of fatal CVD.  
Moderate risk (MR) subjects were considered to be at moderate risk when their SCORE 
was ≥1% and <5% at 10 years.  
The low risk (LR) category applied to individuals with SCORE < 1%. 
 




2.1.4 Methods for recruiting follow up participants 
A patient information sheet was posted to those that were already recruited and 
consented to a willingness to take part in future studies. These participants where 
contacted by phone after two weeks to assess their interest in volunteering to provide 
a follow up sample for the study. An appointment was scheduled for the interested 
participants. During this appointment, a blood sample was collected and the blood 
pressure was recorded. 
2.2 Methods for blood sample collection 
A total volume of 35 ml of blood was collected from all recruited participants (apart from 
the sub studies and the follow up participants). This volume was divided as follows 
(Figure 4): 
 3 x 8 ml of EDTA tubes for the research lab – VACUETTE K3E K3EDTA – 455036 
 1 x 4 ml of serum tube for the research lab – VACUETTE Z serum clot activator -  
454092 
 1 x 4 ml of EDTA tube for hospital lab (to measure the full blood count (FBC)) – 
VACUETTE K3E K3 EDTA – 454036 
 1 x 3.5 ml of serum separator tube (yellow cap) (to measure the cholesterol) – 
BD Vacutainer SSTTM II advance - 367956 
For the participants recruited from the catheterisation lab, blood was collected from the 
sheath inserted into the radial artery (or, on occasions, the femoral artery when the 
radial artery couldn’t be accessed). The arterial blood was collected straight into a 50-
ml syringe and immediately transferred into blood tubes using a 21 G syringe (BD 




Participants recruited among the Western Trust and Ulster University staff were 
received at the clinical translational research and innovation centre (C-TRIC). A 35 ml of 
venous blood was collected by a trained phlebotomist using a butterfly needle 
(VACUETTE safety blood collection set 21G x 3/4 ‘’ 0.9 x 19 mm – 450091) as well as a 
luer adapter (Greiner bio one luer adapter – 20G 16C05A) and a BD Vacutainer.  
For a subset of participants recruited from the catheterisation lab (n=39), venous blood 
and arterial blood was collected (a total of 40 ml was collected). This was to compare 
the effect of the sampling site on the studied markers. The venous blood was collected 
by a trained phlebotomist prior to the angiogram procedure using the same material 
mentioned above. 
For another subset of participants recruited from the catheterisation lab (n=6), blood 
was collected from different sampling sites by the consultant cardiologist (10 ml from 
each site): 
 Peripheral artery (PA) (radial or femoral artery) 
 Central vein (CV) (femoral vein) 
 Central coronary artery (CCA) 
 Culprit lesion (when present) 
 Coronary sinus 
 Post-balloon sample 
 Post-PCI sample 
 Post-heparin sample 
From the follow up participants (n=16), 8 ml of venous blood was collected by a trained 





Figure 4: Types and volumes of the blood samples collected from patients recruited 
from the catheterisation laboratory in Altnagelvin Area Hospital and from the hospital 
and Ulster University staff. CVD: Cardiovascular disease, HR: high risk, LR: low risk, MR: 
moderate risk, SCORE: Systematic COronary Risk Evaluation; risk, VHR: very high 
A saliva sample was also collected when possible from recruited participants, although 
not used in the current study but as part of a larger study. The saliva sample was taken 
using the Omnigene oral kit for collection of microbial RNA and DNA OM-505. The 
sample was left a room temperature for no longer than 3 weeks before aliquoting and 




2.3 Methods for spinning, aliquoting and storing blood 
samples 
After the blood samples were collected, the blood tubes were kept on ice (or at 4◦C) 
until processing. The blood was processed within 4 hours of collection. Plasma (from 2 
EDTA 8 ml tubes) and serum (4 ml) tubes were spun down at 2000 relative centrifugal 
force (RCF), at 4◦C for 15 minutes. Plasma and serum were then aliquoted into 500 ul 
aliquots and stored at -80◦C for further downstream applications. 
Buffy coat from both EDTA tubes (8 ml each) were collected and washed twice with 1X 
phosphate buffer saline (PBS). Once washed, one buffy coat was then resuspended 1 ml 
of RNAlater® Stabilization Solution (AM7020). RNAlater® RNA Stabilization Solution 
stabilises and protects cellular RNA in intact, unfrozen tissue samples, eliminating the 
need to immediately process tissue samples or to freeze samples in liquid nitrogen for 
later processing. Samples were then stored at -80◦C for further RNA extraction. The 
other washed buffy coat was suspended in 1 ml of M-PER™ Mammalian Protein 
Extraction Reagent (78501) and immediately placed on ice and then stored at -80◦C until 
further protein extraction. M-PER Mammalian Protein Extraction Reagent is a mild 
detergent lysis that extracts soluble proteins in non-denatured state. The remaining 8 
ml EDTA tube was stored as it is at -80◦C until further DNA extraction (whole blood tube). 





Figure 5: Processing of the blood tubes until further analysis. EDTA: 
Ethylenediaminetetraacetic acid; M-PER: Mammalian Protein Extraction Reagent; RCF: 
relative centrifugal force 
Sample aliquots were all stored into Sarstedt® boxes and were divided into a primary 
and a backup -80 alarmed freezers. A sample map was created for all the samples to 
track the sample location, the number of thaws (samples were thawed no more than 3 
times), the volume used, the volume left and the type of experiment that was performed 
on each aliquot. All samples were handled according to the Good Clinical Practice (GCP) 






Table 1: TACE, TNFR1, TNFR2 and TIMP3 protein levels measured in different types of 
samples 
Type of sample TACE sTNFR1 sTNFR2 TIMP3 
Arterial         
Venous         
Arterial and venous         
Different sampling 
sites 
        
Serum              
Timepoint 1         
Timepoint 2         
Spun down plasma      
Fresh plasma      
TACE protein levels were measured in arterial samples, venous samples, arterial and venous 
samples from the same patients, in different sampling sites, in the serum, on timepoint one and 
2, in plasma samples after being spun down, and in plasma samples collected on the day. 
TNFR1, TNFR2 and TIMP3 protein levels were measured in arterial samples, venous samples, 
arterial and venous samples from the same patients, in different sampling sites, on timepoint 
one and 2. TACE: Tumour necrosis factor alpha converting enzyme; TIMP3: Metalloproteinase 
inhibitor 3; TNFα: Tumour necrosis factor alpha; TNFR1: Tumour necrosis factor alpha receptor 
1; TNFR2: Tumour necrosis factor alpha receptor 2. 
 
2.4 Method for extracting proteins stored in M-PER™ 
Mammalian Protein Extraction Reagent (#78501) – 
ThermoFisher Scientific, (Illinois, USA) - in -80◦C 
This procedure was followed according to the manufacturer’s instructions. Frozen 
samples in M-PER® were slowly thawed on ice. The mixture was then shaken gently for 
10 minutes and the cell debris was removed by centrifugation at 15,000 RCF for 15 
minutes. The supernatant was then transferred to a new tube and immediately stored 
at -80◦C. 
Note: M-PER® Reagent does not contain protease inhibitors. The effect of adding a 




change the amount of proteins recovered and did not affect downstream applications 
such as the BCA assay used for protein quantification. 
Table 2: Different methods for proteins extractions and protein yield. 
Type of sample (MD013) Protein concentrations (BCA) (ug/ml) 
Proteins extracted after freezing down buffy coat 
Buffy coat + M-PER at -80◦C 14637.284 
Buffy coat + Protease inh. + MPER at -
80◦C 
16312.372 
Buffy coat + M-PER at -80◦ add protease 
inh. after thawing (before analysis) 
9594.396 
Proteins extracted from fresh buffy coat 
Fresh buffy coat + M-PER and extract 
proteins 
15009.334 
Fresh buffy coat + M-PER + protease inh. 
and extract proteins 
5217.474 
 
BCA: bicinchoninic acid assay; M-PER: Mammalian Protein Extraction Reagent; Protease inh.: 
protease inhibitor 
2.5 Method for quantifying proteins using the bicinchoninic 
acid (BCA) assay protein assay kit (23225) – Pierce Thermo 
Scientific, (Illinois, USA) 
BCA was performed according to the manufacturer’s instructions in a 96-well plate. 
Standards were prepared by diluting the contents of one Albumin Standard (BSA) 
ampoule into several clean vials and adding the appropriate volume of diluent (PBS was 
used in this case). The volume of working reagent needed was determined per the 
number of samples to quantify using the following formula: 
(number of standards + number of samples) × (number of replicates) × (200 ul of working 
reagent) = total volume working reagent (WR) required 
The working reagent (WR) was then prepared by mixing 50 parts of BCA Reagent A with 




used, 20 ul of PBS was mixed with 5 ul of standard or sample and then 200 ul or working 
reagent was added to each well. The plate was placed on a plate shaker for 30 seconds 
and then incubated at 37◦C for 30 minutes. The plate was then read at 562 nm. 
For creating the standard curve and calculating the sample concentrations, the following 
software was used: https://www.myassays.com/ 
Only a coefficient of variation (CV) of less than 20% was accepted between replicates. If 
one replicate was out of this range, the remaining duplicates were used for the analysis. 
Samples with more than one replicate out of range were analysed again. A new standard 
curve was made for each plate. 
Note: The coefficient variation (CV) is the ratio of the standard deviation to the mean: 
CV = st.dev/mean  
Note: Samples with a protein concentration out of the range of the standard curve 
required a 10-fold dilution. The calculated concentration was then multiplied by 10 in 
order to get the final concentration.  
2.6 TACE ELISA 
2.6.1 Method for measuring tumour factor necrosis alpha 
converting enzyme (TACE) protein levels in the plasma by ELISA 
- Human TACE ELISA Kit - RAB0003 SIGMA, (Missouri, USA) 
TACE ELISA was performed according to the manufacturer’s instructions. Samples were 
diluted 2-fold in assay/sample diluent buffer (buffer C - item L - RABELADC-30ML); (200 
ul of sample + 200 ul of diluent). The 8 standards were prepared by serial dilution in the 




buffer for the lowest standard concentration (5000 pg/ml; 2500 pg/ml; 1250 pg/ml; 625 
pg/ml; 312.5 pg/ml; 156.3 pg/ml; 78.15 pg/ml; 0 pg/ml). All reagents were at room 
temperature before starting the experiment (which was between 22◦ and 28◦C). 
Samples were run in triplicate and 100 ul of diluted sample or prepared standard were 
added per well. Wells were covered and incubated for 2.5 hours at room temperature 
(between 22◦C and 28◦C) with gentle shaking. The solution was discarded and the plate 
was washed 4 times using the 1X prepared wash buffer (initially at 20X – diluted with 
deionised water) and blotted against paper towels to remove any remaining wash 
buffer. A volume of 100 ul of 1X prepared biotinylated detection antibody (diluted 80-
fold with prepared diluent buffer B - Item E1 - RABELADB-15ML) was added to each well 
and the plate was incubated for one hour at room temperature with gentle shaking. 
The solution was discarded and the plate was washed 4 times using the 1X prepared 
wash buffer and blotted against paper towels to remove any remaining wash buffer. A 
volume of 100 ul of 1X prepared HRP-Streptavidin solution (diluted 200-fold with 
prepared diluent buffer B –Item E1 - RABELADB-15ML) was added to each well and the 
plate was incubated for 45 minutes at room temperature with gentle shaking. The 
solution was discarded and the plate was washed 4 times using the 1X prepared wash 
buffer and blotted against paper towels to remove any remaining wash buffer. A volume 
of 100 ul of ELISA Colorimetric TMB Reagent (Item H - RABTMB3) was added to each well 
and the plate was Incubated for 30 minutes at room temperature in the dark with gentle 
shaking. A volume of 50 ul of Stop Solution (Item I - RABSTOP3) was added to each well 
and the plate was read immediately at 450 nm.  
For the result analysis, the mean absorbance was calculated for each set of triplicate 




parametric logistic regression curve. The sample concentration was then calculated 
after multiplying by the dilution factor. For creating the standard curve and calculating 
the sample concentrations, the following website was used: 
https://www.myassays.com/. Only a coefficient of variation (CV) of less than 20% was 
accepted between replicates. If one replicate was out of this range, the remaining 
duplicates were used for the analysis. Samples with more than one replicate out of range 
were analysed again. A new standard curve was made for each plate. 
Note: When detecting low concentrations between 200 and 0 pg/ml, the CVs were 
higher than usual. The sensitivity of the TACE ELISA kit provided by the manufacturer 
was 50 pg/ml.  
TACE ELISA inter-assay CV = 19.68 % 
To calculate the inter assay CV (%), a sample was measured on two occasions on 
different plates and an average mean was calculated on each of those occasions. The 
standard deviation (SD) was calculated from those means followed by the CV (SD divided 
by the average of both measurements). The intra-assay CV was then calculated by 





Table 3: Inter-assay coefficient of variation (CV) of TACE ELISA for the measurement of 
TACE plasma protein levels 
 
TACE ELISA intra-assay CV = 11.91 % 
To calculate the intra assay CV (%), samples were analysed in triplicates, the mean 
concentration was calculated for each sample, standard deviation (SD) was calculated. 
The CV was then calculated by dividing the SD by the mean and then converted into 
percentage. The inter-assay CV was calculated by averaging the individually calculated 

























VHR-C-003 8571 208 2121 468 5346 4560.839 0.853131 85.31311
VHR-C-004 9656 205 7361 468 8508.5 1622.81 0.190728 19.07281
VHR-C-057 1607 281 1198 15 1402.5 289.2067 0.206208 20.6208
VHR-C-067 313.4 21 541.4 531 427.4 161.2203 0.377212 37.72119
VHR-C-068 473.9 20 433 530 453.45 28.92067 0.063779 6.377918
VHR-C-069 2398 20 2604 530 2501 145.664 0.058242 5.82423
VHR-C-070 3389 20 3763 530 3576 264.4579 0.073954 7.395356
VHR-C-071 1568 17 1922 527 1745 250.3158 0.143447 14.34475
VHR-C-121 2992 24 2881 155 2936.5 78.48885 0.026729 2.672871
VHR-C-143 475 15 493.4 128 484.2 13.01076 0.026871 2.687064
VHR-C-150 1575 36 1027 373 1301 387.4945 0.297844 29.78436
VHR-C-183 512.8 10 644 78 578.4 92.77241 0.160395 16.03949
VHR-C-184 1796 10 1807 78 1801.5 7.778175 0.004318 0.431761
VHR-C-185 131.9 10 234.4 78 183.15 72.47845 0.395733 39.57327
VHR-C-186 1847 10 2555 78 2201 500.6316 0.227456 22.74564
MD-001 3140 3342 3241 142.8356 0.044071 4.407145




Table 4: Intra-assay coefficient of variation (CV) of TACE ELISA for the measurement of 
TACE plasma protein levels 
 
Missing values refer to TACE plasma protein levels that were below the limit of detection 
of the assay. 
Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%)
VHR-C-001 8.6 VHR-C-026 - VHR-C-051 - VHR-C-076 5.6 VHR-C-101 - VHR-C-126 - VHR-C-151 -
VHR-C-002 - VHR-C-027 - VHR-C-052 - VHR-C-077 20.2 VHR-C-102 - VHR-C-127 - VHR-C-152 -
VHR-C-003 5.8 VHR-C-028 - VHR-C-053 8.37 VHR-C-078 - VHR-C-103 3.48 VHR-C-128 - VHR-C-153 37.4
VHR-C-004 1.37 VHR-C-029 - VHR-C-054 10.74887 VHR-C-079 22.70769 VHR-C-104 4.81 VHR-C-129 4.5 VHR-C-154 0.922
VHR-C-005 - VHR-C-030 4.37 VHR-C-055 - VHR-C-080 - VHR-C-105 - VHR-C-130 6.899093 VHR-C-155 4.34
VHR-C-006 - VHR-C-031 5.22 VHR-C-056 3.452825 VHR-C-081 - VHR-C-106 - VHR-C-131 - VHR-C-156 -
VHR-C-007 - VHR-C-032 - VHR-C-057 2.96 VHR-C-082 2.06 VHR-C-107 - VHR-C-132 - VHR-C-157 0.477
VHR-C-008 - VHR-C-033 - VHR-C-058 17.2 VHR-C-083 7.65 VHR-C-108 - VHR-C-133 24.68264 VHR-C-158 -
VHR-C-009 - VHR-C-034 - VHR-C-059 2.79 VHR-C-084 - VHR-C-109 - VHR-C-134 - VHR-C-159 -
VHR-C-010 11.8 VHR-C-035 2.01 VHR-C-060 - VHR-C-085 - VHR-C-110 45.8 VHR-C-135 1.99 VHR-C-160 -
VHR-C-011 24.8 VHR-C-036 - VHR-C-061 - VHR-C-086 - VHR-C-111 12.1 VHR-C-136 9.35 VHR-C-161 29.8
VHR-C-012 - VHR-C-037 - VHR-C-062 - VHR-C-087 - VHR-C-112 - VHR-C-137 - VHR-C-162 21.28755
VHR-C-013 - VHR-C-038 - VHR-C-063 - VHR-C-088 3.75 VHR-C-113 3.87 VHR-C-138 3.97 VHR-C-163 10.90123
VHR-C-014 - VHR-C-039 - VHR-C-064 36.2 VHR-C-089 - VHR-C-114 23.2 VHR-C-139 - VHR-C-164 -
VHR-C-015 - VHR-C-040 - VHR-C-065 - VHR-C-090 - VHR-C-115 13.4 VHR-C-140 - VHR-C-165 -
VHR-C-016 10.9 VHR-C-041 2.75 VHR-C-066 - VHR-C-091 - VHR-C-116 11.15664 VHR-C-141 20 VHR-C-166 -
VHR-C-017 - VHR-C-042 - VHR-C-067 12.2 VHR-C-092 - VHR-C-117 - VHR-C-142 19.4 VHR-C-167 30
VHR-C-018 3.77 VHR-C-043 - VHR-C-068 4.71 VHR-C-093 - VHR-C-118 19.8 VHR-C-143 15.4 VHR-C-168 -
VHR-C-019 - VHR-C-044 16.3 VHR-C-069 3.41 VHR-C-094 6.3 VHR-C-119 5.18 VHR-C-144 - VHR-C-169 18.2
VHR-C-020 - VHR-C-045 - VHR-C-070 3.64 VHR-C-095 - VHR-C-120 - VHR-C-145 - VHR-C-170 -
VHR-C-021 7.83 VHR-C-046 23.4 VHR-C-071 1.17 VHR-C-096 - VHR-C-121 1.35 VHR-C-146 35.9 VHR-C-171 -
VHR-C-022 - VHR-C-047 - VHR-C-072 41.3 VHR-C-097 - VHR-C-122 - VHR-C-147 43.9 VHR-C-172 -
VHR-C-023 - VHR-C-048 1.28 VHR-C-073 - VHR-C-098 - VHR-C-123 22.6 VHR-C-148 - VHR-C-173 -
VHR-C-024 - VHR-C-049 5.37 VHR-C-074 - VHR-C-099 - VHR-C-124 - VHR-C-149 2.82 VHR-C-174 -
VHR-C-025 - VHR-C-050 - VHR-C-075 6.96 VHR-C-100 - VHR-C-125 - VHR-C-150 6.33 VHR-C-175 -
Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%)
VHR-C-176 - VHR-C-201 7.71 LR-1 10.5 LR-26 - LR-51 - LR-76 30 No-CAD 1 -
VHR-C-177 24.6 VHR-C-202 - LR-2 7.09 LR-27 6.37 LR-52 1.27 LR-77 6.79 No-CAD 2 -
VHR-C-178 - VHR-C-203 - LR-3 2.69 LR-28 - LR-53 7.96 LR-78 5.27 No-CAD 3 -
VHR-C-179 - VHR-C-204 17.7 LR-4 27.3 LR-29 1.51 LR-54 24.8 LR-79 - No-CAD 4 2.86
VHR-C-180 22.7 VHR-C-205 3.07 LR-5 - LR-30 - LR-55 - LR-80 9.67 No-CAD 5 5.02
VHR-C-181 - VHR-C-206 - LR-6 - LR-31 - LR-56 - LR-81 6.54 No-CAD 6 -
VHR-C-182 4.411842 VHR-C-207 - LR-7 - LR-32 54.2 LR-57 16.1 LR-82 3.09 No-CAD 7 -
VHR-C-183 6.8 VHR-C-208 - LR-8 - LR-33 18.2 LR-58 - LR-83 - No-CAD 8 22.94245
VHR-C-184 4.07 VHR-C-209 2.35 LR-9 5.52 LR-34 3.15 LR-59 11.5 LR-84 2.31 No-CAD 9 -
VHR-C-185 - VHR-C-210 5.45 LR-10 - LR-35 - LR-60 9.02 LR-85 16.3 No-CAD 10 19.7
VHR-C-186 3.14 VHR-C-211 - LR-11 - LR-36 6.15 LR-61 9.99 LR-86 - No-CAD 11 -
VHR-C-187 - VHR-C-212 3.28 LR-12 - LR-37 6.57 LR-62 8.29 LR-87 4.65 No-CAD 12 -
VHR-C-188 - VHR-C-213 39.6 LR-13 12.9 LR-38 - LR-63 18.3 LR-88 - No-CAD 13 0.898
VHR-C-189 8.6 VHR-C-214 23 LR-14 1.49 LR-39 - LR-64 29.6 LR-89 - No-CAD 14 21.4
VHR-C-190 - VHR-C-215 - LR-15 1.31 LR-40 - LR-65 - LR-90 - No-CAD 15 -
VHR-C-191 11.7 VHR-C-216 1.69 LR-16 6.71 LR-41 21.1 LR-66 1.45 LR-91 - No-CAD 16 -
VHR-C-192 12.2 VHR-C-217 - LR-17 15 LR-42 - LR-67 - LR-92 1.7 No-CAD 17 -
VHR-C-193 - VHR-C-218 - LR-18 2.18 LR-43 - LR-68 4.77 LR-93 14.5 No-CAD 18 5.58
VHR-C-194 - VHR-C-219 - LR-19 - LR-44 42.6 LR-69 35.4 LR-94 3.89 No-CAD 19 -
VHR-C-195 34.9 VHR-C-220 2.21 LR-20 - LR-45 - LR-70 - LR-95 7.63 No-CAD 20 7.43
VHR-C-196 - VHR-C-221 3.52 LR-21 - LR-46 - LR-71 11.6 LR-96 2.8 No-CAD 21 -
VHR-C-197 13.8 LR-22 11 LR-47 5.2 LR-72 3.62 LR-97 5.01 No-CAD 22 0.864
VHR-C-198 - LR-23 - LR-48 - LR-73 1.45 LR-98 0.318 No-CAD 23 38.9
VHR-C-199 - LR-24 - LR-49 32 LR-74 49.3 LR-99 1.42
VHR-C-200 - LR-25 - LR-50 - LR-75 5.38 LR-100 1.46




2.6.2 Method for measuring tumour factor necrosis alpha 
converting enzyme (TACE) protein levels in preparations of 
extracted proteins by ELISA - Human TACE ELISA Kit - RAB0003 
SIGMA, (Missouri, USA) 
Total protein levels measured by BCA in samples stored in MPER® were normalised. A 
volume of extracted protein was used to obtain a final concentration of 5000 ug/ml of 
total proteins (5 ug/ul) and diluted in assay/sample diluent buffer (Buffer C) accordingly. 
The following formula was used: 
Initial Concentration x Initial Volume = Final concentration x Final volume 
Concentration calculated by the BCA assay x volume to use = 5 ug/ul x 400 ul 
Volume to use (ul) = 
5 ug/ul x 400 ul
Concentration calculated by the BCA assay 
 
The total volume used for the ELISA was 400 ul and samples were run in triplicates (100 
ul per well). Samples were not diluted in that case and the result was relative to the 
same amount of total proteins used for all the samples (5000 ug/ml or 5 ug/ul). 
The TACE ELISA procedure was followed as in section 2.6.1. 
Table 5: Intra-assay coefficient of variation (CV) of TACE ELISA for the measurement of 
cell membrane bound TACE protein levels 
 
Patient ID %CV Patient ID %CV Patient ID %CV Patient ID %CV
VHR-C-001 4.02 VHR-C-006 3.47 VHR-C-033 n/a LR-3 4.66
VHR-C-002 3.56 VHR-C-011 2.41 VHR-C-034 1.07 LR-4 3.64
VHR-C-003 0.199 VHR-C-012 1.12 VHR-C-056 3.15 LR-5 1.06
VHR-C-005 1.33 VHR-C-013 6.45 VHR-C-048 29.2 LR-6 7.59
VHR-C-008 1.37 VHR-C-014 22.3 VHR-C-055 13.2 LR-7 7.67
VHR-C-009 4.34 VHR-C-016 2.1 LR-12 6.07 LR-8 28.2
VHR-C-010 4.94 VHR-C-017 7.06 LR-13 9.87 LR-9 10.4
VHR-C-015 3.61 VHR-C-018 8.68 LR-14 16.7 LR-10 5.68
VHR-C-045 1.43 VHR-C-022 0.264 LR-15 3.74 LR-11 20.1
VHR-C-046 4.79 VHR-C-023 4.89 LR-16 4.03 LR-19 6.27
VHR-C-032 3.16 LR-2 48.4 LR-18 2.38 LR-20 26.7




2.7 Soluble TNFR1 ELISA 
2.7.1 Method for measuring soluble tumour necrosis factor 
receptor 1 sTNFR1/TNFRSF1A protein levels in the plasma by 
ELISA – Human TNF RI/TNFRSF1A Immunoassay R&D - DRT100 
(Minneapolis, USA) 
TNFR1 ELISA was performed according to the manufacturer’s instructions. Plasma 
samples were diluted 10-fold in Calibrator Diluent RD6O - 895120 (80 ul + 720 ul). The 8 
standards were prepared by serial dilution in the same Calibrator Diluent RD6O with 500 
pg/ml as the highest standard and only using the calibrator diluent for the lowest 
standard concentration (500 pg/ml; 250 pg/ml; 125 pg/ml; 62.5 pg/ml; 31.2 pg/ml; 15.6 
pg/ml; 7.8 pg/ml; 0 pg/ml). All reagents were at room temperature before starting the 
experiment (which was between 22◦ and 28◦C). 
A volume of 50 ul of Assay Diluent HD1-7 (895160) was added to each well. Samples 
were run in triplicate and 200 ul of diluted sample or prepared standard were added per 
well. Wells were covered and incubated for 2 hours at room temperature (which was 
between 22◦C and 28◦C). Wells were washed three times with the prepared wash buffer 
(20 ml of concentrated wash buffer with 480 ml of deionised water) and the plate was 
blotted against paper towels to remove any remaining wash buffer. A volume of 200 μL 
of sTNFRI Conjugate (890118) was added to each well. Wells were covered with a new 
adhesive strip and the plate was incubated for 2 hours at room temperature. Wells were 
washed three times with the prepared wash buffer and blot plate against paper towels 
to remove any remaining wash buffer. A volume of 200 μL of prepared Substrate 




(895001). The plate was incubated for 20 minutes at room temperature and protected 
from light. 
A volume of 50 μL of Stop Solution (895032) was added to each well and the plate was 
gently tapped to ensure thorough mixing. The optical density of each well was 
determined within 30 minutes, using a microplate reader set to 450 nm with a 
wavelength correction set to 540 nm. For result analysis, a wavelength correction was 
made by subtracting all the readings at 540 nm from the readings at 450 nm. This 
subtraction corrected for optical imperfections in the plate. The average zero standard 
optical density was subtracted from all the readings. Then, the triplicate readings were 
averaged for each standard and sample.  
A standard curve was created from the standards readings using a 4-parametric logistic 
regression curve. The sample concentration was then calculated after multiplying by the 
dilution factor. For creating the standard curve and calculating the sample 
concentrations, the following website was used: https://www.myassays.com/. The 
average of the minimum detectable concentration provided by the ELISA kit was 0.77 
pg/mL. Only a coefficient of variation (CV) of less than 20% was accepted between 
replicates. If one replicate was out of this range, the remaining duplicates were used for 
the analysis. Samples with more than one replicate out of range were analysed again. 
TNFR1 ELISA intra-assay CV = 4.2 % 






Table 6: Inter-assay and intra-assay coefficient of variation (CV) of TNFR1 ELISA for 
the measurement of TNFR1 plasma protein levels  
 
 
Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%)
VHR-C-001 10.8 VHR-C-026 1.77 VHR-C-051 2.29 VHR-C-076 2.04 VHR-C-101 5.98 VHR-C-126 2.17 VHR-C-151 2.97
VHR-C-002 5.03 VHR-C-027 2.79 VHR-C-052 1.97 VHR-C-077 2.13 VHR-C-102 10.9 VHR-C-127 7.32 VHR-C-152 3.99
VHR-C-003 1.76 VHR-C-028 2.66 VHR-C-053 3.41 VHR-C-078 7.87 VHR-C-103 2.97 VHR-C-128 4.45 VHR-C-153 5.9
VHR-C-004 2.92 VHR-C-029 2.63 VHR-C-054 8 VHR-C-079 4.19 VHR-C-104 0.666 VHR-C-129 6.25 VHR-C-154 4.99
VHR-C-005 5.18 VHR-C-030 9.47 VHR-C-055 3.89 VHR-C-080 2.22 VHR-C-105 11.5 VHR-C-130 5.77 VHR-C-155 0.915
VHR-C-006 5.12 VHR-C-031 2.76 VHR-C-056 3.7 VHR-C-081 5.03 VHR-C-106 1.82 VHR-C-131 4.56 VHR-C-156 5.39
VHR-C-007 1.87 VHR-C-032 4.04 VHR-C-057 3.61 VHR-C-082 10.9 VHR-C-107 3.83 VHR-C-132 3.35 VHR-C-157 6.94
VHR-C-008 0.747 VHR-C-033 7.72 VHR-C-058 2.69 VHR-C-083 2.64 VHR-C-108 2.02 VHR-C-133 3.63 VHR-C-158 5.29
VHR-C-009 4.14 VHR-C-034 0.921 VHR-C-059 2.05 VHR-C-084 2.97 VHR-C-109 7.55 VHR-C-134 2.44 VHR-C-159 1.11
VHR-C-010 7.63 VHR-C-035 1.54 VHR-C-060 1.21 VHR-C-085 2.9 VHR-C-110 3.17 VHR-C-135 2.08 VHR-C-160 1.59
VHR-C-011 2.07 VHR-C-036 3.29 VHR-C-061 2.26 VHR-C-086 2.31 VHR-C-111 2.9 VHR-C-136 2.5 VHR-C-161 3.38
VHR-C-012 2.74 VHR-C-037 8.39 VHR-C-062 2.18 VHR-C-087 4.78 VHR-C-112 1.4 VHR-C-137 4 VHR-C-162 2.51
VHR-C-013 4.07 VHR-C-038 2.11 VHR-C-063 3.63 VHR-C-088 1.08 VHR-C-113 2 VHR-C-138 3.03 VHR-C-163 1.98
VHR-C-014 8.36 VHR-C-039 1.86 VHR-C-064 6.96 VHR-C-089 1.15 VHR-C-114 0.182 VHR-C-139 4.17 VHR-C-164 1.22
VHR-C-015 7.84 VHR-C-040 4.39 VHR-C-065 6.74 VHR-C-090 4.9 VHR-C-115 1.57 VHR-C-140 8.46 VHR-C-165 4.14
VHR-C-016 9.93 VHR-C-041 0.15 VHR-C-066 5.84 VHR-C-091 4.16 VHR-C-116 4.25 VHR-C-141 1.18 VHR-C-166 4.12
VHR-C-017 4.47 VHR-C-042 1.81 VHR-C-067 0.935 VHR-C-092 5.42 VHR-C-117 1.19 VHR-C-142 4.22 VHR-C-167 0.422
VHR-C-018 5.52 VHR-C-043 1.71 VHR-C-068 4.37 VHR-C-093 1.17 VHR-C-118 7.6 VHR-C-143 6.18 VHR-C-168 3.05
VHR-C-019 9.11 VHR-C-044 3.9 VHR-C-069 7.74 VHR-C-094 1.48 VHR-C-119 6 VHR-C-144 3.67 VHR-C-169 3.58
VHR-C-020 3.07 VHR-C-045 1.8 VHR-C-070 6.17 VHR-C-095 5.38 VHR-C-120 3.64 VHR-C-145 3.51 VHR-C-170 3.2
VHR-C-021 5.12 VHR-C-046 3.71 VHR-C-071 1.73 VHR-C-096 4.46 VHR-C-121 7.15 VHR-C-146 6.03 VHR-C-171 2
VHR-C-022 8.69 VHR-C-047 3.65 VHR-C-072 1.08 VHR-C-097 3.94 VHR-C-122 2.64 VHR-C-147 2.61 VHR-C-172 1.49
VHR-C-023 3.72 VHR-C-048 4.44 VHR-C-073 4.66 VHR-C-098 9.76 VHR-C-123 2.55 VHR-C-148 5.65 VHR-C-173 0.338
VHR-C-024 3.42 VHR-C-049 4.63 VHR-C-074 6.6 VHR-C-099 8.35 VHR-C-124 1.24 VHR-C-149 3 VHR-C-174 1.95
VHR-C-025 1.8 VHR-C-050 0.726 VHR-C-075 6.07 VHR-C-100 5.3 VHR-C-125 12.5 VHR-C-150 3.47 VHR-C-175 1.5
Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%)
VHR-C-176 1.94 VHR-C-201 1.87 LR-1 6.67 LR-26 2.1 LR-51 5.9 LR-76 9.25 No-CAD 1 2.78
VHR-C-177 2.58 VHR-C-202 1.2 LR-2 12.6 LR-27 0.407 LR-52 3.33 LR-77 0.231 No-CAD 2 0.53
VHR-C-178 6.66 VHR-C-203 6.3 LR-3 2.86 LR-28 2.61 LR-53 7.01 LR-78 2.72 No-CAD 3 2.42
VHR-C-179 3.9 VHR-C-204 6.03 LR-4 5.52 LR-29 0.565 LR-54 5.13 LR-79 3.88 No-CAD 4 0.782
VHR-C-180 0.947 VHR-C-205 3.89 LR-5 1.47 LR-30 6.11 LR-55 16.2 LR-80 2.5 No-CAD 5 5.2
VHR-C-181 3.07 VHR-C-206 2.74 LR-6 0.767 LR-31 1.41 LR-56 10.8 LR-81 5.59 No-CAD 6 2.49
VHR-C-182 2.81 VHR-C-207 5.15 LR-7 2.96 LR-32 5.09 LR-57 7.67 LR-82 0.175 No-CAD 7 1.02
VHR-C-183 3.82 VHR-C-208 0.335 LR-8 4.12 LR-33 2.92 LR-58 1.76 LR-83 3 No-CAD 8 7.64
VHR-C-184 2.42 VHR-C-209 2.12 LR-9 8.18 LR-34 8.33 LR-59 4.19 LR-84 2.64 No-CAD 9 1.32
VHR-C-185 3.35 VHR-C-210 7.3 LR-10 4.28 LR-35 6.43 LR-60 1.28 LR-85 2.39 No-CAD 10 9.34
VHR-C-186 0.993 VHR-C-211 4.12 LR-11 2.15 LR-36 2.62 LR-61 5.38 LR-86 1.64 No-CAD 11 1.24
VHR-C-187 1.31 VHR-C-212 3.28 LR-12 4.89 LR-37 2.84 LR-62 5.92 LR-87 4.5 No-CAD 12 4.1
VHR-C-188 4.04 VHR-C-213 3.55 LR-13 2.65 LR-38 3.86 LR-63 5.37 LR-88 8.01 No-CAD 13 1.43
VHR-C-189 2.9 VHR-C-214 3.97 LR-14 3.12 LR-39 1.89 LR-64 9.88 LR-89 13.6 No-CAD 14 1.26
VHR-C-190 2.97 VHR-C-215 9.56 LR-15 0.953 LR-40 9.72 LR-65 5.56 LR-90 5.36 No-CAD 15 14.7
VHR-C-191 4.92 VHR-C-216 6.66 LR-16 1.96 LR-41 8.16 LR-66 3.62 LR-91 7.34 No-CAD 16 5.54
VHR-C-192 2.83 VHR-C-217 10.3 LR-17 1.26 LR-42 11.8 LR-67 5 LR-92 7.21 No-CAD 17 5.29
VHR-C-193 5.08 VHR-C-218 1.76 LR-18 6.89 LR-43 5.02 LR-68 3.74 LR-93 22 No-CAD 18 11.9
VHR-C-194 4.52 VHR-C-219 6.5 LR-19 1.23 LR-44 7 LR-69 8.13 LR-94 0.969 No-CAD 19 1.35
VHR-C-195 1.46 VHR-C-220 5.61 LR-20 3.41 LR-45 2.66 LR-70 7.06 LR-95 9.23 No-CAD 20 3.21
VHR-C-196 0.84 VHR-C-221 4.65 LR-21 0.4 LR-46 5.9 LR-71 3.83 LR-96 2.84 No-CAD 21 1.83
VHR-C-197 3.99 LR-22 0.73 LR-47 4.82 LR-72 2.81 LR-97 2.86 No-CAD 22 6.32
VHR-C-198 1.29 LR-23 4.65 LR-48 6.36 LR-73 3.93 LR-98 0.449 No-CAD 23 3.01
VHR-C-199 5.81 LR-24 3.51 LR-49 3.38 LR-74 8.27 LR-99 2.13
VHR-C-200 2.49 LR-25 3.23 LR-50 5.53 LR-75 8.05 LR-100 3.02











CV (%) of Means
VHR-C-084 3005 2.97 3583 4.98 3294 408.7077 12.40764176





2.7.2 Method for measuring soluble tumour necrosis factor 
receptor 1 sTNFR1/TNFRSF1A protein levels in preparations of 
extracted proteins by ELISA - Human TNF RI/TNFRSF1A 
Immunoassay R&D - DRT100 (Minneapolis, USA) 
Total protein levels measured by BCA in samples stored in MPER® were normalised. A 
volume of extracted protein was used to obtain a final concentration of 5000 ug/ml of 
total proteins (5 ug/ul) and diluted in Calibrator Diluent RD6O accordingly. The 
following formula was used: 
Initial Concentration x Initial Volume = Final concentration x Final volume 
Concentration calculated by the BCA assay x volume to use = 5 ug/ul x 400 ul 
Volume to use (ul) = 
5 ug/ul x 400 ul
Concentration calculated by the BCA assay 
 
The volume was made up to 800 ul using the Calibrator Diluent RD6O and samples 
were run in triplicates (200 ul per well). Samples were not diluted in that case and the 
result was relative to the same amount of proteins used for all the samples (5000 
ug/ml or 5 ug/ul). The TNFR1 ELISA procedure was followed as in section 2.7.1. 
Table 7: Intra-assay coefficient of variation (CV) of TNFR1 ELISA for the measurement 
of cell membrane bound TNFR1 protein levels  
 
Sample ID CV(%) Sample ID CV(%)
VHR-C-015 1.61 LR-8 1.35
VHR-C-016 1.72 LR-9 10.3
VHR-C-018 5.84 LR-10 7.61
VHR-C-011 10.5 LR-11 9.44
VHR-C-012 4.36 LR-12 8.75
VHR-C-013 5.98 LR-13 5.08
VHR-C-014 7.93 LR-14 8.2




2.8 Soluble TNFR2 ELISA 
2.8.1 Method for measuring soluble tumour necrosis factor 
receptor 2 sTNFR2/TNFRSF1B in the plasma by ELISA – Human 
TNF RII/TNFRSF1B Immunoassay R&D - DRT200 (Minneapolis, 
USA) 
TNFR2 ELISA was performed according to the manufacturer’s instructions. Plasma 
samples were diluted 10-fold in Calibrator Diluent RD6O - 895120 (80 ul + 720 ul). The 
8 standards were prepared by serial dilution in the same Calibrator Diluent RD6O with 
500 pg/ml as the highest standard and only using the calibrator diluent for the lowest 
standard concentration (500 pg/ml; 250 pg/ml; 125 pg/ml; 62.5 pg/ml; 31.2 pg/ml; 
15.6 pg/ml; 7.8 pg/ml; 0 pg/ml). 
A volume of 50 ul of Assay Diluent RD1-6 (895158) was added to each well. Samples 
were run in triplicate and 200 ul of diluted sample or prepared standard were added 
per well. Wells were covered and incubated for 2 hours at room temperature. Wells 
were washed three times with the prepared wash buffer (20 ml of concentrated wash 
buffer with 480 ml of deionised water) and the plate blotted against paper towels to 
remove any remaining wash buffer. A volume of 200 μL of sTNFRII Conjugate (890122) 
was added to each well. Wells were covered with a new adhesive strip and the plate 
was incubated for 2 hours at room temperature. Wells were washed three times with 
the prepared wash buffer and blot plate against paper towels to remove any remaining 
wash buffer. A volume of 200 uL of prepared Substrate Solution to each well (10 ml of 
color reagent A (895000) + 10 ml of color reagent B (895001). The plate was incubated 




Stop Solution (895032) was added to each well and the plate was gently tapped to 
ensure thorough mixing. The optical density of each well was determined within 30 
minutes, using a microplate reader set to 450 nm with a wavelength correction set to 
540 nm. For result analysis, a wavelength correction was made by subtracting all the 
readings at 540 nm from the readings at 450 nm. This subtraction corrected for optical 
imperfections in the plate. The average zero standard optical density was subtracted 
from all the readings. Then, the triplicate readings were averaged for each standard 
and sample. A standard curve was created from the standards readings using a 4-
parametric logistic regression curve. The sample concentration was then calculated 
after multiplying by the dilution factor. For creating the standard curve and calculating 
the sample concentrations, the following website was used: 
https://www.myassays.com/.  The average of the minimum detectable concentration 
provided by the kit was 0.6 pg/mL. Only a coefficient of variation (CV) of less than 20% 
was accepted between replicates. If one replicate was out of this range, the remaining 
duplicates were used for the analysis. Samples with more than one replicate out of 
range were analysed again. A new standard curve was made for each plate. 
TNFR2 ELISA intra-assay CV = 4.2 % 











Table 8: Inter-assay and intra-assay coefficient of variation (CV) of TNFR2 ELISA for 
the measurement of TNFR2 plasma protein levels  
 
 
Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%)
VHR-C-001 3.09 VHR-C-026 9.55 VHR-C-051 1.09 VHR-C-076 0.513 VHR-C-101 2.1 VHR-C-126 1.96 VHR-C-151 2.83
VHR-C-002 5.13 VHR-C-027 2.43 VHR-C-052 6 VHR-C-077 2.31 VHR-C-102 3.4 VHR-C-127 2.79 VHR-C-152 5.49
VHR-C-003 3.35 VHR-C-028 9.99 VHR-C-053 3.02 VHR-C-078 4.42 VHR-C-103 3.49 VHR-C-128 3.99 VHR-C-153 0.663
VHR-C-004 3.32 VHR-C-029 0.511 VHR-C-054 3.41 VHR-C-079 0.738 VHR-C-104 3.74 VHR-C-129 2.54 VHR-C-154 2.64
VHR-C-005 1.83 VHR-C-030 2.63 VHR-C-055 4.18 VHR-C-080 4.33 VHR-C-105 3.33 VHR-C-130 5.12 VHR-C-155 0.796
VHR-C-006 0.811 VHR-C-031 2.45 VHR-C-056 1.49 VHR-C-081 4.21 VHR-C-106 6.64 VHR-C-131 7.66 VHR-C-156 8.29
VHR-C-007 9.28 VHR-C-032 0.92 VHR-C-057 1.65 VHR-C-082 4.26 VHR-C-107 3.55 VHR-C-132 7.41 VHR-C-157 4.64
VHR-C-008 3.37 VHR-C-033 3.57 VHR-C-058 5.31 VHR-C-083 2.64 VHR-C-108 2.12 VHR-C-133 1.82 VHR-C-158 3.36
VHR-C-009 1.99 VHR-C-034 1.22 VHR-C-059 3.61 VHR-C-084 6.52 VHR-C-109 1.62 VHR-C-134 1.11 VHR-C-159 2.57
VHR-C-010 4.38 VHR-C-035 4.3 VHR-C-060 4.15 VHR-C-085 1.27 VHR-C-110 4.94 VHR-C-135 6.06 VHR-C-160 1.18
VHR-C-011 21.5 VHR-C-036 3.15 VHR-C-061 2.72 VHR-C-086 2.28 VHR-C-111 1.61 VHR-C-136 3.55 VHR-C-161 2.48
VHR-C-012 4.67 VHR-C-037 1.35 VHR-C-062 5.05 VHR-C-087 1.95 VHR-C-112 3.19 VHR-C-137 7.29 VHR-C-162 11
VHR-C-013 2.52 VHR-C-038 6.55 VHR-C-063 4.61 VHR-C-088 1.14 VHR-C-113 1.67 VHR-C-138 10.3 VHR-C-163 3.74
VHR-C-014 2.01 VHR-C-039 2.16 VHR-C-064 13.3 VHR-C-089 3.45 VHR-C-114 8.41 VHR-C-139 4.73 VHR-C-164 5.48
VHR-C-015 3.09 VHR-C-040 1.46 VHR-C-065 6.69 VHR-C-090 8.15 VHR-C-115 1.57 VHR-C-140 1.06 VHR-C-165 4.03
VHR-C-016 4.14 VHR-C-041 4.56 VHR-C-066 4.89 VHR-C-091 5.21 VHR-C-116 2.03 VHR-C-141 0.771 VHR-C-166 1.94
VHR-C-017 4.96 VHR-C-042 6.29 VHR-C-067 16.5 VHR-C-092 6.14 VHR-C-117 2.68 VHR-C-142 1 VHR-C-167 5.47
VHR-C-018 2.42 VHR-C-043 3.72 VHR-C-068 9.94 VHR-C-093 6.31 VHR-C-118 4.06 VHR-C-143 3.35 VHR-C-168 2.04
VHR-C-019 3.63 VHR-C-044 11.1 VHR-C-069 5.53 VHR-C-094 3.96 VHR-C-119 4.27 VHR-C-144 3.62 VHR-C-169 1.57
VHR-C-020 2.66 VHR-C-045 6.1 VHR-C-070 0.0308 VHR-C-095 5.56 VHR-C-120 2.63 VHR-C-145 0.721 VHR-C-170 3.83
VHR-C-021 12.7 VHR-C-046 2.63 VHR-C-071 4.73 VHR-C-096 0.707 VHR-C-121 2.69 VHR-C-146 3.5 VHR-C-171 5.55
VHR-C-022 5.83 VHR-C-047 6.61 VHR-C-072 4.38 VHR-C-097 1.12 VHR-C-122 1.77 VHR-C-147 4.97 VHR-C-172 12
VHR-C-023 5.28 VHR-C-048 1.89 VHR-C-073 2.33 VHR-C-098 4.88 VHR-C-123 3.5 VHR-C-148 3.58 VHR-C-173 2.31
VHR-C-024 3.36 VHR-C-049 5.64 VHR-C-074 7.12 VHR-C-099 5.61 VHR-C-124 1.86 VHR-C-149 6.19 VHR-C-174 4.19
VHR-C-025 7.94 VHR-C-050 1.13 VHR-C-075 2.62 VHR-C-100 1.13 VHR-C-125 4.22 VHR-C-150 3.66 VHR-C-175 3.83
Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%)
VHR-C-176 2.5 VHR-C-201 5.56 LR-1 1.52 LR-26 4.61 LR-51 3.82 LR-76 4.3 No-CAD 1 4.85
VHR-C-177 2.91 VHR-C-202 10.4 LR-2 1.67 LR-27 1.34 LR-52 2.11 LR-77 5.56 No-CAD 2 3.14
VHR-C-178 4.59 VHR-C-203 2.13 LR-3 3.79 LR-28 6.48 LR-53 7.57 LR-78 6.64 No-CAD 3 2.14
VHR-C-179 3.79 VHR-C-204 3.68 LR-4 1.8 LR-29 3.79 LR-54 2.35 LR-79 9.54 No-CAD 4 2.54
VHR-C-180 4.41 VHR-C-205 7.66 LR-5 3.88 LR-30 3.43 LR-55 8.15 LR-80 4.92 No-CAD 5 0.385
VHR-C-181 4.46 VHR-C-206 2.83 LR-6 4.09 LR-31 2.78 LR-56 5.95 LR-81 2.08 No-CAD 6 12.8
VHR-C-182 0.656 VHR-C-207 3.76 LR-7 3.11 LR-32 8.82 LR-57 0.872 LR-82 3.38 No-CAD 7 6.25
VHR-C-183 3.75 VHR-C-208 7.3 LR-8 5.32 LR-33 7.61 LR-58 6.53 LR-83 2.13 No-CAD 8 2.19
VHR-C-184 1.76 VHR-C-209 3.68 LR-9 2.11 LR-34 2.98 LR-59 5.63 LR-84 1.54 No-CAD 9 1.73
VHR-C-185 1.86 VHR-C-210 4.08 LR-10 0.591 LR-35 6.92 LR-60 5.31 LR-85 0.832 No-CAD 10 3.29
VHR-C-186 2.04 VHR-C-211 2.05 LR-11 0.366 LR-36 7.99 LR-61 5.47 LR-86 12.4 No-CAD 11 1.92
VHR-C-187 2.06 VHR-C-212 8.33 LR-12 2.98 LR-37 0.497 LR-62 5.16 LR-87 2.11 No-CAD 12 1.89
VHR-C-188 1.33 VHR-C-213 3.79 LR-13 3.85 LR-38 8.27 LR-63 8.53 LR-88 3.63 No-CAD 13 4.19
VHR-C-189 2.12 VHR-C-214 8.87 LR-14 3.83 LR-39 4.07 LR-64 3.18 LR-89 9.6 No-CAD 14 2.2
VHR-C-190 1.78 VHR-C-215 7.04 LR-15 11.4 LR-40 3.65 LR-65 3.2 LR-90 6.86 No-CAD 15 2.35
VHR-C-191 6.25 VHR-C-216 9.95 LR-16 0.677 LR-41 6.42 LR-66 4.38 LR-91 1.92 No-CAD 16 6.03
VHR-C-192 6.45 VHR-C-217 4.28 LR-17 7.21 LR-42 2.18 LR-67 4.39 LR-92 3.39 No-CAD 17 1.72
VHR-C-193 5.94 VHR-C-218 2.4 LR-18 0.476 LR-43 3.78 LR-68 2.21 LR-93 2.52 No-CAD 18 7.24
VHR-C-194 7.87 VHR-C-219 3.12 LR-19 7.03 LR-44 8.89 LR-69 11 LR-94 1.95 No-CAD 19 4
VHR-C-195 2.86 VHR-C-220 2.91 LR-20 7.65 LR-45 2.72 LR-70 11.9 LR-95 2.12 No-CAD 20 4.67
VHR-C-196 4.97 VHR-C-221 1.68 LR-21 3.3 LR-46 0.756 LR-71 4.57 LR-96 4.27 No-CAD 21 1.95
VHR-C-197 3.29 LR-22 4.54 LR-47 7.56 LR-72 7.71 LR-97 2.91 No-CAD 22 3.44
VHR-C-198 2.95 LR-23 1 LR-48 2.96 LR-73 8.28 LR-98 2.8 No-CAD 23 4.38
VHR-C-199 3.96 LR-24 1.89 LR-49 2.76 LR-74 6.93 LR-99 5.3
VHR-C-200 5.09 LR-25 6.88 LR-50 9.53 LR-75 0.646 LR-100 0.598











CV (%) of 
Means
VHR-C-122 3994 1.77 3608 1.35 3801 272.9432 7.180827





2.8.2 Method for measuring soluble tumour necrosis factor 
receptor 2 sTNFR2/TNFRSF1B protein levels in preparations of 
extracted proteins by ELISA - Human TNF RII/TNFRSF1B 
Immunoassay R&D - DRT200 (Minneapolis, USA) 
Total protein levels measured by BCA in samples stored in MPER® were normalised. A 
volume of extracted protein was used to obtain a final concentration of 5000 ug/ml of 
total proteins (5 ug/ul) and diluted in Calibrator Diluent RD6O accordingly. The 
following formula was used: 
Initial Concentration x Initial Volume = Final concentration x Final volume 
Concentration calculated by the BCA assay x volume to use = 5 ug/ul x 400 ul 
Volume to use (ul) = 
5 ug/ul x 400 ul
Concentration calculated by the BCA assay 
 
The volume was made up to 800 ul using the Calibrator Diluent RD6O and samples 
were run in triplicates (200 ul per well). Samples were not diluted in that case and the 
result was relative to the same amount of proteins used for all the samples (5000 
ug/ml or 5 ug/ul). The TNFR2 ELISA procedure was followed as in section 2.8.1. 
Table 9: Intra-assay coefficient of variation (CV) of TNFR2 ELISA for the measurement 
of cell membrane bound TNFR2 protein levels  
 
Sample ID CV (%) Sample ID CV (%)
VHR-C-015 12.8 LR-8 4.31
VHR-C-016 1.15 LR-9 4.14
VHR-C-018 4.86 LR-10 4.07
VHR-C-011 3.57 LR-11 4.06
VHR-C-012 12.3 LR-12 2.16
VHR-C-013 6.4 LR-13 2.11
VHR-C-014 1.23 LR-14 2.09




2.9 TIMP3 ELISA 
2.9.1 Method for measuring TIMP3 protein levels in the plasma 
by ELISA- TIMP3 (MIG-5) Human ELISA -abcam ab119608 
(Cambridge, UK) 
TIMP3 ELISA was performed according to the manufacturer’s instructions. Samples 
were diluted 2-fold in the sample diluent buffer (200 ul of sample + 200 ul of diluent).  
The 6 standards were prepared by serial dilution in the same diluent with 10000 pg/ml 
as the highest standard and only using the assay/sample diluent buffer for the lowest 
standard concentration (10000 pg/ml; 5000 pg/ml; 2500 pg/ml; 1250 pg/ml; 625 
pg/ml; 0 pg/ml). 
Samples were run in triplicate and 200 ul of diluted sample or prepared standard were 
added per well. Wells were covered and incubated at 37°C for 90 minutes. The cover 
was removed and the contents of each well were discard contents and the plate was 
blotted onto paper towels. Wells were not left to dry at any time. A volume of 100 uL 
of prepared 1X Biotinylated Anti-Human TIMP3 antibody (diluted 100-fold with the 
Antibody Diluent Buffer) were added into each well and the plate was incubated at 
37°C for 60 minutes. The plate was washed three times with 0.01M PBS and each time 
the washing buffer was left to stay in the wells for one minute. The washing buffer was 
then discarded and the plate was blotted onto paper towels.  A volume of 100 uL of 
prepared 1X Avidin-Biotin-Peroxidase Complex (ABC) working solution (diluted 100-
fold with ABC Diluent Buffer) was added into each well and incubate the plate at 37°C 
for 30 minutes. The plate was washed five times with 0.01M PBS and each time the 




then discarded and the plate was blotted onto paper towels. A volume of 90 uL of TMB 
color developing agent was added into each well and incubate plate at 37°C in dark for 
20 - 25 minutes. A volume of 100 uL of TMB Stop Solution was added into each well. 
The color changed into yellow immediately. The optical density absorbance of the 
plate was read at 540 nm in a microplate reader within 30 minutes after adding the 
stop solution. For the result analysis, the mean absorbance was calculated for each set 
of triplicate standards and samples. A standard curve was created from the standards 
using a 4-parametric logistic regression curve. The sample concentration was then 
calculated after multiplying by the dilution factor. For creating the standard curve and 
calculating the sample concentrations, the following website was used: 
https://www.myassays.com/. The limit of sensitivity provided by the kit was < 2pg/ml. 
Only a coefficient of variation (CV) of less than 20% was accepted between replicates. 
If one replicate was out of this range, the remaining duplicates were used for the 
analysis. Samples with more than one replicate out of range were analysed again. A 
new standard curve was made for each plate. 
TIMP3 ELISA intra-assay CV = 5.5%  
TIMP3 ELISA inter-assay CV = 26.6%  
Note: To calculate the inter-assay CV, the tested samples were measured for the 
second time after a total of 1 year and 3 months. This questions the issue of TIMP3 
degradation over time. For all of the patient samples, TIMP3 levels were measured 
within 6 months of blood collection and the intra-assay CV was 5.5%. This shows that 
TIMP3 protein measurement from a frozen plasma aliquot should take place as close 




Table 10: Inter-assay and intra-assay coefficient of variation (CV) of TIMP3 ELISA for 
the measurement of TIMP3 plasma protein levels  
 
 
Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID
VHR-C-001 4.76 VHR-C-026 1.27 VHR-C-051 5.71 VHR-C-076 8.28 VHR-C-101 3.35 VHR-C-126 1.33 VHR-C-151 1.64
VHR-C-002 8.19 VHR-C-027 2.34 VHR-C-052 2.37 VHR-C-077 0.574 VHR-C-102 0.347 VHR-C-127 1.65 VHR-C-152 1.51
VHR-C-003 1.61 VHR-C-028 2.29 VHR-C-053 9.99 VHR-C-078 1.85 VHR-C-103 1.65 VHR-C-128 5.3 VHR-C-153 3.3
VHR-C-004 1.73 VHR-C-029 10.7 VHR-C-054 39.2 VHR-C-079 35.6 VHR-C-104 2.11 VHR-C-129 2.11 VHR-C-154 6.47
VHR-C-005 16 VHR-C-030 28.9 VHR-C-055 3.07 VHR-C-080 5.72 VHR-C-105 2.43 VHR-C-130 4.94 VHR-C-155 2.45
VHR-C-006 4.72 VHR-C-031 5.92 VHR-C-056 2.75 VHR-C-081 5.32 VHR-C-106 1.55 VHR-C-131 3.58 VHR-C-156 9.12
VHR-C-007 2.41 VHR-C-032 3.54 VHR-C-057 2.84 VHR-C-082 9.72 VHR-C-107 1.98 VHR-C-132 10.6 VHR-C-157 16.7
VHR-C-008 3.77 VHR-C-033 4.64 VHR-C-058 0.396 VHR-C-083 5.12 VHR-C-108 3.05 VHR-C-133 5.91 VHR-C-158 6.62
VHR-C-009 3.06 VHR-C-034 6.12 VHR-C-059 2.64 VHR-C-084 3.96 VHR-C-109 2.1 VHR-C-134 1.37 VHR-C-159 7.47
VHR-C-010 1.79 VHR-C-035 3.21 VHR-C-060 4.09 VHR-C-085 6.63 VHR-C-110 1.5 VHR-C-135 3.13 VHR-C-160 4.92
VHR-C-011 1.79 VHR-C-036 62.8 VHR-C-061 3.22 VHR-C-086 2.32 VHR-C-111 6.94 VHR-C-136 8.67 VHR-C-161 4.37
VHR-C-012 2.61 VHR-C-037 58.8 VHR-C-062 4.08 VHR-C-087 2.11 VHR-C-112 3.2 VHR-C-137 4.58 VHR-C-162 15.7
VHR-C-013 2.45 VHR-C-038 1.14 VHR-C-063 4.22 VHR-C-088 10.3 VHR-C-113 8.57 VHR-C-138 4.64 VHR-C-163 10.5
VHR-C-014 0.586 VHR-C-039 3.16 VHR-C-064 1.96 VHR-C-089 4.05 VHR-C-114 12.6 VHR-C-139 2.91 VHR-C-164 4.23
VHR-C-015 6.75 VHR-C-040 4.49 VHR-C-065 2.34 VHR-C-090 3.19 VHR-C-115 4.35 VHR-C-140 0.0804 VHR-C-165 0.846
VHR-C-016 5.93 VHR-C-041 1.43 VHR-C-066 0.657 VHR-C-091 11.1 VHR-C-116 2.77 VHR-C-141 3.95 VHR-C-166 3.22
VHR-C-017 4.11 VHR-C-042 3.54 VHR-C-067 2.27 VHR-C-092 1.24 VHR-C-117 6.3 VHR-C-142 0 VHR-C-167 0.491
VHR-C-018 13.2 VHR-C-043 2.66 VHR-C-068 5.41 VHR-C-093 10.4 VHR-C-118 0.745 VHR-C-143 2.16 VHR-C-168 11.8
VHR-C-019 28.7 VHR-C-044 3.15 VHR-C-069 7.9 VHR-C-094 8.02 VHR-C-119 4.95 VHR-C-144 2.51 VHR-C-169 6.12
VHR-C-020 9.89 VHR-C-045 2.45 VHR-C-070 3.63 VHR-C-095 3.42 VHR-C-120 5.13 VHR-C-145 1.02 VHR-C-170 24.8
VHR-C-021 3.86 VHR-C-046 4.38 VHR-C-071 19.9 VHR-C-096 13.6 VHR-C-121 3.38 VHR-C-146 8 VHR-C-171 2.77
VHR-C-022 3 VHR-C-047 1.83 VHR-C-072 3.56 VHR-C-097 2.2 VHR-C-122 2.97 VHR-C-147 3.35 VHR-C-172 1.72
VHR-C-023 4.05 VHR-C-048 9.63 VHR-C-073 1.93 VHR-C-098 3.32 VHR-C-123 4.38 VHR-C-148 2.86 VHR-C-173 8.11
VHR-C-024 2.52 VHR-C-049 0.65 VHR-C-074 1.75 VHR-C-099 3.86 VHR-C-124 4.93 VHR-C-149 3.84 VHR-C-174 4.31
VHR-C-025 3.21 VHR-C-050 3.15 VHR-C-075 2.43 VHR-C-100 3.89 VHR-C-125 n/a VHR-C-150 2.56 VHR-C-175 3.98
Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID CV (%) Patient ID
VHR-C-176 3.33 VHR-C-201 5.02 LR-1 8.16 LR-26 1.97 LR-51 3.37 LR-76 1.59 No-CAD 1 0.737
VHR-C-177 1.04 VHR-C-202 6.78 LR-2 16.8 LR-27 3.83 LR-52 1.33 LR-77 17.8 No-CAD 2 8.32
VHR-C-178 5 VHR-C-203 4.7 LR-3 6.14 LR-28 4.64 LR-53 2.01 LR-78 4.35 No-CAD 3 6.71
VHR-C-179 3.95 VHR-C-204 3.83 LR-4 4.26 LR-29 1.6 LR-54 2.39 LR-79 2.99 No-CAD 4 3.26
VHR-C-180 1.15 VHR-C-205 4.68 LR-5 10.7 LR-30 2.49 LR-55 0.955 LR-80 3.48 No-CAD 5 3
VHR-C-181 0.796 VHR-C-206 2.27 LR-6 6 LR-31 5.75 LR-56 1.51 LR-81 10.3 No-CAD 6 2.13
VHR-C-182 2.68 VHR-C-207 5.09 LR-7 7.37 LR-32 4.17 LR-57 1.7 LR-82 5.98 No-CAD 7 0.794
VHR-C-183 1.46 VHR-C-208 13.7 LR-8 13.6 LR-33 4.25 LR-58 6.79 LR-83 3.91 No-CAD 8 8.37
VHR-C-184 9.73 VHR-C-209 5.44 LR-9 4.49 LR-34 6.98 LR-59 1.6 LR-84 5.04 No-CAD 9 2.46
VHR-C-185 18.1 VHR-C-210 7.09 LR-10 7.23 LR-35 6.02 LR-60 3.12 LR-85 4.97 No-CAD 10 1.6
VHR-C-186 3.09 VHR-C-211 3.28 LR-11 8.34 LR-36 6.27 LR-61 2.09 LR-86 0.698 No-CAD 11 1.14
VHR-C-187 2.69 VHR-C-212 2.92 LR-12 6.33 LR-37 3.9 LR-62 2.41 LR-87 2.72 No-CAD 12 2.85
VHR-C-188 0.22 VHR-C-213 3.46 LR-13 2.92 LR-38 5.01 LR-63 2.48 LR-88 4.86 No-CAD 13 6.33
VHR-C-189 5.02 VHR-C-214 7.76 LR-14 6.06 LR-39 9.09 LR-64 7.65 LR-89 1.94 No-CAD 14 5.4
VHR-C-190 8.3 VHR-C-215 3.05 LR-15 8.3 LR-40 6.21 LR-65 0.399 LR-90 5.66 No-CAD 15 2.85
VHR-C-191 4.02 VHR-C-216 10.3 LR-16 2.79 LR-41 12.3 LR-66 3.05 LR-91 2.64 No-CAD 16 11.1
VHR-C-192 4.11 VHR-C-217 8.47 LR-17 2.73 LR-42 8.66 LR-67 5.86 LR-92 0.833 No-CAD 17 8.21
VHR-C-193 5.83 VHR-C-218 8.35 LR-18 1.44 LR-43 5.36 LR-68 2.41 LR-93 4.19 No-CAD 18 4.48
VHR-C-194 1.29 VHR-C-219 3.08 LR-19 2.17 LR-44 5.91 LR-69 1.55 LR-94 5.26 No-CAD 19 5.41
VHR-C-195 6.82 VHR-C-220 13.2 LR-20 3.44 LR-45 5.77 LR-70 2.71 LR-95 4.68 No-CAD 20 4.55
VHR-C-196 5.47 VHR-C-221 6.93 LR-21 3 LR-46 11.8 LR-71 4.57 LR-96 2.99 No-CAD 21 6.03
VHR-C-197 5.9 LR-22 2.77 LR-47 3.34 LR-72 4.76 LR-97 12.6 No-CAD 22 0.856
VHR-C-198 5.61 LR-23 5.66 LR-48 20.3 LR-73 4.62 LR-98 1.6 No-CAD 23 15.8
VHR-C-199 8.91 LR-24 14.7 LR-49 2.05 LR-74 5.57 LR-99 4.19
VHR-C-200 3.86 LR-25 1.79 LR-50 2.15 LR-75 2.54 LR-100 1.21











CV (%) of 
Means
VHR-C-046 1628 4.38 934.2 12.8 1281.1 490.5907 38.29449





2.9.2 Method for measuring TIMP3 protein levels in 
preparations of extracted proteins by ELISA - TIMP3 (MIG-5) 
Human ELISA -abcam ab119608 (Cambridge, UK) 
Total protein levels measured by BCA in samples stored in MPER® were normalised. A 
volume of extracted protein was used to obtain a final concentration of 5000 ug/ml of 
total proteins (5 ug/ul) and diluted in the assay diluent accordingly. The following 
formula was used: 
Initial Concentration x Initial Volume = Final concentration x Final volume 
Concentration calculated by the BCA assay x volume to use = 5 ug/ul x 400 ul 
Volume to use (ul) = 
5 ug/ul x 400 ul
Concentration calculated by the BCA assay 
 
The volume was made up to 400 ul using the assay diluent and samples were run in 
triplicates (100 ul per well). Samples were not diluted in that case and the result was 
relative to the same amount of proteins used for all the samples (5000 ug/ml or 5 
ug/ul). The TIMP3 ELISA procedure was followed as in section 2.9.1. 
Table 11: Intra-assay CV (%) of TIMP3 ELISA for cell bound TIMP3 
 
Patient ID CV (%) Patient ID CV (%)
VHR-C-008 4.44 LR-8 0
VHR-C-009 4.73 LR-9 5.66
VHR-C-010 55 LR-10 12.2
VHR-C-011 13.9 LR-11 5.08
VHR-C-012 2.84 LR-14 10.3
VHR-C-013 5.28 LR-15 0
VHR-C-014 12.2 VHR-C-002 4.91
VHR-C-015 3.99 VHR-C-003 6.33
LR-6 14.3 LR-12 7.6
LR-7 4.64 LR-13 4.04




2.10 Method for Meso Scale ELISA - Proinflammatory 
Panel 1 (human) Kit – IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, 
IL-12p70, IL-13, TNF-α - MSD® MULTI-SPOT Assay System - 
K15049D (Maryland, USA) 
MSD measures the levels of protein targets within a single, small-volume sample. The 
assays in the Proinflammatory Panel 1 (human) are sandwich immunoassays. The 
provided MSD plates are pre-coated with capture antibodies on independent and well-
defined spots, as shown in the layout below. Multiplex assays are provided on 10-spot 
MULTI-SPOT® plates individual assays. The sample is added in each well and a solution 
containing detection antibodies conjugated to electrochemiluminescent labels (MSD 
SULFO-TAGTM) over the course of one or more incubation periods. Analytes in the 
sample bind to capture antibodies immobilized on the working electrode surface; 
recruitment of the detection antibodies by the bound analytes completes the 
sandwich. The MSD buffer is then added and creates the appropriate chemical 
environment for electrochemiluminescence (ECL). The plate is then loaded into an 
MSD instrument where a voltage applied to the plate electrodes causes the captured 
labels to emit light. The instrument measures the intensity of emitted light (which is 
proportional to the amount of analyte present in the sample) and provides a 
quantitative measure of each analyte in the sample. V-PLEX assay kits have been 
validated according to the principles outlined in “Fit-for-Purpose Method 
Development and Validation for Successful Biomarker Measurement” by J. W. Lee, et 





Figure 6: Multiplex plate spot diagram showing placement of analyte capture 
antibodies.  
Procedure: 
The procedure was followed according to the manufacturer’s instructions. Samples 
were diluted 2-fold using Diluent 2 (R51BB-3) (25 ul of sample + 25 ul of diluent). A 
total of 8 standards/calibrators were prepared by serial dilution using Diluent 2.  The 
plate was washed 3 times with prepared wash buffer (1X PBS + 0.05% Tween). Samples 
and standards/calibrators were run in duplicates.  A volume of 50 ul of prepared 
samples and calibrators were added per well. The plate was sealed and incubated at 
room temperature for 2 hours with vigorous shaking (~ 7000 rpm). The plate was 
washed 3 times with wash buffer. Detection antibody was prepared by combining 60 
ul of each of the SULFO-TAC Anti-human INF-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-
12p70, IL-13, TNF-α antibodies with 2400 ul of Diluent 3. A volume of 25 ul of detection 
antibody solution was added to each well. The plate was sealed and incubated at room 
temperature for 2 hours with vigorous shaking.  The plate was washed 3 times with 
wash buffer. Read buffer (2X) was prepared by combining 10ml of Read Buffer T (4X) 
with 10 ml of deionised water. A volume of 150 ul of read buffer was added to each 
well and the plate was then analysed on the MSD instrument. The sample 




workbench 4.0 software after 4-parameter logistic regression curves were calculated 
for each assay by the software. 
Notes: 
 All results were under 1.5 million counts to avoid overlays 
 All samples were checked to see where they fit within the standard curve. For 
IL-13, IL-1β, IL-2 and IL-4, many samples were out of range and below the lower 
limit of detection (LLOD) – highlighted in grey in Table 13. 
Table 12 shows the sensitivity characteristics of the assay. The lower limit of detection 
(LLOD) is a calculated concentration corresponding to the signal 2.5 standard 
deviations above the background (zero calibrator). The upper limit of quantification 
(ULOQ) is the highest concentration at which the CV of the calculated concentration is 
<20% and the recovery of each analyte is within 80% to 120% on the known value. The 
lower limit of quantification (LLOQ) is the lowest concentration at which the CV of the 
calculated concentration is <20% and the recovery of each analyte is within 80% to 
120% on the known value. The quantitative range of the assay lies between the LLOQ 
and the ULOQ and both values are kit specific and are provided in the certificate of 
analysis of each kit (Table 13, 14, 15). 
Only a coefficient of variation (CV) of less than 20% was accepted between replicates. 
If one replicate was out of this range, the remaining duplicates were used for the 
analysis. Samples with more than one replicate out of range were analysed again. A 





Table 12:  MSD assay specificity and sensitivity 





















Lower limit of 
quantification 
(LLOQ) 
(pg/ml) - Kit 






0.20 0.05-0.62 0.227 7.47 938 
IL-10 Within 
range 
0.03 0.01-0.15 0.0369 0.680 233 
IL12p70 Within 
range 
0.11 0.02-0.89 0.0705 1.22 315 
IL-13 Below 
range 
0.24 0.03-0.73 0.508 4.21 353 
IL-1β Below 
range 
0.04 0.01-0.27 0.0586 2.14 375 
IL-2 Below 
range 
0.09 0.01-0.29 0.0500 0.890 938 
IL-4 Below 
range 
0.02 0.01-0.05 0.0139 0.450 158 
IL-6 Within 
range 
0.06 0.01-0.11 0.0461 1.58 488 
IL-8 Within 
range 
0.04 0.01-0.15 0.0532 1.13 375 
TNF-α Within 
range 






Table 13: LLOD and ULOD for all MSD plates  
 









pg/ml LLOD Range LLOD ULOD LLOD ULOD LLOD ULOD LLOD ULOD LLOD ULOD LLOD ULOD LLOD ULOD LLOD ULOD LLOD ULOD LLOD ULOD
IFN-γ 0.05-0.62 0.244808867 1730 0.227115 1730 0.414597 1730 0.173964 1730 0.524654 1730 0.518077 1730 0.215284 1730 0.600931 1730 0.588312 1730 185.85 860.4806
IL-10 0.01-0.15 0.064040228 370 0.036868 370 0.021192 370 0.018854 370 0.023467 370 0.019006 370 0.050341 370 0.028973 370 0.030361 370 165.15 175.2978
IL-12p70 0.02-0.89 0.11146197 496 0.070479 496 0.103041 496 0.057392 496 0.051144 496 0.078394 496 0.061885 496 0.059301 496 0.053894 496 156.15 235.2256
IL-13 0.03-0.73 0.386130079 504 0.508292 504 0.421683 504 0.363534 504 0.295871 504 0.299856 504 0.283343 504 0.306452 504 0.531063 504 123.3 276.7011
IL-1β 0.01-0.27 0.135322795 566 0.058639 566 0.219547 566 0.024395 566 0.072278 566 0.049246 566 0.264571 566 0.070767 566 0.182093 566 1301.4 275.7704
IL-2 0.01-0.29 0.116676073 1620 0.049997 1620 0.05605 1620 0.043558 1620 0.043792 1620 0.044943 1620 0.062173 1620 0.073191 1620 0.069579 1620 322.2 774.2651
IL-4 0.01-0.05 0.011580485 249 0.013922 249 0.011264 249 0.010609 249 0.013834 249 0.011177 249 0.012832 249 0.011924 249 0.028824 249 128.7 123.597
IL-6 0.01-0.11 0.034329577 756 0.046051 756 0.04607 756 0.042457 756 0.039955 756 0.054009 756 0.050138 756 0.059345 756 0.087402 756 102.6 395.0765
IL-8 0.01-0.15 0.055290191 661 0.053212 661 0.0711 661 0.03995 661 0.038033 661 0.038207 661 0.046826 661 0.034993 661 0.052971 661 143.1 333.1372
TNF-α 0.01-0.13 0.191278756 373 0.240455 373 0.100063 373 0.08015 373 0.058482 373 0.065091 373 0.067101 373 0.053406 373 0.090883 373 172.35 190.4858
Plate 7 Plate 8 Plate 9 Plate 10Plate 1 Plate2 Plate 3 Plate 4 Plate 5 Plate 6
MSD Assay IFN-γ IL-10 IL-12p70IL-13 IL-1β IL-2 IL-4 IL-6 IL-8 TNF-α




Table 15: Inter assay coefficient of variation for the MSD assays 
 
Missing values (N/A) were below the limit of detection of the assay
Plate Date Internal Ctrl IFN-γ IL-10 IL-12p70 IL-13 IL-1β IL-2 IL-4 IL-6 IL-8 TNF-α
Plate 1 15/02/2017 VHR-C-008 21.541321 0.360524 0.234538 0.665355 N/A 0.274394 N/A 0.716633 13.84981 8.684077
Plate 2 16/02/2017 VHR-C-008 18.601382 0.356337 0.213141 0.665355 N/A 0.199817 N/A 0.723006 12.2595 6.915715
Plate 3 17/02/2017 VHR-C-008 15.075707 0.33638 0.240611 N/A N/A N/A 0.008162 0.70105 12.57177 6.607163
Plate 4 17/02/2017 VHR-C-008 12.986779 0.370859 0.157108 N/A N/A 0.096189 N/A 0.67267 9.258658 4.607896
Plate 5 22/02/2017 VHR-C-008 14.47852 0.364889 0.236633 0.455494 N/A 0.152862 N/A 0.671077 10.06468 5.177284
Plate 6 22/02/2017 VHR-C-008 14.264836 0.323689 N/A N/A N/A 0.071974 N/A 0.639311 10.20554 5.265359
Plate 7 23/02/2017 VHR-C-008 16.832725 0.376562 0.128553 N/A N/A 0.183486 N/A 0.737023 9.944691 4.799646
Plate 8 23/02/2017 VHR-C-008 14.630407 0.401266 0.199278 N/A N/A 0.151286 0.027219 0.736956 9.164484 4.510785
Plate 9 03/03/2017 VHR-C-008 17.980485 0.510732 0.187346 0.592342 N/A 0.188192 N/A 0.849976 10.55634 4.460415
Plate 10 10/04/2017 VHR-C-008 14.378901 0.347319 0.121509 N/A N/A 0.096801 N/A 0.666216 8.482261 3.992848
Mean concentration 16.077106 0.374856 0.190969 0.594637 N/A 0.157222 0.017691 0.711392 10.63577 5.502119
stdev of means 2.620284 0.05237 0.045946 0.098941 N/A 0.063137 0.013476 0.058828 1.712974 1.458488
CV 0.1629823 0.139706 0.240597 0.166389 N/A 0.401575 0.761727 0.082694 0.161058 0.265078





2.11 Method for RNA extraction from samples stored in 
RNAlater® Stabilization solution using the RiboPure™ RNA 
Purification Kit - AM1924- Ambion (California, USA) 
The protocol was followed according to the manufacturer’s instructions. All 
centrifugation steps were carried out at 16000 RCF. Samples were all previously 
stored in RNAlater® Stabilization solution and maintained at -80◦C until further 
extraction. Samples were thawed and then centrifuged for 1 minute. The blood cells 
and plasma proteins formed a large brown or reddish-brown pellet which smeared 
sometimes upward along the side of the tube, and the supernatant was pale pink, 
brown, or colourless. The supernatant and all the fluid above the pellet was 
thoroughly removed. A volume of 800 ul of Lysing Solution and 50 ul of Sodium 
Acetate Solution was added to the cell pellet from RNAlater-stabilised samples. The 
samples were vortexed vigorously to lyse the blood cells and the tube was inverted 
to be sure the solution was homogenous. A volume of 250 uL of Acid-Phenol - 
Chloroform was added it to the cell lysate, and the samples were vortexed for 30 sec. 
The mixture was stored at room temperature for 5 min. The samples were then 
centrifuge at room temperature for 1 min to separate the aqueous and organic 
phases. The aqueous (upper) phase containing the RNA (1-1.2 ml) was transferred to 
a new tube. To each tube of aqueous phase recovered after the Acid-Phenol: 
Chloroform extraction, 600 uL (~one-half volume) of 100% ethanol was added and 
the tubes were and vortexed briefly but thoroughly. A volume of 700 ul of the mixture 
(aqueous phase mixed with ethanol) was added one at a time to a Filter Cartridge 




the filter. The flow-through from the Collection Tube was discarded, and the Filter 
Cartridge was replaced into the same Collection Tube. 
The same procedure was repeated until all the mixture was filtered. A volume of 700 
uL of Wash Solution 1 was applied to the Filter Cartridge assembly and centrifuge for 
30 seconds to pass the solution through the filter. The flow-through from the 
Collection Tube was discarded, and the Filter Cartridge was replaced into the same 
Collection Tube. 700 uL Wash Solution 2/3 (working solution mixed with ethanol) was 
applied to the Filter Cartridge assembly and centrifuged for 30 seconds to pass the 
solution through the filter. The flow-through from the Collection Tube was discarded, 
and the Filter Cartridge was replaced into the same Collection Tube. This step was 
repeated a second time. After discarding the flow-through from the last wash, the 
Filter Cartridge was replaced in the same Collection Tube and the assembly was spun 
for 1 min to remove residual fluid from the filter. The Filter Cartridge was transferred 
into a labelled Collection Tube and 70 uL of Elution Solution (preheated to ~75°C) was 
applied to the centre of the filter. The assembly was left at room temperature for ~20 
sec, then spun for ~20–30 sec at maximum speed to recover the RNA. This step was 
repeated with another 70 ul of Elution Solution. 
After recovering the RNA, a DNase I treatment was performed in order to remove 
contaminating genomic DNA from the eluted RNA. 1/20th of the volume of 20X DNase 
Buffer and 1 μL DNase I (8 U/uL) was added to the eluted RNA. The mixture was 
incubated at 37◦C for 30 minutes. A volume of DNase Inactivation Reagent equal to 
20% of the volume of RNA treated was then added. The tube was vortexed briefly to 




stored at room temperature for 2 min. The samples were then centrifuged for 1 
minute to pellet the DNase Inactivation reagent. The RNA was then transferred into 
a new RNase-free tube. The yield and contamination ratios of the RNA were 
measured using the NanoDrop 2000/2000c Spectrophotometer. 
Notes: 
 Nucleic acids and proteins have absorbance maxima at 260 and 280 nm, 
respectively. A ratio of ~2.0 is generally accepted as “pure” for RNA. 
 Similarly, absorbance at 230 nm is accepted as being the result of other 
contamination (residual phenol, residual guanidine...) The 260/230 values for 
“pure” nucleic acid are often higher than the respective 260/280 values. 
Expected 260/230 values are commonly in the range of 2.0-2.2 (Table 16) 






VHR-C-043 48.3 2.09 1.95 
VHR-C-044 95.6 2.09 2.02 
VHR-C-045 3.4 5.5 0.38 
VHR-C-046 58.5 2.17 1.91 
VHR-C-047 62 2.14 2.02 
VHR-C-048 59.7 2.19 1.94 
VHR-C-049 58.1 2.16 2.04 
VHR-C-050 63.2 2.14 1.9 
VHR-C-051 19 2.46 1.71 
VHR-C-052 98.1 2.12 1.9 
VHR-C-053 78 2.1 1.86 
VHR-C-054 41.5 2.27 1.73 
VHR-C-055 35.8 2.22 1.58 
VHR-C-056 54.7 2.15 1.9 
VHR-C-057 86.4 2.17 2.09 




VHR-C-059 57.3 2.15 1.72 
VHR-C-060 92.3 2.13 1.85 
VHR-C-061 53.8 2.12 1.45 
 
2.12 Method for making up cDNA using the Transcriptor 
First Strand cDNA Synthesis Kit – 04379012001 – Roche 
(Mannheim, Germany) 
Note: Suitable template concentrations may range from 10ng to 5 ug total RNA and 
from 1 to 100 ng of mRNA 
A total of 300 ng of RNA of each extracted RNA sample was converted to cDNA. 
For each tube, the appropriate volume of RNA corresponding to 300 ng was mixed 
with PCR grade water (vial 7 - when needed) to make the volume up to 11 ul and then 
2 ul of Random Hexamer Primer (600 pmol/ul -vial 6) was added to each tube. The 
template-primer mixture was denatured by heating the tube for 10 minutes at 65◦C 
in a thermal block cycler (Techne – Prime – Bibby Scientific) with a heated lid to 
minimise evaporation. This steps ensures the denaturation of RNA secondary 
structures. The tubes were then immediately cooled on ice. To each tube 4 ul of 
Transcriptor Reverse Transcriptase Reaction Buffer, 5x conc (vial 2), 0.5 ul pf 
Protector RNase Inhibitor, 40U/ul (vial 3), 2 ul of Deoxynucleotide Mix, 10 mM each 
(vial 4) and 0.5 ul Transcriptor Reverse Transcriptase 20U/ul (vial 1) were added. The 
tubes were then centrifuged briefly and placed in a thermal block cycler with a 
preheated lid. The Reverse Transcriptase reaction was incubated for 10 minutes at 
25◦C, followed by 60 minutes at 50◦C. The Transcriptor Reverse Transcriptase was 




was set to 4◦C to cool the tubes down. The tubes were then stored at -20◦C until 
further applications. 
Controls: 
For each batch of converted RNA: 
 A water control was used to control the PCR grade water used to make up the 
RNA. In this tube, PCR grade water was added instead of the RNA. 
 A Transcriptor Reverse Transcriptase (minus RT) control was used to control 
for any contamination of the reagents with the enzyme. In this tube, the 
enzyme was not added to the tube. 
 A technical control was prepared to run on each real-time PCR plate in order 
to monitor plate to plate variation. 
These controls for the cDNA step were then used for the quantitative PCR. 
2.13 Method for real-time polymerase chain reaction 
using Roche Light cycler®480 II and the LightCycler® 480 
probe Master reagents (04707494001) and probes – 
Roche (Mannheim, Germany) 
A total volume of 10 ul of PCR mix was prepared for each well of the Multiwell Plate 
and each sample was run in triplicate.  GAPDH was chosen as the reference gene. A 
volume of 1 ul of sample cDNA was mixed with 1.5 ul of PCR grade water to make up 
a total of 2.5 ul of cDNA template for each well. A PCR mix was prepared by combining 
2 ul of PCR grade water (vial 2), 5 ul of LightCycler® 480 Probes Master 2x conc (vial 
1) and 0.5 of either GAPDH (Assay ID 141139), ADAM17/TACE (Assay ID 136022), 




RealTime ready assay probes in each well. The plate was then sealed with the 
LightCycler® 480 Sealing Foil and centrifuged for 2 minutes at 1500 RCF. The plate 
was then transferred into the plate holder of the Roche Light cycler®480 II Instrument 
and the run program was started. The run program ‘Monocolor Hydrolysis Probe/UPL 
Probe’ was selected among the experiment template offered by the LightCycler® 480 
Software Release 1.5.1.62 software which is a 45-cycle amplification and the volume 
was changed to 10 ul. The run was started and the experiment was saved. 
Controls: 
On each plate: 
 The PCR grade water and the minus RT control prepared from the cDNA step 
were run. 
 The same technical control was run on each real-time PCR plate 
 A probe control was run. This was a probe and probe master mix control 
mixed with PCR grade water instead of the template cDNA 
 A cDNA control was run. This was a cDNA template mixed with PCR grade 
water instead of the probe and probe master mix. 
Results analysis: 
Samples, target and reference genes were labelled in the ‘Sample editor’ menu 
(following the plate plan) after choosing the ‘relative quantification’ option in the 
LightCycler® 480 Software Release 1.5.1.62 software. cT (Cycle Threshold) values 




Max’ option. The table was then exported to excel and the mean as well as the 
standard deviation were calculated for each triplicate. 
Note: The Ct (cycle threshold) value is defined as the number of cycles required for the 
fluorescent signal to cross the threshold (i.e. exceeds background level). 
In order to normalise the expression of our target gene (TACE in this example) to the 
reference gene, ΔcT values were calculated by subtracting the cT value of the 
reference gene from the cT value of the target gene: 
ΔcT (TACE) = cT (TACE) – cT (GAPDH) 
2^(-ΔcT) was calculated for each sample which represents the fold increase in gene 
expression of the target gene compared to the reference gene.   
The 2^(-ΔcT) values were then compared among the studied groups. 
Gene efficiencies calculations  
Gene efficiencies calculations were performed prior to real-time PCR relative 
quantification step. This was done by using a serial dilution of a template cDNA and 
then quantifying the gene of interest as well as the reference gene in our serial 
dilution set of samples. Each gene efficiency was then calculated using a standard 
curve using the LightCycler® 480 SW 1.5.1 software and selecting absolute 













Only a coefficient of variation (CV) of less than 20% was accepted between replicates. 
If one replicate was out of this range, the remaining duplicates were used for the 
analysis. Samples with more than one replicate out of range were analysed again. 
Table 17: Inter-assay coefficient of variation (CV) of the Cp values for GAPDH, NLRP3 
and TACE genes 
Inter assay CV (%) for all real-time PCR plates 
6 plates    
VHR-217 (Low Cp value) GAPDH NLRP3 TACE 
Average 22.81667 28.15389 26.28333 
stdev of means 0.609338 0.587815 0.326694 
CV 0.026706 0.020879 0.01243 
CV (%) 2.670585 2.087864 1.24297 
28 plates    
MD-009 (Medium Cp value) GAPDH NLRP3 TACE 
Average 23.54238 28.53768 28.60988 
stdev of means 1.107169 2.055639 1.647659 
CV 0.047029 0.072032 0.057591 
CV (%) 4.702874 7.203247 5.759056 
8 plates    
LR-66 (High Cp value) GAPDH NLRP3 TACE 
Average 28.55875 34.10333 32.08708 
stdev of means 0.658611 0.718263 0.540184 
CV 0.023062 0.021061 0.016835 
CV (%) 2.306161 2.106137 1.683492 
Total Inter-assay CV (%) 
Average of high, medium and low technical controls 
Gene GAPDH NLRP3 TACE 






Table 18: Inter-assay Coefficient of variation for the Cp values of GAPDH, TIMP3 
and IL1B genes 
  
2.14 Method for analysing samples using the Proximity 
Extension Assay (PEA) technology - Proseek® Multiplex 
provided by O-Link Proteomics (Uppsala, Sweden) 
O-Link proteomics performs a detection and sample analysis by high-throughput 
real-time PCR analysis using the Fluidigm® BioMark™ HD System.  
The main steps involved in a Proseek assay are outlined below and this analysis was 
undertaken and provided by O-Link proteomics®. A pair of oligonucleotide-labeled 
antibodies, known as Proseek probes, bind to the target protein present in the 
sample. When the two Proseek probes are in close proximity, a new PCR target 
sequence is formed by a proximity-dependent DNA polymerization event. The 
resulting sequence is subsequently detected and quantified using standard real-time 
PCR. Each of the 96-oligonucleotide antibody-pairs contains unique DNA sequences 
allowing hybridization only to each other. Subsequent proximity extension creates 
96 unique DNA reporter sequences which are amplified by real-time PCR. A limiting 
GAPDH TIMP3 IL1B
CTRL Plate 1 27.55 N/A 29.97333
CTRL Plate 2 27.27333 37.55 29.49667
CTRL Plate 3 26.87333 37.99 29.64667
CTRL Plate 4 27.06333 38.17 29.37667
CTRL Plate 5 27.34 38.41 29.68
CTRL Plate 6 27.18333 37.47 30.05667
CTRL Plate 7 27.62 39.03 30.87333
CTRL Plate 8 27.13667 38.015 30.30667
CTRL Plate 9 26.81 37.82 29.82667
Average 27.20556 38.05688 29.91519
Std dev of means 0.275086 0.499735 0.460314
CV 0.010111 0.013131 0.015387





factor of multiplexed immunoassays is the antibody cross-reactivity which restricts 
the degree of multiplexing of most assays to below 10-plex. Cross-reactive events are 
not detected with Proseek Multiplex since only matched DNA reporter pairs are 
amplified with real-time PCR. This allows for scalable multiplexing without loss of 
specificity and sensitivity. http://www.olink.com/data-you-can-trust/technology/  
 
Figure 8: Proximity Extension Assay (PEA) technology steps 
In order to prepare the samples, a sample map was created for all the samples that 
would be analysed and 30 ul of plasma was pipetted into each well of a 96-well plate.  
A total of 4 plates were prepared. The plates were then sealed, covered, placed on 
ice and shipped to O-Link Proteomics lab in Uppsala, Sweden for protein 
measurement. The assay results were sent back and the statistical data analsysis was 
carried out as part of this project and results are in Chapter 6.  
Controls: 




 2 incubation controls: Non-human antigens which monitor potential variation 
in all three steps. 
 1 extension control: An antibody with both DNA-tags always in proximity 
which monitors the extension step and is used for normalisation across the 
samples 
 1 detection control: A complete double stranded amplicon which controls the 
Amplification/Detection steps 
External controls: Added to separate wells on the plate 
 Inter-plate control (IPC): Pool of 92 antibodies, each with one of the pairs of 
unique DNA tags on it positioned in fixed proximity (i.e 92x extension control). 
Used for normalisation and compensates for potential sequence biases and 
variation between runs/plates. 
 Negative control: Buffer with no antigens. Sets the background levels (LOD) 
for all proteins. 
The quality of the entire run is evaluated by calculating the standard deviations of 
incubation control 1, incubation control 2 and detection control. These values should 
be below a pre-determined quality threshold.  The quality of each sample is assessed 
by evaluation of the deviation from the median value for incubation control 2 and 
detection control. The recommended maximum deviation is ± 0.3. The IPC controls 
are used for studies including more than 90 samples and there is a third quality 





Figure 9: Controls used for the Proseek Multiplex technique 
Results Analysis: 
Proseek Multiplex uses relative quantification. The data from the analysis is 
presented as normalized protein expression (NPX) values, which is an arbitrary unit 
on log2 scale. This means that an increase in one NPX corresponds to a doubling of 
the concentration. Proseek is a relative quantification method which means that 
even if two proteins have the same NPX values, their actual concentration may differ. 
NPX is generated by a combination of the Fluidigm multiplex real-time PCR system 
and O-Link’s data normalisation procedure and is performed to minimise both intra- 
and inter-assay variation. Samples where values were below the detected level were 
replaced with ‘Not a number/NaN’. 
Data pre-processing and analysis – stepwise overview: Proseek generates Cq values 
and NPX values are obtained by the following method: (Normalization and quality 





dC qanalyte = Cq analyte – Cq Ext Ctrl 
2.Interplate Control 
ddCq analyte = dCq analyte – dCq Interplate Ctrl 
3.Normalization against a correction factor 
NPX = Correction factor –  dd Cqanalyte 
Normalized Protein eXpression (NPX) values 
Log 2 scale: high NPX value = high protein concentration 
For CV calculations, linear 2NPX values were used 





Figure 10: Inter and intra-assay coefficient of variation of the proteins analysed by 
O-link for cardiovascular disease panel II (CVDII) and III (CVDIII).  
  
Figure 11: Quality control measurements of the proteins analysed by O-link for 
cardiovascular disease panel II (CVDII) and III (CVDIII). 
 














2.15 Methods for performing the colony forming assay 
(CFA) 
The protocol for performing the CFA was adapted form Martin-Ramirez et al ((160) 
and Ingram et al (161) – with minor modifications. 
2.15.1 Preparation of collagen coated 96-well plates 
A collagen type I solution was prepared (Corning® collagen I, eat tail, 354236, 
Maryland, USA). The collagen solution was diluted to 50 ug/ml using a 0.02N acetic 
acid solution (where the acid was previously filtered using a 0.2 um filter) as the 
Corning Collagen I is insoluble at neutral pH. A plate of 96-wells was coated using the 
diluted collagen type I solution at 5 ug/cm2 with 50 ul of collagen solution per well. 
The plate was incubated at room temperature for one hour before the liquid was 
aspirated and the plate washed three times with PBS. 
2.15.2 Preparation of endothelial colony forming cells (ECFCs) 
culture medium 
The reagents enclosed in the EGM-2 BulletKit (Lonza - CC-3162, Maryland, USA) were 
thawed. hEGF, GA-100 (gentamycine, amphotericin-B), FBS, VEGF (vascular 
endothelial growth factor), hFGF-B (human fibroblast growth factor), R3-IGF-1 
(insulin like growth factor), ascorbic acid and heparin were added to 500 ml of EGM-
2. The culture medium was also supplemented with 100 ml of additional FBS 
previously inactivated at 56◦C for 30 minutes. The media was aliquoted into 50 ml 




2.15.3 White blood cell isolation 
A total of 18 ml of blood was collected into EDTA vacunatiner blood tubes (VACUETTE 
K3E K3EDTA – 455036). The blood tubes were kept at room temperature until 
processing. Isolation of peripheral mononuclear blood cells (PBMCs) was then 
performed using the Histopaque®-1077 from sigma (10771). The volume of 18 ml of 
blood was diluted 1:1 with PBS and then for every 9 ml of diluted blood, 4.5 ml of 
Histopaque-1077 was used. The 4.5 ml of Histopaque-1077 were firstly added at the 
bottom of the tube and the diluted blood was slowly and gently layered on top of the 
Histopaque-1077 layer while making sure that the ficoll layer is not disturbed. 
The tubes were then centrifuged at 2000 rpm for 20 minutes. The layer of white 
blood cells was then collected into a new fresh tube. The cells were then washed 
twice with PBS by spinning at 1500 rpm for 15 minutes. The cell pellet was then gently 
suspended in 15 ml BOEC medium and then aliquoted at 150 ul of cell suspension per 
well. The cells were incubated at 37◦C 5%CO2 for 24 hours and then the non-
adherent cells were discarded. The media was replaced every two days the first week 
and every three days the following weeks. In general, colonies take around three 
weeks to appear. After three weeks, the number of colonies were counted. Cells 
were identified as well-circumscribed monolayers with a cobblestone morphology as 






Figure 14: ECFC isolated from patient VHR-030 after CD45 depletion by autoMACS 


































Chapter 3  
TACE/ADAM17 and TNFα identify 
and further stratify individuals at 







Background: Tumour necrosis factor alpha converting enzyme (TACE) is known to 
cleave tumour necrosis factor alpha (TNFα) amongst many other cytokines and 
inflammatory mediators associated with increasing the risk of major adverse 
cardiovascular events (MACE). TACE gene expression was found to be increased in 
acute myocardial infarction and complications such as heart failure and arrhythmias. 
However, TACE plasma protein levels have not yet been explored in CVD individuals. 
The aim of this study was to measure TNFα and TACE in individuals at various levels 
of cardiovascular risk. 
Methods: Participants were recruited from the cardiac catheterisation laboratory or 
by email advertisement. All participants were assigned a risk score using the 
European Society of Cardiology (ESC) SCORE risk chart. Group 1 was defined as very 
high risk participants (VHR) with a 10-year risk SCORE ≥10% risk of fatal 
cardiovascular disease (CVD). Group 2 were defined as low, moderate and high risk 
participants (non-VHR) with a 10-year risk SCORE <10% risk of fatal CVD. TNFα plasma 
protein levels as well as TACE plasma and cell membrane bound protein levels were 
measured by ELISA. TACE mRNA levels were measured by quantitative real-time PCR.   
Results: A total of 344 participants were recruited. TNFα plasma protein levels and 
TACE mRNA levels were significantly higher in the VHR group (n=229) compared to 
non-VHR group (n=115) (4.711 ± 2.453 pg/ml vs. 2.770 ± 0.752 pg/ml, p<0.0001 and 
0.05366 ± 0.03127 vs. 0.03755 ± 0.02051, p<0.01 respectively). TNFα plasma protein 
levels remained higher in the VHR group with previous myocardial infarction (MI) 
(5.399 ± 2.368 pg/ml vs. 4.389 ± 2.433 pg/ml; p<0.01) or previous percutaneous 




despite medical and clinical management. However, TACE mRNA levels were 
significantly lower in the VHR group with a previous PCI (0.04624 ± 0.02494 vs. 
0.05708 ± 0.03331 with p<0.05). There was no significant difference in TACE plasma 
protein levels between VHR and non-VHR groups (p=0.642). The VHR group however, 
had significantly higher cell membrane bound TACE levels compared to the non-VHR 
group (383.9 ± 259.6 pg/ml in VHR vs. 221.9 ± 78.8 pg/ml in non-VHR participants, 
p<0.0001). 
Conclusion: Results demonstrate that TNFα and TACE can identify VHR individuals 
and may add value to current risk prediction models. Additionally, this study shows 
that despite clinical management in VHR participants with a previous PCI, TNFα 
plasma levels remain high whereas TACE mRNA levels are low. This suggests that 
there are mechanisms in place behind TACE downregulation and TNFα over secretion 
after a PCI that need further understanding. On the other hand, this is the first study 
to measure both TACE gene expression and TACE protein levels (plasma and cell 
bound form) in individuals at various levels of cardiovascular risk. This study also 
provides preliminary evidence for the cell membrane bound form of TACE as valuable 
target for future therapy development. Additional studies are however required to 







Cardiovascular disease (CVD) is the leading cause of morbidity and mortality 
worldwide. Coronary Artery Disease (CAD), the largest contributor of CVD, accounts 
for 6.7 million deaths worldwide (WHO global status report on noncommunicable 
diseases, 2014).  Importantly, most patients who die from CAD have no previous 
symptoms and currently, there is no definitive way to predict cardiovascular events. 
Clinicians rely on the use of risk factors such as age, high cholesterol, obesity, 
smoking, high blood pressure, diabetes, and chronic kidney disease, some of which 
are used in scoring systems, to predict who is most susceptible. However, these 
scoring systems have been intensely criticised because of their lack of predictive 
values in all cases as some patients who are assigned a low score based on one risk 
factor develop CAD while others who are assigned high scores never develop CAD. 
There is therefore a critical need to develop better tests to predict those at risk of 
either primary or secondary cardiovascular events. 
 CAD initiation and progression is due to atherosclerosis which is the result of an 
imbalanced lipid metabolism and a maladaptive immune response leading to chronic 
inflammation in the arterial wall (6,7).  Atherosclerosis was once thought to be 
associated with a passive build-up of plaque but is now recognised as an 
inflammatory disease (162). Some inflammatory pathways are known to have 
involvement in the initiation of the atherosclerotic lesion (163) while others have 
been shown to play an important role in plaque rupture and thrombosis (164). 




uncover the underlying state of the disease and the likelihood of the occurrence of 
major adverse cardiovascular events (MACE). 
In the present study, the inflammatory pathway involving tumour necrosis factor 
alpha (TNFα) and tumour necrosis factor alpha converting enzyme (TACE) (also 
known as ADAM17) is explored. TACE is a membrane bound protein responsible for 
the ectodomain shedding of a variety of inflammatory markers, including TNFα, most 
of which play role in the initiation and progression of CAD (151,152). It is already well-
established that TNFα levels are higher in participants with an acute myocardial 
infarction (AMI) (153,154) with higher levels in AMI participants compared to stable 
angina participants (165). Since TNFα has been extensively investigated in CAD, 
studying the main enzyme responsible for cleaving membrane TNFα could provide 
further insight on the role of this pathway in CAD. TACE gene expression levels and 
surface protein expression have been measured in previous studies either by 
quantitative real-time PCR, immunohistochemistry or flow cytometry techniques. In 
those studies, TACE was found to be increased in myocarditis (166), advanced 
congestive heart failure (167), aortic aneurysm (168), hypertension (169), AMI (165), 
AMI and complications such as heart failure and arrhythmias (170,171) and 
atherosclerotic ischemic stroke (172). However, despite the major role of TACE in 
several inflammatory processes, the assessment of its value as a potential CVD 
biomarker by measuring its plasma levels in CVD individuals hasn’t been previously 
explored. TACE internalisation is its major form of its self-elimination (173,174). 
However, TACE has been detected on the surface of microparticles released from 
platelets and endothelial cells in the plasma (175,176). To date, TACE plasma levels 




associated vasculitis (AAV), clinical malaria and Alzheimer’s disease (176–178), but  
were not previously measured in individuals with CAD. The main aim of this study 
was therefore to measure the different forms of TACE protein in terms of plasma, 
cell membrane bound and gene expression levels together with TNFα plasma levels 
in order to assess their role in CVD risk stratification. 
3.2 Participants and Methods 
Refer to section 2.1 in Chapter 2 for a detailed description of the participant 
recruitment process, the risk score used and the methods for blood processing.  
3.2.1 Demographic information  
The presence of comorbidities such as hypertension, diabetes, chronic kidney disease 
(glomerular filtration rate (GFR) < 60 ml/min), arthritis, depression or any other 
condition was recorded for each participant after consulting the participant’s 
hospital notes as well as the Northern Ireland electronic care record (NIECR). The 
presence of a previous myocardial infarction (MI), percutaneous coronary 
intervention (PCI), Coronary artery bypass graft (CABG) or stroke were recorded. 
Hyperlipidaemia was considered present if 1 of 3 criteria was met: total cholesterol 
≥5.0 mmol/L, self-reported hyperlipidaemia or if hyperlipidaemia was mentioned in 
the participant’s notes or on the electronic care records. Medical and family history 
were collected from each participant. Body mass index (BMI) was calculated from 
baseline investigation measurements of height (cm) and weight (kg). Physical activity 
was ascertained from questionnaire data on leisure-time exercise during the past 




classified as current smokers. Participants’ employment status, alcohol consumption 
and diet was also recorded. No information about race/ethnicity was collected. Acute 
coronary syndrome VHR (ACS-VHR) participants admitted for major adverse 
cardiovascular events (MACE) were defined as VHR participants admitted with an 
ACS (unstable angina, non-ST-segment elevation myocardial infarction or ST-
segment elevation myocardial infarction) who have previously had an MI, a PCI, a 
CABG or a stroke. Follow up MACE were defined either within 6 months or after 6 
months as any deaths, admission for ACS or stroke and transient ischemic attack 
(TIA). The angiogram outcome was reported in terms of the severity of the 
atherosclerotic lesion based on the angiogram report that was issued by the 
consultant cardiologist. The angiogram outcome was classified as mild, moderate, 
severe, very severe disease, major obstruction or triple vessel disease. 
3.2.2 Measurement of TNFα plasma protein levels 
Refer to section 2.10 in Chapter 2.  
3.2.4 Measurement of TACE gene expression 
Refer to section 2.11, 2.12 and 2.13 in Chapter 2. 
3.2.5 Measurement of plasma TACE plasma protein levels 
Refer to section 2.6.1 in Chapter 2. 
3.2.6 Measurement of cell membrane bound TACE protein 
levels 




3.2.7 Statistical methods 
Data analysis was performed using the IBM® SPSS version 23 software (SPSS Inc., 
Chicago, IL). In the analysis, cases with missing data were excluded pairwise. 
Normality tests were conducted for all explored continuous variables. Variables that 
did not follow normal distribution were transformed using a logarithmic function to 
allow their use in parametric methods of analysis. Descriptive statistics were carried 
out with standard methods using Student T-test when comparing the means of two 
groups, ANOVA when comparing the means of more than two groups and Pearson 
Chi Square test when comparing categorical variables. Continuous variables were 
expressed as mean ± SD whereas categorical variables were expressed as 
percentages. An analysis of covariates (ANCOVA - also known as a hierarchical 
multiple regression) was used to compare the levels of each variable between 
different groups while controlling for confounding factors. Because our cohorts were 
not age and sex matched, age and gender were controlled for in the statistical 
analysis. Age and gender are recognised as confounding effects because increased 
age as well as male gender are associated with CVD (179) and they have also shown 
to be associated with the variability of the measured biomarker levels in a linear 
regression model applied in the study (180). Within the comparisons among the VHR 
cohort, no adjustments were made unless a covariate was associated with both the 
biomarker and the outcome as previously descried paper by Kamangar et al. 
regarding confounding variables in epidemiological studies (180). Pearson’s 
correlation was used to evaluate the correlation between variables. A logistic 




predict the cohort membership (VHR or non-VHR). A multinomial logistic regression 
analysis was performed to investigate whether the measured variables can 
effectively predict the severity of the plaque burden. Statistical significance was 
defined as values of p<0.05 (two-tailed). 
3.3. Results 
3.3.1 Population Demographics 
A total of 344 participants were recruited consecutively over a period of two 
years. The VHR (n=229) group consisted of ACS-VHR (n=127) and ELEC-VHR (n=102) 
participants. The non-VHR (n=115) group consisted of low risk (LR) (n=81), moderate 
risk (MR) (n=32) and high risk (HR) (n=2) participants. All recruited participants were 
assigned a risk SCORE according to the European Society of Cardiology (ESC) 
guidelines. The VHR group had a SCORE ≥ 10% and the non-VHR group had a SCORE 
< 10%. Table 1 and 2 provide the full descriptive statistics of the population. The 
mean age of the VHR participants at study entry was 65 years and 21% were women. 
A proportion of 56% had a history of hypertension, 19% were diabetic and 19% were 
current smokers. The mean age of the non-VHR participants was 46 years and 70% 
were women. A proportion of 13% percent had hypertension (who were more likely 







Table 1: Population demographics of participants at various levels of 
cardiovascular risk classified according to the SCORE risk chart. 
  










229 32 81   229 115   
Age (years) 65 56 41 <0.0001 65 46 <0.0001 
Male (n; %) 170; 78.6  16; 50.0 16; 19.7 <0.0001  
(Chi 2) 
170; 78.6 34; 29.6 <0.0001  


















26.7 ± 5.5 0.0087 29.1 ± 6.4 27.5 ± 5.9 0.0188 
Systolic BP 
(mmHg) 
131 ± 24 137 ± 2 119 ± 14 <0.0001 131 ± 24 124 ± 20 0.0111 
Diastolic BP 
(mmHg) 












1.2 ± 0.5 1.6 ± 0.4 1.6 ± 0.4 <0.0001 1.2 ± 0.5 1.6 ± 0.4 <0.0001 




2.9 ± 2.3 2.4 ± 3.8 0.008 12.0 ± 31.2 2.5 ± 3.4 0.002 
One way ANOVA was used to compare the VHR, MR and LR cohorts. Student t-test was used to 
compare VHR to non-VHR. (BMI: body mass index; BP: blood pressure; CRP: C-reactive protein; 
HDL: high density lipoprotein; LDL: low density lipoprotein; LR: low risk; MR: moderate risk; 
SCORE: Systematic COronary Risk Evaluation risk score; VHR: very high risk; non-VHR: non-very 









Table 2: Medical history and lifestyle characteristics of participants at various levels 
cardiovascular risk classified according to the SCORE risk chart. 








229 32 81 229 115 




9; 28.1 5; 6.17 <0.0001 128; 55.9 15; 13.0 <0.0001 




20; 62.5 35; 43.2 0.0404 134; 58.5 57; 49.6 0.115 
GFR <60 
ml/min 
45; 20.0 1; 3.4 2; 2.5 0.000154 45; 20.0 3; 2.7 <0.0001 
Arthritis 35; 15.3 5; 15.6 1; 1.2 0.0029 35; 15.3 6; 5.2 0.00656 
Depression 43; 18.8 4; 12.5 7; 8.6 0.0858 43; 18.8 11; 9.6 0.0267 
Employed  33.3 26; 79.3 80; 98.8 <0.0001 33.3 104; 92.9 <0.0001 
Current 
smokers 




9; 29.0 35; 43.2 <0.0001 110; 50.4 45; 39.1 <0.0001 
Pearson’s chi square test was used to compare VHR, MR and LR groups and the VHR and non-VHR 
groups. (GFR: Glomerular filtration rate; LR: low risk; MR: moderate risk; non-VHR: non-very high 


















Table 3: TNFα plasma and TACE plasma and gene expression levels in participants at 
various levels of cardiovascular risk classified according to the SCORE risk chart. 
  




p value  
(adjusted)* 
Number of participants 229 32 81     
TNFα plasma levels 
(pg/ml) 































p value  
(adjusted)* 
Number of participants 229 115     
TNFα plasma levels 
(pg/ml) 






0.03755 ± 0.02051 (n=114) p<0.0001 0.006 




905.90 ± 3750.23 0.044 0.642 
ANCOVA analysis was used to compare the cohorts. Two p values were calculated to assess the 
impact of the covariates on the analysis. (LR: low risk; MR: moderate risk; non-VHR: non-very 
high risk; SCORE: Systematic COronary Risk Evaluation risk score; TACE: tumour necrosis factor 
alpha converting enzyme, TNFα: tumour necrosis factor alpha; VHR: very high risk  
*adjusted for age and gender for TNFα plasma levels, TACE gene expression and TACE plasma levels.  
For statistical analysis TNFα plasma levels, TACE gene expression and TACE plasma levels were 
transformed using a log transformation as values did not follow the normal distribution  
3.3.2 TNFα plasma levels were higher in VHR participants 
To determine whether TNFα levels were different in individuals at various levels of 
cardiovascular risk, TNFα soluble levels were measured in the plasma. Results 
showed that TNFα plasma levels were significantly higher in VHR compared to non-
VHR participants (4.711 ± 2.453 pg/ml vs. 2.770 ± 0.752 pg/ml; p<0.0001) (Figure 1a) 




significantly with increasing cardiovascular risk with the highest levels in the VHR 
category and the lowest levels in the LR category (p<0.0001) (Figure 1b and Table 3).  
To investigate whether TNFα plasma levels could further stratify the VHR 
population, various subgroups were compared. TNFα plasma levels were higher in 
VHR participants who had experienced a previous myocardial infarction (MI) 
compared to those that had not experienced a previous MI (5.399 ± 2.368 pg/ml vs. 
4.389 ± 2.433 pg/m; p<0.01) (Figure 1c). To explore whether previous MI stratified 
both ACS-VHR and ELEC-VHR, TNFα plasma levels were compared in ACS-VHR and 
ELEC-VHR. The present data showed that TNFα plasma levels were also significantly 
higher in ACS-VHR participants with a previous MI compared to ACS-VHR participants 
with no previous MI (5.919± 3.028 pg/ml vs. 4.401± 2.609 pg/ml; p<0.05) and in ELEC-
VHR participants with a previous MI compared to ELEC-VHR participants with no 
previous MI (5.035± 1.720 pg/ml vs. 4.355 ± 2.109 pg/ml; p<0.05).  
In terms of revascularisation, TNFα plasma levels were higher in VHR participants 
who had underwent a previous percutaneous coronary intervention (PCI) compared 
to VHR participants who had not undergone a previous PCI (5.260 ± 2.337 pg/ml vs. 
4.454 ± 2.471 pg/ml; p<0.01) (Figure 1d). This difference was also observed in ACS-
VHR participants with a previous PCI compared to ACS-VHR participants with no 
previous PCI (5.707 ± 3.106 pg/ml vs. 4.500 ± 2.643 pg/ml; p<0.05) and in ELEC-VHR 
participants with a previous PCI compared to ELEC-VHR participants with no previous 
PCI (4.982 ± 1.675 pg/ml vs. 4.374 ± 2.159 pg/ml; p<0.05). Interestingly, however, 




bypass surgery (CABG). In addition, TNFα plasma levels were not significantly 
different between ACS-VHR and ELEC-VHR individuals. 
VHR participants with a previous MI and a previous PCI were both more likely to 
be on statin (90.4%; p<0.0001 and 91.8% p<0.0001 respectively), anti-platelet 
(90.4%; p<0.0001 and 91.8%; p<0.0001 respectively) and anti-hypertensive therapy 
(90.4%; p<0.0001 and 93.2%; p<0.0001 respectively) and had both lower levels of 
total cholesterol (3.76 ± 0.96 vs. 4.38 ± 1.41; p<0.01 and 3.73 ± 1.00 vs. 4.41 ± 1.40; 
p<0.001 respectively) compared to those with no previous MI or a previous PCI.  
In terms of first cardiovascular event and recurrent MACE, results showed that 
TNFα plasma levels were higher in ACS-VHR participants admitted for recurrent 
MACE compared to ACS-VHR participants admitted for their first event (5.594 ± 3.878 
vs. 4.114 ± 1.635; p<0.01) (Figure 1e).  
Regarding VHR participants with different comorbidities, TNFα plasma levels 
were higher in VHR participants with diabetes (19.2%) compared to non-diabetics 
(5.328 ± 1.958 vs. 4.564 ± 2.539; p<0.01). TNFα plasma levels were also higher in VHR 
participants with hypertension (55.9%) compared to VHR participants with no 
hypertension (5.161 ± 2.851 vs. 4.141 ± 1.676; p<0.05). Furthermore, TNFα plasma 
levels were higher in VHR participants with a diagnosis of heart failure (15.7%) (5.320 
± 2.191 vs. 4.600 ± 2.489; p<0.05) compared to those with no diagnosis of heart 
failure. In addition, TNFα plasma levels were higher in VHR individuals with arthritis 
compared to those with no arthritis (5.790 ± 3.578 vs. 4.517 ± 2.146; p<0.01) and in 
VHR participants with glomerular filtration rate (GFR) of less than 60 ml/min 




p<0.05). Interestingly, participants with a GFR of less than 60 ml/min were more likely 
to be ACS-VHR (p<0.05). 
Moreover, TNFα plasma levels were higher in VHR participants on statin (4.972 ± 
2.625 vs. 4.079 ± 1.795; p<0.01), anti-platelet (5.085 ± 2.685 vs. 3.975 ± 1.660; p<0.01) 






Figure 1: TNFα plasma protein levels are higher in participants at very high 
cardiovascular risk. TNFα plasma protein levels were measured by ELISA using the 
MSD® MULTI-SPOT Assay System. Figure 1a: TNFα plasma levels are higher in VHR 
participants compared to non-VHR participants. Figure 1b: TNFα plasma levels are 
higher with increasing cardiovascular risk. Figure 1c: TNFα plasma levels are higher 
in VHR participants with previous MI compared to VHR participants with no previous 
MI. Figure 1d: TNFα plasma levels are higher in VHR participants with previous PCI 
compared to VHR participants with no previous PCI. Figure 1e: TNFα plasma levels 
in ACS-VHR participants admitted for MACE. (ACS: acute coronary syndrome; LR: 
low risk; MACE: Major adverse cardiovascular events; MI: myocardial infarction; 
MR: moderate risk; non-VHR: non-very high risk participants; PCI: Percutaneous 




VHR: very high risk). Statistical analysis was performed by ANCOVA. **p<0.01; 
****p<0.0001 
3.3.3 TACE mRNA levels were higher in VHR participants 
To explore whether TACE gene expression was associated with cardiovascular risk, 
TACE mRNA levels were measured in peripheral blood mononuclear cells (PBMCs). 
Results demonstrated that TACE mRNA levels were higher in VHR participants 
compared to non-VHR participants (0.05366 ± 0.03127 vs. 0.03755 ± 0.02051; 
p<0.01) (Figure 2a). In addition, TACE mRNA levels increased significantly with 
increasing cardiovascular risk where the expression was highest in the VHR category 
and the lowest in the LR category (p<0.05) (Figure 2b and Table 3). 
To investigate whether TACE gene expression could further stratify the VHR 
population, various subgroups were compared. Results indicate that TACE mRNA 
levels were lower in VHR participants who had underwent previous PCI compared to 
VHR participants who had not undergone a previous PCI (0.04624 ± 0.02494 vs. 
0.05708 ± 0.03331 with p<0.05) (Figure 2c). In relation to whether previous PCI 
differentiated between both ACS-VHR and ELEC-VHR participants, results showed 
that TACE mRNA levels tended to be lower in ACS-VHR individuals with a previous PCI 
compared to ACS-VHR individuals with no previous PCI (0.0476 ± 0.02558 vs. 0.05615 
± 0.03119; p=0.117) and in ELEC-VHR with a previous PCI compared to ELEC-VHR 
participants with no previous PCI (0.04535 ± 0.02478 vs. 0.05868 ± 0.03690; 
p=0.054). However, TACE mRNA levels were not significantly different between ACS-




VHR participants with a previous PCI were more likely to be on statin (91.8% 
p<0.0001), anti-platelet (91.8%; p<0.0001) and anti-hypertensive therapy (93.2%; 
p<0.0001) and had lower levels of total cholesterol (3.73 ± 1.00 vs. 4.41 ± 1.40; 
p<0.001).  
3.3.4 Cell membrane bound TACE protein levels were higher in 
VHR participants 
After measuring TACE gene expression in the PBMCs, one could speculate whether 
cell membrane bound TACE protein levels were also associated with cardiovascular 
risk. Therefore, cell membrane bound TACE protein levels were measured in the 
PBMCs in a random sample of participants. Data showed that cell membrane bound 
TACE protein levels were higher in VHR (n=80) vs. non-VHR (n=36) participants (383.9 
± 259.6 pg/ml vs. 221.9 ± 78.8 pg/ml with p<0.0001) (Figure2d). Additionally, cell 
membrane bound TACE protein levels appeared to be higher in MR vs LR participants 
(275.5 ± 86.36 pg/ml vs 209.71 ±73.25 pg.ml with p=0.057). Cell membrane bound 
TACE levels were not statistically different in ACS-VHR compared to ELEC-VHR 
participants. However, cell bound TACE levels were higher in ACS-VHR admitted for 
a first cardiovascular event compared to non-VHR participants (415.89 ± 294.60 vs 
209.71 ± 73.25, p<0.01). Moreover, cell membrane bound TACE protein levels were 
not statistically different between VHR participants with a previous MI compared to 
those with no previous MI or in VHR participants with a previous PCI compared to 




3.3.5 TACE plasma levels were not significantly different 
between VHR and non-VHR participants 
To test if TACE protein is detectable in the plasma and whether levels are associated 
with cardiovascular risk, TACE plasma levels were measured. Results demonstrated 
that TACE plasma levels were only significantly different between VHR and non-VHR 
participants before adjustment (p<0.05) but the statistical significance was lost after 
adjustment for age and gender (p= 0.642) (Figure 2e and Table 3) where age was a 
strong confounder. Furthermore, TACE plasma levels were not statistically different 
in ACS-VHR compared to ELEC-VHR participants or in VHR participants with a previous 
MI compared to those with no previous MI or in VHR participants with a previous PCI 





Figure 2: TACE gene expression, protein expression and plasma levels in 
participants at various levels of cardiovascular risk. TACE gene expression was 
measured in the peripheral blood mononuclear cells (PBMCs) by quantitative real-
time PCR and normalised to GAPDH. Cell membrane bound TACE protein levels were 
measured by ELISA following a total protein extraction from the PBMCs after 
normalisation to 5000ug/ml of total protein. TACE plasma protein levels were 
measured by ELISA. Figure 2a: TACE gene expression is higher in VHR compared to 
non-VHR participants. Figure 2b: TACE gene expression is higher with increasing 
cardiovascular risk. Figure 2c: TACE gene expression is higher in VHR participants with 
previous PCI compared to VHR participants without a previous PCI. Figure 2d: Cell 
membrane bound TACE protein levels are higher in VHR compared to non-VHR 




participants. (LR: low risk; MR: moderate risk; non-VHR: non-very high risk 
participants; PCI: Percutaneous coronary intervention; TACE: tumour necrosis factor 
alpha converting enzyme; VHR: very high risk). Statistical analysis was performed by 
ANCOVA. *p<0.05, **p<0.01, ****p<0.0001 
3.3.6 CRP plasma levels did not further differentiate between 
VHR participant sub-groups 
To investigate whether TNFα and TACE have a superior value to CRP measurement 
in VHR individuals, CRP levels were compared across various VHR subgroups. Results 
showed that CRP plasma levels were not significantly different between ACS-VHR 
compared to ELEC-VHR participants (p=0.942). Furthermore, CRP plasma levels were 
not different between VHR participants with a previous MI compared to those with 
no previous MI (p=0.942) or in participants with a previous PCI compared to those 
with no previous PCI (p=0.887). Additionally, CRP plasma levels were not significantly 
different between VHR diabetic participants compared to VHR non-diabetic 
participants (p=0.286) or between VHR participants with heart failure compared to 
VHR participants with no heart failure (p=0.815). Moreover, CRP plasma levels were 
not significantly different between VHR participants with a GFR less than 60 ml/min 
compared to those with a GFR higher than 60 ml/min (p=0.475). CRP plasma levels 
were also not significantly different between VHR participants admitted for a 
recurrent MACE compared to those admitted for their first event (p=0.294).  
3.3.7 TACE gene expression correlated positively with TNFα 
plasma levels and both proteins can predict cardiovascular risk 
To explore whether TNFα and TACE levels correlated with different variables 




mRNA levels correlated positively with TNFα plasma levels, age and body mass index 
(BMI) (p<0.01, p<0.001 and p<0.05 respectively) and TACE plasma levels correlated 
negatively with age (p<0.05). TNFα plasma levels correlated positively with C reactive 
protein (CRP) plasma levels, age and BMI (p<0.01, p<0.0001 and p<0.05 respectively) 
and negatively with cholesterol levels (p<0.0001). Refer to Table 5 for full correlation 
matrix and p values.  
To investigate whether a panel combining TNFα and TACE mRNA levels could 
significantly predict the presence of a cardiovascular risk, a logistic regression 
analysis was performed (section 3.2.7). Results indicated that TACE gene expression 
and TNFα plasma levels could collectively predict the cohort membership (VHR or 



















































1 -.052 -.101 -.003 -.130* -.070 -.046 .051 
Sig. (2-
tailed) 
  .348 .064 .961 .017 .219 .437 .373 







-.052 1 .162** .105 .208** .112 .100 -.085 
Sig. (2-
tailed) 
.348   .003 .077 .000 .050 .092 .138 






-.101 .162** 1 .186** .470** .126* .109 -.272** 
Sig. (2-
tailed) 
.064 .003   .002 .000 .026 .067 .000 





-.003 .105 .186** 1 .100 .115 -.114 -.116 
Sig. (2-
tailed) 
.961 .077 .002   .091 .062 .076 .059 
N 286 283 284 286 286 264 243 264 
Age (years) Pearson 
Correlation 
-.130* .208** .470** .100 1 .080 .205** -.307** 
Sig. (2-
tailed) 
.017 .000 .000 .091   .159 .000 .000 
N 336 331 334 286 336 312 288 311 
BMI (Kg/m2) Pearson 
Correlation 
-.070 .112 .126* .115 .080 1 .099 -.016 
Sig. (2-
tailed) 
.219 .050 .026 .062 .159   .103 .783 





-.046 .100 .109 -.114 .205** .099 1 .074 
Sig. (2-
tailed) 
.437 .092 .067 .076 .000 .103   .224 






.051 -.085 -.272** -.116 -.307** -.016 .074 1 
Sig. (2-
tailed) 
.373 .138 .000 .059 .000 .783 .224   
N 311 306 309 264 311 289 268 311 
Highlighted cells refer to a significant result. (BMI: body mass index; BP: blood pressure; CRP: C-
reactive protein; TACE: tumour necrosis factor alpha converting enzyme, TNFα: tumour necrosis 





3.3.8 TACE and TNFα plasma levels did not correlate with 
angiographic outcome 
To explore if TNFα and TACE levels could determine the plaque burden in VHR 
participants, a multinomial logistic regression analysis was carried out (section 3.2.7). 
This showed that the measured biomarkers were not able to effectively predict the 
angiographic outcome and the severity of the plaque burden. In addition, an ANOVA 
analysis did not show any difference between the biomarker levels and the different 




















p value  
Demographic and 
History (n; %) 
      
Gender       




0.5453 ± 0.319 
0.4470 
4.655 ± 2.489 
0.3370 
Female (49; 21.4) 
477.741 ± 
1239.84 
0.5040 ± 0.028 4.9169 ± 2.33 
Diabetes mellitus       





5.328 ± 1.958 
0.007 
Absent (185; 80.8) 721.81 ± 2557.47 
0.05290 ± 
0.03299 
4.564 ± 2.539 
Heart failure       
Present (36; 15.7) 





5.320 ± 2.191 
0.042 
Absent (193; 84.3) 
827.65 ± 2963.77 
0.05340 ± 
0.01315 
4.600 ± 2.489 
Renal function       
GFR < 60 (45; 20) 
1053.18 ± 
4282.93 0.347 
0.0550 ± 0.0303 
0.778 5.731 ± 2.62 0.02 
GFR > 60 (180; 80) 675.50 ± 2237.94 0.0534 ± 0.0317 4.50 ± 2.36 
Hypertension       





5.161 ± 2.851 
0.021 
Absent (101; 44.1) 684.17 ± 1924.52  
0.05251 ± 
0.02789 
4.141 ± 1.676 
Dyslipidaemia       





4.613 ± 1.752  
0.714 
Absent (95; 41.5) 636.80 ± 1765.69 
0.05281 ± 
0.03133 
4.850 ± 3.200  
Arthritis       
Present (35; 15.3) 





5.790 ± 3.578 
0.003 
Absent (194; 84.7) 
762.71 ± 2907.60 
0.05364 ± 
0.0313 
4.517 ± 2.146 
Depression       
Present (43; 18.8) 





4.784 ± 1.835 
0.067 
Absent (186; 81.2) 
798.85 ± 2965.32 
0.05510 ± 
0.03264 
4.694 ± 2.579 
Present or previous 
cancer 
      










Absent (202; 88.2) 
644.80 ± 2132.61 
0.05219 ± 
0.02958 
4.640 ± 2.484 
Smoking status       
None (66; 30.3) 820.51 ± 2134.71 
0.21 
0.0512 ± 0.026 
0.253 




843.83 ± 3510.60 0.0596 ± 0.0364 5.020 ± 2.875 
Current (42; 19.3) 311.69 ± 897.17 0.0464 ± 0.0229 4.342 ± 2.390 
Pharmacotherapy       
Statin therapy       





4.972 ± 2.625 
0.002 
Absent (62; 27.3) 641.31 ± 1778.00 
0.05603 ± 
0.03437 
4.079 ± 1.795 
Antiplatelet 
therapy 
      





5.085 ± 2.685 
0.002 
Absent (73; 32.1) 653.87 ± 1733.81 
0.05592 ± 
0.03380 
3.975 ± 1.660 
Antihypertensive 
therapy 
      





5.007 ± 2.630 
0.005 
Absent (55; 24.2) 753.18 ± 1963.55 
0.05354 ± 
0.03190 
3.856 ± 1.520 
Antianginal 
therapy 
      
Present (88; 38.8) 





5.104 ± 2.510 
0.033 
Absent (139; 61.2) 
711.36 ± 2409.20 
0.05551 ± 
0.03145 
4.490 ± 2.399 
Diuretic therapy       
Present (56; 24.7) 





5.547 ± 3.260  
0.023 
Absent (171; 75.3) 
681.40 ± 2624.79 
0.05099 ± 
0.02944 
4.460 ± 2.070 
Drug naïve       
Present (54; 23.7) 





3.926 ± 1.575 
0.033 




4.960 ± 2.629 
Clinical Variables       
ACS-VHR (127; 55.5) 









677.52 ± 2565.61 
0.05289 ± 
0.03277 
4.642 ± 1.975 
Previous MI        







5.399 ± 2.368  
0.01 
Absent (156; 68.1) 605.31 ± 1645.34 
0.05456 ± 


















5.919± 3.028  
0.020 





4.401± 2.609  












5.035± 1.720  
0.023 


















5.260 ± 2.337 
0.009 
Absent (56; 68.1) 
684.65 ± 2319.61 
0.05708 ± 
0.03331 4.454 ± 2.471 














5.707 ± 3.106 
0.028 
Absent (99; 78.0) 
625.70 ± 1623.64 
0.05615 ± 
0.03119 4.500 ± 2.643  







Present (45; 44.1) 





4.982 ± 1.675  
0.028 
Absent (57; 55.9) 
787.03 ± 3203.51 
0.05868 ± 
0.03690 4.374 ± 2.159  





Present (22; 9.6) 





6.005 ± 4.441 
0.102 
Absent (207; 90.4) 
739.37 ± 2802.03 
0.05299 ± 
0.03118 
4.573 ± 2.110 
Previous MI, PCI or 
CABG 
      







5.380 ± 2.905 
0.001 
Absent (129; 56.3) 
505.65 ± 1423.70 
0.05546 ± 
0.03312 
4.192 ± 2.905 
Diagnosis upon 
admission 
      
Stable Angina (85; 
37.1) 
681.56 ± 2753.69 
0.106 
0.0557 ± 0.0341 
0.744 










NSTEMI < 1 week 
(77; 33.6) 
472.89 ± 1040.14 0.0559 ± 0.0306 4.835 ± 2.949 
STEMI < 1 week (7; 
3.0) 
96.30 ± 177.65 0.0521 ± 0.444 4.867 ± 1.888 
Other (39; 17.03)       
ACS-VHR 
participants 
admitted for MACE 
      
Present (45; 35.4) 
1045.36 ± 
4259.01 0.28 
0.0550 ± 0.0300 
0.999 
5.594 ± 3.878 
0.007 
Absent (82; 64.6) 649.42 ± 1727.99 0.0538 ± 0.0304 4.114 ± 1.635 
Participants with 
no previous MI, PCI 
or CABG 
 
     
ACS-VHR (84, 65.1) 





4.179 ± 1.686 
0.542 
ELEC-VHR (45, 34.9) 
259.48 ± 541.41 0.05865 ± 
0.03778 
4.217 ± 2.240 
Prognostic 
variable       
Follow-up MACE        
Within 6 months (5; 
2.2) 
99.68 ± 161.66 
0.801 
0.0495 ± 0.0258 
0.798 
6.118 ± 0.716 




0.4814 ± 0.0308 5.022 ± 2.246 
Absent (213; 93.0) 684.72 ± 2413.31 0.5404 ± 0.3150  4.662 ± 2.483 
Highlighted cells refer to p values <0.05 (ACS: acute coronary syndrome participants; CABG: Coronary 
artery bypass surgery; ELEC: elective participants; GFR: Glomerular filtration rate; MACE: major 
adverse cardiovascular events MI: Myocardial Infarction; NSTEMI: non-ST elevation myocardial 
infarction; PCI: percutaneous coronary intervention; STEMI: ST elevation myocardial infarction; TACE: 







The results of this study demonstrated that TNFα and TACE could be potential 
markers for CVD risk. In addition, TNFα and TACE were able to further stratify 
individuals within the VHR group who were at higher risk of MACE with a higher 
sensitivity compared to CRP.  
3.4.1 TNFα plasma and TACE mRNA levels identified and 
further stratified VHR participant sub-groups 
This study demonstrated that TNFα plasma levels were higher in VHR participants 
compared to non-VHR individuals corroborating previous results (153,154,181). 
Additionally, TNFα plasma levels were sufficiently sensitive in identifying 
cardiovascular risk in parallel to the SCORE risk which is a novel finding. Interestingly, 
in this study, TNFα plasma levels were higher in VHR participants with a previous MI 
compared to VHR participants with no previous MI and in VHR participants with 
previous PCI compared to VHR participants with no previous PCI. This was observed 
in both ACS-VHR and ELEC-VHR individuals. Participants with a previous MI and PCI 
were more likely to be on statin, antiplatelet and antihypertensive therapy. This 
indicates that, in these participants, medical management and revascularisation 
strategies fail to lower TNFα plasma levels post-MI and post-PCI. Persistent high TNFα 
plasma levels post-MI were attributed to endothelial dysfunction in diabetic patients 
with a previous MI (182) and it was shown that statins can protect the endothelial 
cells from TNFα induced inflammation (183). However, many studies have discussed 
the controversial effects of inhibiting TNFα in CVD and suggested that minimal levels 




relation to the occurrence of cardiovascular events has been previously reported 
(185). In agreement with these results, the current study shows that TNFα plasma 
levels were higher in ACS-VHR participants admitted for recurrent MACE compared 
to ACS-VHR participants admitted for their first cardiovascular event. Persistently 
elevated TNFα plasma levels post-MI have been linked to an increased risk of MACE 
(181). These results suggest that although TNFα might not be an ideal target in CVD, 
it could be used as a potential biomarker for recurrent MACE. Interestingly, TNFα 
plasma levels were not significantly higher in VHR participants with a previous CABG 
compared to those with no previous CABG. This demonstrates the previously 
reported superior value of CABG as a revascularisation strategy as opposed to PCI 
(186). 
In view of the previous results, levels of TACE, the enzyme responsible for TNFα 
cleavage, were measured. This was to explore whether TACE levels could add value 
to the CVD risk assessment. Results showed that, similarly to TNFα plasma levels, 
TACE gene expression was higher in VHR compared to non-VHR participants. 
Interestingly, in contrast to what was observed with TNFα plasma levels, TACE gene 
expression was lower in VHR participants with a previous PCI compared to VHR 
participants with no previous PCI. This trend was also observed in ACS-VHR and ELEC-
VHR individuals. Since participants with a previous PCI were on statin, antiplatelet 
and antihypertensive therapy, this highlights the possible effect of medical 
management and revascularisation strategies on lowering TACE gene expression. 
Nevertheless, it appears that after a PCI and the initiation of a post-PCI medical 
therapy, despite a decrease in TACE gene expression, TNFα plasma levels remain 




that, when present, could enhance TNFα shedding (187), and moreover, there is 
evidence that TNFα could be cleaved by other sheddase such as ADAM10 (188) 
matrix metalloproteinase 7 (189) or matrix metalloproteinase 13 (190). Additionally, 
circulating TNFα might not be biologically active as it might be captured by circulating 
tumour necrosis factor alpha 1 (TNFR1) and 2 (TNFR2) soluble receptors (191). It is 
noteworthy to mention that membrane cholesterol depletion has been shown to 
increase TACE shedding activity and could explain the observed higher TNFα plasma 
levels following statin treatment post MI and post PCI (192,193). On the other hand, 
TACE is known to regulate angiogenesis in cardiomyocytes following MI and when 
upregulated within the normal range, is suggested to provide protective effects post-
MI (194). In the present study, TACE downregulation in participants with a previous 
PCI could be associated with adverse outcomes. However, the mechanisms behind 
this effect need further understanding. 
However, unlike TNFα levels and TACE gene expression, CRP plasma levels were 
not able to identify VHR participants with a previous MI or a previous PCI. This 
strengthens the value of TNFα and TACE in potentially characterising different 
subgroups of VHR individuals with CVD. In addition, CRP plasma levels were not able 
to identify VHR participants with diabetes, heart failure or renal failure. This provides 
additional evidence of the superior role of TNFα and TACE in further stratifying VHR 
individuals. The value of combining TNFα and TACE measurement in a possible 
biomarker screening panel for primary prevention of a CVD event was reflected in a 
logistic regression model. This panel was able to successfully assign participants into 
either VHR or non-VHR group in 79.6% of the cases (r=0.449 and p<0.0001). However, 




optimisation and the measurement of protein levels, when possible, might be more 
practical (137).  
3.4.2 Exploration of TACE plasma and cell membrane bound 
levels in individuals at various levels of cardiovascular risk 
In biomarker development, it is essential for the marker to be measured quickly and 
effectively so the results can orient a patients’ clinical management upon admission. 
As measuring TACE mRNA levels requires different steps before obtaining a result, 
this could delay admission and initiation of an appropriate therapy. Therefore, two 
alternative strategies to TACE measurement were explored. The aim of the first 
strategy was to investigate whether TACE plasma levels were detectable in 
participants with CVD and whether plasma levels showed a similar pattern to TNFα 
plasma and TACE mRNA levels. To date, this is the first study to measure active TACE 
plasma levels in a cohort with CVD. Interestingly, TACE plasma levels showed a 
completely opposite trend compared to TNFα and TACE gene expression levels. TACE 
plasma levels appeared to be lower in VHR compared to non-VHR participants but 
failed to reach statistical significance when controlled for age and gender. However, 
it is noteworthy that TACE plasma levels were hardly detectable in some participants 
and were extremely high in other participants which highlights a need for further 
assay development.  
These results demonstrated that TACE protein can be detected in the plasma 
which has also been proven in other studies where plasma TACE levels were detected 
in several inflammatory diseases (176–178) and second, that there is a mechanism 




to be a membrane bound protein whose presence on the cell surface is essential in 
order to cleave the substrates effectively (151,152). Some studies however, have 
reported the presence of an active form of TACE protein in the plasma (176,177) 
where its activity has been measured using a Fluorescence Resonance Energy 
Transfer assay. Nevertheless, whether TACE can effectively cleave distant substrates 
in vivo is unknown. The major known mechanism of TACE elimination from the cell 
surface is its internalisation (173,174). Although, there is evidence of TACE being 
detected at the surface of microparticles released from platelets and endothelial cells 
in the plasma (175,176). Therefore, it appears that there is a mechanism responsible 
for TACE shedding from the cell surface that could be similar to TACE closest family 
member ADAM10 which has also been successfully detected in the plasma or serum 
by ELISA in a previous study (195). 
As TACE plasma levels followed a trend where levels were lower in VHR compared 
to non-VHR participants, it is possible that in VHR participants, TACE might be 
retained on the cell surface and thus, would exhibit reduced release into the 
bloodstream. Once retained on the cell surface, TACE would shed a higher number 
of inflammatory proteins which could aggravate local and systemic inflammation 
increasing MACE risk in VHR individuals.  
To test this hypothesis, a second strategy for TACE measurement was explored. 
Cell membrane bound TACE protein levels were measured by ELISA after extracting 
total proteins from a buffy coat preparation and normalising the protein levels before 
analysis for all participants. The results validated the proposed theory and showed 




participants. Therefore, in VHR participants, following an increase in TACE gene 
expression, TACE protein synthesis is increased. Hence, there is probable a 
mechanism in place that retains TACE on the cell surface leading to an increase in the 
shedding of inflammatory transmembrane proteins aggravating local and systemic 
inflammation in VHR individuals. To study this effect, some of TACE associated 
proteins could be investigated such as Tissue Inhibitor Of Metalloproteinase 3 
(TIMP3) (Refer to Chapter 4) and other proteins that are known to modulate TACE 
activity  such as Four and a half LIM domains protein 2 (FHL2) (196), Synapse-
associated protein 97 (SAP97) (197) and Protein tyrosine phosphatase, non-receptor 
type 3 (PTPH1) (198). Moreover, this data provides preliminary evidence that TACE 
might be a good target for biological therapeutics. However, new findings 
demonstrate that TACE pro and anti-atherosclerotic effects are cell specific and a cell 
targeted approach should rather be considered with regards to TACE inhibition (199–
201). This might be possible by developing targeted TACE therapy as it was recently 
shown in an model of irritable bowel disease (202). Further work is required to fully 
elucidate the atherogenic effects of TACE. In fact, the authors have shown that a bi-
specific inhibitor, that targets cell membrane bound TACE and a pro-inflammatory 
cytokine, was able to increase its concentration at the cell surface and reduce 
inflammation in irritable bowel disease. The efficacy of such a promising 
therapeutical model should be tested in CVD (202).  
3.4.3 Strengths and Limitations 
Strengths of the study design include the strict plasma sample collection procedure 




on recruitment days and the near-complete information on baseline CVD risk factors 
and follow up events within a year of initial recruitment. Some limitations of the 
present study should also be acknowledged. The number of participants with follow 
up MACE events within one year was low, however, participants are still being 
followed up for MACE events over one year of recruitment. In addition, the definition 
of MACE in this study was restricted to recurrent ACS, stroke TIA and death. However, 
several studies include HF and atrial fibrillation (AF) (203,204) in the definition for 
MACE as well. By including HF and AF in the MACE definition, the total number of 
patients who develop MACE within a year of admission increases to 13.5% as 
opposed to 7.0% when HF and AF are not included. Moreover, the number of high 
risk (HR) participants was only limited to 2 participants and they were therefore 
included in the non-VHR cohort as the definition of the VHR cohort was restricted to 
those with evidence of atheroma as per coronary angiogram. In terms of potential 
biases resulting from the biochemical measurements used in the present study, it is 
important to consider that TACE plasma levels were below the limit of detection in 
many participants. We have used a validated TACE ELISA assay (RAB0003 SIGMA) as 
the other available assays were customised and required a validation by the user 
(R&D ELISA DuoSet). In addition, TACE gene expression could not be measured in 5 
participants as RNA was not obtained from those participants and TNFα plasma levels 
were below the limit of detection in 2 participants and they were therefore excluded 





Figure 3: Proposed model using TACE and TNFα to identify and further stratify VHR 
participants. (ACS: acute coronary syndrome participants; GFR: Glomerular filtration rate; 
MACE: major adverse cardiovascular events MI: Myocardial Infarction; PCI: percutaneous 
coronary intervention; TACE: tumour necrosis factor alpha converting enzyme; TNFα: tumour 






In this study, TACE gene expression and protein levels (plasma and cell bound form) 
were measured for the first time in individuals at various levels of cardiovascular risk. 
Results demonstrate that TACE and TNFα are associated with cardiovascular risk and 
recurrent events. In addition, after a PCI, TNFα plasma levels remain high whereas 
TACE mRNA levels are low despite clinical and medical management which underline 
the need to further investigate the mechanisms behind this process after a PCI. On 
the other hand, this data provides an insight into the mechanism of action of TACE 
and highlights the need for future work to further investigate the best way to 
measure TACE as a marker for CVD risk. This work also provides preliminary evidence 
of the cell membrane bound form of TACE which may be a valuable target for future 
therapy development. Additional studies are however required to investigate this 
















Chapter 4  
TNFR1, TNFR2 and TIMP3 identify 
and further stratify individuals at 







Background: Inflammation plays a crucial role in cardiovascular disease (CVD). 
Tumour Necrosis Factor Alpha Converting Enzyme (TACE) is a membrane bound 
enzyme responsible for cleaving transmembrane Tumour Necrosis Factor Alpha 
(tmTNFα) and its associated receptors releasing soluble TNFα, Tumour Necrosis 
Factor Alpha Receptors 1 and 2 (TNFR1 and TNFR2). TNFR1 receptor is a major 
initiator of inflammation causing endothelial cell dysfunction whereas TNFR2 
receptor has more favourable effects by activating angiogenic and survival pathways. 
Metalloproteinase inhibitor 3 (TIMP3) is the only known endogenous TACE inhibitor. 
Clinical studies exploring the potential role of such biomarkers in predicting major 
adverse cardiovascular events (MACE) risk in very high risk (VHR) individuals is 
lacking. The main purpose of this study was to evaluate whether TNFR1, TNFR2 and 
TIMP3 levels are associated with cardiovascular risk. 
Methods: Participants were recruited from the cardiac catheterisation laboratory or 
by email advertisement. Group 1 was defined as VHR participants with a 10-year risk 
SCORE ≥10% risk of fatal CVD. VHR participants were subdivided in Acute Coronary 
Syndrome (ACS-VHR) and elective percutaneous coronary intervention participants 
(ELEC-VHR). Group 2 were defined as low, moderate and high risk participants (non-
VHR) with a 10-year risk SCORE <10% risk of fatal CVD. TNFR1, TNFR2 and TIMP3 
plasma protein levels as well as cell membrane bound TNFR1, TNFR2, TIMP3 and 
TACE protein levels were measured by enzyme-linked immunosorbent assay (ELISA). 
TIMP3 mRNA levels were measured by quantitative real-time PCR.  
Results: A total of 344 participants were recruited. The VHR (n=229) group consisted 




consisted of low risk (LR) (n=81), moderate risk (MR) (n=32) and high risk (HR) (n=2) 
participants. TNFR1 plasma protein levels were higher in the VHR compared to the 
non-VHR group (1291 ± 1158 pg/ml vs. 817.4 ± 208.6 pg/ml; p<0.01) and levels were 
also higher in ACS-VHR vs. ELEC-VHR participants (1359 pg/ml ± 775 vs. 1103 pg/ml 
± 629; p<0.001). TNFR2 plasma protein levels were numerically higher in the VHR 
compared to the non-VHR group (2839 pg/ml ± 1314 vs. 2099 pg/ml ± 620.1; 
p=0.057) but TNFR2 plasma protein levels were not significantly different in ACS-VHR 
compared to ELEC-VHR participants (p=0.185). TIMP3 mRNA levels were lower in the 
VHR compared to the non-VHR group (0.0001094 ± 0.0001122 vs. 0.0001946 ± 
0.000305; p<0.05). The ratio of cell membrane bound TNFR2 to TNFR1 protein levels 
was lower in the VHR compared to the non VHR group (1.127 ± 0.376 vs. 1.494 ± 
0.604; p<0.05). The ratio of cell membrane bound TIMP3 to TACE protein levels 
showed that in VHR participants, TACE was not effectively inhibited (3.927 ± 3.064 
vs. 9.660 ± 5.239; p<0.0001). 
Conclusion: TNFR1 and TNFR2 plasma protein levels can identify VHR participants as 
well as, in the case of TNFR1, discriminate between ACS-VHR and ELEC-VHR 
participants, which is a novel finding. This is the first report of TIMP3 downregulation 
in individuals with CVD. The ratio of cell membrane bound TNFR2 to TNFR1 and 
TIMP3 to TACE protein levels were also investigated for the first time in CVD 
individuals and were both lower in the VHR compared to the non-VHR group 
highlighting a shift towards a pro-inflammatory state in VHR individuals. These 
proteins should be further investigated as potential biomarkers that may help further 






Tumour necrosis factor alpha converting enzyme (TACE), also known as ADAM17, is 
a cell membrane bound protein responsible for the ectodomain shedding of a variety 
of inflammatory markers, including tumour necrosis factor alpha (TNFα), which play 
a role in the initiation and progression of cardiovascular disease (CVD) (151,152). 
TACE is known to shed TNF receptors 1 (TNFR1) and 2 (TNFR2) releasing their soluble 
forms (151). TNFα superfamily molecules have been linked to CVD and acute 
coronary syndromes (ACS) in many previous studies (205–207), however, their 
exploration in individuals with varying levels of cardiovascular risk has not been 
previously reported. 
TNFR1 and TNFR2 are two transmembrane receptors that have opposing effects 
when it comes to their signalling biology (208). TNFR1 receptor pathways have 
unfavourable effects, increasing inflammation and causing endothelial cell 
dysfunction whereas TNFR2 receptor pathways have more favourable effects by 
activating angiogenic and survival pathways (209,210). Soluble TNFα and 
transmembrane TNFα (tmTNFα) bind to TNFR1 whereas only tmTNFα is believed to 
bind to TNFR2 (211). Additionally, TNFR2 has a higher affinity and a longer TNF-
binding half-life compared to TNFR1 (212). High circulating levels of TNFR1 have been 
associated with Parkinson’s disease (213) and renal disease (214) whereas high 
circulating levels of TNFR2 have been linked to rheumatoid arthritis (215) and 
diabetes (216). Furthermore, high circulating levels of both TNFR1 and TNFR2 soluble 
receptors have been associated with diabetic complications (206) as well as CVD and 




Tissue Inhibitor of Metalloproteinase 3 (TIMP3) is the only known endogenous 
inhibitor of TACE (217) that binds to its catalytic domain in the extracellular matrix 
(218). TIMP3 was previously reported to prevent inflammation and related metabolic 
disorders such as insulin resistance and glucose intolerance (219,220) and is 
downregulated in circulating human monocytes in people at high risk of diabetes 
(221).  
TNFR1, TNFR2 and TIMP3 have been linked separately to CVD, however, clinical 
studies exploring the potential role of this inflammatory pathway in predicting major 
adverse cardiovascular events (MACE) in very high risk individuals is lacking. The first 
aim of this study was to explore any association between TNFR1, TNFR2 and TIMP3 
plasma protein levels with CVD risk. The second aim was to investigate whether these 
biomarker levels are capable of further stratifying individuals at very high risk of 
MACE. 
 4.2 Participants and Methods 
Refer to section 2.1 in Chapter 2 for a detailed description of the participant 
recruitment process, the risk score used and the methods for blood processing.  
4.2.1 Demographic information  
Refer to section 3.2.1 in Chapter 3 for a detailed description of the demographic 




4.2.3 Measurement of TNFR1, TNFR2 and TIMP3 plasma 
protein levels  
Refer to section 2.7.1, 2.8.1 and 2.9.1 in Chapter 2. 
4.2.4 Measurement of TIMP3 gene expression 
Refer to section 2.11, 2.12 and 2.13 in Chapter 2. 
4.2.5 Cell membrane bound TNFR1, TNFR2, TIMP3 and TACE 
protein levels 
Refer to section 2.4, 2.5, 2.7.2, 2.8.2 and 2.9.2 in Chapter 2. 
4.2.6 Statistical methods 
Statistical analysis was carried out as described in section 3.2.7 in Chapter 3  
Additionnaly, in this analysis, an inverse function was assigned for TNFR1 and TNFR2 
plasma levels variables and a log transformation was applied to the TIMP3 plasma 
level variables to allow their use in parametric methods of analysis. In the ANCOVA 
analysis, body mass index (BMI) was controlled for because BMI levels were 
statistically different between the VHR and the non-VHR group and because BMI 
levels were associated with the variability in TNFR1 and TNFR2 plasma levels in a 





4.3.1 Population Demographics 
Refer to section 3.3.1 in Chapter 3 and Table 1 and 2 in Chapter 3. 
 
Table 1: TNFR1, TNFR2, TIMP3 and TACE levels in participants at various levels of 
cardiovascular risk classified according to the SCORE risk chart. 




p value  
(adjusted)* 
Number of participants 229 32 81     
sTNFR1 plasma levels (pg/ml)  







sTNFR2 plasma levels (pg/ml)  







TIMP3 plasma levels (pg/ml)  












p value  
(adjusted)* 
Number of participants 229 115     
sTNFR1 plasma levels (pg/ml)  1291 ± 1158 817.4 ± 208.6 p<0.0001 0.006 
sTNFR2 plasma levels (pg/ml)  2971.0 ± 2199.0 2133.0 ± 614.0 p<0.0001 0.057 
TIMP3 plasma levels (pg/ml)  3397.0 ± 2668.0 3144.0 ± 2516.0 0.396 0.486 
  VHR Non-VHR p value 
TACE cell bound (pg/ml) 
383.9 ± 259.6 
(n=80) 
221.9 ± 78.8 (n=36)  p<0.0001 








TIMP3 cell bound (pg/ml) 
1331.13 ± 
1101.10 (n=28) 
1806.15 ± 1260.91 
(n=18) 
0.104 
TNFR1 cell bound (pg/ml) 
271.71 ± 338.33 
(n=23) 
126.93 ± 49.08 
(n=15) 
0.004 
TNFR2 cell bound (pg/ml) 
261.82 ± 218.68 
(n=23) 
185.83 ± 92.32 
(n=15) 
0.212 
TIMP3 plasma /TIMP3 cell 
bound ratio 
5.993 ± 9.051 
(n=27) 
2.177 ± 2.142 (n=18) 0.028 
TNFR2/TNFR1 cell bound ratio  
1.127 ± 0.376 
(n=23) 
1.494 ± 0.604 (n=15) 0.044 
TIMP3/TACE cell bound ratio 
3.927 ± 3.064 
(n=28) 
9.660 ± 5.239 (n=18) <0.0001 
TNFR1 plasma /TNFR1 cell 
bound ratio 
7.131 ± 5.796 
(n=23) 




TNFR2 plasma /TNFR2 cell 
bound ratio 
14.57 ± 9.16 
(n=23) 
11.78 ± 6.58 (n=15) 0.316 
ANCOVA analysis was used to compare the cohorts. Two p values were calculated to assess 
the impact of the covariates on the analysis. (VHR: very high risk; MR: moderate risk; LR: low 
risk; non-VHR: non-very high risk; SCORE: Systematic COronary Risk Evaluation risk score; TNFR1: 
tumour necrosis factor receptor 1; TNFR2: tumour necrosis factor receptor 2; TIMP3: tissue 
inhibitor of metalloproteinase 3; TACE: tumour necrosis factor alpha converting enzyme).  
*adjusted for age, gender and BMI. For statistical analysis TNFR1 and TNFR2 plasma levels values 
were transformed using an inverse function and TIMP3 plasma levels were transformed using a log 
transformation. 
4.3.2 TNFR1 plasma protein levels were higher in VHR 
participants 
To explore whether TNFR1 levels are associated with cardiovascular risk, TNFR1 
plasma levels were measured in this plasma. This showed that TNFR1 plasma protein 
levels were significantly higher in the VHR compared to the non-VHR group (1291 ± 
1158 pg/ml vs. 817.4 ± 208.6 pg/ml; p<0.01) (Figure 1a). Additionally, TNFR1 plasma 
levels increased significantly with increasing cardiovascular risk with the highest 
levels in the VHR category and the lowest levels in the LR category (p<0.05) (Figure 
1b and Table 1).  
The potential of TNFR1 plasma levels in further differentiating between VHR 
subgroups was examined. In terms of acute events, TNFR1 plasma levels were 
significantly higher in ACS-VHR participants admitted for an acute coronary 
syndrome compared to ELEC-VHR participants (p<0.01) (Figure 1c). Subsequently, 
TNFR1 plasma levels were investigated in order to evaluate whether they could 
specifically identify VHR individuals with first or recurrent acute cardiovascular 
events. First, data showed that TNFR1 plasma levels were numerically higher in ACS-




cardiac events compared to ELEC-VHR participants with no previous cardiac events 
(1215.22 ± 674.81 pg/ml vs. 1052.35 ± 648.25 pg/ml; p=0.060). Second, results 
demonstrated that TNFR1 plasma levels were also numerically higher in ACS-VHR 
participants admitted for recurrent MACE (1882.92 ± 2190.94 pg/ml vs. 1196.52 ± 
672.11 pg/ml; p=0.064) (Figure 1d) compared to ACS-VHR participants admitted for 
their first cardiovascular event.  
To investigate whether TNFR1 plasma levels were associated with MACE within 
one year of follow-up, MACE were recorded for the recruited participants within a 
year of initial admission. Results showed that TNFR1 plasma levels were numerically 
higher on admission in participants who developed MACE after 6 months (p=0.061).  
When it comes to revascularisation strategies, TNFR1 plasma levels were 
numerically higher in VHR participants with a previous myocardial infarction (MI) 
compared to VHR participants with no previous MI (1539.44 ± 1770.45 pg/ml vs. 
1175.00 ± 699.17 pg/ml; p=0.069). To investigate whether this difference was 
independent of acute events, TNFR1 plasma levels were compared across ACS-VHR 
and ELEC-VHR with and without a previous MI. Results indicated that TNFR1 plasma 
levels were significantly higher in ACS-VHR participants with a previous MI compared 
to ACS-VHR participants with no previous MI (2011.18 ± 2610.37 pg/ml vs. 1262.99 ± 
729.27; p<0.05) and in ELEC-VHR participants with a previous MI compared to ELEC-
VHR participants with no previous MI (1210.32 ± 631.38 pg/ml vs. 1030.31 ± 592.52 
pg/ml; p<0.05). 
In regards to VHR participants comorbidities, TNFR1 plasma levels were 




(1537.01 ± 891.82 pg/ml vs. 1232.70 ± 1207.32 pg/ml; p<0.001). VHR participants 
with a diagnosis of heart failure had significantly higher TNFR1 plasma levels 
compared to VHR participants with no heart failure (2067.63 ± 2526.31 pg/ml vs. 
1146.45 ± 542.96 pg/ml; p<0.0001) and in support of this, participants who were on 
diuretic therapy also had significantly higher TNFR1 plasma levels (1656.99 ± 1021.68 
pg/ml vs.  1175.45 ± 1183.46 pg/ml; p<0.0001). A glomerular filtration rate (GFR) of 
less than 60 ml/min in VHR participants was associated with higher TNFR1 plasma 
levels (2243.31 ± 2235.13 pg/ml vs. 1066.24 ± 439.42 pg/ml; p<0.0001) and these 
participants were also more likely to be ACS-VHR individuals (p<0.05). TNFR1 plasma 
levels were also higher in VHR participants with present or previous cancer (2239.29 
± 2770.95 pg/ml vs. 1164.44 ± 625.13 pg/ml; p<0.001). However, TNFR1 plasma 
levels were lower in VHR participants with depression compared to VHR participants 





Figure 1: TNFR1 plasma protein levels are higher in participants at very high 
cardiovascular risk. TNFR1 plasma protein levels were measured by ELISA. Figure 1a: 
TNFR1 plasma levels are higher VHR compared to non-VHR participants. Figure 1b: 
TNFR1 plasma levels are higher with increasing cardiovascular risks. Figure 1c: TNFR1 
plasma levels are higher in acute coronary syndrome VHR compared to elective VHR 
participants, Figure 1d: TNFR1 plasma levels are higher in acute coronary syndrome 
VHR participants with recurrent MACE compared to acute coronary syndrome VHR 
participants with no recurrent MACE. (ACS: acute coronary syndrome; LR: low risk; 
MACE: Major adverse cardiovascular events; MI: myocardial infarction; MR: moderate 
risk; non-VHR: non-very high risk participants; PCI: Percutaneous coronary intervention; 
TNFα: tumour necrosis factor alpha; VHR: non-very high risk; VHR: very high risk). 
Statistical analysis was performed by ANCOVA for figure 1a, 1b and 1d and by Student 





4.3.3 TNFR2 plasma protein levels were higher in VHR 
participants 
In order to examine whether TNFR2 was able to different between individuals at 
various levels of cardiovascular risk, TNFR2 levels were measured in the plasma. The 
current study showed that TNFR2 plasma protein levels were numerically higher in 
the VHR group compared to the non-VHR group but failed to reach statistical 
significance (2971.0 ± 2199.0 pg/ml vs. 2133.0 ± 614.0 pg/ml; p=0.057) (Figure 2a, 
Figure 2b and Table 1). However, there was no statistical difference in TNFR2 plasma 
levels between ACS-VHR and ELEC-VHR participants (p=0.185) or in VHR participants 
with a previous MI (p=0.530) or PCI (p=0.373). Additionally, TNFR2 plasma levels 
were not associated with MACE within one year of admission (p=0.453). 
Regarding the comorbidities present in VHR participants, similarly to TNFR1, TNFR2 
plasma levels were significantly higher in VHR participants with diabetes (3269.52 ± 
1478.42 pg/ml vs. 2899.71 ± 2335.73 pg/ml; p<0.05) compared to VHR participants 
with no diabetes. TNFR2, like TNFR1, plasma levels discriminated between VHR 
participants with heart failure compared to VHR participants with no heart failure 
(4066.22 ± 4562.90 pg/ml vs. 2766.43 ± 1296.48 pg/ml; p<0.01). Furthermore, like 
TNFR1, TNFR2 plasma levels were higher in VHR participants on diuretic therapy 
compared to VHR participants not on diuretic therapy (3363.79 ± 1474.43 pg/ml vs. 
2835.63 ± 2380.94 pg/ml; p<0.05). VHR participants with a GFR less than 60 ml/min 
also had higher TNFR2 plasma levels (4546.22 ± 4095.44 pg/ml vs. 2606.99 ± 1112.57 




 To explore whether TNFR1 and TNFR2 were collectively associated with 
cardiovascular risk, ratio of TNFR1 to TNFR2 plasma protein levels was calculated. 
Results indicated that ratio of TNFR1 to TNFR2 plasma protein levels was not 
significantly different between the VHR and the non-VHR group (p=393). 
Interestingly, ratio of TNFR1 to TNFR2 plasma protein levels was higher in ACS-VHR 
compared to ELEC-VHR participants (0.4701 ± 0.2329 vs. 0.4157 ± 0.1025; p<0.05). 
R1/R2 ratio was significantly higher in VHR participants with heart failure compared 
to VHR participants with no heart failure (0.5192 ± 0.3172 vs. 0.4322 ± 0.1498; p<0.05 
respectively). Nevertheless, R1/R2 ratio was not significantly different between the 
VHR and the non-VHR group (p=0.393). 
 
Figure 2: TNFR2 plasma protein levels in participants at various levels of 
cardiovascular risk. TNFR2 plasma protein levels were measured by ELISA. Figure 2a: 
TNFR2 plasma levels in VHR compared to non-VHR participants. Figure 2b: TNFR2 
plasma levels across VHR, MR and LR participants. (LR: low risk; MR: moderate risk; 
non-VHR: non-very high risk; TNFR2: tumour necrosis factor alpha receptor 2; VHR: 




4.3.4 TIMP3 plasma protein levels were not statistically 
different between VHR and non-VHR participants whereas 
TIMP3 mRNA levels were lower in VHR participants  
To investigate if TIMP3 levels could differentiate between individuals at various levels 
of cardiovascular risk, TIMP3 protein and gene expression levels were measured. 
Results showed that TIMP3 plasma levels were not statistically different between 
VHR and non-VHR participants (p=0.486) (Figure 3a and Table 1). However, TIMP3 
plasma levels were higher in VHR participants on antihypertensive therapy and anti-
anginal therapy (3679.15 ± 2933.52 pg/ml vs. 2507.24 ± 1218.44 pg/ml; p<0.01 and 
3737.67 ± 2820.73 pg/ml vs. 3184.70 ± 2554.98 pg/ml; p<0.05 respectively). When it 
comes to TIMP3 gene expression, results demonstrated that TIMP3 mRNA levels 
were lower in VHR compared to no-VHR participants (0.0001094 ± 0.0001122 vs. 
0.0001946 ± 0.000305; p<0.05) (Figure 3b). To investigate whether TIMP3 gene 
expression was different in VHR subgroups, ACS-VHR and ELEC-VHR participants 
were compared. Data showed that TIMP3 gene expression was lower in ACS-VHR 
compared to ELEC-VHR participants (0.00007818 ± 0.00005755 (n=15) vs. 0.0001595 





Figure 3: TIMP3 levels in VHR and non VHR participants. TIMP3 plasma protein levels 
were measured by ELISA. TIMP3 gene expression was measured was measured in the 
peripheral blood mononuclear cells (PBMCs) by quantitative PCR and normalised to 
GAPDH. Cell membrane bound TACE and TIMP3 levels were measured by ELISA 
following a total protein extraction from the PBMCs after normalisation to 5000ug/m 
of total protein. Figure 3a: TIMP3 plasma levels in VHR participants compared to non-
VHR participants. Figure 3b: TIMP3 gene expression is lower in VHR compared to non 
VHR participants. Figure 3c: Cell bound TIMP3 over TACE ratio is lower in VHR 
compared to non-VHR participants (non-VHR: non-very high risk; TACE: Tumour 
necrosis factor alpha converting enzyme; TIMP3: tissue inhibitor of metalloproteinase 
3; VHR: very high risk). Statistical analysis was performed by ANCOVA for figure 3a 
and Student t-test for the rest. *p<0.05, ****p<0.0001 
 
4.3.5 Cell membrane bound TNFR1, TNFR2, TIMP3 and TACE 
protein levels in VHR participants 
To further validate the results of plasma TNFR1, TNFR2 and TIMP3 protein levels, cell 
membrane bound TNFR1, TNFR2, TIMP3 and TACE protein levels were explored 




TNFR1, TNFR2, TIMP3 and TACE protein levels were measured in a subgroup of 
participants randomly selected. Results demonstrated that cell membrane bound 
TACE protein levels were higher in VHR (n=80) vs. non VHR participants (n=36) (383.9 
pg/ml ± 259.6 vs. 221.9 pg/ml ± 78.8; p<0.0001). 
In addition, cell membrane bound TNFR1 protein levels were higher in VHR vs. 
non VHR participants (p<0.01) (Figure 4a) however, cell membrane bound TNFR2 
levels were not significantly different (p=0.212). Interestingly, the ratio of cell 
membrane bound TNFR2 to TNFR1 protein levels was lower in VHR participants 
compared to non-VHR participants (1.127 ± 0.376 vs. 1.494 ± 0.604; p<0.05) (Figure 
4c).  
On the other hand, the ratio of plasma TIMP3 over cell membrane bound TIMP3 
protein levels was higher in VHR compared to non VHR participants (5.993 ± 9.051 
vs. 2.177 ± 2.142; p<0.05). Nevertheless, the ratio of cell membrane bound TIMP3 to 
TACE protein levels was lower in VHR compared to non VHR participants (3.927 ± 





Figure 4: Cell membrane bound TNFR1 and TNFR2 protein levels in VHR and non 
VHR participants. Cell membrane bound TNFR1 and TNFR2 protein levels were 
measured by ELISA following a total protein extraction from the PBMCs after 
normalisation to 5000ug/ml. Figure 4a: Cell membrane bound TNFR1 protein levels 
are higher in VHR compared to non VHR participants. Figure 4b: Cell membrane 
bound TNFR2 protein levels in VHR compared to non VHR participants. Figure 4c: Cell 
membrane bound TNFR2 over TNFR1 protein levels ratio is lower in VHR compared to 
non VHR participants. (non-VHR: non-very high risk; TNFR1: tumour necrosis factor 
alpha receptor 1, TNFR2: tumour necrosis factor alpha receptor 2; VHR: very high 
risk). Statistical analysis was performed by Student t-test. *p<0.05 
 
4.3.6 TNFR1 and TNFR2 plasma protein levels correlated 
positively 
To explore whether TNFR1 and TNFR2 levels correlated with different variables 
explored in the study, a correlation analysis was performed (section 3.2.7 in Chapter 




p<0.0001). In addition, TNFR1 plasma protein levels correlated positively with age, 
body mass index (BMI) and C reactive protein (CRP) levels (r=0.515; p<0.0001, 
r=0.164; p<0.01; 0.164; p<0.01) and negatively with cholesterol levels (r=-0.275; 
p<0.0001). On the other hand, TNFR2 plasma protein levels correlated positively with 
age and BMI (r=0.390; p<0.0001 and r=0.174; p<0.01) and negatively with cholesterol 
levels (r=-0.274; p<0.0001) (Table 2).  































1 .735** .038 -.515** -.164** -.054 .275** -.164** 
Sig. (2-
tailed) 
  .000 .486 .000 .003 .360 .000 .005 






.735** 1 .065 -.390** -.174** -.025 .274** -.061 
Sig. (2-
tailed) 
.000   .232 .000 .002 .670 .000 .300 







.038 .065 1 .043 -.041 .028 .011 .104 
Sig. (2-
tailed) 
.486 .232   .428 .464 .640 .845 .078 
N 340 340 340 340 316 292 314 290 
Age (years) Pearson 
Correlation 
-.515** -.390** .043 1 .061 .212** -.303** .101 
Sig. (2-
tailed) 
.000 .000 .428   .280 .000 .000 .086 
N 340 340 340 340 316 292 314 290 
BMI (kg/m2) Pearson 
Correlation 
-.164** -.174** -.041 .061 1 .103 -.012 .090 
Sig. (2-
tailed) 
.003 .002 .464 .280   .089 .834 .140 







-.054 -.025 .028 .212** .103 1 .076 -.112 
Sig. (2-
tailed) 
.360 .670 .640 .000 .089   .212 .080 





.275** .274** .011 -.303** -.012 .076 1 -.116 
Sig. (2-
tailed) 
.000 .000 .845 .000 .834 .212   .058 





-.164** -.061 .104 .101 .090 -.112 -.116 1 
Sig. (2-
tailed) 
.005 .300 .078 .086 .140 .080 .058   
N 290 290 290 290 268 247 267 290 
Highlighted cells refer to a significant correlation. TNFR1 and TNFR2 plasma levels were 
transformed using an inverse function, therefore, the correlation coefficients have an 
inversed sign and were interpreted in opposite. (BMI: body mass index; CRP: C-reactive 




enzyme; TIMP3: tissue inhibitor of metalloproteinase 3; TNFα: Tumour necrosis factor 
alpha; TNFR1: tumour necrosis factor alpha receptor 1; TNFR2: tumour necrosis factor 
alpha receptor 2; VHR: very high risk). Pearson’s correlation was used to evaluate the 
correlation between variables. 
*Correlation is significant at the 0.05 level  
**Correlation is significant at the 0.01 level 
 
4.3.7 CRP plasma levels did not further differentiate between 
VHR participant sub-groups 
Refer to section 3.3.6 in Chapter 3. 
4.3.8 TNFR1, TNFR2 and TIMP3 plasma protein levels did not 
predict angiographic outcome 
To explore whether TNFR1, TNFR2 and TIMP3 levels could determine the plaque 
burden in VHR participants, a multinomial logistic regression analysis was carried out 
(section 3.2.7 in Chapter 3). A multinomial logistic regression analysis showed that 
the measured biomarkers were not able to effectively predict the angiographic 
outcome. In addition, ANOVA analysis did not show any difference between the 









p value  
TNFR2 plasma 
levels (pg/ml) 
p value  
TIMP3 plasma 
levels (pg/ml) 
p value  
Demographic and 
History (n; %) 
            
Gender             
Male (180; 78.6) 1273.12 ± 1246.12 
0.275 
2909.79 ± 2319.03 
0.329 
3401.05 ± 2720.93 
0.897 
Female (49; 21.4) 1357.47 ± 756.48  3194.75 ± 1688.92 3382.75 ± 2491.47 
Diabetes mellitus             
Present (44; 19.2) 1537.01 ± 891.82 
0.001 
3269.52 ± 1478.42 
0.029 
3636.29 ± 2630.16 
0.268 
Absent (185; 80.8) 1232.70 ± 1207.32 2899.71 ± 2335.73 3340.25 ± 2681.06 
Heart Failure             
Present (36; 15.7) 2067.63 ± 2526.31 
<0.0001 
4066.22 ± 4562.90 
0.008 
3673.14 ± 2809.42 
0.324 
Absent (193; 84.3) 1146.45 ± 542.96 2766.43 ± 1296.48 3345.65 ± 2645.44 
Renal function             
GFR < 60 (45; 20) 2243.31 ± 2235.13 
<0.0001 
4546.22 ± 4095.44 
<0.0001 
3295.58 ± 3021.49 
0.721 
GFR > 60 (180; 80) 1066.24 ± 439.42 2606.99 ± 1112.57 3440.58 ± 2600.27 
Hypertension             
Present (128; 55.9) 1432.94 ± 1420.85 
0.102 
3218.53 ± 2740.46 
0.547 
3492.06 ± 2716.37 
0.367 
Absent (101; 44.1) 1111.50 ± 659.34 2656.76 ± 1144.93 3276.83 ± 2614.35 
Dyslipidaemia              
Present (134; 58.5) 1166.50 ± 600.69 
0.249 
2734.97 ± 1196.20 
0.285 
3426.48 ± 2439.58 
0.368 
Absent (95; 41.5) 1467.03 ± 1639.55 3303.36 ± 3084.65 3355.74 ± 2973.91 
Arthritis             
Present (35; 15.3) 1269.50 ± 721.23 
0.64 
2781.90 ± 1099.22 
0.958 
3735.10 ± 2699.06 
0.337 
Absent (194; 84.7) 1295.09 ± 1221.55 3004.84 ± 2343.69 3336.15 ± 2665.05 
Depression             
Present (43; 18.8) 1195.45 ± 477.64 
0.028 
2729.37 ± 1044.05 
0.336 
3692.24 ± 3211.30 
0.653 
Absent (186; 81.2) 1313.30 ± 1264.12 3026.57 ± 2386.70 3328.91 ± 2531.38 
present or previous 
cancer 
            
Present (27; 11.8) 2239.29 ± 2770.95 
0.001 
4502.74 ± 5201.40 
0.075 
3255.11 ± 1956.31 
0.666 
Absent (202; 88.2) 1164.44 ± 625.13 2765.99 ± 1276.33 3416.12 ± 3752.71 
Smoking             
none (66; 30.3) 1157.64 ± 531.68 
0.074 
2899.58 ± 1333.70 
0.896 




1430.37 ± 1572.08 3124.24 ± 2837.42 3540.49 ± 2798.60  
current (42; 19.3) 1118.28 ± 307.86 2539.00 ± 827.09 3293.09 ± 2683.45 
Pharmacotherapy 
(n; %) 
            
Statin therapy             
Present (165; 72.7) 1331.99 ± 1324.71 
0.733 
3028.38 ± 2463.10  
0.861 
3527.96 ± 2851.86 
0.292 
Absent (62; 27.3) 1193.78 ± 521.57 2799.71 ± 1265.70 3041.89 ± 2082.24 
Antiplatelet 
therapy 
            
Present (154; 67.8) 1325.28 ± 1329.44 
0.154 
2952.38 ± 2393.44 
0.369 
3635.63 ± 3006.40 
0.171 
Absent (73; 32.1) 1228.78 ± 690.99 2994.51 ± 1742.01 2888.00 ± 1659.95 
Antihypertensive 
therapy 
            
Present (172; 76.8) 1347.68 ± 1302.31  
0.683 
2986.69 ± 2352.67 
0.445 
3679.15 ± 2933.52 
0.006 
Absent (55; 24.2) 1127.14 ± 494.53 2900.98 ± 1656.87 2507.24 ± 1218.44 
Anti-anginal 
therapy 
            




Absent (139; 61.2) 1245.30 ± 750.31 2885.00 ± 1446.55 3184.70 ± 2554.98 
Diuretic therapy             
Present (56; 24.7) 1656.99 ± 1021.68 
<0.0001 
3363.79 ± 1474.43 
0.013 
3475.25 ± 2424.43 
0.404 
Absent (171; 75.3) 1175.45 ± 1183.46 2835.63 ± 2380.94 3368.99 ± 2749.54 
Drug naïve             
Present (54; 23.7) 1095.19 ± 477.23 
0.782 
2826.33 ± 1640.02 
0.813 
2760.77 ± 1363.49 
0.147 
Absent (174; 76.3) 1352.19 ± 1296.73 3001.65 ± 2354.62 3578.09 ± 2933.57 
Clinical Variables 
(n; %) 
            
ACS-VHR (127; 55.5) 1439.73 ± 1440.60 
0.002 
3198.97 ± 2762.81 
0.185 
3356.92 ± 2527.43 
0.988 
ELEC-VHR (102; 44.5) 1106.60 ± 612.67 2786.74 ± 1117.28 3447.20 ± 2845.62 
Previous MI              
Present (73; 31.9) 1539.44 ± 1770.45 
0.069 
3397.89 ± 3388.02 
0.53 
3385.49 ± 2856.55 
0.965 
Absent (156; 68.1) 1175.00 ± 699.17 2770.90 ± 1286.84 3402.60 ± 2584.89 
Previous MI ACS  
            
Present (30; 23.6) 2011.18 ± 2610.37   0.035 4261.47 ± 5012.56 0.398 3013.39 ± 1608.56 0.79 
Absent (97; 76.4) 1262.99 ± 729.27  2870.23 ± 1402.28  3463.15 ± 2748.49  
Previous MI ELEC  
            
Present (43; 42.1) 1210.32 ± 631.38 0.036 2795.39 ± 1193.57 0.583 3645.09 ± 3468.99 0.761 
Absent (59; 57.8) 1030.31 ± 592.52  2607.56 ± 1061.62  3302.98 ± 2310.09  
Previous PCI             
Present (73; 31.9) 1476.43 ± 1758.32 
0.482 
3320.81 ± 3299.32 
0.373 
3341.96 ± 2772.40 
0.989 
Absent (56; 68.1) 1204.50 ± 715.78 2807.00 ± 1404.60 3423.00 ± 2626.73 
Previous PCI ACS              
Present (28; 22.0) 1969.82 ± 2695.94 0.076 4198.36 ± 5084.83 0.133 3184.46 ± 1734.11  0.737 
Absent (99; 78.0) 1289.81 ± 750.23  2916.19 ± 1524.59  3405.69 ± 2715.44  
Previous PCI ELEC              
Present (45; 44.1) 1169.43 ± 589.81 0.134 2774.78 ± 1073.21 0.305 3439.96 ± 3272.09 0.744 
Absent (57; 55.9) 1056.28 ± 630.80  2617.24 ± 1155.56  3452.92 ± 2488.40  
Previous CABG              
Present (22; 9.6) 1261.80 ± 790.64 
0.225 
2680.20 ± 939.42 
0.287 
3339.40 ± 2147.24 
0.884 
Absent (207; 90.4) 1294.29 ± 1191.69 3001.65 ± 2291.92 3403.27 ± 2721.97 
Previous MI, PCI or 
stent 
            
Present (100; 43.7) 1462.44 ± 1568.07 
0.399 
3248.79 ± 2937.52 
0.375 
3433.87 ± 2665.03 
0.575 
Absent (129; 56.3) 1158.41 ± 667.68 2755.24 ± 1354.08 3368.65 ± 2680.78 
Diagnosis upon 
admission 
            
Stable Angina (85; 
37.1) 
1089.76 ± 607.54 
<0.0001 
2665.46 ± 1184.38 
0.324 




1217.10 ± 718.27 2885.19 ± 1565.10 3058.00 ± 1763.03 
NSTEMI < 1 week 
(77; 33.6) 
1599.52 ± 1773.96 3417.92 ± 3382.58 3330.37 ± 2372.66 
STEMI < 1 week (7; 
3.0) 
1240.86 ± 374.45 2763.00 ± 695.33 3080.14 ± 1336.24 
Other (39; 17.03)             
ACS participants 
admitted for MACE 
            
Present (45; 35.4) 1882.92 ± 2190.94 
0.064 
3877.78 ± 4147.86 
0.267 
3105.04 ± 1775.69 
0.902 
Absent (82; 64.6) 1196.52 ± 672.11 2826.30 ± 1459.91 3495.15 ± 2858.20 
No previous MI, PCI 
or CABG 
  




ACS-VHR (84, 65.1) 1215.22 ± 674.81 
0.06 
2855.92 ± 1455.10 
0.316 
3455.36 ± 2836.15 
0.725 
ELEC-VHR (45, 34.9) 1052.35 ± 648.25 2567.31 ± 1133.34 3206.81 ± 2385.44 
Prognostic 
variable (n; %)            
Follow-up MACE             
Within 6 months (5; 
2.2) 
1708.04 ± 930.91 
0.061 
3847.00 ± 1939.68 
0.453 
3842.40 ± 3333.99 
0.624 After 6 months (11; 
4.8) 
2137.97 ± 1618.90 3379.18 ± 1928.64 2741.85 ± 1579.92 
Absent (213; 93.0) 1237.65 ± 1121.52 2929.10 ± 2219.55 3420.52 ± 2702.14 
Cells highlighted with dark grey have a p value <0.05 and cells highlighted with light grey 
have a p value of <0.01. GFR: Glomerular filtration rate; ACS: acute coronary syndrome 
participants; ELEC: elective participants; MI: Myocardial Infarction, PCI: percutaneous coronary 
intervention CABG: Coronary artery bypass surgery; NSTEMI: non-ST elevation myocardial 







The results of this present investigation demonstrated that TNFR1, TNFR2 and TIMP3 
could identify individuals at cardiovascular risk and could also further stratify those 
at higher risk of MACE demonstrating a higher value compared to CRP measurement. 
Cell membrane bound TNFR1, TNFR2, TIMP3 and TACE protein levels provide further 
insight on the potential role of this inflammatory pathway as a therapeutical target 
in CVD. 
4.4.1 TNFR1 and TNFR2 plasma protein levels characterised VHR individuals 
Soluble TNFR1 and TNFR2 circulating levels have been previously linked to different 
inflammatory diseases (206) and were previously explored in CVD (207). However, in 
the aforementioned studies, soluble TNFR1 and TNFR2 levels were only associated 
with the presence of co-morbidities in CVD participants and were not compared 
across individuals at various levels of cardiovascular risk.  
The present investigation demonstrated that TNFR1 plasma protein levels were 
higher in VHR compared to non-VHR participants. Furthermore, increasing levels of 
TNFR1 plasma levels accompanied increasing cardiovascular risk in parallel to the 
assigned SCORE risk. In addition, TNFR2 plasma protein levels followed a trend where 
levels were higher in VHR compared to non-VHR participants. This suggests that 
TNFR1 and TNFR2 plasma levels could both be considered as markers for 
cardiovascular risk with TNFR1 proving to be of higher sensitivity in characterising 
cardiovascular risk compared to TNFR2. Furthermore, TNFR1 plasma protein levels 
tended to be higher in VHR participants admitted for a primary or recurrent 




for acute events in individuals with or without CVD history. This difference was not 
detected by CRP levels which suggests that TNFR1 has a superior value compared to 
CRP and could potentially be useful in further stratifying VHR individuals. 
When it comes to individuals with a previous MI, our results demonstrated that 
TNFR1 plasma protein levels remained high in VHR participants with a previous MI 
despite statin, anti-platelet and anti-hypertensive therapy. This was also observed 
when we looked at ACS-VHR and ELEC-VHR participants with a previous MI. 
Nonetheless, CRP levels were not statistically different between VHR participants 
with previous MI compared to VHR participants with no previous MI which further 
strengthens the role of TNFR1 as a potential biomarker in further stratifying VHR 
individuals. On the other hand, based on the evidence that both soluble levels of 
TNFR1 and TNFR2 are known to contribute to inflammation (207) the ratio of TNFR1 
and TNFR2 plasma levels was explored. Higher TNFR1 to TNFR2 plasma ratio in ACS-
VHR compared to ELEC-VHR participants reflected the acute phase response 
following an ACS and the possibility of using such a ratio in ACS diagnosis.  
Moreover, TNFR1 plasma protein levels appeared to be higher in VHR participants 
who developed MACE after one year of admission which is in line with previous 
findings highlighting the role of TNFR1 in predicting mortality in patients post-MI 
(222). This supports the role of TNFR1 not only as a diagnostic marker for acute MACE 
but also as a prognostic marker for future MACE. These results need to be replicated 
in larger cohorts. 
On the other hand, TNFR1 and TNFR2 plasma protein levels were higher in VHR 




when certain comorbidities are present along with CVD as reported previously 
(207,223). In fact, since it has been shown that TNFR1 and TNFR2 plasma protein 
levels were higher in diabetic patients who developed CVD as a complication, this 
suggests that these two soluble receptors could be associated with the development 
of cardiovascular complications in an already established disease such as diabetes 
(206) or chronic kidney disease (224).  
4.4.2 TNFR1 and TNFR2 cell membrane bound protein levels in VHR 
individuals 
It is well established that TNFR1 and TNFR2 receptors have opposing actions when it 
comes to their signalling pathways (208). TNFR1 increases inflammation and 
endothelial dysfunction whereas TNFR2 activates angiogenic and survival pathways 
(209,210). The opposing roles of TNFR1 and TNFR2 cell membrane receptors has also 
been highlighted in neurodegenerative disease (225), where cell membrane bound 
TNFR1 to TNFR2 receptor ratio was increased in the hippocampus with aging  (226), 
and also in heart failure (227). In this present work, cell membrane bound TNFR2 to 
TNFR1 receptor ratio was explored in the peripheral blood cells to provide further 
insight into its role in CVD. TNFR2 to TNFR1 receptor ratio was lower in VHR 
compared to non-VHR participants. This indicates that VHR participants have a low 
number of TNFR2 relative to TNFR1 on the cell surface of their peripheral blood cells 
which could suggest that the balance between those receptors is more likely to shift 
towards a pro-inflammatory state potentially increasing MACE risk in the VHR group. 
In line with these findings, cell membrane bound TNFR1 protein levels were higher 




receptor ratio is important in modulating cell response to TNFα (228). When it comes 
to the regulation of TNF receptors, it has been suggested that the TNFR1 promoter is 
constitutively active at low levels in all cell types (229) whereas TNFR2 promoter is 
inducible and expressed exclusively by immune cells, endothelial cells and some 
neuronal populations (230). This indicates that the presence of TNFR2 on those cell 
types is essential for modulating the inflammatory response to TNFα. 
4.4.3 TIMP3 is downregulated in VHR individuals 
TIMP3 is the only known endogenous inhibitor of TACE (217). In this present study, 
TIMP3 plasma protein levels were not statistically different between participants at 
various levels of cardiovascular risk. However, since TIMP3 is known to regulate 
blood pressure (231), plasma levels were found to be higher in VHR participants on 
antihypertensive therapy compared to VHR participants not on antihypertensive 
therapy which indicates a need to further understand the potential benefit of higher 
TIMP3 levels as a result of anti-hypertensive therapy. Nevertheless, our results 
showed that TIMP3 was under expressed in VHR compared to non-VHR participants. 
This suggests that, in contrast to an increase in TACE gene expression in patients with 
CVD (170), TIMP3 gene expression is decreased. TIMP3 was also downregulated in 
ACS-VHR participants compared to ELEC-VHR participants indicating that close to an 
ACS, TIMP3 gene expression is particularly decreased. Down-regulation of TIMP3 has 
been previously shown to increase TACE expression and TNFα production by 
placental trophoblast cells (232). In addition, a loss of TIMP3 has shown to increase 
the risk of atherosclerosis in ApoE null mice (233). However, the mechanisms behind 




where TIMP3 is showing utility as a potential therapeutical strategy in heart failure 
(234).  
The ratio of plasma TIMP3 over cell bound TIMP3 protein levels was higher in VHR 
compared to non VHR individuals indicating that in VHR individuals, a higher 
proportion of TIMP3 is released into the plasma compared to the amount of TIMP3 
retained on the cell surface. TIMP3 retained on the cell surface is known to be 
associated with TACE to form dimer structures that inhibit TACE activity and 
substrate shedding (235,236). A lower proportion of TIMP3 on the cell surface results 
in an insufficient TACE inhibition which was reflected by the cell membrane bound 
TIMP3 to TACE protein levels ratio which was significantly lower in VHR participants. 
When TACE is ineffectively inhibited by TIMP3, it shifts into its monomer active form, 
and subsequently cleaves a higher number of transmembrane proteins aggravating 
local and systemic inflammation (235). TIMP3 has been recently suggested to 
decrease adipocyte differentiation (237) which highlights a potential role of this 
protein in the lipid retention and possibly in the formation of an atherosclerotic 
lesion (238). 
4.4.4 Strengths and Limitations 
Refer to section 3.4.3 in Chapter 3.  
In addition to the aforementioned limitations, the number of participants tested for 
membrane bound forms of TNFR1, TNFR2 and TIMP3 was limited, however, 
preliminary data shows a significant difference between the levels of those surface 
markers as well as the ratios between VHR and non VHR participants and ongoing 




Concerning the inter-assay CV of the TIMP3 ELISA, the reasons behind a high CV are 
discussed in the Methods section II.IX.I. This shows that TIMP3 measurement over 
time in the sample plasma sample resulted in a high inter-assay CV which would 
suggest that TIMP3 might degrade over time and might need to be measured as close 
to blood collection as possible. 
 
Figure 5: Proposed model using TNFR1, TNFR2 and TIMP3 in identifying and further 
stratifying VHR participants. (ACS: acute coronary syndrome participants; GFR: 
Glomerular filtration rate; MACE: major adverse cardiovascular events MI: Myocardial 
Infarction; PCI: percutaneous coronary intervention; TNFR1: tumour necrosis factor 
receptor 1; TNFR2: tumour necrosis factor receptor 2; TIMP3: tissue inhibitor of 
metalloproteinase 3; TACE: tumour necrosis factor alpha converting enzyme; VHR: 






These results indicate that plasma TNFR1 and TNFR2 protein levels can differentiate 
between VHR and non-VHR participants. Additionally, TNFR1 can identify individuals 
admitted for their first or secondary acute cardiovascular event. This is the first 
report of TIMP3 downregulation in CVD individuals. Furthermore, the ratio of cell 
membrane bound TNFR2 to TNFR1 and TIMP3 to TACE protein levels were also 
investigated for the first time and were both lower in VHR compared to non-VHR 
participants highlighting a shift towards a pro-inflammatory state in the VHR group. 
These proteins should be further investigated as biomarkers or therapeutic targets 



















Evaluating the Value of a 
Proinflammatory Panel in 







Background: The immune system plays a major role in the initiation and progression 
of atherosclerosis which results in coronary artery disease (CAD), one of the major 
subtypes of cardiovascular disease (CVD). Several treatment strategies targeting the 
immune system are currently being developed to decrease CAD occurrence and 
complications. A large number of inflammatory mediators are known to contribute 
to atherosclerosis, however, their role in predicting cardiovascular risk and recurrent 
cardiac events is not fully characterised. The aim of this present work was to evaluate 
the value of a panel combining several inflammatory proteins in determining 
cardiovascular risk and in further stratifying participants with an established CAD. 
Methods: Participants were recruited from the cardiac catheterisation laboratory or 
by email advertisement. Group 1 was defined as very high risk participants (VHR) with 
a 10-year risk SCORE ≥10% risk of fatal CVD. VHR participants were subdivided in 
Acute Coronary Syndrome (ACS-VHR) and elective percutaneous coronary 
intervention participants (ELEC-VHR). Group 2 were defined as low, moderate and 
high risk participants (non-VHR) with a 10-year risk SCORE <10% risk of fatal CVD. 
INF-γ, IL-10, IL-12p70, IL-13, IL-1β, IL-2, IL-4, IL-6, IL-8 and TNFα plasma protein levels 
were measured using the MSD® MULTI-SPOT Assay System.  
Results: At total of 344 participants were recruited. The VHR (n=229) group consisted 
of ACS-VHR (n=127) and ELEC-VHR (n=102). The non-VHR (n=115) group consisted of 
low risk (LR) (n=81), moderate risk (MR) (n=32) and high risk (HR) (n=2) participants. 
IFN-γ (9.93 ± 42.02 pg/ml vs. 8.22 ± 11.43 pg/ml, p<0.01), IL-6 (2.06 ± 2.80 pg/ml vs. 
0.066 ± 0.512 pg/ml, p<0.0001), IL-8 (8.16 ± 10.00 pg/ml vs. 3.50 ± 1.99 pg/ml, 




protein levels were able to significantly differentiate between very high risk (VHR) 
and non-VHR participants. IL1B mRNA levels were higher in the VHR compared to 
non-VHR participants (0.0654 ± 0.0413 vs. 0.0335 ± 0.0272; p<0.01). IFN-γ (10.19 ± 
53.03 pg/ml vs. 8.52 ± 9.12 pg/ml; p<0.01) and IL-6 (2.75 ± 3.57 pg/ml vs. 1.20 ± 0.70 
pg/ml; p<0.001) plasma levels were higher in ACS-VHR compared to ELEC-VHR. IFN-
γ (20.88 ± 89.61 pg/ml vs. 4.52 ± 3.78 pg/ml; p<0.01), IL-12p70 (0.35 ± 0.44 pg/ml vs. 
0.28 ± 0.42 pg/ml; p<0.05) and IL-8 (9.87 ± 10.92 pg/ml vs. 7.48 ± 12.31 pg/ml; 
p<0.01) plasma levels were higher in ACS participants admitted for recurrent major 
adverse cardiovascular events (MACE). IL-6 plasma levels were associated with follow 
up MACE within 6 months of admission (p<0.05). 
Conclusion: This study shows that IL-6, IL-8, INF-γ, TNFα and IL-1β can differentiate 
between VHR and non-VHR CVD participants. Additionally, IL-6, IL-8, INF-γ, IL-12p70 
and TNFα were able to further characterise VHR sub-groups in terms of co-
morbidities and primary or recurrent cardiovascular events. These results highlight 
the importance of evaluating immune markers in CVD risk assessment and 
demonstrate that a multimarker approach could make risk stratification in VHR 






Inflammation plays a major role in the initiation and complications of atherosclerosis 
which results in coronary artery disease, one of the major subtypes of cardiovascular 
disease (CVD). Targeting the immune system to treat CVD initiated with the 
Cardiovascular Inflammation Reduction Trial (CIRT), where a low dose of 
methotrexate was used, and the ongoing Canakinumab Anti-Inflammatory 
Thrombosis Outcomes Study (CANTOS) where canakinumab is used to target 
interleukin 1 beta (IL-1β) (239). IL-1β is normally produced after activation by caspase 
1 through the NLRP3 inflammasome and in the CANTOS trial, now in phase 3, 
canakinumab was shown to reduce recurrent events (in terms of heart attack, stroke 
and cardiovascular death) in participants who survived a heart attack. The lesson 
learned from these trails is that additional pro or anti-inflammatory mediators need 
to be explored in order to assess their value in predicting recurrent major adverse 
cardiovascular events (MACE) to potentially use them as a treatment target or as 
therapy in CVD. 
 Several inflammatory mediators are known to contribute to atherosclerosis, 
however, their role in primary and secondary CVD prevention needs further 
understanding. Some of those inflammatory mediators include interleukin 6 (IL-6) 
and interleukin 2 (IL-2) which were associated with the development of CVD 
(240,241). IL-6 is known to contribute to myocardial damage and chronic heart failure 
(242) whereas IL-2 causes severe depression of cardiac function. When IL-2 was 
combined to an interleukin 2 antibody complex it reduced cardiac remodelling 




other hand, Interleukin 8 (IL-8) is known to maintain a proinflammatory environment 
around the culprit lesion leading to cardiac events (245) and levels were shown to be 
higher in unstable coronary artery disease (246). Moreover, Interferon γ (IFN-γ) is a 
major macrophage activating factor that induces the release to TNFα (247) and has 
consequently a major role in CVD (248). In contrast, Interleukin 10 (IL-10) has been 
associated with an anti-inflammatory response and a decreased risk in developing 
heart failure in patients post myocardial infarction (MI) after primary angioplasty. 
Nevertheless, IL-10 levels were positively associated with cardiovascular risk in the 
elderly without prior CVD events (249). It was shown that Interleukin 13 (IL-13) 
deficiency aggravated healing and remodelling in male mice after myocardial 
infarction (250). On the other hand, interleukin 4 (IL-4) was proposed as a potential 
therapeutical target for cardiac fibrosis (251) whereas interleukin 12 (IL-12) is known 
to have a controversial role in CAD (252,253). In addition, it is already well-
established that TNFα levels are higher in patients with an acute myocardial 
infarction (AMI) (153,154) with higher levels in AMI patients compared to stable 
angina patients (165). These inflammatory markers have been investigated in 
separate studies that linked them to different clinical or biological aspects of CVD. 
Therefore, the role of such inflammatory markers in establishing an individual’s 
cardiovascular risk is not clear. As biomarker research is moving towards a 
multimarker approach, several validated inflammatory protein panels are already 
commercialised. However, these protein panels need to be tested in clinical practice 
to assess whether they add knowledge to the current risk prediction tools. Therefore, 




10 proteins involved in the immune and inflammatory response in order to 
determine its utility in predicting cardiovascular risk in different participant groups. 
5.2 Participants and Methods 
Refer to section 2.1 in Chapter 2 for a detailed description of the participant 
recruitment process, the risk score used and the methods for blood processing. 
5.2.1 Demographic information  
Refer to section 3.2.1 in Chapter 3 for a detailed description of the demographic 
information that was collected in this study. 
5.2.2 Measurement of inflammatory plasma protein levels 
Refer to section 2.10 in Chapter 2. 
5.2.3 Measurement of IL1B gene expression 
Refer to section 2.11, 2.12 and 2.13 in Chapter 2. 
5.2.4 Statistical methods 
Statistical analysis was carried out as described in section 3.2.7 in Chapter 3 
5.3 Results 
5.3.1 Populaition Demographics 





Table 1: INF-γ, IL-10, IL-12p70, IL-13, IL-1β, IL-2, Il-4, IL-6, IL-8 and TNFα levels in 
participants at various levels of cardiovascular risk classified according to the SCORE risk 
chart. 
  








229 32 81 
  
IFN-γ (pg/ml) 9.93 ± 42.02 8.93 ± 11.27 7.99 ± 11.68 0.199 0.024 
IL-10 (pg/ml) 0.375 ± 0.600 0.256 ± 0.114 0.399 ± 1.17 0.428 0.139 
IL-12p70 (pg/ml) 0.299 ± 0.345 0.208 ± 0.139 0.226 ± 0.162 0.022 0.199 
IL-13 (pg/ml) 0.782 ± 0.611 0.828 ± 0.791 0.530 ± 0.368 0.002 0.018 
IL-1β (pg/ml) 0.407 ± 1.052 0.194 ± 0.106 0.166 ± 0.117 0.091 0.087 
IL-2 (pg/ml) 0.266 ± 0.275 0.211 ± 0.111 0.243 ± 0.321 0.102 0.245 
IL-4 (pg/ml) 0.0323 ± 0.1451 0.0171 ± 0.0059 0.0186 ± 0.0145 0.566 0.459 
IL-6 (pg/ml) 2.06 ± 2.80 0.930 ± 0.638 0.563 ± 0.424 <0.0001 0.001** 
IL-8 (pg/ml) 8.16 ± 10.00 4.80 ± 2.72 3.01 ± 1.35 <0.0001 <0.0001 











IFN-γ (pg/ml) 9.93 ± 42.02 8.22 ± 11.43 0.092 0.003 
IL-10 (pg/ml) 0.375 ± 0.600 0.358 ± 0.990 0.189 0.39 
IL-12p70 (pg/ml) 0.299 ± 0.345 0.220 ± 0.155 0.005 0.084 
IL-13 (pg/ml) 0.782 ± 0.611 0.625 ± 0.542 0.003 0.05 
IL-1β (pg/ml) 0.407 ± 1.052 0.185 ± 0.120 0.05 0.111 
IL-2 (pg/ml) 0.266 ± 0.275 0.231 ± 0.272 0.028 0.775 
IL-4 (pg/ml) 0.0323 ± 0.1451 0.018 ± 0.013 0.295 0.395 
IL-6 (pg/ml) 2.06 ± 2.80 0.066 ± 0.512 <0.0001 <0.0001 
IL-8 (pg/ml) 8.16 ± 10.00 3.50 ± 1.99 <0.0001 <0.0001 




0.0654 ± 0.0413 0.0335 ± 0.0272 0.003 
ANCOVA analysis was used to compare the cohorts. Two p values were calculated to assess 
the impact of the covariates on the analysis. All proteins were measured in the plasma 
except IL1B which represent mRNA levels. (LR: low risk; MR: moderate risk; IL-1β: Interleukin 
1 beta; IL-2: Interleukin 2; IL-4: Interleukin4; IL-6: Interleukin 6; IL-8: Interleukin 8; IL-10: 
Interleukin 10; IL-12p70: Interleukin 12 subunit 70; IL-13: Interleukin 13; IFN-γ: Interferon 
gamma; non-VHR: non-very high risk; TNFα: Tumour necrosis factor alpha; VHR: very high 
risk. Proteins not in bold and in italic had very low limit of detection level and their values 




*adjusted for age and gender and BMI for IL-6. For statistical analysis, all protein levels were 
transformed using a log transformation as values did not follow the normal distribution. 
** MR vs. LR (p=0.028) 
 
5.3.2 INF-γ, IL-6 and IL-8 plasma protein levels were higher in 
VHR participants 
In order to evaluate whether a panel combining 10 inflammatory proteins could add 
value to the existing CVD, risk assessment scores, a combination of proteins from the 
MSD® Proinflammatory Panel 1 were measured in individuals at various levels of CVD 
risk.  
Results demonstrated that INF-γ (9.93 ± 42.02 pg/ml vs. 8.22 ± 11.43 pg/ml; 
p<0.01), IL-6 (2.06 ± 2.80 pg/ml vs. 0.066 ± 0.512 pg/ml; p<0.0001) and IL-8 (8.16 ± 
10.00 pg/ml vs. 3.50 ± 1.99 pg/ml; p<0.0001) plasma protein levels were significantly 
higher in the VHR compared to the non-VHR group. Additionally, INF-γ (p<0.05), IL-6 
(p<0.001) and IL-8 (p<0.0001) plasma levels significantly increased with increasing 
cardiovascular risk (Table 1 and Figure 1). Furthermore, IL-6 plasma levels were 
significantly higher in MR participants compared to LR participants (0.930 ± 0.638 
pg/ml vs. 0.563 ± 0.424 pg/ml; p<0.05) (Table 1 and Figure 1b).  
Regarding IL-13 and IL-4 measurements, IL-13 and IL-4 plasma levels were higher 
in VHR compared to non-VHR participants. Nevertheless, due to problems with the 
assay’s low limit of detection as well as the assay’s high coefficient of variation in 
some of the tested samples, IL-13 and IL-4 plasma levels could not be clinically 
interpreted. Most of IL-1β plasma levels were also below the limit of detection of the 




gene expression was analysed and levels were higher in VHR compared to non-VHR 
participants (0.0654 ± 0.0413 vs. 0.0335 ± 0.0272; p<0.01) (Table 1 and Figure 1d). 
On the other hand, IL-10, IL-12p70, and IL-2 plasma levels did not show any 
significant difference in the studied cohorts. 
 
Figure 1: INF-γ, IL-6, IL-8 and IL-1β levels are higher in participants at very high 
cardiovascular risk. INF-γ, IL-6 and IL-8 plasma protein levels were measured using the 
MSD® MULTI-SPOT Assay System. IL-1β mRNA levels were measured by quotative real-
time PCR and normalised to GAPDH. Figure 1a: IFN-γ plasma levels are higher in VHR vs. 
non-VHR participants. Figure 1b: IL-6 plasma levels are higher in VHR vs. non-VHR 
participants. Figure 1c: IL-8 plasma levels are higher in VHR vs. non-VHR participants. 
Figure 1d: IL-1β gene expression levels are higher in VHR vs. non-VHR levels. IL-1β: 
Interleukin 1 beta; IL-2: Interleukin 2; IL-4: Interleukin4; IL-6: Interleukin 6; IL-8: 
Interleukin 8; IL-10: Interleukin 10; IL-12p70: Interleukin 12 subunit 70; IL-13: Interleukin 
13; IFN-γ: Interferon gamma; non-VHR: non-very high risk; VHR: very high risk. Statistical 





5.3.3 INF-γ, IL-6, IL-8, IL12-p70 and IL-10 plasma protein levels 
differentiated between VHR participant subgroups 
Proteins from the MSD ® Proinflammatory panel 1 were explored to assess whether 
VHR individuals could be further classified into subgroups according to their 
cardiovascular history and associated comorbidities. 
5.3.3.1 Markers associated with acute cardiovascular events 
Results demonstrated that IFN-γ and IL-6 plasma protein levels were higher in VHR 
participants with an acute coronary syndrome (ACS-VHR) compared to VHR elective 
percutaneous intervention participants (ELEC-VHR) (10.19 ± 53.03 pg/ml vs. 8.52 ± 
9.12 pg/ml; p<0.01 and 2.75 ± 3.57 pg/ml vs. 1.20 ± 0.70 pg/ml; p<0.001 
respectively). In addition, when evaluating the proteins associated with recurrent 
major adverse cardiovascular events (MACE), results showed that IFN-γ (20.88 ± 
89.61 pg/ml vs. 4.52 ± 3.78 pg/ml; p<0.01), IL-12p70 (0.35 ± 0.44 pg/ml vs. 0.28 ± 
0.42 pg/ml; p<0.05) and IL-8 (9.87 ± 10.92 pg/ml vs. 7.48 ± 12.31 pg/ml; p<0.01) 
plasma levels were higher in ACS-VHR participants admitted for recurrent MACE 
compared to ACS-VHR participants admitted for their first cardiovascular event. 
Interestingly however, INF-γ plasma levels were lower in ACS-VHR participants 
admitted for their first cardiovascular event who had no previous cardiac events 
compared to ELEC-VHR participants with no previous cardiac events (4.59 ± 3.91 
pg/ml vs. 7.79 ± 6.62 pg/ml; p<0.0001). In contrast, IL-6 plasma levels were higher in 
ACS-VHR participants admitted for their first cardiovascular event who had no 
previous cardiac events compared to ELEC-VHR participants with no previous cardiac 




5.3.3.2 Markers associated with medical and clinical management 
Regarding VHR participants with a revascularisation strategy, data showed that IL-8 
plasma levels were higher in VHR participants with a previous percutaneous coronary 
intervention (PCI) compared to VHR participants with no previous PCI (9.10 ± 8.82 vs. 
7.72 ± 10.51 pg/ml; p<0.01). This trend was also observed regardless of whether VHR 
individuals were ACS-VHR or ELEC-VHR participants. In fact, IL-8 plasma levels were 
higher in ACS-VHR participants with a previous PCI compared to ACS-VHR 
participants with no previous PCI (8.802 ± 7.144 pg/ml vs. 8.914 ± 12.897 pg/ml; 
p=0.80) and in ELEC-VHR participants with a previous PCI compared to ELEC-VHR 
participants with no previous PCI (9.285 ± 9.798 pg/ml vs. 6.893 ± 3.651 pg/ml; 
p=0.092). Additionally, IL-8 plasma levels were also higher in VHR participants with a 
previous coronary artery bypass graft (CABG) compared to VHR participants with no 
previous CABG (10.40 ± 12.84 vs. 7.92 ± 9.66 pg/ml; p<0.05).  
VHR participants with a previous PCI or CABG were more likely to be on statin 
(91.8%; p<0.0001, 100%; p<0.0001), anti-platelet (91.8%; p<0.0001, 86.4%; 
p<0.0001) and anti-hypertensive therapy (93.2%; p<0.0001, 90.9%; p<0.0001) and 
had lower levels of total cholesterol (3.73 ± 1.00 mmol/L vs. 4.40 ± 1.40 mmol/L; 
p<0.001 and 3.55 ± 0.90 mmol/L vs. 4.27 ± 1.34 mmol/L; p<0.05 respectively).  
In addition, the present results demonstrated that IFN-γ (5.12 ± 5.31 pg/ml vs. 
10.82 ± 45.61 pg/ml; p<0.05), IL-12p70 (0.27 ± 0.49 pg/ml vs. 0.31 ± 0.29 pg/ml; 
p<0.01) and IL-8 (8.03 ± 14.75 pg/ml vs. 8.22 ± 8.07 pg/ml; p<0.05) plasma levels were 




5.3.3.3 Markers associated with follow-up events and CVD 
comorbidities 
The current data suggested that IL-6 plasma levels were associated with follow up 
MACE within 6 months (p<0.05).  
Additionally, when it comes to VHR participants with CVD comorbidities, our 
results demonstrated that IL-6 plasma levels were higher in VHR participants with 
diabetes compared to VHR participants with no diabetes (2.32 ± 2.63 pg/ml vs. 2.00 
± 2.84 pg/ml; p<0.05). Interestingly, IL-6 plasma levels were higher in VHR 
participants who currently smoked (p<0.05). Moreover, IL-6 (3.30 ± 3.43 pg/ml vs. 
1.83 ± 2.62 pg/ml; p<0.0001) plasma levels were higher in VHR participants with 
heart failure compared to VHR participants with no heart failure, whereas INF-γ (4.85 
± 3.34 pg/ml vs. 10.29 ± 43.23 pg/ml; p<0.05) plasma levels were lower. 
Furthermore, IFN-γ (12.25 ± 52.66 pg/ml vs. 5.81 ± 5.35 pg/ml; p<0.05) and IL-
12p70 (0.35 ± 0.44 pg/ml vs 0.24 ± 0.15 pg/ml; p<0.05) plasma levels were higher in 
VHR participants with hypertension compared to those with no hypertension. On the 
other hand, IL-8 plasma levels were higher in VHR participants with arthritis 
compared to those with no arthritis (13.01 ± 19.44 pg/ml vs. 7.28 ± 6.82 pg/ml; 
p<0.01) whereas IL-10 plasma levels were lower in VHR participants with 
dyslipidaemia (0.30 ± 0.32 pg/ml vs. 0.48 ± 0.85 pg/ml; p<0.05). (Table 2, Figure 2 and 
3). 
5.3.3.4 Markers associated with angiographic outcome  
Protein from the MSD® proinflammatory panel were explored to assess whether they 




multinomial logistic regression analysis (section 3.2.7 in Chapter 3), results showed 
that IL-12p70 plasma levels appeared to predict angiographic outcome with a p value 
nearly reaching significance (p=0.052). IL-12p70 plasma levels were the highest in 
participants with very severe coronary artery disease compared to participants who 
had an occlusion and those who had a triple vessel disease (0.3604 ± 0.5060 pg/ml, 
0.3482 ± 0.4486 pg/ml and 0.2561 ± 0.1322 pg/ml respectively with p=0.052). 
Looking at this more closely, data showed that participants with the highest levels of 
IL-12p70 were more likely not to have had a previous MI and not to be on medication. 
Among VHR participants with a very severe coronary artery disease, 14.5 % had a 
previous MI and 33.3% were not on medication as opposed to VHR participants with 
occlusion among whom 24.4% had a previous MI and 14.6% were not on medication 
and VHR participants with triple vessel disease among whom 17.8% had a previous 
MI and 21.4% were not on medication.  
 
Figure 2: IFN-γ plasma protein levels in VHR participants. INF-γ plasma protein levels 
were measured using the MSD® MULTI-SPOT Assay System. Figure 2a: INF-γ plasma levels 
were higher in ACS-VHR vs ELEC-VHR participants; Figure 2b: INF-γ plasma levels were 
higher in ACS participants admitted for recurrent MACE compared to ACS-VHR 
participants admitted for their first event; Figure 2c: INF-γ plasma levels were lower in 
ACS-VHR participants compared to ELEC-VHR participants with no previous CVD history. 
ACS: acute coronary syndrome participants; CVD: cardiovascular disease; ELEC: elective 
participants; CABG: coronary artery bypass graft; IFN-γ Interferon gamma; MACE: major 




intervention; VHR: very high risk. Statistical analysis was performed by Student t-test for 
figure 2a and 2c and by ANCOVA for figure 2b. **p<0.01, ****p<0.0001 
 
Figure 3: IL-6, IL-12p70 and IL-8 plasma protein levels in VHR participants. IL-6, IL-12p70 
and IL-8 plasma protein levels were measured using the MSD® MULTI-SPOT Assay 
System. Figure 3a: IL-6 plasma levels were higher in ACS-VHR vs. ELEC-VHR participants; 
Figure 3b: IL-6 plasma levels were higher in ACS-VHR vs ELEL-VHR with no previous CVD 
history; Figure 3c: IL-8 plasma levels were higher in ACS-VHR participants admitted for 
MACE vs. ACS-VHR participants admitted for first CVD; Figure 3d: IL-12p70 plasma levels 
were higher in ACS-VHR participants admitted for MACE vs. ACS-VHR participants 
admitted for first CVD; ACS: acute coronary syndrome participants; ELEC: elective 
participants; CABG: coronary artery bypass graft; IFN-γ Interferon gamma; MACE: major 
adverse cardiovascular events, MI: myocardial infarction, PCI: percutaneous coronary 
intervention; VHR: very high risk. Statistical analysis was performed by Student t-test for 




5.3.4 Assessing the value of a multimarker model in predicting 
cardiovascular risk. 
In order to evaluate whether the aforementioned significant proteins from the MSD® 
proinflammatory panel were able to predict VHR or non/VHR group membership, a 
logistic regression analysis was performed (section 3.2.7 in Chapter 3). This showed that 
a panel combining INF-γ, IL-6, IL-8 and TNFα plasma levels was able to predict 85.8% of 
the VHR/non-VHR group membership (p<0.0001) as opposed to 79.3%, 75.2% and 76.9% 
when using IL-6, IL-8 and TNFα alone respectively. The r square of the combined model 
was 0.667 which suggests that 66.7% of the variability is predicted by the combined 
model.  
5.3.5 A cluster analysis to further stratify VHR cohort using INF-
γ, IL-6, IL-8 and TNFα plasma protein levels 
To explore whether VHR individuals could be further stratified according to the levels of 
their inflammatory markers, a two-way cluster analysis was carried out. Using IFN-γ, IL-
6, IL-8 and TNFα plasma levels generated two clusters within the VHR cohort. The choice 
of those proteins was based on their ability to identify VHR participants and their 
aptitude in further differentiating between VHR sub-groups. Participants in cluster 1 
(n=140) had lower plasma levels of IFN-γ (4.68 ± 3.45 pg/ml vs. 17.28 ± 64.03 pg/ml; 
p<0.0001), IL-6 (1.24 ± 0.97 vs. 3.35 ± 4.04 pg/ml; p<0.0001), IL-8 (5.42 ± 2.66 pg/ml vs. 
12.81 ± 15.00 pg/ml; p<0.0001) and TNFα (3.63 ± 0.98 pg/ml vs. 6.53 ± 3.06 pg/ml; 
p<0.0001) compared to cluster 2 (n=85). Cluster 2 also grouped older participants (68 ± 
10 years vs. 64 ± 11 years; p<0.01), participants with a lower total cholesterol levels (3.93 




21 mmHg vs. 134 ± 25 mmHg; p<0.05), higher levels of IL-10 (0.498 ± 0.873 pg/ml vs. 
0.296 ± 0.346 pg/ml; p<0.0001), higher levels of IL-12p70 (0.369 ± 0.370 pg/ml vs. 0.257 
± 0.326 pg/ml; p<0.000), higher levels of IL-2 (0.318 ± 0.396 pg/ml vs. 0.233 ± 0.151 
pg/ml; p<0.05) and higher levels of CRP (22.77 ± 48.35 mg/L vs. 7.30 ± 18.57 mg/L; 
p<0.01) compared to cluster 1. In addition, cluster 2 also had a higher percentage of VHR 
participants admitted for recurrent MACE (54.3% vs. 24.3%; p<0.0001), a higher 
percentage of VHR participants with previous MI (43.5% vs 24.3%; p<0.01), a higher 
percentage of VHR participants with previous PCI (42.4% vs. 25.7%; p<0.0001), a higher 
percentage of VHR diabetic participants (29.4% vs 12.9%; p<0.01) and a higher 
percentage of VHR participants with heart failure (24.7% vs. 10%; p<0.01) compared to 
cluster 1. 
5.3.6 CRP plasma levels did not further differentiate between 
VHR participant sub-groups 
Refer to section 3.3.6 in Chapter 3. 
5.3.7 Correlations between biomarker protein levels 
To explore whether protein levels measured as part of the MSD® proinflammatory panel 
correlated with different variables explored in the study, a correlation analysis was 
performed (section 3.2.7 in Chapter 3). For a full correlation matrix, refer to Table 6 in 
section III of the Appendix. Results indicated that IFN-γ plasma levels correlated 
positively with IL-10, IL-12p70, IL-2, IL-8 and TNFα plasma levels (r=0.284; p<0.0001, 
r=0.166; p<0.01, r=0.176; p<0.01, r=0.120; p<0.05 and r=282; p<0.0001 respectively). IL-
6 plasma levels correlated positively with age, body mass index (BMI), IL-10, IL-8 and 




p<0.001, and r=0.423; p<0.0001 respectively) and negatively with total cholesterol levels 
(r=-0.200; p<0.0001). IL-8 plasma levels correlated positively with age, systolic blood 
pressure, IFN-γ, IL-10, IL-12p70, IL-2, IL-6 and TNFα plasma levels (r=0.368; p<0.0001, 
r=0.122; p<0.05, r=0.120; p<0.05, r=0.122; p<0.05, r=0.199; p<0.0001, r=0.162; p<0.01, 
r=0.264; p<0.0001 AND R=0.486; P<0.0001 respectively) and negatively with total 
cholesterol levels (R=-0.234; p<0.0001). IL-12p70 plasma levels correlated positively 
with age, INF-γ, IL-10, IL-2, IL-8 and TNFα plasma levels (r=0.151; p<0.01, r=0.166; 
p<0.01, 0.143; p<0.01, r=0.221; p<0.0001, r=0.199; p<0.0001 and r=0.300; p<0.0001 
respectively). TNFα plasma levels correlated positively with C reactive protein (CRP) 
plasma levels, age and BMI (p<0.01, p<0.0001 and p<0.05 respectively) and negatively 




Table 2: Inflammatory protein levels in very high risk participants 














































































































































































































Diabetes mellitus  
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Diuretic therapy  













































































































































































































































































Previous MI   








































































































































































Previous CABG   



















































































































































































































































































































































































































































no previous MI, 
PCI or CABG 
 























































































Follow-up MACE   



































































































































Highlighted cells refer to p values <0.05. (ACS: acute coronary syndrome participants; CABG: Coronary artery bypass surgery; ELEC: elective participants; GFR: 
Glomerular filtration rate; MACE: major adverse cardiovascular events MI: Myocardial Infarction; NSTEMI: non-ST elevation myocardial infarction; PCI: percutaneous 





The present investigation identified potential candidate biomarkers from the MSD® 
proinflammatory panel that could improve the current CVD risk assessment tools. 
Furthermore, these proteins demonstrated a superior value to CRP measurement in 
further stratifying individuals at VHR of MACE risk. However, some of the tested proteins 
had a low limit of detection and a high coefficient of variations when tested in plasma 
samples. Such panels, once optimised, can be measured in large prospective longitudinal 
studies to assess their additional value in assessing CVD risk.  
5.4.1 IFN-γ, IL-6, IL-8 and TNFα identified individuals at cardiovascular risk 
Levels of IN-γ, IL-6, IL-8 and TNFα have been explored in separate studies, however, their 
collective role in identifying individuals at various levels of cardiovascular risk hasn’t 
been evaluated yet. In the present study IFN-γ, IL-8, IL-6, and TNFα plasma protein levels 
significantly differentiated between VHR and non-VHR participants. In addition, IL-6 
plasma protein levels could also distinguish between MR and LR participants. Previous 
evidence has showed that IFN-γ plays an important role in atherosclerosis and plaque 
stability (254) however, IFN-γ plasma levels haven’t been previously measured in 
participants at different levels of cardiovascular risk. Additionally, IL-8 is known to be 
involved in maintaining an inflammatory environment surrounding the plaque (245) and 
IL-8 levels have been shown to be higher in unstable coronary artery disease (246). 
Furthermore, IL-6 levels have been linked to cardiovascular risk for over a decade (255) 
and many studies have associated IL-6 with CVD risk (256) but also with melanoma (257) 
and influenza (258). Similarly, although TNFα plasma levels have been measured in 
individuals with CVD (153), TNFα is a systematic inflammatory cytokine and is also 




highlights one of the major problems associated with biomarker development which is 
non-specificity since levels tend to be associated with other diseases and therefore 
complicate the diagnostic. One of the solutions to this problem is combining markers in 
an inflammatory panel which will then compensate for the non-specificity that individual 
biomarkers might face (261,262). The important clinical value of such a multimarker 
panel is reflected in a logistic regression model which demonstrated that combining IFN-
γ, IL-6, IL-8 and TNFα plasma level measurement resulted in an 85.8% accurate 
prediction of the VHR/non-VHR group membership as opposed to 79.3%, 75.2% and 
76.9% when using IL-6, IL-8 and TNFα alone respectively. Furthermore, when age, 
gender and BMI were added to this model, the accuracy of predicting cohort 
membership increased to 91.7% (p<0.0001). This highlights the significant value of using 
a multimarker approach in predicting cardiovascular risk. In addition, some markers in 
the panel showed to be useful in further stratifying individuals at very high risk of CVD 
as discussed in section 5.4.2. 
On the other hand, the value of IL-1β as a therapeutic target in CVD has proven to 
be effective as the ongoing Canakinumab Anti-Inflammatory Thrombosis Outcomes 
Study (CANTOS) trial is showing promising results (263). Furthermore, IL-1β has been 
linked to atherothrombotic disease and plaque destabilisation as well as adverse 
remodelling after a myocardial infarction (MI) (264). Therefore, keeping in mind the 
importance of IL-1β as a therapeutic target in CVD, its additional value to a multimarker 
CVD panel was assessed. Nevertheless, in the present study, the measurement of 
plasma IL-1β resulted in many values below the limit of detection of the MSD® assay 
(refer to the Methods section II.X in the appendices). In fact, measuring IL-1β levels in 




assays in previous studies (265). Therefore, to compensate for this analytical problem 
and to evaluate whether IL-1β has a potential value in CVD risk assessment, IL1B gene 
expression was measured. Results showed that IL1B mRNA levels were higher in VHR 
compared to non-VHR participants. Therefore, despite the clinical value demonstrated 
by IL-1β gene expression evaluation in CVD risk assessment, including IL-1β protein 
measurement in a panel test might require optimisation.  
5.4.2 IFN-γ, IL-6, IL-8 and IL12-p70 can further differentiate between VHR 
participants 
The present data indicated that IFN-γ and IL-6 plasma levels were higher in ACS-VHR 
compared to ELEC-VHR participants. These results are in line with previous reports of 
higher INF-γ and IL-6 levels in participants with acute MI (266,267). IL-6 is a pro-
inflammatory cytokine involved in acute phase response and, in addition to its release 
from T cells and macrophages, has been shown to be produced by muscles (268). High 
IL-6 levels have been previously reported in participants with STEMI (269) (also shown 
in the present study - Table 2) which suggests that the source of IL-6 after an MI could 
also originate from the heart muscle. Interestingly, it has been reported that muscle 
produced IL-6 has anti-inflammatory effects and dampers TNFα response (270). This 
could mean that the release of IL-6 following an acute phase response partially aims to 
counteract a critical increase in inflammation. Moreover, IL-6 plasma levels were 
associated with MACE within a 6-months follow up period which has been previously 
reported (266,267,271). However, our study shows that IL-6 plasma levels were 
particularly higher in participants who developed MACE within 6 months after admission 




In terms of recurrent cardiovascular events, the present study showed that IL-12p70 
and IL-8 plasma levels were higher in ACS-VHR participants admitted for recurrent MACE 
compared to ACS-VHR participants admitted for their first cardiovascular event and in 
VHR participants who were on medication compared to participants who were not. 
Participants on medication were more likely to have had a previous MI, PCI or CABG. 
This shows first that IL-12p70 and IL-8 could be possible markers for acute events in 
participants with a CVD history and second, that medical treatment fails to decrease the 
levels of IL-12p70 and IL-8 plasma levels. Interestingly, INF-γ plasma levels were lower 
in ACS-VHR participants admitted for their primary cardiovascular event compared to 
ELEC-VHR participants but were higher in ACS-VHR participants admitted for their 
recurrent MACE. This effect could be due to medical treatment since participants 
admitted for recurrent MACE were on medication and INF-γ plasma levels were higher 
in VHR individuals on medication. 
Is a matter of fact, IL-12p70 is a heterodimer of IL-12 formed by alpha helices coded 
by two separate IL-12 genes (IL-12 p35 and IL-12 p40). IL-12 levels have been shown to 
be related to adverse outcomes in participants with STEMI (272) and to endothelial 
dysfunction (273) and in the present study, IL-12p70 levels were higher in ACS-VHR 
participants admitted for recurrent MACE. However, IL-12/23 inhibitors, majorly used in 
psoriasis and psoriasis arthritis treatment, have been shown to cause MACE (274) which 
highlights a need to further understand the consequences of completely inhibiting IL-12 
in CVD. Furthermore, in this present study, IL-12p70 levels seemed to predict 
angiographic outcome and were found to be higher in participants with a very severe 
plaque burden who were also more likely to be drug naïve and to have no previous CVD 




in participants with three affected coronary arteries compared to those with one 
affected coronary artery (272). 
Based on INF-γ, IL-6, IL-8 and TNFα plasma levels of a cluster analysis could further 
stratify the VHR participants into 2 clusters. Cluster 2 grouped a higher percentage of 
VHR individuals with a severe CVD history in terms of recurrent MACE, previous MI or 
PCI, diabetes and heart failure. Cluster 2 also grouped older participants with a high body 
mass index (BMI) who have high inflammatory markers with high plasma levels of C 
reactive protein (CRP), IL-10, IL-12p70 and IL-2. This shows that participants belonging 
to cluster 2 require a closer follow up as they are at higher risk of MACE due to higher 
levels of inflammatory proteins and a severe cardiac history. Therefore, the present 
cluster analysis demonstrates that, in order to accurately predict the risk of recurrent 
MACE, a multimarker panel needs to account for the extent of increases in biomarker 
levels and needs to combine risk factors that assess an individual’s cardiac history and 
comorbidities. 
5.4.3 Strengths and Limitations 
Refer to section 3.4.3 in Chapter 3 
In terms of potential biases resulting from the biochemical measurements used in the 
present study, it is important to consider that IL-13, IL-1β and IL-4 plasma levels were 
below the limit of detection of the used assay. However, IL-1β gene expression levels 
were measured in a subset of participants. There were 5 values that were below the 
limit of detection for INF-γ assay, 5 for the IL-10 assay, 36 for the IL-2 assay, 1 for the IL-
6 assay, 1 for the IL-8 assay and 12 for the IL-12p70 assay which also had a high 





Figure 4: Proposed summary diagram highlighting the role of INF-γ, IL-6, IL-8 and IL-
12p70 in cardiovascular risk stratification. ACS-VHR: acute coronary syndrome 
participants; MACE: major adverse cardiovascular events, NSTEMI: non-ST segment 
elevation myocardial infarction; STEMI: ST-segment elevation myocardial infarction; 






This study shows that IL-6, IL-8, INF-γ and IL-1β can differentiate between individuals at 
various levels of CVD risk. Additionally, IL-6, IL-8, INF-γ and IL-12p70 can further stratify 
the VHR group. A panel combining such inflammatory markers could make risk 
stratification in these VHR participants much more effective and may identify individuals 
at higher risk of developing MACE. The results of this study need to be replicated in 
larger cohorts in prospective longitudinal studies in order to define the steps needed for 
















Chapter 6  
Biomarker Discovery set:  
A proteomic approach for 
identifying individuals at various 






Background: Biomarker discovery in cardiovascular disease (CVD) is moving towards a 
multimarker rather than a single marker approach. Since multiple inflammatory and 
immune pathways are involved in CVD, measuring one marker could be seen as too 
simplistic and is unlikely to capture an individual’s susceptibility to develop first or 
recurrent major adverse cardiovascular events (MACE). Current traditional risk scoring 
systems are not ideally predictive as many patients calculated to have high scores do 
not suffer from CVD while others found to have low scores present with cardiovascular 
events. In this current study, using a traditional scoring system to assign scores to 
individuals at risk of CVD, we aimed to investigate whether a panel combining a set of 
184 inflammatory proteins, known to be involved in immunity, atherosclerosis, plaque 
rupture and thrombosis could add value to this risk prediction tool and help further 
stratify individuals with CVD.  
Methods: Participants were recruited from the cardiac catheterisation laboratory or by 
email advertisement. Group 1 was defined as very high risk participants (VHR) with a 10-
year risk SCORE ≥10% risk of fatal CVD. Group 2 were defined as low, moderate and high 
risk participants (non-VHR) with a 10-year risk SCORE <10% risk of fatal CVD. Proteins 
from the cardiovascular panel II and III were measured in the plasma using multiplex 
proximity extension assays (PEA) by Olink Proteomics®. 
Results: A total of 297 participants were recruited consecutively. The VHR group (n=208) 
consisted of acute coronary syndrome VHR (ACS-VHR) (n=113) and elective 
percutaneous intervention participants (ELEC-VHR) (n=95). The non-VHR group (n=89) 
consisted of low risk (LR) (n=61) and moderate risk (n=28) participants. A total of 72 




(p<0.01), PON3 (p<0.01) and CNTN1 (p<0.0001) were able to differentiate between VHR 
and non-VHR participants. A total of 77 proteins including ADAMTS-13 (p<0.0001), 
VEGF-D (p<0.0001), BOC (p<0.0001), PDL-2 (p<0.0001), protein AMBP (p<0.05), OPN 
(p<0.0001) and TRAP (p<0.0001) were able to identify ACS-VHR participants admitted 
for their first cardiovascular event. A total of 40 proteins including TNFSF13B (p<0.01), 
IL18-BP (p<0.01), TNFRSF11A (p<0.01), BOC (p<0.01), TNFR2 (p<0.01) and EGFR (p<0.05) 
identified ACS-VHR participants admitted for recurrent MACE. A total of 79 proteins 
including KIM1 (p<0.0001), IL-1RT1 (p<0.0001), Gal-3 (p<0.0001), REN (p<0.0001), VSIG2 
(p<0.0001), FABP4 (p<0.001), GIF (p<0.001), PON3 (p<0.01) and HO-1 (p<0.05) 
characterised VHR participants with diabetes whereas a total of 71 proteins including 
TRAIL-R2 (p<0.0001), FGF-21 (p<0.001), ADM (p<0.0001), TNFRS11A (p<0.0001), CTRC 
(p<0.001) and SRC (p<0.05) characterised VHR participants with heart failure. 
Conclusion: This proteomic approach evaluating 184 proteins from two CVD protein 
panels highlights a number of novel proteins that were able to differentiate between 
individuals at various levels of CVD risk. In addition, a number of distinct proteins further 
stratified VHR participants in relation to their CVD history (whether they had a primary 
or a recurrent MACE) or according to their co-morbidities (diabetes, heart failure, 
chronic kidney disease). Such protein panels need to be further investigated and tested 
in larger cohorts in order to fully evaluate their utility in stratifying individuals at risk 








Biomarker discovery in cardiovascular disease (CVD) faces several increasing challenges. 
Co-morbidities are prevalent amongst those with CVD, including conditions such as 
diabetes mellitus, heart failure, chronic kidney disease, metabolic disorders and also 
depression (275–278). Since these pathologies share common biological pathways, 
measuring one specific biomarker may be seen as too simplistic.   
The search for CVD biomarkers began in the mid-1960s when creatine kinase and its 
cardiospecific isoform creatine kinase-MB were established as indicators of acute 
myocardial damage (279). Later, cardiac troponins emerged as a biomarker based on 
which participants admitted with an acute coronary syndrome (ACS) were classified 
(280,281) and natriuric peptides (NP) as biomarkers for heart failure (282). Despite years 
of research, very few CVD biomarkers have managed to make it into clinical practice, 
mainly due to issues in relation to assay specificity, standardisation and legal 
considerations (283). 
The Framingham Study, which started in 1950, (284), initiated the development of 
several risk scoring systems that incorporated several biomarkers such as such as 
systolic blood pressure and cholesterol levels in order to assess CVD risk in an individual 
with no prior CVD history (285). Framingham risk scores (90), as well as others, such as 
the Systemic Coronary Risk Evaluation (SCORE) (83) and the Prospective Cardiovascular 
Münster (PROCAM) study (286) risk scores are accepted risk prediction tools to guide 
clinical decision-making. While these scores can inform treatment decisions, they leave 
ample room for improvement as they have been extensively criticised (95). This is 
because current risk scores use risk factors to establish CVD risk, however, traditional 




with an average risk score who are mistakenly considered to be at intermediate or low 
risk because they have none or only one of the CVD risk factors (287). In contrast, many 
patients who are classified as high-risk individuals do not experience a cardiovascular 
event even in the long term (288). This suggests that improved risk prediction models 
are necessary. 
The complexity of CVD (289) demonstrates that one single biomarker is unlikely to 
capture the individual predisposition to the disease. However, improving CVD risk scores 
using new biomarkers has proven a major challenge. For example, C-reactive protein 
improves CVD risk prediction in the general population, but its predictive value is limited 
because of its strong correlation with other risk factors, such as body mass index and 
smoking (290) and it is also well-known that C-reactive protein is elevated in several 
inflammatory conditions apart from CVD (291). Due to CVD multifactorial causes, 
biomarker research is quickly moving towards a multimarker approach. The interest in 
generating multimarker scores that use a composite of several biomarkers (measured in 
parallel) to predict disease risk and patient outcomes is increasing (292–296). 
Biomarkers belonging to different pathways involved in atherosclerosis could be 
measured collectively to provide a better understanding of the underlying and ongoing 
inflammation and the moment it reaches a critical point when a vulnerable plaque is 
more likely to rupture and an ACS is more likely to occur. This approach would allow the 
identification of individuals at very high risk and help treat them more efficiently with 
the available resources in a context where CVD is now concomitant with obesity, 
hypertension, diabetes mellitus and an aging population.  
In the present study, using the European risk SCORE chart, we investigated whether 




plaque rupture and thrombosis, could add value to this risk prediction model and help 
further stratify participants with CVD.  
6.2 Participants and Methods 
Refer to section 2.1 in Chapter 2 for a detailed description of the participant 
recruitment process, the risk score used and the methods for blood processing. 
6.2.1 Demographic information  
Refer to section 3.2.1 in Chapter 3 for a detailed description of the demographic 
information that was collected in this study. 
6.2.2 Method for analysing plasma samples using the Proximity 
Extension Assay (PEA) technology - Proseek® Multiplex provided 
by O-Link Proteomics (CVDII and CVDIII) 
Refer to section 2.14 in Chapter 2 and Figure 12 and 13 in section 2.14 in Chapter 2.  
6.2.3 Statistical methods 
Statistical analysis was carried out as described in section 3.2.7 in Chapter 3 
In addition, body mass index (BMI) was adjusted for when it significantly contributed to 
the variability in the measured proteins. Protein levels that were significantly different 
between the compared cohorts were selected. A logistic regression was used to examine 
whether the totality of the significant proteins could effectively predict the cohort 
membership. An ideal candidate biomarker would have measurements that yield 
different bell curves for each group of participants with different means and minimal 




groups with confidence. Therefore, volcano plots were created for each two cohorts that 
were compared between each other. For each protein, minus Log(10) of the p value was 
plotted against the Log(2) of the difference in average NPX of the measured protein 
between the compared cohorts. Using the proteins that were statistically significant 
among our cohorts, we performed a principal component analysis (PCA) to examine how 
many components the measured proteins formed and whether these components were 
inter-correlated in terms of biological pathways. Using proteins which levels were 
statistically significant when comparing VHR participants with MACE and VHR 
participants with no MACE, VHR participants were further stratified. A two-way cluster 
analysis was performed to explore how many clusters the VHR participants form. 
Differences in those clusters were then explored using a crosstab chi square as well as 
an ANOVA. A multinomial logistic regression analysis was then performed to investigate 
whether the selected proteins can effectively predict the severity of the plaque burden. 
Pearson’s correlation was used to evaluate the correlation between variables. Statistical 
significance was defined as values of p<0.05 in general. However, when conducting an 
ANCOVA statistical significance was set at <0.07. 
6.3 Results and Discussion 
In order to assess the value of proteomic research in CVD risk assessment, two CVD 
protein panels (CVDII and CVDIII) combining a total of 184 proteins were measured by 
multiplex proximity extension assay (PEA) technology. The measured proteins are part 
of pathophysiological pathways implicated in global inflammation, immune response 
and cell adhesion, among many others (Figure 12 and 13 in section 2.14 of Chapter 2), 
and most of them are widely expressed in the body. This proteomic approach identified 




participants at various levels of CVD risk. Several promising biomarkers were also able 
to further stratify participants with an established CVD at risk of major adverse 
cardiovascular events (MACE).  
6.3.1 Biomarkers of cardiovascular risk 
6.3.1.1 Participant recruitment 
A total of 297 participants were recruited consecutively over a period of two years. The 
very high risk (VHR) (n=208) participants consisted of acute coronary syndrome (ACS-
VHR) (n=113) and elective percutaneous intervention (ELEC-VHR) participants (n=95). 
The non-VHR (n=89) participants consisted of low risk (LR) (n=61) and moderate risk 
(n=28) participants. Table 1 and 2 provide the full descriptive statistics of the population. 
The mean age of the VHR participants at study entry was 65 years and 20% were women. 
A proportion of 56% had a history of hypertension, 19% were diabetic and 19% were 
current smokers. The mean age of the non-VHR participants was 46 years and 70% were 
women. A proportion of 13% had hypertension (MR=28) and 3% were current smokers.  
Table 1: Population demographics of participants at various levels of cardiovascular risk 
classified according to the SCORE risk chart. 
  











208 28 61  89  
Age (years) 65 57 41 <0.0001 46 <0.0001 
Male (n; %) 167; 80.3 15; 53.6 12; 19.7 <0.0001 
 (Chi 2) 
27; 30.3 <0.0001 
(Chi 2) Female (n; %) 41; 19.7 13; 46.4 49; 80.3 62; 69.7 
Weight (Kg) 86.5 ± 19.5 83.1 ± 18.9 74.5 ± 14.9 <0.0001 77.3 ± 16.7 <0.0001 
Height (cm) 171.2 ± 9.4 
168.6 ± 
10.5 
166.7 ± 8.2 0.004 167.3 ± 9.0 0.001 
BMI (Kg/m2) 29.2 ± 6.5 29.3 ± 6.6 26.9 ± 5.8 0.045 27.7 ± 6.1 0.059 
Systolic BP 
(mmHg) 


















1.2 ± 0.5 1.6 ± 0.4 1.6 ± 0.4 <0.0001 1.6 ± 0.4 <0.0001 
TG (mmol/L) 1.8 ± 2.2 1.2 ± 0.5 1.1 ± 0.7 0.019 1.1 ± 0.7 0.005 
CRP (mg/L) 12.6 ± 33.7 3.0 ± 2.5 2.4 ± 3.6 0.026 2.5 ± 3.5 0.007 
One way ANOVA was used to compare the VHR, MR and LR cohorts. Student t-test was used to 
compare VHR to non-VHR. (BMI: body mass index; BP: blood pressure; CRP: C-reactive protein; 
HDL: high density lipoprotein; LDL: low density lipoprotein; LR: low risk; MR: moderate risk VHR: 
very high risk; non-VHR: non-very high risk; TG: triglycerides). 
Table 2: Medical history and lifestyle characteristics of participants at various levels 
cardiovascular risk classified according to the SCORE risk chart. 








208 28 61  89  
  n; %   n; %  
Hypertension 117; 56.3 8; 28.6 4; 6.6 <0.0001 12; 13.5 <0.0001 
Diabetes 39; 18.8 0; 0 0; 0  0; 0  
Dyslipidaemia 119; 57.2 19; 67.9 27; 44.3 0.078 46; 51.7 0.226 
GFR<60  44; 21.1 1; 4.0 2; 3.4 0.001 3; 3.6 <0.0001 
Arthritis 34; 16.3 5; 17.9 1; 1.6 0.01 6; 6.7 0.026 
Depression 34; 19.2 4; 14.3 7; 11.5 0.337 11; 12.4 0.15 
Employment 
status  
57; 32.6 19; 76.0 60; 98.4 <0.0001 80; 91.9 <0.0001 
Current 
smokers 
38; 19.3 2; 7.4 1; 1.6 0.002 3; 3.4 <0.0001 
Ex-smokers 99; 50.2 8; 29.6 26; 42.6 <0.0001 35; 34 <0.0001 
Exercise 89; 62.2 21; 80.8 47; 78.3 0.029 69; 77.5 0.008 
Alcohol 
consumption 
101; 59.8 16; 61.5 52; 86.7 0.001 70; 79.1 0.002 
Pearson’s chi square test was used to compare VHR, MR and LR groups and the VHR and 
non-VHR groups. (VHR: very high risk; MR: moderate risk; LR: low risk; non-VHR: non-




6.3.1.2 Selection of potential proteins that differentiated between 
different cardiovascular risk groups 
In order to select the proteins that significantly differentiated between two cohorts, 
mean NPX values were calculated for each protein in each cohort (VHR, MR, LR and non-
VHR cohorts) and p values were generated when comparing two cohorts. Figure 1, 2, 3 
and 4 are volcano plots representing the -Log10 of the p value plotted against the 
difference in the average NPX for each protein in each cohort (VHR/MR, VHR/LR, MR/LR 
and VHR/non-VHR respectively). The proteins that are at the top left or right side of the 
plot are the ones that show a strong statistical difference as well as a high difference 
between the protein means in the compared cohorts. It is noteworthy to mention that 
each 1 NPX value correspond to a 2-fold increase in the protein concentration. Table 1 
in section III of the appendix shows the list of proteins that were statistically different 
when compared across risk groups, the p values as well as the NPX mean and difference. 
Below is the list of significant proteins that were able to differentiate between two risk 
groups and that were explored in the context of the current literature. 
Among 49 proteins, those that strongly differentiated between the VHR and MR 
cohorts were Matrix metalloproteinase-7 (MMP7) (p<0.0001), Tartrate-resistant acid 
phosphatase type 5 (TRAP) (p<0.0001), Lectin-like oxidized LDL receptor 1 (LOX-1) 
(p<0.05) and Osteoclast-associated immunoglobulin-like receptor (hOSCAR) (p<0.0001) 
(Figure 1). MMP7 in a metalloproteinase known to break the extracellular matrix and 
has been suggested to contribute to plaque instability in atherosclerosis (297). LOX-1 is 
known bind, internalise and degrade oxidised low-density lipoprotein and has been 




evidence in the literature of the role of TRAP and hOSCAR in CVD and their role should 
be further investigated in prospective studies. Interestingly, hOSCAR have been 
associated with osteoporosis (299), however TRAP is known to be expressed by 
macrophages and increased expression has been recently linked to cancer (300).  
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Figure 1: Volcano plot representing the p value against the difference in mean NPX 
between VHR and MR participants. -Log10 of the p value was plotted against the 
difference between the average of the NPX value (VHR-MR). Proteins to the far left or 
right side of the graph have a significant fold in change (whether higher or lower) with a 
very significant p value (p<0.0001). NPX: normalised protein ratio 
 
Some of the proteins that strongly differentiated between the VHR and the LR 
cohorts include MMP7 (p<0.0001), Lactoylglutathione lyase (GLO1) (p<0.0001), Lectin-
like oxidized LDL receptor 1 (LOX-1) (p<0.0001), Carcinoembryonic antigen related cell 
adhesion molecule 8 (CEACAM8) (p<0.001), and Matrix metalloproteinase-12 (MMP12) 
(p<0.01) (Figure 2). Polymorphisms in GLO1 have been associated with vascular diseases 
(301) whereas MMP12 has been suggested as a candidate molecule for the prevention 




disease (303). However, there is little evidence in the literature on the role of CEACAM8, 
an adhesion molecule produced by granulocytes (304), in CVD and the mechanisms 
behind this interaction needs further understanding. 
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Figure 2: Volcano plot representing the p value against the difference in mean NPX 
between VHR and LR participants. -Log10 of the p value was plotted against the 
difference between the average of the NPX value (VHR-LR). Proteins to the far left or 
right side of the graph have a significant fold in change (whether higher or lower) with a 
very significant p value (p<0.0001). NPX: normalised protein ratio 
 
The proteins that strongly differentiated between the MR and the LR cohorts were 
LOX-1 (p<0.05), Pappalysin-1 (PAAPA) (p<0.05), Tumour necrosis factor receptor 
superfamily member 11A (TNFRSF11A) (p<0.05), cathepsin D (CTSD) (p<0.05) (Figure 3). 
PAPPA cleaves insulin like growth factor binding proteins and has been recently shown 
to be a potential marker of vulnerable plaques (295) whereas CTSD has previously been 
associated with MACE (305). However, TNFRSF11A and is known to regulate the 
interactions between T cells and dendritic cells (306) and have not been investigated 
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Figure 3: Volcano plot representing the p value against the difference in mean NPX 
between MR and LR participants. -Log10 of the p value was plotted against the 
difference between the average of the NPX value (MR-LR). Proteins to the far left or 
right side of the graph have a significant fold in change (whether higher or lower) with 
a very significant p value (p<0.0001). NPX: normalised protein ratio 
 
The best candidate proteins that differentiated between the VHR and the non-VHR 
cohorts were Matrix metalloproteinase-7 (MMP7) (p<0.0001), Matrix 
metalloproteinase-12 (MMP12) (p<0.0001), Renin (REN) (p<0.001), 
Growth/differentiation factor 15 (GDF-15) (P<0.01), Paraoxonase (PON3) (p<0.01) and 
Contactin-1 (CNTN1) (p<0.0001) (Figure 4). REN plasma activity has been recently linked 
to increased risk of MACE and congestive heart failure in participants with high systolic 
blood pressure (307). GDF-15 has been proposed as a new biomarker for CVD, stable 
coronary artery disease (CAD), ACS and heart failure (308). In addition, the role of the 
paraoxonase enzymes in CVD has been outlined especially through their involvement in 
the lipid metabolism (309) while the association between CNTN1 and new CVD onset 
has been also previously highlighted (122). Nevertheless, there are no studies that have 
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Figure 4: Volcano plot representing the p value against the difference in mean NPX 
between VHR and non-VHR participants. -Log10 of the p value was plotted against the 
difference between the average of the NPX value (VHR-nonVHR). Proteins to the far left or 
right side of the graph have a significant fold in change (whether higher or lower) with a 
very significant p value (p<0.0001). NPX: normalised protein ratio 
 
Among the aforementioned proteins, it appears that MMP7 and LOX-1 were able to 
differentiate between more than two risk groups and their role in CVD has been 
previously described (297,298). However, in the present study, these proteins showed 
to have an important potential in CVD risk assessment and should be further explored 
in prospective studies as candidate biomarkers. In addition, CNTN1 and PON3 were both 
lower in VHR compared to MR (p<0.01; p<0.05), LR (p<0.01; p<0.05) and non-VHR 
participants (p<0.0001; p<0.05) suggesting that these two proteins might play a 
protective role in CVD which needs further understanding. 
Among the other proteins that also showed to significantly differentiate between 
CVD risk groups (VHR/MR, VHR/LR, MR/LR and VHR/nonVHR) (Table 3), some haven’t 




on the mechanisms behind their interaction with CVD. These proteins included 
Hydroxyacid Oxidase 1 (HAOX1), Azurocidin 1 (AZU1), Alpha-L-Iduronidase (IDUA), 
Macrophage receptor with collagenous structure (MARCO), Prolargin, (PRELP), 
Interleukin 17 Receptor A (IL17-RA), Neurogenic locus notch homolog protein 3 (Notch 
3), CD84, Matrix extracellular phosphoglycoprotein (MEPE), Cathepsin Z cardiovascular 
(CTSZ), 2,4 Dienoyl-CoA reductase (DERC1), Galectin 4 (Gal4), Interleukin-18-binding 
protein (IL18BP), Integrin Subunit Beta 2 (TGB2), Programmed cell death 1 ligand 2 (PD-
L2), Spondin 1 (SPON1), Proto-oncogene tyrosine-protein kinas (SRC), Lymphotoxin Beta 
Receptor (LTBR) and TNF Receptor Superfamily Member 13B (TNFRSF13B). As a matter 
of fact, despite little evidence in the literature associating these proteins with CVD, they 
are included in the cardiovascular disease panel II (CVDII) and III (CVDIII) provided by 
Olink Proteomics®. However, some of these proteins have been shown to be involved in 
inflammatory response, immune response, MAPK cascade, proteolysis, response to 
hypoxia, response to peptide hormone, wound healing, catabolic processes and 
chemotaxis (Figure 12 and 13 in section 2.14 in Chapter 2). Therefore, their inclusion in 
the panel is based on exploratory data that suggested a possible role in CVD.  
In order to visualize the general inflammatory trend between VHR and non-VHR 
individuals, a heat map was generated (Figure 5). On the other hand, to investigate 
whether some proteins were able to differentiate between more than two risk groups, 
Venny 2.0 online tool was used. The results in Table 3 and Figure 6 represent the 
proteins that were unique or in common between risk groups (Venny 2.0, (Oliveros, J.C. 
(2007-2015) Venny - http://bioinfogp.cnb.csic.es/tools/venny/index.html). This 
demonstrated that LOX-1 and MMP9 were able to distinguish between all three risk 




to MMP9 as the p values and the difference in NPX mean levels generated by LOX-1 
protein levels were higher when comparing two risk groups. 
 
Figure 5: Heat map representing normalized protein levels (z-score) in the VHR and non-VHR 
cohort. This heatmap was generated using the online tool www2.heatmapper.ca/expression. The 
green colour represents high protein expression and the red colour represents low protein 
expression. The clustering method applied was set to average linkage and the distance 
measurement method was set to Euclidian. The non-VHR participants tended to cluster together. 
The list of proteins are at the bottom of the heat map and the participants are on the right side 






Figure 6: Diagram generated by Venny 2.0. This diagram represents the number of 
proteins that differentiated between two risk groups and were unique to those two risk 
groups (24 proteins for VHR/MR, 27 proteins for VHR/LR and 4 proteins for MR/LR). It 
also represents the number of proteins that differentiated between two risk groups and 
were common between two risk groups (22 proteins that differentiated between 
VHR/MR and VHR/LR, 1 protein that differentiated between VHR/LR and MR/LR and 1 
protein that differentiated between MR/LR and VHR/MR). Finally, it represents the 2 
proteins that differentiated between two risk groups and that were common between 
VHR/MR, VHR/LR and MR/LR risk groups. (Venny 2.0, (Oliveros, J.C. (2007-2015). LR: low 






Table 3: List of proteins that differentiated between different risk groups generated by 
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CD84 
     
This table represents the number of proteins that differentiated between two risk groups 
and were unique to those two risk groups (24 proteins for VHR/MR, 27 proteins for VHR/LR 
and 4 proteins for MR/LR). It also represents the number of proteins that differentiated 
between two risk groups and were common between two risk groups (22 common proteins 
that differentiated between VHR/MR and VHR/LR, 1 common protein that differentiated 
between VHR/LR and MR/LR and 1 common protein that differentiated between MR/LR 
and VHR/MR). Finally, it represents the 2 proteins that differentiated between two risk 




6.3.1.3 Properties shared by the proteins that differentiated 
between different CVD risk groups – Enrichment Analysis 
In order to further understand the underlying biological and pathological pathways that 
the aforementioned proteins share, the online database Enrichr 
(http://amp.pharm.mssm.edu/Enrichr/) was used to obtain information from the Gene 
Ontology (biological processes), the Jansen DISEASE, the REACTOME and STRING 
(version 10.5) online databases and is summarised in Table 2 in section III of the 
Appendix. Most of the proteins were shown to be involved in coronary artery disease 
(CAD), cerebrovascular disease, hypertension and arthritis pathways. Some of the 
notable biological pathways represented by the measured proteins that were induced 
as a comparison between the different health/disease classes included increased 
neutrophil degranulation (VHR/MR, VHR/LR and VHR/nonVHR), higher acute and 
chronic inflammatory response (VHR/MR, VHR/LR and VHR/nonVHR) as well as positive 
regulation of cell proliferation (VHR/MR). 
6.3.1.4 Logistic regression analysis of the proteins that differentiated 
between different CVD risk groups 
To explore whether the proteins that differentiated between two risk groups (Table 3) 
were effective in predicting cardiovascular risk, a logistic regression analysis was 
performed. This showed that a model combining the proteins that statistically 
differentiated between two risk groups was significantly able to predict cohort group 
membership (Table 4). This suggests that a panel combining multiple protein markers 




Once the optimal markers are selected, a specific CVD panel, that could combine a 
technology close to new proximity extension assay (PEA) technology used in this study 
(310), could be designed and validated in large cohorts.  
However, it is important to consider the threshold in terms of the number of 
proteins, and possibly risk factors, that need to be added to a certain model in order to 
achieve an effective risk prediction. It appears that after increasing the number of 
proteins (Table 4), the improvement in terms of risk prediction is stagnant. Therefore, it 
is important to find this optimal threshold and choose the proteins that have the 
greatest contribution to this risk assessment model and validate them in prospective 
studies. Once selected, and with the help of algorithms computing random forest 
models (311), those potential proteins could be combined in a multimarker panel, in 
addition to other CVD risk factors, to possibly assess either CVD risk of first or recurrent 
events or the response to therapy.  
Table 4: Logistic regression analysis predicting group membership. 
Cohort 
Protein 
number p value 
Percentage of 
correct prediction 
by the model 
VHR/MR proteins:  



















LR: low risk; MR: moderate risk; non-VHR: non-very high risk VHR: very high risk. A Binary 




6.3.1.5 Correlation analysis between all measure proteins  
To examine whether the measured proteins levels were inter-correlated, Pearson 
correlation analysis was performed. Refer to Table 3 in section III of the appendix for an 
example of this correlation. Most of the proteins correlated positively with each other 
significantly. This highlights the presence of underlying interactions between different 
biological pathways in CVD and strengthens the idea that a multimarker approach is the 
way to move forward to improve the assessment of an individual’s CVD risk (section 
6.3.1.4). Among all the measured proteins, PON3, ADAMTS-13, Chymotripsin C (CTRC) 
and growth/differentiation factor 2 (GDF-2) appeared to correlate negatively with most 
of the measured proteins which suggests that they could have an anti-inflammatory and 
cardioprotective role in CVD.  This is proven by some reports indicating that 
paraoxanases enzymes, such as PON3, are known to be involved in the lipid metabolism 
(309). Additionally, low levels of ADAMTS-13, which is known to cleave von willbrand 
factor to control blood clotting, have been linked to adverse outcomes in CVD (312).  The 
role of GDF2 and CTRC in CVD hasn’t been intensively studied. In addition, it is important 
to keep in mind that the development of multimarker panels need to take into account 
this inter protein correlation since individuals with high levels of one marker will likely 




6.3.1.6 Principle component analysis: Generating protein 
components to further understand the underlying inflammatory 
pathways in CVD 
In order to investigate whether the list of the aforementioned proteins could be reduced 
to form protein components, a principal component analysis was carried out. This was 
to explore whether this analysis could group proteins in terms of the underlying 
inflammatory pathways that are active in CVD.  
The proteins from section 6.3.1.2 (all proteins from Table 3) that were able to 
significantly differentiate between different risk groups, formed 9 components where 
each component captured a direction in the variability of the data. Each component 
grouped a number of proteins that highly correlated between each other and that had 
a high contribution to the variability in the component. This is referred to as the protein 
factor loading. A protein with a highest factor loading within a component is known to 
contribute the most to the variability of the data within this component. The first 
generated component is usually known to capture the most variability in the data and 
the more variability there is, the more components will be generated. The 9 extracted 
significant components were able to explain 58.8% of the total variability in the data. 
For each component, a factor score was generated for each participant. This factor score 
is a linear composite of the optimally-weighted observed proteins in one component 
and is assigned for each participant.  
Table 8 shows the list of proteins in each component (with a threshold for the factor 
loading set at 0.3) as well as the main biological pathway for each component according 




the highest contribution to component 1 which explained 26.86% of the total variability 
in the data. On the other hand, HAOX1 had the highest contribution to component 2 
which explained 7.04% of the total variability of the data. Table 5 provides the list of 
proteins and their factor loadings in each component and Figure 7 shows the 
participants factor scores of components 2, 6 and 8 plotted against component 1. 
Results showed that VHR participants had a high factor score for component 1 and 2 
whereas non-VHR participants had a low factor score for component 1 and 2. Proteins 
in component 1 are mainly part of biological pathways involving inflammatory response 
and proteins in component 2 are known to positively regulate inflammatory response. 
This translates into a high proinflammatory state in VHR compared to the non-VHR 
participants (Figure 7a). On the other hand, VHR participants had high factor scores for 
component 6 which groups proteins involved in the cell interactions at the vascular wall. 
Therefore, in addition to their high inflammatory state, VHR participants had a higher 
number of proteins interacting at the vascular wall as opposed to non-VHR participants 
(Figure 7b). In addition, most of the proteins in component 6 are known to be involved 
in the initiation or progression of the atherosclerotic lesion (313–316). VHR participants 
had high factor scores for component 8, which grouped proteins involved in cytokine 
activation and apoptosis signalling, as opposed to non-VHR participants which would 
suggest a pro-cytokine activation and a pro-apoptotic state in VHR participants (Figure 
7c). 
These results demonstrated that a set of potential markers can be grouped in a 
number of components where each one represents a specific biological pathway in CVD. 
Evaluating where each individual stands in relation to these components/pathways 




well as the underlying state of CVD. Designing a multimarker panel needs to account for 
the different inflammatory pathways in CVD where each pathway is represented by its 
most significant proteins. A PCA could then be used to evaluate which proteins 
contribute majorly to the pathway in question and help design an optimal panel with 





Table 5: Principal component analysis of the proteins that significantly differentiated between risk groups. Extracted components and main biological 
pathway for the proteins grouped in each component. 








































































































































Percentage of total variance explained 
26.86 % 7.04 % 5.14 % 4.45 % 4.17 % 3.10 % 3.1 % 2.55 % 2.40 % 
TNFRSF11A .707 IGFBP_1 -.326 PRELP .351 EGFR .339 IL_6 .303 CXCL1 -.844 FABP4 -.550 TNF_R1 -.387 EGFR .340 
NT_proBNP .631 HAOX1 .713 MARCO .659 DCN .359 U_PAR .370 JAM_A -.794 FGF_21 -.326 LTBR -.406 GDF_15 -.399 
PlGF .626 ACE2 .688 TIE2 .584 PRELP .310 IL16 .385 SRC -.764 PCSK9 -.394 TNFRSF10C -.333 Gal_9 -.344 
EGFR -.624 CTSD .587 CD163 .502 SCF .310 AZU1 .885 CD84 -.726 PTX3 .327 GLO1 .303 TNFRSF13B -.311 
TRAIL_R2 .620 TR_AP .506 HOSCAR .456 LPL .327 LOX_1 .815 GLO1 -.537 LEP -.779 ADAM_TS13 .631 SPON1 -.344 
TNF_R1 .601 SCF -.477 Gal_9 .449 MMP_2 .722 PRTN3 .807 IDUA -.319 RARRES2 -.563 MEPE -.549 PSP_D -.717 
TNFRSF10A .594 HO_1 .442 TNFRSF13B .427 CNTN1 .714 CEACAM8 .728     PAPPA .491 AXL -.533 MMP_12 -.688 
DCN .585 LPL -.367 IL16 .397 Notch_3 .712 MMP_9 .727     LDL receptor -.468 IL_1RT1 -.484 MMP_7 -.547 
FABP4 .576 PON3 -.324 IL1RL2 .341 SPON1 .443 RETN .516     IL_1ra -.466 ICAM_2 -.451 REN -.503 
TFF3 .574 LDL receptor .331 AXL .325 OPG .407 PTX3 .392     CXCL16 -.375 CXCL16 -.400 CHIT1 -.433 
LTBR .550         PCSK9 .407 TNFRSF10C .374     Gal_3 -.397 MMP_3 -.335 Gal_3 -.428 
IL_4RA .548         AXL .419 IL_1ra .462     Gal_4 -.309 IL_18BP -.312 Gal_4 -.385 
OPN .545         IL_1RT1 .360 vWF .361         IL2_RA -.368 IL2_RA -.376 
PRELP .537                             vWF -.364 
GDF_15 .529                             MCP_1 -.321 
FGF_21 .506                                 
IGFBP_1 .481                                 
IL_6 .458                                 
CD4 .436                                 
U_PAR .396                                 
Gal_9 .363                                 
CNTN1 -.371                                 
SPON1 .310                                 
OPG .364                                 
RETN .349                                 
PTX3 .337                                 
MMP_7 .305                                 
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Principal component analysis was performed using the proteins that were able to significantly differentiate between VHR and non-VHR participants. 9 
components were generated with percentage of the total variance explained by each component. Each component groups the proteins that have a factor 
loading higher than 0.3. The list of proteins within each component was then inputted into Gene Ontology, the Reactome pathways or the Jensen 





Figure 7: Principal components based on the proteins that significantly differentiated 
between risk groups compared between VHR and non-VHR participants. Component 1 
grouped proteins involved in inflammatory response, component 2 grouped proteins 
implicated in positive regulation of inflammatory response, component 6 grouped 
proteins associated with the cell surface interactions at the vascular wall and component 
8 grouped proteins involved in involved in cytokine activation and apoptosis signalling. 
The plotted values correspond to the participant factor scores for each of component 1, 
2, 6 and 8. In Blue are the very high risk (VHR) participants and in orange are the non-
VHR participants. Figure 7a: Represents component 1, and 2. VHR participants have a 
high factor score for component 1 and 2 whereas non-VHR participants have a low factor 
score for component 1 and 2. Figure 7b: Represents component 1 and 6. VHR participants 
have a high factor score for component 1 and 6 whereas non-VHR participants have a 
low factor score for component 1 and 2. Figure 7c: Represents component 1 and 8. VHR 
participants have a high factor score for component 1 and 8 whereas non-VHR 




6.3.2 Biomarkers differentiating between very high risk (VHR) 
participant subgroups 
6.3.2.1 Multivariate analysis to select relevant proteins that 
differentiate between VHR subgroups (Table 9) 
In order to explore whether the 184 measured proteins were able to further distinguish 
between VHR participants, a multivariate analysis (ANCOVA) was conducted. This 
revealed a set of proteins that characterised VHR participants with an acute 
cardiovascular event and VHR participants with CVD comorbidities. Refer to Table 4 in 
section III of the appendix for a full list of significant proteins in each VHR subgroup and 
p values. Below is the list of proteins that were significantly able to distinguish between 
VHR subgroup of participants and are described in the context of the current literature 
(Figure 8, 9, 10, 11, 12, 13, 14). 
6.3.2.1.1 ACS-VHR compared to ELEC-VHR participants 
Among the 86 proteins that differentiated between acute coronary syndrome (ACS-VHR) 
and elective percutaneous intervention (ELEC-VHR) participants we cite, Macrophage 
receptor MARCO (MARCO) (p<0.0001), C-C motif chemokine 15 (CCL15) (p<0.0001), 
Osteoprotegerin (OPG) (p<0.0001), Polymeric immunoglobulin receptor (PIgR) 
(p<0.0001) which protein levels were higher in ACS-VHR vs. ELEC-VHR and Tissue factor 
pathway inhibitor (TFPI) (p<0.0001), P-selectin glycoprotein ligand 1 (PSGL-1) (p<0.0001) 
Fatty acid binding protein 2 (FABP2) (p<0.001) and Brother of CDO (BOC) (p<0.0001) 
which protein levels were lower in ACS-VHR vs. ELEC-VHR (Figure 8). OPG has been 




whereas TFPI inhibits tissue factor activity and has been shown to attenuate thrombus 
formation (318). PSGL-1 has been reported to be involved in the recruitment of 
monocytes to the atherosclerotic lesion site (319) whereas polymorphisms in FABP2 
have been linked to insulin resistance and cardiovascular risk (320). However, there is 
little evidence of the role of MARCO, CCL15, PIgR and BOC in CVD. It is noteworthy that 
CRP plasma levels were not significantly different in ACS-VHR compared to ELEC-VHR 
participants (p=0.942) (Refer to section 3.3.6 in Chapter 3) which suggests that the 
previously mentioned proteins are good candidates for further investigation as markers 
of acute cardiovascular events a could prove to be better in further stratifying VHR 
individuals compared to the present CVD biomarkers.  
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Figure 8: Volcano plot representing the p value against the difference in mean NPX 
in protein levels between VHR-ACS and VHR-ELEC participants. -Log10 of the p value 
was plotted against the difference between the average of the NPX value (ACS-ELEC). 
Proteins to the far left or right side of the graph have a significant fold in change 
(whether higher or lower) with a very significant p value (p<0.0001). (ACS: Acute 






 In addition, following the PCA in section 6.3.1.6, the factor scores generated for 
the ACS-VHR and ELEC-VHR were plotted for component 1 and 2 (Figure 9) highlighting 
the importance of the pro-inflammatory response following an ACS. 
 
Figure 9: Principal components based on the proteins that significantly differentiated 
between risk groups compared between VHR and non-VHR participants. Component 1 
grouped proteins involved in inflammatory response and component 2 grouped proteins 
implicated in positive regulation of inflammatory response. The plotted values 
correspond to the participant factor scores for each of component 1 and 2. In Blue are 
the Elective percutaneous intervention (ELEC-VHR) participants and in red are the acute 
coronary syndrome (ACS-VHR) participants. ELEC-VHR individuals have a high factor 
loading for component 1 and 2 compared to the ELEC-VHR individuals.  
 
6.3.2.1.2 ACS-VHR compared to ELEC-VHR participants with no history of 
previous CVD 
A total of 77 proteins distinguished between ACS-VHR and ELEC-VHR participants with 
no previous CVD history. These proteins included A disintegrin and metalloproteinase 
with thrombospondin motifs 13 (ADAMTS-13) (p<0.0001), vascular endothelial growth 
factor D (VEGF-D) (p<0.0001), Brother of CDO (BOC) (p<0.0001) and programmed cell 




compared to ELEC-VHR participants with no previous CVD.  Protein AMBP (p<0.05), 
Osteopontin (OPN) (p<0.0001) and Tartrate resistance acid phosphatase 5 (TRAP) 
(p<0.0001) protein levels were higher in ACS-VHR compared to ELEC-VHR participants 
with no previous CVD (Figure 10). Low protein levels of ADAMTS-13 have been 
associated with CVD as well as haematological disorders (312). In the present study, 
ADAMTS-13 levels were lower in ACS-VHR individuals admitted for their primary acute 
event and are suggested to predict future cardiovascular events (321). OPN has emerged 
as a potential biomarker and mediator in CVD (322) and in the current study, levels were 
associated with acute primary events. Protein AMBP is a complex glycoprotein secreted 
in plasma which role is not fully understood, however, this protein has been recently 
suggested as a potential biomarker for CVD (323). On the other hand, the role of PD-L2 
BOC and TRAP in CVD hasn’t been previously outlined. Such proteins should be tested 
further as biomarkers for first cardiovascular events. 
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Figure 10: Volcano plot representing the p value against the difference in mean NPX in 
protein levels between VHR-ACS and VHR-ELEC with no previous CVD history. -Log10 
of the p value was plotted against the difference between the average of the NPX value 
(ACS-ELEC). Proteins to the far left or right side of the graph have a significant fold in 




coronary syndrome participants; CVD: Cardiovascular disease; ELEC: Elective 
participants; NPX: normalized protein expression). 
6.3.2.1.3 ACS-VHR participants admitted for recurrent MACE compared to ACS-
VHR participants admitted for their first cardiovascular event  
Among the 40 proteins that differentiated between ACS-VHR participants admitted for 
recurrent MACE and ACS-VHR participants admitted for their first cardiovascular event 
we mention Tumour necrosis factor ligand superfamily member 13B (TNFSF13B) 
(p<0.01), Interleukin 18 binding protein (IL18-BP) (p<0.01), Tumour necrosis factor 
receptor superfamily member 11A (TNFRSF11A) (p<0.01), Brother of CDO (BOC) 
(p<0.01), Tumour factor alpha receptor 2 (TNFR2) (p<0.01) which protein levels were 
higher in ACS-VHR participants admitted for recurrent MACE compared to ACS-VHR 
participants admitted for their first cardiovascular event. Epidermal growth factor 
receptor (EGFR) (p<0.05) protein levels were lower in in ACS-VHR participants admitted 
for recurrent MACE compared to ACS-VHR participants admitted for their first 
cardiovascular event (Figure 11). IL18-BP has been reported to have a protective role in 
a murine model of cardiac ischemia/reperfusion injury (324) and higher plasma levels in 
individuals with acute secondary events could reflect a protective mechanism of the 
body in acute phase response. TNFR2 soluble levels have been previously linked to CVD 
co-morbidities (207) and in the present study, were associated with recurrent events. 
EGFR activation has been implicated in blood pressure regulation, endothelial 
dysfunction, atherogenesis, and cardiac remodelling (325). Low plasma levels of EGFR 
following an acute secondary event, as shown in the current study, could be associated 
with adverse outcomes. Nevertheless, TNFSF13B, TNFRSF11A, BOC haven’t been 
measured in CVD participants yet. The previously mentioned proteins could be potential 




Interestingly, it appears that BOC is a marker for ACS events (whether primary or 
secondary) and hasn’t been investigated previously in CVD and the present results are 
in favour of its role as a potential diagnostic biomarker in CVD. 
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Figure 11: Volcano plot representing the p value against the difference in mean NPX 
in protein levels between ACS participants admitted for MACE and ACS participants 
admitted for their first cardiovascular event. -Log10 of the p value was plotted against 
the difference between the average of the NPX value (ACS.MACE-ACS.noMACE). Proteins 
to the far left or right side of the graph have a significant fold in change (whether higher 
or lower) with a very significant p value (p<0.0001). (ACS: Acute coronary syndrome 
participants; MACE: major adverse cardiovascular events; NPX: normalized protein 
expression). 
6.3.2.1.4 Participants with a previous MI, PCI or CABG 
Plasma levels of a total of 77 proteins were higher in VHR participants with previous MI, 
PCI or CABG compared to those with no previous MI, PCI or CABG. These proteins 
included V-set and immunoglobulin domain containing protein 2 (VSIG2) (p<0.0001), 
Brother of CDO (BOC) (p<0.0001) (particularly in those who were acute with a previous 
MI (p<0.01) or a previous PCI (p<0.05)), Prostasin (PRSS8) (p<0.0001), Interleukin 16 




previous MI, PCI or CABG compared those with no previous MI, PCI or CABG, we 
highlight LDL receptor (p<0.05) and Tissue factor mi pathway inhibitor (TFPI) (p<0.05) 
(Figure 12). PRSS8 has been linked to hypertension (326) whereas IL16 has been shown 
to promote cardiac fibrosis and myocardial stiffening in heart failure participants (327). 
Moreover, polymorphisms in the LDLR gene and LDL receptor protein levels have been 
associated with atherosclerosis and CVD (328,329). Low circulating plasma levels of LDLR 
after a statin therapy need to be closely investigated. However, there little evidence of 
the role of VSIG2 in CVD. Interestingly, CRP plasma levels were not different in VHR 
participants with a previous MI (p=0.121) or a previous PCI (p=0.887) (n=294) which 
indicates that the previously mentioned proteins could be promising biomarkers for 
treatment response in CVD. 
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Figure 12: Volcano plot representing the p value against the difference in mean NPX in 
protein levels between VHR participants with previous MI, PCI or CABG and VHR 
participants with no previous MI, PCI or CABG. -Log10 of the p value was plotted against 
the difference between the average of the NPX value (Previous MI, PCI, CABG – no 
previous MI, PCI, CABG). Proteins to the far left or right side of the graph have a 
significant fold in change (whether higher or lower) with a very significant p value 
(p<0.0001). (CABG: coronary artery bypass grafting, MI: myocardial infarction, PCI: 




6.3.2.1.5 VHR participants with diabetes 
A total of 83 proteins were able to differentiate between VHR diabetic participants 
compared to VHR non-diabetic participants. Among those proteins, those with higher 
levels in the VHR diabetic participants included Kidney injury molecule 1 (previously TIM 
now KIM1) (p<0.0001), Interleukin-1 receptor type 1 (IL-1RT1) (p<0.0001), Galectin 3 
(Gal-3) (p<0.0001), Renin (REN) (p<0.0001), V-set and immunoglobulin domain 
containing protein 2 (VSIG2) (p<0.0001), Fatty acid binding protein adipocyte (FABP4) 
(p<0.001) and Gastric intrinsic factor (GIF) (p<0.001). Protein which levels were lower in 
VHR diabetic vs. VHR non-diabetic participants included Paraoxonoase 3 (PON3) 
(p<0.01) and Heme oxygenase 1 (HO-1) (p<0.05) (Figure 13). KIM1 protein levels have 
been linked to renal disease in diabetic participants (330) and have also been associated 
with cardiovascular risk (331). IL1RT1 gene has been shown to have a role in diabetes 
(332) and to regulate infarct healing and cardiac remodelling (333). Gal-3 and FABP4 
have been associated with the development of CVD (334,335) and diabetes (336,337), 
whereas REN has been shown to predict cardiovascular mortality (307) and diabetes 
(338) in participants with hypertension. PON3 is an antioxidant molecule which has been 
shown to prevent atherosclerosis nevertheless, its role in diabetes is less studied (339). 
On the other hand, HO-1 has potent anti-inflammatory and anti-oxidative functions in 
CVD and diabetes (340,341) and higher levels could be associated with a protective 
effect in VHR indivduals with diabetes. However, the role of VSIG2 and GIF in CVD and 
diabetes is less clear. Such proteins could be markers for VHR patients at high risk of 
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Figure 13: Volcano plot representing the p value against the difference in mean NPX in 
protein levels between VHR diabetic participants and VHR non-diabetic participants. -
Log10 of the p value was plotted against the difference between the average of the NPX 
value (Diabetic – non-diabetic). Proteins to the far left or right side of the graph have a 
significant fold in change (whether higher or lower) with a very significant p value 
(p<0.0001). (NPX: normalized protein expression). 
 
6.3.2.1.6 VHR participants with heart failure 
A total of 71 protein were able to distinguish between VHR participants with heart 
failure compared to the VHR participants with no heart failure. Proteins which levels 
were higher in VHR participants with heart failure included TNF related apoptosis-
inducing ligand receptor 2 (TRAIL-R2) (p<0.0001), Fibroblast growth factor 21 (FGF-21) 
(p<0.001), Adrenomedullin (ADM) (p<0.0001) and Tumour necrosis factor receptor 
superfamily member 11A (TNFRSF11A) (p<0.0001). Among the proteins which levels 
were lower in VHR participants with heart failure compared to VHR participants with no 
heart failure we underline, Chymotrypsin C (CTRC) (p<0.001) and Proto-oncogene 
tyrosine-protein kinase (SRC) (p<0.05) (Figure 14). FGF-21 has been reported to be 




diastolic dysfunction in participants with heart failure (343). In addition, ADM, which is 
known to regulate vasodilatation and nitric oxide production, has been suggested to 
play a protective role in CVD and heart failure (344). However, the role of TNFRS11A and 
CTRC in CVD and heart failure is less clear. Since heart failure is a major complication 
after an ACS (345), such proteins could be markers for VHR patients at high risk of 
developing heart failure and could also prove to be promising new therapeutical targets. 
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Figure 14: Volcano plot representing the p value against the difference in mean NPX in 
protein levels between VHR participants with heart failure and VHR participants with 
no heart failure -Log10 of the p value was plotted against the difference between the 
average of the NPX value (HF- no HF). Proteins to the far left or right side of the graph 
have a significant fold in change (whether higher or lower) with a very significant p value 




6.3.2.2 Cluster analysis to further stratify the VHR cohort using 
proteins associated with MACE risk 
To explore whether the significant proteins associated with MACE events (proteins from 
group 1, 2 and 4 in Table 4 in section III of the appendix) could further stratify VHR 
individuals based on their plasma levels, a cluster analysis (two-way cluster analysis) was 
performed. Results showed that the VHR cohort formed two clusters with cluster 2 
(n=59) grouping participants who had higher levels of most of the inflammatory markers 
compared to cluster 1 (n=149) (Figure 15) (Refer to Table 5 in section III of the appendix 
for the protein levels in each cluster). Cluster 2 grouped older participants, participants 
who were likely to be admitted for an ACS and for recurrent MACE. Cluster 2 also 
grouped participants who were more likely to be diabetic, to have had a previous MI or 
PCI, and to be on CVD medication. The proteins that contributed majorly to the cluster 
classification were: Perlecan (PLC), Trefoil factor 3 (TFF3), Tumour necrosis factor alpha 
receptor 1 (TNFR1) and 2 (TNFR2), Growth/differentiation factor 15 (GDF15), 
Adrenomedullin (ADM), TNF Receptor Superfamily Member 14 (TNFRSF14), Urokinase 
receptor (UPAR) and Lymphotoxin Beta Receptor (LTBR) which were all higher in cluster 
2 (p<0.0001). Among these significant proteins, PLC has an essential function in skeletal 
muscle and cardiovascular development (346) with a promising role in preventing stent-
restenosis since it inhibits smooth muscle cells activity and thrombosis while enhancing 
endothelial cell proliferation (347). ADM has been proposed to be a biomarker of 
prognosis and survival in participants with coronary artery disease or heart failure (344). 
In addition, TNFRSF14 is a contributor in atherogenesis by activating proinflammatory 
cytokines and matrix metalloproteinases (348). UPAR has been intensively studied in 
chronic kidney disease (CKD) and has been suggested as a biomarker for CVD in 




driven inflammation in atherosclerotic lesions (350). However, the role of TFF3 in CVD is 
less studied.  
These results highlight and support the role of such proteins in further stratifying 
individuals with an established CVD based on protein levels alone. Such proteins require 
further prospective studies to assess their role in clinical practice. This data also brings 
to attention the importance of cluster analysis in patient stratification. Therefore, based 
on differences in plasma levels of significant protein, individuals with a critical pro-
inflammatory state and a severe CVD history can form a distinctive group within the 
global VHR cohort. This highlights the need to define protein level thresholds within the 
VHR cohort. Individuals with very high levels of inflammatory markers could require 
intensive medical management and close follow-up. 
 
Figure 15: Difference in proteins means (NPX) between cluster 2 and cluster 1 subgroups within the 
VHR cohort. A two way cluster analysis was performed which grouped participants into two clusters 
where particpiants belonging to same cluster share common charactersitics. Each cluster was defined 





Figure 16: Summary diagram - Proteomic approach for the selection of potential CVD 
biomarkers of cardiovascular risk and MACE risk. CVD: cardiovascular disease; GFR: glomerular 
filtration rate; LR: low risk, MACE: major adverse cardiovascular events; MR: moderate risk, PC: 





6.3.3 Multimarker approach in biomarker research and 
development 
In biomarker research, the consensus nowadays has shifted towards a multimarker 
approach due to CVD complexity and since it is now better understood that one single 
biomarker is unlikely to capture the individual’s predisposition to disease development. 
Previous studies have investigated the role of some of the proteins that were highlighted 
in this study in CVD. However, each study focused on one single biomarker alone linking 
it to a specific biological pathway, a specific clinical outcome or a specific CVD co-
morbidity. This study highlighted the importance in using multimarker panels in 
assessing CVD risk and further stratifying individuals at high risk of MACE. However, such 
panels need to be optimised to select the proteins that are the most representative of 
the different CVD inflammatory pathways. In addition, the number of optimal proteins 
needed in order to achieve the most effective risk prediction needs to be addressed. 
Such panels could be useful in CVD risk assessment, but also in predicting cardiac events 
and treatment response (137). New models and algorithms combining such proteins in 






Figure 17: Summary diagram of a proteomic analysis: Potential proteins for CVD risk 
stratification. Proteins in bold were able to differentiate between more than two cohorts. Proteins 
in italic were lower in the two compared subgroups. ACS: acute coronary syndrome; CABG: 
coronary artery bypass grafting; LR: low risk, MACE: major adverse cardiovascular events; MI: 
myocardial infarction MR: moderate risk, PCI: percutaneous coronary intervention; VHR: very high 
risk. 
6.3.4 Strengths and limitations 
Refer to section 3.4.3 in Chapter 3.  
In relation to the natriuretic peptides (NP) that were measure in this study; BNP and NT-
pro BNP protein levels were below the limit of detection of the assay in many 
participants, therefore, they were excluded from the analysis. However, the analysis of 
the available results showed a strong association with cardiovascular risk. 
6.4 Conclusion 
The present investigation has several potential clinical implications. First, it highlights 
candidate biomarkers that can stratify individuals at various levels of CVD risk. Second, 




risk individuals in relation to their CVD history (whether they have a primary or a 
secondary event/MACE) or according to their co-morbidities (diabetes, heart failure, 
chronic kidney diseases). This study also points out the importance of a multimarker 
approach in reflecting the underlying inflammatory pathways in CVD and in establishing 















Biomarkers predicting MACE risk 
within one year of admission in 







Background: Traditional cardiovascular disease (CVD) risk factors are effective in 
primary prevention but less effective when it comes to secondary prevention and the 
prediction of major adverse cardiovascular events (MACE). Additionally, the processes 
and biological pathways behind recurrent heart attacks, stent restenosis, persistent 
angina, drug resistance and sudden deaths are not clear. In this present study, we 
explore the association between MACE risk and a number of proteins involved in the 
immune response, plaque formation and thrombosis in participants with established 
CVD. 
Methods: Participants were recruited from the cardiac catheterisation laboratory or by 
email advertisement. Participants were all at very high risk (VHR) with a 10-year risk 
SCORE ≥10% risk of fatal CVD. TACE, TNFR1, TNFR2 and TIMP3 plasma protein levels 
were measured by ELISA. INF-γ, IL-10, IL-12p70, IL-13, IL-1β, IL-2, IL-4, IL-6, IL-8 and TNFα 
plasma protein levels were measured using MSD® MULTI-SPOT Assay System. TACE 
mRNA levels were measured by quantitative real-time PCR. CVDII and CVDIII panels 
were measured in the plasma by multiplex proximity extension assays (PEA) by Olink® 
proteomics. 
Results: At total of 229 VHR participants were recruited. TNFR1 (HR; 5.474; p<0.05), IL-
6 (HR: 10.29; p<0.001), ST2 (HR: 4.37; p<0.01), IL4RA (HR:7.51; p<0.01), IL1RT1 
(HR:11.89; p<0.01), IL1RT2 (HR: 7.242; p<0.01), PDL2 (HR:11.34; p<0.01), ADM (HR:3.37; 
p<0.01), THBS2 (HR:13.64; p<0.01), CCL16 (HR:5.60; p<0.05), RARRES2 (HR:20.30; 
p<0.05), GDF15 (HR:2.17; p<0.05), PI3 (HR:1.78; p<0.05) and SPON1 (HR:7.96; p<0.05) 
plasma protein levels were higher on admission in VHR participants who developed 
MACE within a year of admission compared to those with no readmission within this 




(HR:0.324; p<0.05) plasma protein levels were lower on admission in participants who 
developed MACE within a year of admission compared to those with no readmission 
within this year.  
Conclusion: In conclusion, the present investigation underlines previously reported and 
novel associations between several inflammatory proteins and MACE risk. These CVD 
markers should be taken forward into biomarker development for MACE risk 
assessment. If adopted in clinical practice, such biomarkers have the potential to reduce 
the number of CVD participants who develop recurrent events by identifying them 






Biomarkers and risk factors associated with cardiovascular risk and the development of 
a first cardiovascular event in patients with no previous cardiac history have been 
intensively studied (81). Traditional cardiovascular risk factors such as high cholesterol 
levels, hypertension and smoking are relevant in primary prevention. In addition, the 
inflammatory and immune pathways behind the development of atherosclerosis and 
eventually first cardiovascular events are well established (351).  
 Nevertheless, biomarkers and risk factors associated with the development of 
recurrent major adverse cardiovascular events (MACE) need better understanding as 
the processes and biological pathways behind recurrent heart attacks, stent restenosis, 
persistent angina, drug resistance and sudden deaths are less clear. The management 
of coronary artery disease (CAD), one of the major causes of cardiovascular disease 
(CVD), with revascularisation strategies and aggressive medical therapy is proving to be 
insufficient as the occurrence of MACE remains very high (18). At present, there are no 
available test that could reveal which person is more likely to develop MACE. Risk scores, 
such as the GRACE and the TIMI scores (106) are in place to evaluate if a patient 
admitted with a first cardiovascular event is likely to develop a secondary event based 
on a number of characteristics upon admission. However, these risk scores present 
many limitations and are not widely used in clinical practice (106) and therefore need to 
be improved to include different factors and markers that are associated with recurrent 
events (352).  
 We undertook the present investigation to evaluate the association between several 
markers and MACE risk in individuals with an established CVD using two of the most 




looked at the pathway involving tumour necrosis factor alpha (TNFα), its converting 
enzyme (TACE) as well as both of its receptors 1 (TNFR1) and 2 (TNFR2) and endogenous 
inhibitor (TIMP3). This was to evaluate whether MACE can be predicted by a panel of 
biomarkers that interact with each other in a well-studied biological pathway. Second, 
we followed an inductive proteomic method to evaluate the association between MACE 
risk and a large set of inflammatory proteins known to be involved in immunity, 
atherosclerosis, plaque rupture and thrombosis. 
7.2 Participants and Methods 
Refer to section 2.1 in Chapter 2 for a detailed description of the participant 
recruitment process, the risk score used and the methods for blood processing. 
Participants were all at very high risk (VHR) as per the European low risk SCORE chart 
which is used to determine the 10-year risk of fatal CVD in low risk regions of Europe 
by gender, age, systolic blood pressure, total cholesterol and smoking status for all 
recruited individuals who were from Ireland.  
7.2.1 Demographic information  
Refer to section 3.2.1 in Chapter 3 for a detailed description of the demographic 
information that was collected in this study. 
7.2.2 MACE follow up 
Major adverse cardiovascular events (MACE) were regarded as any deaths, admissions 
for acute coronary syndrome (ACS) or stroke and were recorded for all the VHR 




Care Record (NIECR). The one year follow-up period was then subdivided into MACE 
within 6 months and MACE after 6 months. 
7.2.4 Measurement of TACE, TNFR1, TNFR2 and TIMP3 plasma 
protein levels 
Refer to section 2.6.1, 2.7.1, 2.8.1, 2.9.1 in Chapter 2.  
7.2.5 Measurement of TACE gene expression 
Refer to section 2.11, 2.12 and 2.13 in Chapter 2. 
7.2.6 Measurement of TNFα, IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-
10, IL-12p70 and IL-13 plasma protein levels 
Refer to section 2.10 in Chapter 2.  
7.2.7 Analysis of O-link Cardiovascular panel II and III (O-link 
Proteomics®) in plasma samples 
Refer to section 2.14 in Chapter 2. 
7.2.8 Statistical methods 
Statistical analysis was carried out as described in section 3.2.7 in Chapter 3  
In addition, a cox regression model was used to calculate the hazard ratios for the 
measured biomarkers and the development of MACE over time. Logarithmic values 
were used for biomarker levels. Each increase in one unit corresponds to the calculated 





7.3.1 Participant recruitment 
Refer to section 3.3.1 in Chapter 3. 
Table 1 and 2 provide the full descriptive statistics of the population. Follow-up MACE 
were recorded within one year of admission and were divided into events within 6 
months and after 6 months of admission. MACE were defined as any deaths, admissions 
for acute coronary syndrome (ACS) and stroke. After a follow-up duration of 1 year and 
among 229 VHR participants, 6.98 % of participants developed MACE in total; 2.18% 
developed MACE within 6 months and 4.80% developed MACE after 6 months.  








Male  180 78.6 
Female  49 21.4 
Diabetes mellitus  
Present  44 19.2 
Absent 185 80.8 
Heart Failure  
Present  36 15.7 
Absent  193 84.3 
Renal function  
GFR < 60  45 20 
GFR > 60  180 80 
Hypertension  
Present  128 58.9 
Absent  101 44.1 
Dyslipidaemia  
Present  134 58.5 
Absent  95 41.5 
Arthritis  
Present 35 15.3 
Absent  194 84.7 
Depression  
Present  43 18.8 
Absent  186 81.2 
Present or previous cancer  
Present  27 11.8 



































none  66 30.3 
ex-smoker  110 50.4 
current  42 19.3 
Pharmacotherapy (n; %)  
Statin therapy  
Present  165 72.7 
Absent  62 27.3 
Antiplatelet therapy  
Present  154  67.8 
Absent  73 32.1 
Antihypertensive therapy  
Present  172 76.8 
Absent  55 24.2 
Anti-anginal therapy  
Present  88 38.8 
Absent  139 61.2 
Diuretic therapy  
Present  56 24.7 
Absent  171 75.3 
Drug naïve  
Present  54 23.7 
Absent  174 76.3 
Clinical Variables (n; %)  
VHR-ACS  127 55.5 
VHR-ELEC  102 44.5 
Previous MI   
Present  73 31.9 
Absent  156 68.1 
Previous PCI  
Present  73 31.9 
Absent  56 68.1 
Previous CABG   
Present  22 9.6 
Absent  207 90.4 
Previous MI, PCI or CABG  
Present  100 43.7 
Absent  129 56.3 
Diagnosis upon admission  
Stable Angina  85 37.1 
Unstable Angina 21 9.2 
NSTEMI < 1 week  77 33.6 
STEMI < 1 week  7 3.0 
Other  39 17.03 
ACS participants admitted for MACE  
present  45 35.4 
absent  82 64.6 
Participants with no previous MI, PCI or 
CABG 
 
ACS-VHR  84 65.1 




ACS: acute coronary syndrome participants; CABG: Coronary artery bypass surgery; ELEC: 
elective participants; GFR: Glomerular filtration rate; MACE: major adverse cardiovascular 
events MI: Myocardial Infarction; NSTEMI: non-ST elevation myocardial infarction; PCI: 
percutaneous coronary intervention; STEMI: ST elevation myocardial infarction; VHR: very high 
risk.  
Table 2: Descriptive statistics of VHR participants who developed MACE within a 
year. 
 No MACE (n=213) MACE (n=16) p 
value 
 mean  
Std. 
deviation mean  
Std. 
deviation 
Age (years) 65 11 74 7 0.001 
Cholesterol levels (mmol/L) 4.2 1.3 3.5 0.8 0.022 
Systolic BP (mmHg) 131 23 134 30 0.61 
BMI (Kg/m2) 29.1 5.8 30.3 11.7 0.469 
 n; % n; %  
Diabetes  34; 18.3 5; 31.3 0.171 
Heart Failure  29; 13.6 7; 43.8 0.005 
GFR<60  38; 18.2 7; 43.8 0.022 
On medication  160; 75.5 14; 87.5 0.222 
ACS participants  117; 54.9 10; 62.5 0.375 
Statin therapy  152; 72.0 13; 81.3 0.318 
Antiplatelet therapy  142; 67.3 12; 75 0.37 
Antihypertensive therapy  157; 74.4 15; 93.8 0.065 
Previous MI, PCI or CABG  93; 43.7 7; 43.8 0.569 
ACS: acute coronary syndrome participants; BMI: body mass index; BP: blood pressure; 
CABG: Coronary artery bypass surgery; GFR: Glomerular filtration rate; MACE: major 
adverse cardiovascular events; MI: Myocardial Infarction; NSTEMI: non-ST elevation 
myocardial infarction; PCI: percutaneous coronary intervention; STEMI: ST elevation 
myocardial infarction; VHR: very high risk. A Student t-test was performed to compare 
means of continuous variables and a Pearson chi square test was performed to compare 
percentages of categorical variables.  
7.3.2 Biomarkers associated with MACE within 1 year of admission  
In order to investigate whether the measured proteins were associated with MACE 
occurrence, VHR participants who developed MACE within 6 months or after 6 months 
were compared to those who were not readmitted within the year. Results showed that 
TNFR1 plasma protein levels were higher upon admission in participants who developed 
MACE within a year (p<0.05) and levels tended to be higher in participants who 
developed MACE after 6 months with a p value near significance (p=0.061). On the other 




developed MACE within a year (p<0.05) and were particularly higher among the 
participants who developed MACE within 6 months (p<0.05) (Table 1). Among the VHR 
individuals who developed MACE over time, 62.5% (n=10) were ACS-VHR and 37.5% 
(n=6) were ELEC-VHR. In the Olink analysis, TNFR1 and IL-6 plasma protein levels were 
also higher in VHR participants who developed MACE within a year of admission 
(p<0.001 and p<0.05). Refer to Table 7 in section III of the Appendix for the full list of 
proteins and p values. 
Among the proteins tested as part of the CVDII and CVDIII Olink® proteomic panel, 
Retinoic acid receptor responder protein 2 (RARRES2) (p<0.001), C-C motif chemokine 
16 (CCL16) (p<0.001), Interleukin-1 receptor type 1 (IL1RT1) (p<0.001), Trefoil factor 3 
(TFF3) (p<0.01), Adrenomedullin (ADM) (p<0.01), C-X-C chemokine motif 16 (CXCL16) 
(p<0.004), Transferrin receptor protein 1 (TR) (p<0.005), TNF-related apoptosis-inducing 
ligand receptor 2 (TRAILR2) (p<0.006), Matrix metalloproteinase 3 (MMP3) (p<0.007), 
Lymphotoxin-beta receptor (LTBR) (p<0.008), Tumour necrosis factor receptor 
superfamily member 14 (TNFRSF14) (p<0.008), Programmed cell death 1 ligand 2 (PDL2) 
(p<0.008), Growth/differentiation factor 15 (GDF15) (p<0.01), Ephrin type-B receptor 4 
(EPHB4) (p<0.05), Interleukin-2 receptor subunit alpha (IL2RA) (p<0.05), Tyrosine-
protein phosphatase non-receptor type substrate 1 (SHPS1) (p<0.05), Agouti related 
protein (AGRP) (p<0.05), Interleukin 1 receptor 2 (IL1RT2) (p<0.05), Kallikrein-6 (KLK6) 
(p<0.05), Thrombospondin 2 (THBS2) (p<0.05), Interleukin-4 receptor subunit alpha 
(IL4RA) (p<0.05), Elafin (PI3) (p<0.05), Perlecan (PLC) (p<0.05), Renin (REN) (p<0.05), V-
set and immunoglobulin domain-containing protein 2 (VSIG2) (p<0.05), Insulin-like 
growth factor-binding protein 2 (IGFBP2) (p<0.05), Urokinase plasminogen activator 




Alpha-1-Microglobulin/Bikunin Precursor (AMBP) (p<0.05), Cathepsin D (CTSD) (p<0.05), 
Receptor for advanced glycosylation end products (RAGE) (p<0.05), Tumour necrosis 
factor alpha receptor 2 (TNFR2) (p<0.05), Granulins (GRN) (p<0.05), Complement 
component C1q receptor (CD93) (p<0.05), Proteinase activated receptor 1 (PAR1) 
(p<0.05), Spondin 1 (SPON1) (p<0.05), Interleukin 1 receptor-like 1 (ST2) (p<0.05), 
Fibroblast growth factor 21 (FGF21) (p<0.05), Carboxypeptidase 1 (CPA1) (p<0.05), C-C 
motif chemokine 15 (CCL15) (p<0.05) and Insulin like growth factor binding protein 7 
(IGFBP7) (p<0.05) protein levels were higher in VHR participants who developed MACE 
within a year of admission. On the other hand, Plasma A disintegrin and 
metalloproteinase with thrombospondin motifs 13 (ADAMTS13) (p<0.01), Alpha-L-
iduronidase (IDUA) (p<0.05), C-C motif chemokine 22 (CCL22) (p<0.05) and Interleukin 1 
receptor like 2 (IL1RL2) (p<0.05) protein levels were lower in participants who developed 
MACE within a year of admission compared to those with no readmission within a year. 
Plasma protein levels that were particularly higher in VHR participants who developed 
MACE within 6 months were TR (p<0.05), TNFRSF14 (p<0.05), GDF15 (p<0.05), AGRP 
(p<0.05), THBS2 (p<0.05), PI3 (p<0.05), IL-6 (p<0.05) and VSIG2 (p=0.051). Plasma 
protein levels that were particularly higher in VHR participants who had a MACE after 6 
months were CCL16 (p<0.01), CCL16 (p<0.01), IL1RT1 (p<0.01), TNFR1 (p<0.01), TFF3 
(p<0.01), ADM (p<0.01), CXCL16 (p<0.01), TRAILR2 (p<0.05), MMP3 (p<0.05), LTBR 
(p<0.05), PD-L2 (p<0.05), EPHB4 (p<0.05), IL2RA (p<0.05), SHPS1 (p<0.05), IL1RT2 




7.3.3 Biomarker associated with MACE occurrence within a year from initial 
time of admission: Survival analysis 
In order to link biomarker levels with MACE development over time, a cox proportional 
regression model was used and hazard ratios were calculated for all the significant 
proteins that were selected from the previous step (Table 4). For every unit increase in 
TNFR1 or IL-6 plasma levels (log levels), the risk of developing MACE increased by 5.47 
and 10.29 folds respectively (HR; 5.474; p<0.05 and HR: 10.29; p<0.001). This significant 
difference was confirmed by the Proseek assay with an increase of 1.6-fold for TNFR1 
and 2.4-fold for IL-6 (HR: 1.603; p=0.058 and HR: 2.391; p<0.0001). The Proseek assay 
provides results expressed as normalised protein ratio (NPX). 
The tested proteins from Olink CVDII and CVDIII panels showed that plasma ST2 (HR: 
4.37; p<0.01), IL4RA (HR:7.51; p<0.01), IL1RT1 (HR:11.89; p<0.01), CCL22 (HR: 0.249; 
p<0.01), IL1RT2 (HR: 7.242; p<0.01), PDL2 (HR:11.34; p<0.01), ADM (HR:3.37; p<0.01), 
THBS2 (HR:13.64; p<0.01), CCL16 (HR:5.60; p<0.05), RARRES2 (HR:20.30; p<0.05), 
ADAM_TS13 (HR:0.022; p<0.05), GDF15 (HR:2.17; p<0.05), IDUA (HR:0.324; p<0.05), PI3 
(HR:1.78; p<0.05) and SPON1 (HR:7.96; p<0.05) protein levels were linked to MACE 
occurrence over time (Table 3). In addition, in our present study, CRP plasma levels could 




Table 3: Biomarkers hazard ratios and MACE occurrence over time in VHR 
participants. 
Protein 
p value  
(ranked by p 
value) 
Hazard ratio 
95.0% confidence interval for 
hazard ratio 
Lower Upper 
(Log unit)         
CRP 0.126 1.966 0.860 4.496 
sTNFR1  0.045 5.474 1.042 28.760 
IL-6  0.001 10.29 2.444 43.334 
(NPX unit)         
IL_6 <0.0001 2.391 1.469 3.892 
ST2 0.002 4.367 1.751 10.892 
IL_4RA 0.004 7.508 1.907 29.558 
IL_1RT1 0.005 11.884 2.077 67.981 
CCL22 0.007 0.249 0.091 0.681 
IL_1RT2 0.007 7.242 1.733 30.262 
PD_L2 0.009 11.337 1.812 70.944 
ADM 0.01 3.368 1.334 8.5 
THBS2 0.01 13.643 1.869 99.608 
CCL16 0.011 5.605 1.487 21.122 
RARRES2 0.011 20.302 2.009 205.185 
ADAM_TS13 0.013 0.022 0.001 0.454 
GDF_15 0.014 2.175 1.172 4.036 
IDUA 0.034 0.324 0.115 0.917 
PI3 0.036 1.776 1.039 3.037 
SPON1 0.046 7.965 1.035 61.317 
REN 0.054 1.885 0.988 3.596 
TNF_R1 0.058 1.603 0.983 2.613 
CXCL16 0.065 3.309 0.928 11.797 
TR 0.065 2.163 0.954 4.905 
EPHB4 0.085 2.882 0.865 9.604 
TFF3 0.089 1.513 0.939 2.437 
TRAIL_R2 0.101 1.717 0.899 3.278 
PLC 0.103 1.827 0.885 3.771 
IL2_RA 0.113 2.108 0.839 5.296 
VSIG2 0.118 1.573 0.891 2.777 
MMP_3 0.124 1.746 0.858 3.554 
IGFBP_7 0.131 1.900 0.825 4.372 
TNF_R2 0.137 1.747 0.838 3.643 
SHPS_1 0.138 2.693 0.727 9.974 
LTBR 0.152 1.633 0.835 3.192 
GRN 0.154 3.559 0.622 20.380 
IGFBP_2 0.156 1.591 0.837 3.021 
PAR_1 0.165 2.563 0.679 9.667 
FGF_21 0.178 1.217 0.914 1.619 
TNFRSF14 0.191 1.456 0.829 2.558 




IL1RL2 0.194 0.383 0.09 1.627 
U_PAR 0.213 1.87 0.699 5.005 
RAGE 0.217 2.087 0.650 6.702 
KLK6 0.219 1.971 0.668 5.822 
CCL15 0.227 1.598 0.747 3.421 
CPA1 0.245 1.391 0.797 2.428 
AGRP 0.258 1.62 0.702 3.736 
CD93 0.403 1.893 0.424 8.448 
CTSD 0.500 1.634 0.393 6.803 
FGF_23 0.694 1.089 0.712 1.666 
A cox regression model was used to calculate the hazard ratios for the measured 
biomarkers and the development of MACE over time. MACE: major adverse 





Figure 1: Survival analysis (Kaplan Meier curves) exploring the association between 
TNFR1 and IL-6 plasma protein levels with MACE occurrence over time. Figure 1a: 
TNFR1 plasma protein levels were divided according to the median value into two 
groups. Values between 482 and 1038 pg/ml are represented by the brown line and 
values between 1038 and 15250 pg/ml are represented by the green line. VHR 




MACE (p<0.05). Figure 1b: IL-6 plasma protein levels were divided according to the 
median value into two groups. Values between 0.27 and 1.171 pg/ml are represented by 
the brown line and values between 1.171 and 22.048 pg/ml are represented by the blue 
line. VHR participants with IL-6 plasma levels above the median were more likely to 
develop MACE (p<0.01). IL-6: interleukin 6; MACE: major adverse cardiovascular events; 
TNFR1: tumour necrosis factor alpha receptor 1. 
7.4 Discussion 
This study highlights the role of potential markers from different inflammatory and 
immune pathways involved in the initiation and progression of atherosclerosis in MACE 
prediction. The choice of those biomarkers was based on previous ex vivo or in vivo 
studies reporting their association with CVD. Recruited participants were all at very high 
risk (VHR) which is defined by a 10% risk of cardiovascular death within 10 years (as per 
the European Society of Cardiology guidelines and the SCORE risk chart) (63). 
7.4.1 TNFR1 and IL-6: Potential biomarkers for MACE risk 
In this study, TNFR1 plasma protein levels were found to be associated with MACE 
within one year of admission with particularly higher levels after 6 months of admission. 
Each one unit increase (log transformed value) in TNFR1 levels was associated with a 
5.47-fold increase of MACE (CI [1.042- 28.760]; p<0.05). TNFR1 has been previously 
associated with death as well as heart failure onset in participants post myocardial 
infarction (MI) (222). TNFR1 has also been linked to cardiovascular events and mortality 
in participants with type 2 diabetes (206) as well as in participants with chronic kidney 
disease (353). The results of this study are in line with previous reports and provide 
further insight on the value of TNFR1 in MACE prediction.  
IL-6 plasma protein levels were associated with MACE with particularly higher levels 
within 6 months after admission. One unit increase (log transformed value) of IL-6 levels 




previously shown that IL-6 is a powerful MACE predictor since high plasma level of IL-6 
have increased the burden of atherosclerosis and cardiovascular risk in participants 
without a history of CVD (354). IL-6 was also found to predict MACE and stent 
thrombosis in participants admitted with unstable angina (355). Since previous studies 
have associated TNFR1 and IL-6 plasma levels with MACE, these results highlight the 
need for further studies to evaluate the adoption of such markers in clinical practice for 
MACE prediction in VHR individuals. 
7.4.2 Proteomic approach for MACE prediction 
The proteomic approach undertaken in this study revealed a number of potential 
proteins that were associated with MACE risk in VHR participants with an already 
established CVD. These proteins included Interleukin 1 receptor-like 1 (IL-1RL1/ST2), 
Interleukin-4 receptor subunit alpha (IL4RA), Interleukin-1 receptor type 1 (IL1RT1), 
interleukin 1 receptor 2 (IL1RT2), programmed cell death ligand 2 (PDL2), 
Adrenomedullin (ADM), Thrombospondin 2 (THBS2), C-C Motif Chemokine Ligand 16 
(CCL16), Retinoic acid receptor responder protein 2 (RARRES2), Growth/differentiation 
factor 15 (GDF15), Elafin (PI3) and spondin 1 (SPON1) which plasma protein levels were 
higher in VHR participants who developed MACE within a year of admission. In contrast, 
A disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13) C-C 
motif chemokine 22 (CCL22), and alpha-L-iduronidase (IDUA) plasma protein levels were 
lower in participants who developed MACE within a year of admission compared to 
those who did not.  
IL-1RL1/ST2 is a member of the toll-like receptor superfamily of proteins and is 
known to be upregulated in myocardial injury to allow an anti-inflammatory response 




suggested to be a marker for acute coronary syndrome (ACS), acute heart failure (357) 
and cardiac stress and was strongly associated with the development of heart failure 
post-ACS in the MELRIN-TIMI 36 trial (358). In the present study, every unit increase in 
ST2 levels was linked to a 4.367-fold increase in MACE risk (HR: 4.367; CI [1.751 – 
10.892]; p<0.01). This confirms the previous reports on the role of ST2 in cardiac stress 
and provides providing further evidence of the potential its role in MACE prediction. 
IL-4RA is known to bind to IL-4 and IL-13 which consequently activates macrophages 
(359) and in the present study, plasma levels were higher in VHR participants who 
developed MACE where every unit increase in IL-4RA plasma levels was accompanied by 
7.508-fold increase in MACE risk (HR: 7.508; CI [1.907 – 29.558]; p<0.01). Little evidence 
exist on the role of IL-4RA in CAD and MACE, however, polymorphisms in IL4RA have 
been linked to familial hypercholesterolemia (360) which underlines a need to further 
investigate the role of IL-4RA in CAD and MACE occurrence. 
IL-1RT1 (also known as CD121a) is the interleukin receptor for IL-1α and IL-1β and 
has been suggested to be a novel inflammatory marker for CAD (361) which was  also 
involved in heart remodelling post-MI (333). This highlights the possible role of IL-1RT1 
with MACE following an ACS which was shown in the present study (HR: 11.884; CI 
[2.077 – 6.7981]; p<0.01). 
In the present investigation, an association between ADM plasma protein levels and 
MACE was also highlighted (HR: 3.360; CI [1.334 – 8.5]; p<0.01). This is supported by 
previous evidence suggesting that ADM is a powerful independent predictor of future 
cardiovascular events in high-risk participants with a predictive value superior to that of 
high sensitivity C reactive protein or adiponectin (362). ADM is a vasodilator peptide 




proliferation (363,364). Therefore, the presence of ADM in the plasma might be higher 
in individuals at risk of MACE in order to counteract the underlying inflammation.  
THBS2 in an extracellular matrix protein and its absence has been linked to increased 
angiogenesis (365) which has been linked to the development of heart failure in 
participants with CVD (366) and this present study supports the link between THBS2 and 
MACE risk (HR: 13.643; CI [1.869 – 99.608]; p<0.01). Higher levels of THBS2 in VHR 
individuals could be linked to the development of heart failure. 
CCL16 is a chemoattractive cytokine for monocytes and lymphocytes (367) and in 
this present study, levels were linked to MACE occurrence where every unit increase in 
CCL16 levels was accompanied by a 5.60-fold increase in MACE risk (CI [1.487 – 21.12]; 
p<0.05). CCL16 has been recently associated with CVD risk in postmenopausal women 
(368), however, its value in MACE prediction hasn’t been assessed yet.  
RARRES2, also known as chimerin, is a recently discovered adipokine and has been 
linked to inflammation and increased oxidative stress in obese participants (369) as well 
as CVD (370) and acute coronary syndrome (ACS) (371). The results of the present study 
show that RARRES2 was strongly associated with MACE occurrence with a hazard ratio 
of 20.302 (CI [2.009 - 205.185]; p<0.05). RARRES could be a potential marker for MACE 
risk in obese individuals.  
GDF-15 has immunosuppressive, anti-inflammatory and anti-apoptosis properties 
and has been linked to CVD, obesity, cancer and kidney injury (372). GDF-15 has been 
recently suggested as a biomarker for CVD and for MACE (373) with a unique capacity in 
capturing CVD development, progression, and prognosis, which is not the case for 
clinical risk predictors and other biomarkers (374). This finding is consolidated in the 




upregulated in many disease processes, nevertheless, it is unclear whether it leads to 
the further progression of the disease or provides protection against the disease (375). 
PI3 is an endogenous inhibitor of neutrophil-derived elastases which has been shown 
to present anti-inflammatory activity in pre-clinical models of inflammatory vascular 
injury (376) and in this present study, PI3 was able to predict MACE risk (HR: 1.776; CI 
[1.039 – 3.037]; p<0.05). In CVD, higher levels of anti-inflammatory mediators, such as 
Pl3, will attempt to counteract pro-inflammatory mediators and reflect a self defence 
mechanism of the body against chronic inflammation.  
On the other hand, there is little evidence of the role of IL-1RT2, PD-L2 and SPON1 
in CAD and MACE prediction. Nonetheless, the current study showed that IL-1RT2, PD-
L2 and SPON1 were linked to an increased MACE risk in VHR participants (HR: 7.242; CI 
[1.733 – 30.262]; p<0.01, HR: 11.337; CI [1.812 – 70.944 p<0.01 and HR: 7.965; CI [1.035 
– 61.37]; p<0.05 respectively). IL-1RT2 binds IL-1α and IL-1β (377) whereas PD-L2 is 
known to downregulate the immune system and promoting self-tolerance (378) and 
SPON1 has been shown to be involved in smooth muscle cell growth and angiogenesis 
(379). The role of such proteins should be further explored in CVD. 
ADAMTS13 cleaves von Willebrand factor in order to decrease its activity and inhibits 
coagulation (380). It is established that low levels of ADAMTS13 levels contribute to 
haematological and cardiovascular disorders (312) and a severe deficiency in ADAMTS13 
results in the clotting disorder known as thrombotic thrombocytopenic purpura (381). 
Our results are in line with these previous reports and show that a unit increase in 
ADAMTS13 levels was associated with a 97.8 % reduction in MACE risk (HR: 0.022; CI 
[0.001 – 0.454]; p<0.05). High level of ADAMTS13 in VHR participants at risk of MACE 




Furthermore, each unit increase in CCL22 and IDUA levels was associated with a 
75.1% and a 67.7% reduction in MACE risk (HR: 0.249; CI [0.091 – 0.681]; p<0.01 and HR: 
0.324; CI [0.115 – 0.917]; p<0.05 respectively). CCL22, mainly produced by macrophages, 
triggers the migration of regulatory T cells and is involved in infections and cancer (382). 
IDUA, on the other hand, is a lysosomal enzyme and, when defective, can cause a 
lysosomal storage disease known as Hurler or Scheie syndrome (383). There is little 
evidence of the role of CCL22 and IDUA in CVD and this requires further exploration as 
it appears that lower levels of those proteins are associated with MACE. 
In summary, combining a set of proteins that showed a significant association with 
MACE risk would allow an early detection to optimise treatment of vulnerable patients. 
The value of such a panel is reflected by a logistic regression model combining all the 
previously significant proteins (n=15) which was able to significantly predict the 
occurrence of a follow-up MACE in 94.2% of the cases (p<0.0001). This highlights the 
importance of a multimarker approach in MACE prediction where a panel combining 
multiple proteins can overcome any individual limitations of clinically relevant proteins 
in terms of low specificity and sensitivity (384).  
7.4.3 Strengths and Limitations 
Refer to section 3.4.3 in Chapter 3.  
In terms of potential biases resulting from the biochemical measurements used in the 
present study, it is important to consider that IL-13, IL-1β, IL-4 and natriuretic peptides 
(BNP and pro-NT BNP) plasma levels were below the limit of detection of the assays used 




that were below the limit of detection for INF-γ assay, 2 for the IL-10 assay, 21 for the 
IL-2 and 9 for the IL-12p70 assay which also had a high coefficient of variation. 
 
Figure 2: Previously established and novel associations between inflammatory proteins and 
MACE risk. MACE: major adverse cardiovascular events; VHR: very high risk. 
 
7.5 Conclusion 
In conclusion, the present investigation highlights previously reported and novel 
associations between several inflammatory proteins and MACE risk. The candidate 
proteins explored in the study should be explored further in large prospective studies to 
assess their clinical value and possibly included in a biomarker panel to assess MACE 
risk. If adopted in clinical practice, such biomarkers can reduce the number of CVD 












Chapter 8  
Exploring Analytical and Technical 






Background: Despite many biomarkers being associated with cardiovascular disease 
(CVD), only few are adopted into clinical practice. Markers that show to effectively 
predict cardiovascular risk in clinical studies often face many challenges when it comes 
to their implementation into a clinical practice. Some of these challenges are due to a 
lack of specificity and sensitivity of the tested biomarkers. In addition, changes in 
biomarker levels according to sampling site and storage conditions are crucial to 
consider in biomarker development. Therefore, we undertook the present investigation 
to evaluate some of the common characteristics that should be present in an ideal 
biomarker. 
Methods: Participants were recruited from the cardiac catheterisation laboratory or by 
email advertisement. Arterial and venous blood samples were collected and were 
measured in different experimental conditions. Blood samples from different sampling 
sites were also collected in a number of participants. All participants were assigned a 
risk score using the European Society of Cardiology (ESC) SCORE risk chart. Group 1 was 
defined as very high risk participants (VHR) with a 10-year risk SCORE ≥10% risk of fatal 
cardiovascular disease (CVD). Group 2 were defined as low, moderate and high risk 
participants (non-VHR) with a 10-year risk SCORE <10% risk of fatal CVD. TACE, TNFR1, 
TNFR2 and TIMP3 plasma protein levels were measured by ELISA. INF-γ, IL-10, IL-12p70, 
IL-13, IL-1β, IL-2, IL-4, IL-6, IL-8 and TNFα plasma protein levels were measured using 
MSD® MULTI-SPOT Assay System. TACE mRNA levels were measured by quantitative 
real-time PCR. CVDII and CVDIII panels were measured in the plasma by multiplex 
proximity extension assays (PEA) by Olink® proteomics. 
Results: TACE, TNFR1, TNFR2 and TIMP3 plasma protein levels were not significantly 




vein (p=0.553; p=0.404; p=0.358 and p=0.792 respectively). However, TNFR1 and TNFR2 
plasma protein levels were higher in the samples taken from the peripheral artery 
compared to the ones that were taken from the central vein and the coronary sinus 
(p<0.05 and p<0.01) and were also higher in samples taken from the central vein 
compared to the coronary sinus (p<0.01 and p<0.01). TACE plasma levels were not 
different when compared between serum samples (p=0.289), samples that were subject 
to different centrifugation speeds (p=0.403), samples measured on the day of collection 
and after 10 days or 78 days (p=0.373) and samples measured on two occasions 
(p=0.537). TACE, TNFR1, TNFR2 and TIMP3 plasma protein levels were not statistically 
different when measured over time in participants before and after a revascularisation 
intervention. In terms of specificity and sensitivity, the proteins that significantly 
distinguished between VHR and non-VHR participants with a high sensitivity and 
specificity were Growth/differentiation factor 15 (GDF-15) (AUC:0.883; p<0.0001), TNF 
related apoptosis-inducing ligand receptor 2 (TRAIL-R2) (AUC:0.869; p<0.0001), Matrix 
metalloproteinase-7 (MMP7) (AUC:0.865; p<0.0001), TNFα (AUC:0.835; p<0.0001), 
Matrix metalloproteinase-12 (MMP12) (AUC:0.825; p<0.0001), Urokinase receptor 
(UPAR) (AUC: 0.814; p<0.0001), IL-6 (AUC: 0.813; p<0.0001), Renin (REN) (AUC: 0.809; 
p<0.0001) and IL-8 (AUC: 0.804; p<0.0001).  
Conclusion: In conclusion, this study highlights the importance of evaluating different 
experimental conditions and measurement methods during biomarker development. 
This process should take place in parallel with assessing the clinical value of any potential 
marker. These crucial steps could help uncover any experimental or technical problems 






A biomarker is defined as a characteristic that is objectively measured and evaluated as 
an indicator of normal biological processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention; a definition that was standardised in 2001 by 
the National Institutes of Health (NIH) working group. A biomarker can be a gene 
mutation, a polymorphism, a protein, or other molecule or clinical measurement that 
indicates a given disease state. Therefore, biomarkers may be measured in a biosample 
(such as a blood, urine, or tissue test), recorded or obtained from a person (blood 
pressure, ECG, or Holter monitor) or from an imaging test (echocardiogram or CT scan) 
(112). Biomarker research has received a lot of attention over the past couple of 
decades. However, biomarkers that have shown efficiency in clinical trials are rarely 
adopted into the routine clinical practice. This is because the translation of biomarker 
research to clinical application faces many challenges in terms of the interpretation of 
biomarker levels, standardisation of measurement methods, optimisation of regulations 
and there are many difficulties overcoming ethical issues (283).  
Non-specificity of biomarkers is one of the many problems that exists in biomarker 
research in cardiovascular disease (CVD) (385). In addition, the prognostic value of 
various already adopted biomarkers (such as troponins and C reactive protein) is not 
clear since these proteins are not usually measured as part of a follow up strategy in 
patients with an established CVD (145,386). In biomarker development, many issues 
need to be addressed beside the clinical relevance of a certain biomarker. In addition to 
accuracy, precision, high sensitivity and specificity, the biomarker needs to be 
acceptable to the patient, tested in a large number of individuals, internationally 




Furthermore, parameters such as changes in biomarker levels according to sampling 
sites, over time and in different storage conditions are crucial. 
Tumour necrosis factor alpha converting enzyme (TACE) is a membrane bound protein 
responsible for the cleavage of tumour necrosis factor alpha (TNFα) and both of its 
receptors tumour necrosis factor alpha receptor 1 (TNFR1) and 2 (TNFR2). Several 
clinical studies have suggested the possible use of such biomarkers to improve the 
current tools used in CVD risk assessment (170,171,206,207). TACE endogenous 
inhibitor metalloproteinase inhibitor 3 (TIMP3) has been previously shown to be 
downregulated in circulating human monocytes in people at high risk of diabetes and 
atherosclerosis (221). In addition, many inflammatory markers such as interleukin 6 (IL-
6) (240), interleukin 8 (IL-8) (246) and interferon gamma (INF-γ) (248), known to play a 
role in atherosclerosis initiation and progression, have been measured in CVD patients. 
Nevertheless, there are no studies that have evaluated the practicalities in terms of 
sensitivity, specificity, accuracy and measurement variability of using such biomarkers 
in clinical practice. 
In this present study, the explored biomarkers have been measured over time, in 
different sampling sites and in different storage conditions. The aim was to assess 
several technical and experimental issues related to biomarker development. 
8.2 Participants and Methods 
Refer to section 2.1 in Chapter 2 for a detailed description of the participant 




8.2.1 Demographic information  
Refer to section 3.2.1 in Chapter 3 for a detailed description of the demographic 
information that was collected in this study. 
8.2.2 Participants blood sample collection  
Blood (35 ml) was collected from all recruited participants in a fasting state. Three 8 ml 
EDTA tubes for the research lab (VACUETTE K3E K3EDTA – 455036), one 4 ml serum tube 
for the research lab (VACUETTE Z serum clot activator -  454092), one 4 ml EDTA tube 
for hospital lab (to measure the full blood count (FBC)) (VACUETTE K3E K3 EDTA – 
454036) and one 3.5 ml of serum separator tube (yellow cap) (to measure CRP, renal 
function and cholesterol levels) (BD Vacutainer SSTTM II advance – 367956) were 
collected. For the participants recruited from the catheterisation laboratory in 
Altnagelvin Hospital, blood was collected from the sheath inserted into the radial artery 
(or, on occasions, the femoral artery when the radial artery couldn’t bet accessed). The 
arterial blood was collected straight into a 50-ml syringe and immediately transferred 
into the blood tubes using a 21 G syringe (BD microlane 3 – 21G 1 ½ Nr.2 0.8 x 40 mm – 
304432). Blood samples were immediately cooled and centrifuged and the plasma was 
aliquoted and frozen at −80◦C until further analysis (Figure 1). 
From a subset of participants recruited from the catheterisation laboratory in 
Altnagelvin Hospital, a total of 40 ml of venous (peripheral vein) (V=30 ml) and arterial 
(peripheral artery) blood (V=10 ml) was collected. This was to compare the effect of the 
sampling site on the studied markers. The venous blood was collected by a trained 
phlebotomist prior to the angiogram procedure using the same blood collection material 




From another subset of participants recruited from the catheterisation laboratory in 
Altnagelvin Hospital, 10 ml of blood was collected from different sampling sites by the 
consultant cardiologist. The different sampling sites include the peripheral artery (PA) 
(radial or femoral artery), central vein (CV) (femoral vein), central coronary artery (CCA), 
culprit lesion (when present), coronary sinus, a post-balloon sample, a post-PCI sample 
and a post-heparin sample (Figure 1). 
Participants recruited among the hospital and Ulster University staff were received 
at the clinical translational research and innovation centre (C-TRIC) and a 35 ml of 
venous blood was collected from the peripheral vein by a trained phlebotomist using a 
butterfly needle (VACUETTE safety blood collection set 21G x 3/4 ‘’ 0.9 x 19 mm – 
450091) as well as a luer adapter (Greiner bio one luer adapter – 20G 16C05A) and a BD 
Vacutainer (Figure 1). 
A venous (peripheral vein) blood sample was collected from some of the previously 
recruited participants who volunteered to give a second blood sample after one year of 
initial blood sample collection. A volume of 8 ml of venous blood was collected by a 
trained phlebotomist using the same material mentioned above (Figure 1). 
8.2.3 Measurement of soluble TACE, TNFR1, TNFR2 and TIMP3 
plasma protein levels 




8.2.4 Measurement of TNFα, IFN-γ, IL-2, IL-6, IL-8, IL-10 and IL-
12p70 plasma protein levels 
Refer to section 2.10 in Chapter 2.  
 
8.2.5 Method for analysing samples using the Proximity 
Extension Assay (PEA) technology - Proseek® Multiplex provided 
by O-Link Proteomics (CVDII and CVDIII) 
Refer to section 2.14 in Chapter 2. 
A detailed definition of the covariates is given in section 3.2.7 in Chapter 3  
8.2.6 Statistical methods 
Data analysis was performed using GraphPad Prism 6 software© and IBM® SPSS version 
23 software (SPSS Inc., Chicago, IL). Variables that did not follow normal distribution 
were transformed using a logarithmic function to allow their use in parametric methods 
of analysis. Continuous variables were expressed as mean ± SD whereas categorical 
variables were expressed as percentages. Unpaired and paired student tests were 
conducted according to the type of analysis. Receiver operating characteristics (ROC) 
curves were calculated for the significant proteins in order to assess the sensitivity and 





8.3 Results and Discussion 
8.3.1 Participant recruitment and blood sample collection 
Refer to section 3.3.1 in Chapter 3 and Table 1 and 2 in Chapter 3. 
Among the participants recruited from the catheterisation laboratory in Altnagelvin 
Hospital, arterial (n=153) or venous (n=47) blood was collected from Group 1. Arterial 
and venous blood (n=38) were collected from Group 2. Blood (n=6) was collected from 
different sampling sites (which included the peripheral artery (PA) (radial or femoral 
artery), central vein (CV) (femoral vein), central coronary artery (CCA), culprit lesion 
(when present), coronary sinus, a post-angioplasty sample, a post-PCI sample and post-
heparin sample (from the peripheral artery) from Group 3. Among the participants 
recruited from the hospital and Ulster University staff, venous blood (n=100) was 
collected from all individuals (Group 4). A follow-up blood sample (n=16) was collected 
from participants who were initially recruited from the catheterisation lab in Altnagelvin 





Figure 1: Types and volumes of the blood samples collected from participants recruited 
from the catheterisation laboratory in Altnagelvin Area Hospital and from the hospital 
and Ulster University staff. CVD: Cardiovascular disease, HR: high risk, LR: low risk, MR: 






Table 1: TACE, TNFR1, TNFR2 and TIMP3 protein levels measured in different types of 
samples 
Type of sample TACE TNFR1 TNFR2 TIMP3 
Arterial blood         
Venous blood         
Arterial and venous blood from same participant         
Different sampling sites from same participant         
Serum               
Timepoint 1         
Timepoint 2         
Spun down plasma      
Fresh plasma measured on the day of collection      
TACE protein levels were measured in arterial samples, venous samples, arterial and venous 
samples from the same participants, in different sampling sites, in the serum, on timepoint one 
and 2, in plasma samples after being spun down, and in plasma samples collected on the day. 
TNFR1, TNFR2 and TIMP3 protein levels were measured in arterial samples, venous samples, 
arterial and venous samples from the same participants, in different sampling sites, on timepoint 
one and 2. TACE: Tumour necrosis factor alpha converting enzyme; TIMP3: Metalloproteinase 
inhibitor 3; TNFα: Tumour necrosis factor alpha; TNFR1: Tumour necrosis factor alpha receptor 
1; TNFR2: Tumour necrosis factor alpha receptor 2. 
Table 2: Assay precision and coefficient of variation for the measured biomarkers. 
Assay precision Inter-assay CV (%) Intra-assay CV (%) 
TACE ELISA (RAB0003 SIGMA) 19.68 11.91 
TIMP3 ELISA (abcam ab119608) 26.57 5.49 
TNFR1 ELISA (R&D - DRT 100) 8.62 4.20 
TNFR2 ELISA (R&D - DRT200) 5.07 4.20 
MSD® MULTI-SPOT Assay System - K15049D 
INF-γ 16.30 5.90 
IL-10 13.97 6.93 
IL-12p70 24.06 23.68 
IL-2 40.16 20.98 
IL-6 8.27 4.61 
IL-8 16.11 3.37 
TNFα 26.51 3.16  
CV: coefficient of variation; IL-10: Interleukin 10; IL-12p70: Interleukin 12 hetoremer 70; IL-2: 
Interleukin 2; IL-6: Interleukin 6; IL-8: Interleukin 8; INF-γ: Interferon gamma; TACE: Tumour 
necrosis factor alpha converting enzyme; TIMP3: Metalloproteinase inhibitor 3; TNFα: Tumour 
necrosis factor alpha; TNFR1: Tumour necrosis factor alpha receptor 1; TNFR2: Tumour necrosis 




8.3.2 Biomarker levels were not statistically different between samples taken 
from the peripheral artery vs. the peripheral vein  
To explore whether TACE, TNFR1, TNFR2 and TIMP3 protein levels were subject to 
differences between sampling sites, blood samples taken from the peripheral artery 
were compared to blood samples taken from the peripheral vein. While the peripheral 
vein might be more relevant in routine practice, in cardiology, the peripheral artery 
could be also useful when it comes to cytokine levels. This is because arterial blood 
provides the circulating levels of cytokines prior to the removal by the body tissues 
(387). 
Results showed that there was no significant difference between TACE, TNFR1, 
TNFR2 and TIMP3 plasma protein levels when compared between blood samples taken 
from the peripheral artery and the peripheral vein (p=0.553; p=0.404; p=0.358 and 
p=0.792 respectively) (Table 3). TACE plasma levels were previously measured in ANCA 
vasculitis and Alzheimer’s disease (176,177), TIMP3 plasma levels were measured in 
patients with oral cancer (388) and TNFR1 and TNFR2 plasma levels were measured in 
patients with CVD. However, the value of such markers as potential biomarkers in CVD 
hasn’t been assessed yet as the authors did not evaluate the sensitivity and specificity 
of their assay and did not explore whether the sampling site affects the measurement. 
Since atherosclerosis mainly affects the body’s arteries, evaluating biomarker levels in 
different sampling sites is crucial as some markers tend to be higher in the arterial 











Arterial (pg/ml) Venous (pg/ml) 
p value 
Mean Std. deviation Mean Std. deviation 
TACE  38 377.3 874.2 483.7 1061 0.462 
TNFR1  18 1214 607.1 1383 591.5 0.405 
TNFR2  18 2795 1355 3344 2101 0.358 
TIMP3  20 2668 2638 2859 1835 0.792 
An unpaired Student t-test was performed. TACE: Tumour necrosis factor alpha converting enzyme; 
TIMP3: Metalloproteinase inhibitor 3; TNFR1: Tumour necrosis factor alpha receptor 1; TNFR2: 
Tumour necrosis factor alpha receptor 2.  
8.3.3 TNFR1 and TNFR2 plasma levels were statistically different according to 
sampling sites 
The present study is the first to compare plasma TNFR1 and TNFR2 protein levels 
between the peripheral artery, the central vein and the coronary sinus. This was done 
in order to investigate whether the concentrations of some markers vary within the 
blood circulation. In addition, differences in protein levels were explored before and 
after angioplasty and PCI procedure and as a consequence of heparin administration. 
Results demonstrated that TNFR1 and TNFR2 plasma protein levels were higher in the 
samples that were taken from the peripheral artery compared to the ones that were 
taken from the central vein and the coronary sinus (1088 ± 213.6 pg/ml vs. 1047 ± 198.5 
pg/ml and 952.8 ± 189.7 pg/ml; p<0.05 for TNFR1 and 2621 ± 980.6 pg/ml vs. 2300 ± 
783.4 pg/ml and 1967 ± 721.3 pg/ml; p<0.01 for TNFR2) (Figure 2). Furthermore, TNFR1 
and TNFR2 plasma levels were higher in the central vein compared to the coronary sinus 
(1047 ± 198.5 pg/ml vs. 952.8 ± 189.7 pg/ml; p<0.01 and 2300 ± 783.4 pg/ml vs. 1967 ± 
721.3 pg/ml; p<0.01) (Figure 2 and Table 4). It was previously shown that the expression 
of TNFR1 in the arterial wall promotes atherosclerosis (390). Also, cerebral ischemia is 
known to induce the expression of TNFα and its receptors in the walls of cerebral 




proteins that are shed in the peripheral artery compared to the central vein and 
coronary sinus and the processes behind this need further understanding. However, it 
is suggested that arterial blood reflects the circulating levels of cytokines prior to the 
removal by the body tissues (387) which would indicate that some markers tend to be 
higher in the arterial circulation compared to the venous circulation. On the other hand, 
it appears that post angioplasty, and post PCI, TNFR1 plasma levels seem to increase 
whereas TNFR2 plasma levels decreased. However, the difference did not reach 
statistical significance probably due to the low number of participants tested (Table 6). 
 
Figure 2: TNFR1 and TNFR2 plasma levels are higher is samples taken from the peripheral 
artery (PA) compared to samples taken from the central vein (CV) and the coronary sinus 
(CS). A paired Student t-test was performed. TNFR1 and TNFR2 plasma levels were measured by 
ELISA in the different sampling sites taken from individuals at very high risk of cardiovascular 


















Culprit lesion post 
angioplasty (n=3) 




















TACE  1773 3145 1809 3260 1652 3010 0.3417 173.7 200.9 150.1 190.9 131.3 227.5 0.4274 
TNFR1  1088 213.6 1047 198.5 952.8 189.7 0.0019 753.9 58.28 785.7 187.1 796 118.4 0.7171 
TNFR2 2621 980.6 2300 783.4 1967 721.3 0.0056 1402 150 1387 36.36 1375 119.9 0.8529 










Culprit lesion post 
angioplasty (n=3) 
Culprit lesion post 













deviation ANOVA (paired) 
TACE  203.9 230.2 183.6 253.3 127.9 221.6 173.7 200.9 150.1 190.9 131.3 227.5 0.412 
TNFR1  987.7 158.3 940.5 124.4 846.2 123.8 753.9 58.28 785.7 187.1 796 118.4 0.0906 
TNFR2 1945 157.7 1739 110.8 1456 46.52 1402 150 1387 36.36 1375 119.9 0.0173 
TIMP3  3403 1748 3030 1220 3300 919.8 5476 2101 3492 1753 4289 787.1 0.3226 
Highlighted p values are significant. Values in bold are the highest among the compared cells. PCI: percutaneous coronary intervention, TACE: tumour necrosis factor 
alpha converting enzyme; TIMP3: metalloproteinase inhibitor 3inhibitor; TNFR1: tumour necrosis factor alpha receptor 1; TNFR2: tumour necrosis factor alpha 





8.3.4 TACE levels were not statistically different in samples measured in 
different experimental conditions 
In order to determine the effect of different experimental conditions on TACE levels, 
TACE protein levels were measured in plasma and serum as well as before and after a 
centrifugation step and over time. Our data demonstrated that there was no significant 
difference in TACE protein levels that were measured in the plasma compared to the 
serum (p=0.289). Moreover, centrifuging the plasma sample for 5 min at 15,000 RCF, in 
order to pellet an microparticles (392), did not affect TACE detection (p=0.403). 
Furthermore, there was also no significant difference when measuring TACE plasma 
protein levels in a sample on the day of collection, after 10 days or after 78 days of 
collection (p=0.373). In addition, measuring the same plasma sample on two occasions 
did not have a significant difference in terms of protein levels (p=0.537) (Table 5). These 
results show that TACE plasma protein levels are not subject to experimental and 
technical changes. These characteristics are important when it comes to biomarker 
development since an ideal biomarker needs to be subject to little experimental 





Table 5: TACE protein levels measured in different experimental conditions 
Experimental conditions 











Serum 366.9 759.9 








0.3729 Measured after 10 days 714.6 877.9 





Measurement 2 901.3 1545 
Days after measurement 1 
after sample collection 
(average in days) 
40 
Days after measurement 2 
after sample collection 








measurement 1 and 2  381.9795588 1148.606872 
0.136 Days between 
measurement 2 and 
measurement 1 (average in 
days) 
364 
Samples were centrifuged for 15000 RCF for 5 min. TACE: Tumour necrosis factor 
alpha converting enzyme 
8.3.5 Biomarker levels in follow up participants 
To investigate whether protein levels change over time in the recruited participants, a 
total of 13 VHR participants volunteered to provide a second blood sample after one 
year of recruitment. Among these participants, 6 had underwent a PCI or coronary 
artery bypass grafting (CABG) between the timepoint of the first and the second blood 
sample. None of the measured biomarkers had significantly different plasma protein 
levels when compared between the first and the second sample (Table 6). Although 




the duration of this increase remains unclear. In most of the studies, the increase in 
inflammatory markers have been measured directly after the PCI or the CABG procedure 
and up to two 2 days after the procedure and haven’t been measured over time.  In 
addition, a PCI or a CABG procedure are normally accompanied by the initiation of a 
drug therapy and therefore, it is quite challenging to assess the efficacy of a PCI or a 
CABG therapy alone without the biased beneficial effect of the drug therapy. 
Furthermore, the number of the follow-up participants that volunteered for a blood 
sample following a PCI or a CABG procedure in this present study was rather low and 
therefore, a statistical difference was not observed. However, follow-up participants are 
still being recruited in this study. 
Table 6: Biomarker levels in a follow up blood sample from VHR participants after 






(n=6) p value 
 Mean  Std. deviation Mean  Std. deviation 
TACE 2358.25 3633.88 2583.90 3621.83 0.215 
TNFα 3.72 1.22 2.78 0.53 0.063 
TNFR1 974.00 234.00 1102.85 177.34 0.237 
TNFR2 2438.50 693.98 2597.33 774.22 0.653 
TIMP3 2473.67 1536.62 1100.67 496.59 0.109 
INF-γ 5.91 5.60 7.08 5.48 0.419 
IL-10 0.22 0.15 0.52 0.56 0.288 
IL-12p70 0.36 0.29 0.20 0.09 0.172 
IL-2 0.21 0.09 0.23 0.08 0.504 
IL-6 1.43 1.26 1.22 0.61 0.651 
IL-8 8.01 8.86 6.09 2.01 0.586 
An unpaired student t-test was performed. CABG: coronary artery bypass grafting; IL-10: 
Interleukin 10; IL-12p70: Interleukin 12 hetoremer 70; IL-2: Interleukin 2; IL-6: Interleukin 6; IL-8: 
Interleukin 8; INF-γ: Interferon gamma; PCI: percutaneous intervention; TACE: Tumour necrosis 
factor alpha converting enzyme; TIMP3: Metalloproteinase inhibitor 3; TNFα: Tumour necrosis 
factor alpha; TNFR1: Tumour necrosis factor alpha receptor 1; TNFR2: Tumour necrosis factor 




8.3.6 ROC curves to assess sensitivity and specificity of the measured 
biomarkers in differentiating between VHR and non-VHR individuals 
In addition to the previously measured proteins, a proteomic approach was used to 
identify biomarkers that were able to differentiate between VHR and non-VHR 
participants.  Refer to Table 8 in section III of the appendix for the full list of proteins, 
area under the curve (AUC) and p values. To test the sensitivity and specificity of the 
best candidate proteins, receiver operating characteristic (ROC) curves were generated 
and the AUC was calculated (Table 7). Growth/differentiation factor 15 (GDF-15), also 
known as macrophage inhibitory cytokine-1, has a major role in regulating inflammation 
and apoptosis in injured tissues (375). GDF-15 has been proposed as a new biomarker 
for CVD, for stable coronary artery disease (CAD), acute coronary syndrome (ACS) and 
heart failure (308). However, the evaluation of its possible role as a biomarker hasn’t 
been previously assessed. In this present study and among all the measure proteins, 
GDF-15 has shown to have the highest sensitivity and specificity in differentiating 
between VHR and non-VHR individuals (AUC:0.883; p<0.0001) suggesting a promising 
role in biomarker development. In addition, TNF related apoptosis-inducing ligand 
receptor 2 (TRAIL-R2) is suggested to cause apoptosis (396), however its role in CVD risk 
assessment needs further exploration (AUC:0.869; p<0.0001). Matrix 
metalloproteinase-7 (MMP7) is known to contribute to plaque instability in 
atherosclerosis (297) whereas Matrix metalloproteinase-12 (MMP12) has been shown 
to be a candidate molecule for the prevention and treatment of cardiometabolic 
diseases (302). These two metalloproteinases which are involved in the breakdown of 
the extracellular matrix and could be promising for biomarker development since they 




(AUC:0.865; p<0.0001 and AUC:0.825; p<0.0001, respectively). Urokinase receptor 
(UPAR) (AUC: 0.814; p<0.0001) has been suggested as a biomarker for CVD in patients 
with chronic kidney disease (CKD) (349) whereas Renin (REN) (AUC: 0.809; p<0.0001) 
plasma activity was recently linked to increased risk of major adverse cardiovascular 
events (MACE) and congestive heart failure in patients with high systolic blood pressure 
(307). In addition, TNFα (AUC:0.835; p<0.0001), IL-6 (AUC: 0.813; p<0.0001), and IL-8 
(AUC: 0.804; p<0.0001) demonstrated high sensitivity and specificity in differentiating 
between VHR and non-VHR individuals. All the previously mentioned proteins had an 
AUC > 0.8. In is noteworthy that CRP levels had and AUC of 0.667 (CI: 0.607 – 0.729; 
p<0.0001) which was lower compared to the aforementioned proteins. Such proteins 
could be potentially added to current CVD diagnostic tools in order to improve current 







Figure 3: AUC values of the proteins that significantly differentiated between VHR and 
non VHR participants (p<0.0001). GDF-15, TRAIL-R2, MMP7, TNFα, MMP12, UPAR, IL-6, 
REN and IL-8 had an AUC over 0.8 suggesting a superior specificity and sensitivity 
compared to the other measured proteins. AUC values were calculated by a Receiver 
Operating Characteristic Curve (ROC). GDF: Growth/differentiation factor 15; TRAIL-R2: 
TNF related apoptosis-inducing ligand receptor 2; MMP7: Matrix metalloproteinase 7; 
TNFα: Tumour necrosis factor alpha; MMP12: matrix metalloproteinase 12; UPAR: 





Figure 4: ROC curves for GDF-12, TRAIL-2, MMP7, TNFα, MMP-12 and U-PAR protein 
levels to assess sensitivity and specificity of the used assays in differentiating between 
VHR and non-VHR individuals. GDF-15 Growth/differentiation factor 15; TRAIL-R2: TNF 
related apoptosis-inducing ligand receptor 2; MMP-7: Matrix metalloproteinase-7; 
TNFα: Tumour necrosis factor alpha; MMP12: Matrix metalloproteinase-12; UPAR: 
Urokinase receptor; ROC: Receiver operating curve. 
8.3.7 Strengths and Limitations 
Refer to section 3.4.3 in Chapter 3 and section 7.4.3 in Chapter 7. 
8.5 Conclusion 
In conclusion, this study highlights the importance of evaluating different experimental 
conditions and measurement methods during biomarker development. This process 
should take place in parallel to the assessment of the clinical value of any potential 
marker. This will help uncover any experimental or technical problems that normally 














Chapter 9  





9.1 Major Findings 
The present study highlights the role of a multimarker panel in improving 
cardiovascular risk assessment and in further stratifying individuals at very high risk of 
cardiovascular events. Such panels, once optimised, should be evaluated in large 
prospective longitudinal studies to validate their clinical value and assess their 
introduction into clinical practice and their value in providing a unique proteomic 
disease signature to each susceptible individual. In addition, this work provides further 
understanding of the biology and the mechanism of action of some of the investigated 
biomarkers. Some of the major findings of the present study are highlighted below: 
TNFα Pathway: Following a Deductive Method in Biomarker Research 
 TACE and TIMP3 are potential therapeutic targets in CVD and may have 
promising potential as CVD biomarkers. 
 TNFR1 is an acute phase marker for primary and secondary cardiovascular 
events. 
 TNFR1 and TNFR2 are specific markers for CVD patients with comorbidities such 
as diabetes, heart and renal failure. 
 A panel combining TNFα, TNFR1 and TNFR2 could have potential in predicting 
major adverse cardiovascular event (MACE). 
Proteomic Analysis: Following an Inductive Method in Biomarker Research 
Overall Findings 
 Multimarker panels have a superior value compared to single marker panels. 
 Multimarker panels need to be optimised to represent proteins from different 




 The clinical validation of such panels needs to be done in parallel to the collection 
of follow-up data and blood samples from individuals in longitudinal studies. 
 In order to guide therapy and management, it is possible to further stratify very 
high risk CVD individuals in high and low risk clusters using protein levels of 
potential markers. 
Specific Findings 
 MMP7, LOX-1, GLO1, MMP12, CTSD, REN, GDF-15, CNTN1, TRAP, hOSCAR, 
CEACAM8, PAAPA, TNFRSF11A, PON3, IL-6, IL-8, INF-γ and IL-1β are potential 
predictors of cardiovascular risk. 
 ADAMTS-13, OPN, VEGF-D, Protein AMBP, BOC, PD-L2 and TRAP are promising 
markers for primary cardiovascular events. 
 TNFSF13B, IL18-BP, TNFRSF11A, BOC, IFN-γ, IL-12p70, IL-8 and EGFR 
characterised patients admitted for MACE. 
 IL-6, ST2, IL4RA, IL1RT1, IL1RT2, PDL2, ADM, THBS2, CCL16, RARRES2, GDF15, 
PI3 and SPON1 CCL22, ADAMTS13 and IDUA are potential markers for follow-
up MACE. 
 KIM1, IL-1RT1, Gal-3, REN, VSIG2, FABP4, GIF, IL-6, PON3, HO-1 identified VHR 
patients with diabetes. 
 TRAIL-R2, FGF-21, ADM, TNFRS11A, INF-γ, IL-6, CTRC and SRC characterised VHR 
patients with heart failure. 





9.2 General Discussion   
9.2.1 The need for better prediction tools 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide 
and even with major advances in medical and clinical management, CVD prevalence is 
increasing with 17.5 million global deaths in 2012 (1). In clinical practice, identifying 
individuals at risk of CVD has improved with the introduction of risk scores which are 
based on the most common CVD risk factors such as total cholesterol levels, diastolic 
blood pressure, diabetes, family history and smoking. Therefore, managing those risk 
factors could possibly delay CVD onset but won’t completely avoid it. Additionally, 
troponin measurement has ameliorated the diagnosis of patients with an acute coronary 
syndrome (ACS). However, troponins are also known to be elevated in other 
inflammatory conditions (such as heart failure, tachyarrhythmias, myocarditis, 
hypertensive emergencies, Takotsubo cardiomyopathies etc.) which might delay an 
accurate diagnosis and the initiation of the appropriate therapy. On the other hand, 
even with optimal medical and clinical management, individuals with established CVD 
and a previous ACS are at high risk of major adverse cardiovascular events (MACE) (397). 
Hence, despite improving early CVD detection, controlling the risk factors and treating 
patients at risk of MACE, CVD management remains far from ideal. 
9.2.2 Identifying patients at very high risk of cardiovascular 
events 
In this present work, using the European SCORE risk chart to assign a score for each 




by measuring promising novel biomarkers from the tumour necrosis factor alpha (TNFα) 
pathway as well as other inflammatory pathways.  
TNFα is shed by tumour necrosis factor alpha converting enzyme (TACE) which is also 
known to shed several inflammatory markers known to be involved in the initiation and 
progression of atherosclerosis including TNFR1 and TNFR2 (220). Nevertheless, 
exploring proteins from this pathway as potential CVD biomarkers hasn’t been assessed 
before.   
On the other hand, in light of major advances in proteomics which are facilitating the 
discovery of potential biomarkers and novel therapeutic targets, we explored a number 
of proteins known to be involved in immunity, atherosclerosis, plaque rupture and 
thrombosis in order to assess their role as potential CVD biomarkers. 
9.2.2.1 TNFα pathway in CVD 
TNFα plasma levels and TACE gene expression were higher in very high risk (VHR) 
compared to non-VHR participants. TNFα plasma levels have been linked to CVD risk for 
over a decade (181) and TACE gene expression was previously shown to be increased in 
small cohorts of patients with acute myocardial infarction (MI) (170,171). However, 
TACE gene expression has not been measured before in a large number of individuals at 
various levels of cardiovascular risk. In addition, both TNFα receptors, tumour necrosis 
factor alpha receptor 1 (TNFR1) and 2 (TNFR2) plasma levels were higher in VHR 
compared to non-VHR participants. The present work is novel as levels of TNFR1 and 
TNFR2 have not been previously compared across individuals at various levels of 
cardiovascular risk. Both soluble receptors have only been associated with the presence 




individuals. In is noteworthy that TNFα, TACE gene expression and TNFR1 levels were 
sensitive enough in identifying risk as levels increased with increasing cardiovascular risk 
in parallel with the assigned SCORE risk. 
The measurement of TNFR2 to TNFR1 cell membrane protein ratio in CVD is novel. 
TNFR1 receptor is a major initiator of inflammation causing endothelial cell dysfunction 
whereas TNFR2 receptor has more favourable effects by activating angiogenic and 
survival pathways (209,210). In this present work, TNFR2 to TNFR1 cell membrane 
protein ratio was lower in VHR compared to non-VHR patients suggesting that the 
balance between those receptors is more likely to shift towards a pro-inflammatory 
state which might be similar to what is observed in endothelial cells.  
For the first time, TACE plasma levels were measured in CVD individuals highlighting 
a trend where levels were lower in VHR compared to non-VHR participants. The 
detection of TACE protein in the plasma highlights the presence of a mechanism behind 
its release into the bloodstream that requires further investigation. TACE is known to be 
a membrane bound protein whose presence on the cell surface is essential for an 
effective cleavage of substrates (151,152). Some studies however, have reported the 
presence of an active form of TACE protein in the plasma (176,177) where its activity 
was measured using a Fluorescence Resonance Energy Transfer assay. TACE has also 
been reported to be present on microparticles of platelet and endothelial origin 
(175,176). Nevertheless, whether TACE can effectively cleave distant substrates in vivo 
is unknown. This study also showed that cell membrane bound TACE protein levels were 
higher in VHR compared to non-VHR participants, which has not been explored 
previously. In summary, in contrast to the presence of low plasma TACE levels, VHR 




levels. This could therefore lead to increased shedding of inflammatory transmembrane 
proteins and a pro-inflammatory state. 
Moreover, this data is in line with a recent study that provided evidence that TACE 
is a good target for biological therapeutics. A bi-specific inhibitor, that targets cell 
membrane bound TACE and a pro-inflammatory cytokine, was able to increase its 
concentration at the cell surface and reduce inflammation in irritable bowel disease 
(202). The efficacy of such a promising therapeutical model should be tested in CVD. 
However, recent evidence has shown that TACE targeting needs to be cell specific and 
needs to take into account the stage of atherosclerosis (200). 
Metalloproteinase inhibitor 3 (TIMP3) is the only known endogenous TACE inhibitor 
and TIMP3 mRNA levels were lower in VHR compared to non-VHR participants. This 
suggests that, in contrast to an increase in TACE expression in individuals with CVD, 
TIMP3 gene expression was decreased. As a result, TIMP3 fails to effectively inhibit TACE 
which would subsequently cleave a higher number of inflammatory transmembrane 
proteins. Plasma TIMP3 to cell membrane bound TIMP3 protein ratio was higher in VHR 
compared to non VHR patients indicating that in VHR individuals, a higher proportion of 
TIMP3 is released into the plasma compared to the amount of TIMP3 retained on the 
cell surface. TIMP3 retained on the cell surface is known to be associated with TACE to 
form dimer structures that inhibit TACE activity and substrate shedding (235,236). A 
lower proportion of TIMP3 on the cell surface results in an insufficient TACE inhibition 
which was also reflected by the cell membrane bound TIMP3 to TACE protein ratio which 
was significantly lower in VHR participants. When TACE is ineffectively inhibited by 
TIMP3, it shifts into its monomer active form, and subsequently cleaves a higher number 




studies have shown that a loss of TIMP3 increased the risk of atherosclerosis in ApoE 
null mice (233).  
This provides further evidence of the role of TACE in CVD where its gene and protein 
expression seems to be increased while its endogenous inhibitor, TIMP3, fails to 
effectively inhibit its proteolytic activity leading to a pro-inflammatory state. Recent 
work has suggested the possibility of adopting a TIMP3 based therapy to offer cardio 
protectivity (234) and this needs further investigation. 
9.2.2.2 Multimarker approach: TNFα inflammatory panel 
Finally, the value of a multimarker versus a single marker approach in assessing an 
individual’s cardiovascular risk was highlighted by the panel we tested which combined 
TNFα, TNFR1 and TNFR2 plasma levels in addition to TACE gene expression. In a binary 
logistic regression model, this 4-marker panel was able to collectively predict VHR/non-
VHR group membership in 82.5% of the cases (p<0.0001) as opposed to 76.9% for TNFα, 
74.7% for TNFR1, 67.7% for TNFR2 and 67.8% for TACE gene expression when all of these 







Figure 1: Increased or decreased levels of proteins from the TNFα inflammatory pathway 
in individuals at very high risk (VHR) of CVD. In patients at very high risk of CVD, TACE gene 
expression and TACE cell membrane bound levels were higher in VHR vs. non-VHR 
individuals. However, TACE plasma protein levels showed a trend where levels were lower 
in VHR vs. non-VHR individuals. TIMP3, TACE endogenous inhibitor, gene expression was 
lower in VHR vs. non-VHR individuals. TACE is known to cleave tmTNFα releasing sTNFα 
which plasma levels were higher in VHR vs. non-VHR individuals. TACE is also known to 
cleave TNFR1 and TNFR2 releasing sTNFR1 and sTNFR2 respectively. sTNFR1 and sTNFR2 
plasma levels were higher in VHR vs. non-VHR individuals. TNFR2 to TNFR1 cell membrane 
bound ratio was lower in VHR vs. non-VHR individuals. 
TACE: Tumour necrosis factor alpha converting enzyme; TIMP3: Tissue inhibitor of 
metalloproteinase 3; tmTNFα: transmembrane tumour necrosis factor alpha; sTNFα: 
soluble tumour necrosis factor alpha; TNFR1: tumour necrosis factor alpha receptor 1; 
TNFR2: tumour necrosis factor alpha receptor 2 
 
9.2.2.3 Exploring new pathways in CVD: A proteomic approach 
It is now accepted that CVD frequently can occur concomitant with other co-morbidities 
such as diabetes, arthritis, depression, renal disease and cancer which all share common 
biological and immune pathways. In this present work, 53.3% of VHR individuals 
presented with a comorbidity (diabetes, arthritis or depression). Therefore, in CVD 
biomarker research, the present consensus is shifting towards a multimarker approach 
as it is becoming clearer that the complexity of CVD is unlikely to be captured by a single 
marker. A proteomic approach that consisted of analysing 193 proteins known to be 




immune response, identified novel proteins which role in CVD risk assessment hasn’t 
been previously described. In addition, well-known associations between potential 
biomarkers and cardiovascular risk were highlighted providing further evidence of their 
promising role in CVD risk assessment. 
Matrix metalloproteinase-7 (MMP7), Lectin-like oxidized LDL receptor 1 (LOX-1), 
Lactoylglutathione lyase (GLO1), Matrix metalloproteinase-12 (MMP12), Cathepsin D 
(CTSD), Renin (REN), Growth/differentiation factor 15 (GDF-15), Contactin-1 (CNTN1), 
Thrombospondin-related adhesive protein (TRAP), Osteoclast-associated 
immunoglobulin-like receptor (hOSCAR), Carcinoembryonic anti-genrelated cell 
adhesion molecule 8 (CEACAM8), Pappalysin-1 (PAAPA), Tumour necrosis factor 
receptor superfamily member 11A (TNFRSF11A), Paraoxonase (PON3), Interleukin-6 (IL-
6), Interleukin 8 (IL-8), Interferon gamma (INF-γ) and interleukin 1 β (IL-1β) protein levels 
were potential predictors of cardiovascular risk. In addition, GDF-15, MMP7, MMP12, 
REN, IL-6 and IL-8 measurement assays had a good specificity and sensitivity which are 
important qualities for novel candidate biomarkers for future development (137). 
Our results are in line with previous reports on GDF-15 as new biomarker for stable 
coronary artery disease (CAD), one of the major forms of CVD, acute coronary syndrome 
(ACS) and heart failure (308). In addition, our study showed that GDF-15 has a good 
sensitivity and specificity. Among the other markers that demonstrated good sensitivity 
and specificity in this study, we cite MMP7 which is known to contribute to plaque 
instability in atherosclerosis (297) and MMP12 which has been suggested as a candidate 
molecule for the prevention and treatment of cardiometabolic diseases (302). In 
addition, REN plasma activity has been recently linked to increased risk of MACE and 




future studies are needed to evaluate whether these markers, alone or as part of a 
multimarker strategy, can improve current risk prediction tools and support therapeutic 
management of patients with CVD. 
Other proteins that were associated with cardiovascular risk but showed lower 
sensitivity and specificity include LOX-1, which is known to be a marker for 
atherosclerosis related events (298) and GLO1 where polymorphisms in the GLO1 gene 
have been associated with vascular diseases (301). In addition, CTSD is known to have a 
role in MACE occurrence (305) whereas paraoxonases enzymes are shown to contribute 
to CVD especially through their involvement in the lipid metabolism (309). Moreover, 
the role of CNTN1 in predicting new CVD onset has also been previously highlighted 
(122). On the other hand, IL-6 levels have been linked to cardiovascular risk for over a 
decade (255,256) whereas IL-8 is known to be involved in maintaining an inflammatory 
environment surrounding the plaque (245) and levels were shown to be higher in 
unstable CAD (246). IFN-γ is known to play an important role in atherosclerosis and 
plaque stability (254) however, IFN-γ plasma levels haven’t been measured yet in 
patients at different levels of cardiovascular risk and have demonstrated a controversial 
role in CVD within this project. IL-1β has long been linked to atherothrombotic disease 
and plaque destabilisation as well as adverse remodelling after an MI (264) and in the 
present study, IL1B gene expression was higher in VHR compared to non-VHR 
participants. IL-1β has proven to be an effective therapeutical target in CAD as the 
ongoing Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) trial is 




This study also highlights a novel role of several proteins such as TRAP, hOSCAR, 
CEACAM8, PAPPA, TNFRSF11A and PON3 in CVD and their role should be further 
investigated in addition to their evaluation as potential CVD biomarkers.  
9.2.3 Identifying CVD individuals at risk of MACE 
As VHR individuals are at high risk of secondary events despite optimal revascularisation 
strategies and medical management, the aim of this present investigation was to also 
explore whether proteins from the TNFα inflammatory pathway as well as proteins from 
other pathways involved in atherosclerosis, plaque rupture, thrombosis and immunity 
allow a sub-classification of VHR individuals in terms of comorbidities as well as MACE 
risk.  
9.2.3.1 TNFα pathway in differentiating between VHR patients 
By exploring the TNFα pathway in VHR patients, we demonstrated that TNFα plasma 
levels remain high in VHR patients with previous MI or previous percutaneous coronary 
intervention (PCI) despite medical and clinical management. Persistent elevated TNFα 
plasma levels post-MI have been linked to an increased MACE risk (181). Previous 
reports have demonstrated the role of TNFα in pre-conditioning the heart against an 
inflammatory environment (398) following a myocardial infarction. This needs further 
exploriation in CVD individuals.   
TACE gene expression was lower in VHR patients with a previous PCI who were also 
on statin, antiplatelet and antihypertensive therapy. TACE is known to regulate 
angiogenesis in cardiomyocytes following MI and, when upregulated within the normal 




downregulation in patients with previous PCI could be associated with adverse 
outcomes. The effect of medical and clinical management on TACE gene expression 
needs further understanding. 
Furthermore, it appears that after a PCI, despite a decrease in TACE gene expression, 
TNFα plasma levels are increased. This could be due to different activators that, when 
present, are known to enhance and modulate TNFα shedding (187) and to different 
sheddase, such as ADAM10 (188), MMP7 (189) or MMP13 (190) that have been 
suggested to be involved in TNFα shedding. Furthermore, circulating TNFα might be 
captured by circulating TNFR1 and TNFR2 soluble receptors as suggested by Van Zee et 
al. and therefore, TNFα might not be biologically active (191).  
 In this current study, TNFR1 plasma levels were higher in participants admitted 
for acute events with higher levels in ACS patients admitted for their primary or 
secondary cardiac event (MACE) which suggests that TNFR1 could be a potential marker 
for acute cardiovascular events. TNFR1 and TNFR2 plasma levels were higher in VHR 
patients with diabetes, heart failure and renal disease indicating that levels tend to be 
even higher when certain comorbidities are present along with CVD as reported 
previously (206,207,224). TNFR1 plasma levels were also increased in VHR patients with 
depression as previously shown (399).  
Plasma levels of TIMP3, which is known to regulate hypertension (231), were higher 
in VHR patients on antihypertensive therapy compared to VHR patients not on 
antihypertensive therapy. TIMP3 was also downregulated in ACS-VHR patients 
compared to elective percutaneous intervention (ELEC-VHR) patients showing that close 
to an ACS, TIMP3 gene expression is particularly decreased. Down-regulation of TIMP3 




placental trophoblast cells (232) providing evidence that a decrease in TIMP3 gene 
expression could be accompanied by an over expression of TACE and an aggravation of 
local and systemic inflammation and the occurrence of acute cardiovascular events. In 
addition, TIMP3 expression has been previously shown to be particulary low in stable 
plaque and high in vulnerable plaques (400) providing further evidence of the 
importantce of TIMP3 in CVD.  
Furthermore, the ability of TNFα, TACE, TNFR1 and TNFR2 in further stratifying VHR 
individuals proved to be superior to CRP. Our results showed that CRP plasma levels 
were not significantly different between ACS-VHR and ELEC-VHR participants admitted 
for a first or recurrent event. Furthermore, CRP plasma levels were not able to identify 
VHR participants with previous MI or PCI or VHR participants with comorbidities such as 
diabetes, heart failure and renal failure. 
 
Figure 2: Levels of proteins from the TNFα inflammatory pathway can differentiate 
between sub-groups of very high risk (VHR) of CVD. In participants at very high risk (VHR) 
of CVD, TNFα plasma levels, TACE gene and protein expression as well as TNFR1 and TNFR2 




as TIMP3 to TACE cell membrane bound ratios were lower in VHR vs. non-VHR participants. 
TNFα plasma levels were higher in VHR individuals admitted for a secondary event, in VHR 
diabetic participants, VHR participants with heart and renal failure, in VHR participants with 
previous MI and a previous PCI and in VHR participants on drug therapy. TNFR1 plasma 
levels were higher in VHR individuals admitted for a primary or a secondary event, in follow-
up participants who developed MACE, in VHR diabetic participants, VHR participants with 
heart and renal failure, in VHR participants with previous MI and in VHR participants on 
drug therapy. TNFR2 plasma levels were higher in VHR diabetic participants, VHR 
participants with heart and renal failure and in VHR participants on drug therapy. TIMP3 
gene expression was lower in ACS-VHR vs. ELEC-VHR participants. TACE gene expression 
was lower in VHR participants with a previous PCI. ACS: Acute coronary syndrome; GFR: 
glomerular filtration rate; MACE: Major adverse cardiovascular events; MI: Myocardial 
infarction; PCI: Percutaneous coronary intervention; TACE: Tumour necrosis factor alpha 
converting enzyme; TIMP3: matrix metalloprotease inhibitor 3; tmTNFα: Transmembrane 
tumour necrosis factor alpha; sTNFα: soluble tumour necrosis factor alpha; TNFR1: tumour 
necrosis factor alpha receptor 1; TNFR2: tumour necrosis factor alpha receptor 2 
9.2.3.2 A proteomic approach in stratifying VHR patients  
The proteomic approach followed in this study identified a set of proteins that 
differentiated between VHR participants in terms of their cardiovascular history and 
associated comorbidities. Several markers were specific to the onset of ACS in 
participants with previous or no previous CVD history, while others were related to 
clinical and medical management. Moreover, some markers were specific to VHR 
participants with diabetes or heart failure highlighting the need to further understand 
the underlying interactions and pathways behind CVD and its associated comorbidities 
which could lead to the discovery of potentially new therapeutic targets. The proteins 
that were able to substratify the VHR cohort are summarised in figure 3. 
9.2.3.2.1 Markers for acute cardiovascular events 
Among the proteins that were able to differentiate between ACS-VHR and ELEC-VHR 
participants, there was little evidence for the role of Macrophage receptor (MARCO), C-




Adhesion Associated, Oncogene Regulated (BOC) in CVD and their role in identifying 
patients with acute cardiovascular events should be explored further. 
 The analysis of ACS-VHR and ELEC-VHR with no previous CVD history provided 
further evidence of the role of the importance of A disintegrin and metalloproteinase 
with thrombospondin motifs 13 (ADAMTS-13) (312), Osteopontin (OPN) (322) and 
Protein AMBP (323) as botential CVD biomarkes. However, the role of programmed 
death ligand 2 (PDL2), BOC and Tartrate resistance acid phosphatase 5 (TRAP) in CVD 
hasn’t been previously outlined. Such proteins should be tested further as biomarkers 
for primary cardiovascular events. 
When considering proteins associated with MACE as opposed to a first 
cardiovascular event, novel and known associations were highlighted. Among these 
assocaitons, IL-12 levels have been previously shown to be related to adverse outcomes 
in patients with STEMI (272) while EGFR activation has been implicated in blood pressure 
regulation, endothelial dysfunction, atherogenesis, and cardiac remodelling (325). 
Nevertheless, Tumour necrosis factor ligand superfamily member 13B (TNFSF13B), 
receptor superfamily member 11A (TNFRSF11A) and BOC haven’t been measured in CVD 
patients yet. Such markers hold a potential role in determining individuals at higher risk 
of secondary events. 
  It appears that BOC is a marker for ACS events and hasn’t been investigated 
previously in CVD. BOC has been reported do be involved in the differentiation of 
myogenic cells (401). However, the present results are in favour of its role as a potential 




9.2.3.2.2 Markers associated with clinical management and comorbidities in 
CVD 
Among the protein levels which differentiated between VHR participants with previous 
MI, PCI or coronary artery bypass grafting (CABG) compared to those with no previous 
MI, PCI or CABG, Prostasin (PRSS8) has been suggested as a potential gene for 
hypertension (326) whereas Interleukin 16 (IL16) has been shown to promote cardiac 
fibrosis and myocardial stiffening in heart failure patients (327). Moreover, LDL receptor 
(LDLR) plasma levels have ben previously shown increase following a statin therapy 
(402). However, there is no evidence of the role of V-set and immunoglobulin domain 
containing protein 2 (VSIG2) in CVD which should be further explored to evaluate the 
mechanisms in place after the initiation of a clinical or a medical treatment in CVD. 
 In relation to VHR individuals who also had diabetes, the proteins that were 
mostly highlighted were Kidney injury molecule 1 (previously TIM and now as KIM1) 
which has been linked to renal disease in diabetic patients (330) and cardiovascular risk 
(331), Galectin 3 (Gal-3) (334,336) and Renin (REN) (307,338) which have also been 
studied in diabetic patients at high risk of CVD. However, the role of VSIG2 and Gastric 
intrinsic factor (GIF) in CVD and diabetes is less clear. These proteins could reflect the 
underlying pathways behind the interaction between CVD and diabetes and could prove 
to be potential therapeutic targets if studied in larger cohorts. 
 When considering the proteins characterised VHR individuals with heart failure, 
Fibroblast growth factor 21 (FGF-21) has been reported to be associated with 
cardiovascular risk (342) and heart failure (343) whereas Adrenomedullin (ADM), which 
is known to regulate vasodilatation and NO production, has been suggested to play a 




factor receptor superfamily member 11A (TNFRS11A) and Chymotrypsin C (CTRC) in CVD 
and heart failure is less clear. Such proteins could hold a promising value in assessing 
CVD patients at high risk of heart failure and could prove to be potential therapeutic 
targets if measured in larger cohorts. 
 
 
Figure 3: Summary diagram of a proteomic analysis: Potential proteins to further stratify 
the VHR cohort. Proteins in bold are able to differentiate between more than two VHR risk 
groups. Proteins in italic are lower in the first group compared to the second. ACS: acute 
coronary syndrome; CABG: coronary artery bypass grafting; MACE: major adverse 
cardiovascular events; MI: myocardial infarction; PCI: percutaneous coronary intervention; 
VHR: very high risk. 
 
9.2.3.3 Biomarkers predicting MACE risk 
Biomarkers associated with cardiovascular risk, and the development of a first 
cardiovascular event, in patients with no previous cardiac history have been intensively 
studied. Nevertheless, biomarkers associated with the development of secondary 




effective test that can accurately predict which patient will develop MACE. Taking 
forward the previously measured inflammatory markers, we aimed to assess their 
association with MACE risk. A summary of this section is provided in figure 4.  
Among the highlighted proteins that were associated with MACE risk, TNFR1 was 
associated with MACE risk within one year of admission showing a trend where levels 
were particularly higher after 6 months of admission whereas IL-6 plasma levels were 
associated with MACE risk within one year and specifically within 6 months after 
admission. These results are in line with previous reports that highlighted an association 
between TNFR1 levels and death as well as heart failure onset in patients post-MI (222) 
and between IL-6 levels and future MACE (266,267,271). Among the other markers that 
demonstrated to be associated with MACE risk, IL-1RL1/ST2 has been previously 
reported to be a marker for ACS and acute heart failure (357) and is also reported to be 
marker for cardiac stress and was strongly associated with the development of heart 
failure post-ACS in the MELRIN-TIMI 36 trial (358). IL-1RT1 has been suggested as a novel 
inflammatory marker for CVD (361) which was  also involved in heart remodelling post-
MI (333). ADM has been shown to be a powerful independent predictor of future 
cardiovascular events in high-risk patients with a predictive value superior to that of high 
sensitivity C reactive protein or adiponectin (362). THBS2 has been linked to the 
development of heart failure in patients with CAD (366) whereas CCL16 has been 
recently associated with CAD risk in postmenopausal women (368), however, their value 
in MACE prediction hasn’t been assessed yet. RARRES2 is a recently discovered 
adipokine that has been linked to inflammation and increased oxidative stress in obese, 
CVD and ACS patients (369–371). GDF-15 has been recently suggested as a biomarker 




development, progression, and prognosis (374). Pl3 is an endogenous inhibitor of 
neutrophil-derived elastases which presented an anti-inflammatory activity in pre-
clinical models of inflammatory vascular injury (376). On the other hand, our results are 
in line with previous reports regarding ADAMTS13 which low levels were shown to 
contribute to haematological and cardiovascular disorders (312) and severe deficiency 
in ADAMTS13 results in a clotting disorder known as thrombotic thrombocytopenic 
purpura (381). However, there is little evidence of the role of interleukin 1 receptor 2 
(IL1RT2), PDL2, alpha-L-iduronidase (IDUA) and C-C motif chemokine 22 (CCL22) in CAD 
and MACE prediction. Further work is needed in order to evaluate the clinical value of 
such proteins in MACE risk assessment. 
A logistic regression model combining all the previously mentioned proteins was able 
to significantly predict follow-up MACE in 94.2% of the cases (p<0.0001). This useful 
model highlights the importance of a multimarker approach not only in CVD primary 
prevention but also in secondary prevention since a model combining several clinically 
relevant markers has a better prediction value compared to a single marker model. 
Therefore, the several limitations that characterise the current CVD biomarkers can be 
overcome by the use of a multimarker approach (384). 
 
Figure 4: Previously established and novel associations between inflammatory proteins 





In addition, the definition of MACE in this study was restricted to recurrent ACS, stroke 
TIA and death. However, several studies include HF and atrial fibrillation (AF) (203,204) 
in the definition for MACE as well. By including HF and AF in the MACE definition, the 
total number of patients who develop MACE within a year of admission increases to 




9.2.3.4 Cluster analysis: a tool to further stratify VHR patients 
Cluster analysis is proving to be an effective technique in patient stratification and 
especially in further stratifying very high risk patients (403). Recently, using a cluster 
analysis, it was possible to determine biomarker signatures of aging (404) as well as 
define novel classes of diabtetes (405). Using the proteins that were able to differentiate 
between VHR individuals who were admitted for a primary or a secondary 
cardiovascular event, and those who developed MACE over time, we aimed to further 
stratify VHR individuals using cluster analysis. The VHR cohort formed two clusters with 
cluster 2 grouping participants with higher levels of most of the inflammatory markers 
compared to cluster 1. When analysed in relation to other characteristics, cluster 2 
grouped older participants, participants who were likely to be admitted for an ACS and 
to be admitted for MACE. Cluster 2 also grouped participants who were more likely to 
be diabetic, to have had a previous MI or PCI, and to be on medication. The proteins that 
contributed majorly to the cluster classification were: Phospholipase C (PLC), Trefoil 
factor 3 (TFF3), Tumour necrosis factor alpha receptor 1 (TNFR1) and 2 (TNFR2), 
Growth/differentiation factor 15 (GDF15), Adrenomedullin (ADM), TNF Receptor 
Superfamily Member 14 (TNFRSF14), Urokinase receptor (UPAR) and Lymphotoxin Beta 
Receptor (LTBR) which were all higher in cluster 2. The expression and activity of PLC 
were previously reported to be elevated in cardiomyocytes under pathological 
conditions such as ischemia and hypertrophy (406) whereas ADM was proposed to be a 
biomarker of prognosis and survival in patients with coronary artery disease or heart 
failure (344). TNFRSF14 is a player in atherogenesis by inducing proinflammatory 
cytokines and matrix metalloproteinases (348). UPAR has been intensively studied in 




with (CKD) (349), in addition, LTBR appears to play a role in macrophage-driven 
inflammation in atherosclerotic lesions (350). However, the role of TFF3 in CVD is 
limited. These results show that the previously mentioned proteins can further stratify 
VHR patients and could be part of a panel that would indicate which VHR patients are at 
higher risk of cardiovascular events. 
9.2.4 Obstacles in translating biomarker research into clinical 
practice 
In the past decade, CVD management has improved with the implementation of risk 
scores charts that guide primary and secondary prevention. However, these risk scores 
have many limitations and leave ample room for improvement but could potentially be 
improved by the addition of biomarkers. However, the translation of biomarker research 
into clinical practice is proving to be very difficult with only two biomarkers currently 
used in CVD clinical practice (troponins and natriuretic peptides). Some of the major 
obstacles to this transition are listed below and some were encountered throughout this 
study. 
9.2.4.1 Restricted number of recruited patients 
As the current analytical methods for biomarker measurement (such as immunological, 
gene expression, flow cytometry and cell culture assays) require a considerable amount 
of time when it comes to sample processing and analysis, this limits the ability to obtain 
a quick result and therefore restricted the number of recruited patients in this present 
study. The solution to this problem lies in the development and validation of biomarker 
panel assays in the research laboratory prior to the assessment of their value in clinical 




results, provide a high level of accuracy, specificity and sensitivity and be able to produce 
quickly interpretable results.  
Another possible solution to increase the number of recruited patients in a study is by 
integrating research within the healthcare system. This would mean that every patient 
who attends the cardiology clinic is automatically asked to consent and volunteer to give 
a blood sample. This will make patient recruitment much more efficient and will 
strengthen and validate the prediction models associating biomarkers with 
cardiovascular outcomes. 
9.2.4.2 Assessing the value of potential biomarkers by patient 
follow-up 
The ideal way to validate the utility of novel biomarkers is by measuring them in the 
same patient over time and linking this biological measurement to any phenotypical and 
clinical data, which might also change over time, in the same patient. In this present 
study, all patients were contacted for to provide a follow-up blood sample, however, 
the number of patients who attended their appointment was very low. A 
multidisciplinary team involving researchers, clinicians and nurses is needed in order to 
facilitate the patient follow up process and the collection of follow-up data. However, 
this could be resolved by integrating research into the clinical practice where every 
patient attending a routine appointment actively participates in research progress by 
providing clinical and biological information throughout the different stages of his/her 
disease. This will provide valuable information and will allow biomarker research to 
progress at a higher speed. On the other hand, in the new era of personalised medicine, 
it is sometimes easy to forget the crucial role that patients play in moving the research 




done by encouraging their interaction via smartphone applications or by organising 
public involvement events. It is essential for patients to understand their contribution 
to CVD research and the global impact that is resulting from their willing to donate a 
simple blood sample. 
Other factors related to the development of the biomarker assay need to be investigated 
during the validation step. For instance, the stability of the biomarker needs to be 
assessed in addition to its specificity, sensitivity, negative and positive predictive values 
among other measurments. In addition, introducing a new biomarker panel into clinical 
practice needs to be cost-effective.  
9.2.4.3 Translation of biomarker research into clinical practice 
Translating biomarker research into clinical practice has proven to be very challenging 
over the years. One possible reason is that most of the clinical studies focused on one 
biomarker alone whereas the novel trend is by developing multiple markers. In addition, 
the value of these markers needs to be assessed longitudinally. Essentially, it is 
important to assess the improvement of risk prediction when the novel biomarker or 
multimarkers are added to the already existing risk scores. This should be evaluated by 
measurements such as c-statistics, the net reclassification improvement (NRI) and 
integrated discrimination improvement (IDI) indexes (99). In addition, novel prediction 
models and algorithms need to be developed in such a way to include known and novel 
markers in addition to phenotypical and clinical data. This will generate a much more 




9.2.4.4 Predicting risk to ultimatlty protect and prevent CVD 
Predicting risk is of no value unless the patient can be protected. Much work is still 
needed in this area because the changes in biomarker levels reflecting an abnormal 
disease state do not as of yet direct changes in therapy or management. Nevertheless, 
using a novel multimarker approach to improve CVD risk prediction prompts the clinician 
and the patient to work together in order to decrease a high CVD risk when present or 
seek to maintain a low risk.  
In addition, in order to assess the practicalities of introducing a new CVD risk prediction 
tool in primary prevention, a close collaboration needs to be organised with the general 
practitioners (GPs) as their role is crucial in indetifying patients that require further 
asssement and follow-up. 
9.2.5 Conclusions and Future Work: The promise of personalised 
medicine is possible with multimarker models 
Personalised medicine uses clinical measurements and parameters to implement a 
therapeutic strategy that is tailored to each individual. The concept of personalised 
medicine is becoming more of a reality with major advances in genetic research such as 
the international Hap-Map project and the Genome-Wide Association Studies (GWASs) 
as well as proteomic research that are revolutionising the field of diagnostics and 
therapies. Nevertheless, despite major technological advances and the ability to 
generate and interpret genomic and proteomic derived data, the impact of this progress 
on clinical practice is happening at a slow rate.  
Alongside the advances in personalised medicine, the interest in biomarker discovery 




highlighted in this study in CVD. However, each study focused on one single marker 
alone linking it to a specific biological pathway, a specific clinical outcome or a specific 
CVD co-morbidity. A substantial amount of research linking proteins and 
polymorphisms to CVD already exists. The following step lies in developing multimarker 
panels that capture specific inflammatory pathways in CVD and optimised to identify 
acute events, recurrent events, risk of heart failure, risk of renal disease, or risk of 
diabetes. New bioinformatic tools and algorithms (407) combining such panels in a risk 
assessment model will facilitate their use in clinical practice. These markers could be 
added to the current cardiovascular risk prediction models and the present CVD 
biomarkers in order to overcome their limitations and provide a more accurate 
prediction of first or recurrent cardiovascular events. 
 It is important to remember that the multidisciplinary nature of personalised 
medicine will require harmonisation across different areas including changes in 
healthcare infrastructure, improvement of diagnostic tests and point of care testing and 
managing ethical and legal issues in relation to data security. Therefore, in order to 
initiate the bench to bedside transition, healthcare professionals, research committees, 
industrial representatives and legal authorities are required to collaborate and merge 
their efforts towards accomplishing one main goal which is improving patient’s 






Figure 5: Improving Cardiovascular Risk Assessment by Incorporating Biomarkers to the 
Traditional Risk Scores. Risk assessment score charts in cardiovascular disease (CVD) are based on 
the traditional risk factors and are used either for primary or secondary prevention. Those risk 
charts are known to have a lot of limitations. CVD risk assessment can be improved by the 
incorporation of biomarkers and can be used in primary or secondary prevention. The development 
and validation of biomarker panels is only possible with a close collaboration between academics, 
researchers and industries. ACS: Acute coronary syndrome; FRISC: fast revascularisation in 
instability in coronary disease; GRACE: Global Registry of Acute Coronary Events; PCI: Percutaneous 
coronary intervention; PROCAM = Prospective Cardiovascular Munster Study; PURSUIT: Platelet 
glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin; QRISK: based on the 
NICE guidelines on lipid modification; SCORE: Systematic COronary Risk Evaluation; TIMI: 
































I. Additional Findings  
I.I Seasonal changes and biomarker levels 
Background: The role of seasonal changes on inflammatory biomarker levels has been 
receiving a lot of interest recently (408) as the incidence of some diseases increases or 
decreases with seasonal changes. It has been found that during the cold seasons, the 
immune system is in a pro-inflammatory state (409,410). Therefore, the incidence of 
seasonal affective disorder (411), arthritis (412), blood pressure (413), cardiovascular 
disease (CVD) and respiratory morbidity and mortality (414) have been shown to occur 
more frequently in the cold compared to the warm seasons. The aim of this present 
study was to compare plasma protein levels of inflammatory and immune markers 
involved in the initiation and complications of CVD across different seasons.  
Results: Recruited participants were all at very high risk (VHR; n=229) and have > 10% 
risk of cardiovascular death within 10 year. Tumour necrosis factor alpha (TNFα) plasma 
levels were the highest in winter (p<0.05) compared to the other seasons. Tumour 
necrosis factor alpha receptor 1 (TNFR1), interleukin 2 and interleukin 8 plasma levels 
were also the highest during the winter season (p<0.01; p<0.01 and p<0.05). 
Discussion: Many factors such as temperature, physical activity, infections and food 
habits are known to increase the incidence of mortality and morbidity due to CVD during 
the winter season (415). Air pollution is also known to be higher during the cold seasons 
(416). In this present study, higher levels of TNFα, TNFR1, IL-2 and IL-8 during the cold 
seasons could be one of many other markers known to be associated with an increase 
in the incidence of CVD and cardiovascular events in the cold seasons (414). In addition, 




known to rise in winter (417) which could precipitate cardiovascular complications 
during the cold seasons.  
Conclusion: Offering an intensive medical therapy combined with a change in lifestyle 
habits and the implementation of public health measures during cold seasons might help 
decrease the incidence of CVD events and complications. 
I.II Endothelial dysfunction and cardiovascular disease 
Background: The endothelium exerts a number of vaso-protective effects, such as 
vasodilation, suppression of smooth muscle cell growth, and inhibits inflammatory 
responses (418). Endothelial dysfunction is involved in atherosclerotic lesion formation 
and is characterised by an up-regulation of adhesion molecules and chemokines leading 
to leukocyte recruitment, an increase in cell permeability leading to low-density 
lipoprotein retention and oxidation, an induced vascular smooth muscle cell 
proliferation and migration (419). Thus, the endothelium is implicated in early lesion 
formation as well as the maintenance of a constant inflammatory environment around 
the lesion leading to complications and plaque rupture (420). Endothelial progenitor 
cells (EPC) are widely believed to be strong biomarkers of vascular risk. Endothelial 
colony forming cells (ECFCs), a subtype of EPCs, represent an endothelial cell type with 
angiogenic capacity, de novo blood vessel formation and vascular repair properties of 
the injured endothelium (421). ECFCs are normally known to be CD31+, CD105+, 
CD146+, CD45- and CD14- and can be obtained after culturing the peripheral 
mononuclear blood cells (PBMCs) in endothelium growth media (422). 
Methods: In this present study, ECFCs were isolated from participants at very high risk 
(VHR) of CVD and participants at low risk (LR) of CVD. VHR participants had > 10% risk of 




cardiovascular death within 10 years according to the SCORE risk chart (ESC guidelines). 
Different blood collection methods were tested to evaluate ECFCs formation in vitro. BD 
cell preparation tubes (CPT® - BD 362753) contained a liquid density medium and a gel 
barrier and required a centrifugation and two washing steps in order to collect the 
PBMCs. Histopaque®-1077 Ficoll extraction technique was also used as another method 
to obtain PBMCs where, in this case, the liquid density medium was added to the 
withdrawn blood, centrifuged and then PBMCs were washed twice before culture. An 
AutoMACS separation step was carried out in order to deplete the PBMCs (collected 
using the CPT® tubes) from CD45+ cells using CD45 antibodies coupled to magnetic 
beads. The collected PBMCs were then cultured as per the colony forming assay (CFA) 
protocol described in Martin-Ramirez et al (160).  
Results and Discussion: A total of 14 VHR and 3 LR participants were recruited. 4 
participants had their PBMCs isolated using the CPT® tubes, 5 using Histopaque®-1077 
Ficoll extraction and 5 had their isolated PBMCs undergo a depletion of cells expressing 
the CD45 surface marker. After performing the colony forming assay for 3 weeks, the 
number of colonies were counted and are expressed in percentages (PBMCs were 
cultured in 96-well plates and each well with a formed colony was regarded as a positive 
well) (Table 1). After CD45 depletion ECFCs appeared much earlier at day 15 whereas 
the rest of the colonies appeared after day 20. Furthermore, the number of colonies 
that were obtained after CD45 depletion appeared to be higher than the ones obtained 
using the CPT® or using Histopaque®-1077 Ficoll extraction (Table 1). This could be due 
to the fact that CD45+ cells are more likely to secrete pro-inflammatory mediators that 
will delay the appearance of the ECFC colonies (423). In addition, the number of ECFC 




obtained in LR participants. This would suggest that the endothelium of the VHR is more 
prone to inflammation and requires repair. These results need to be further explored in 
a larger number of VHR participants in order to assess whether the number of ECFC 
colonies are related to cardiovascular events. 
 
 
Figure 2: ECFC isolated from patient VHR-030 after CD45 depletion by autoMACS (50 x 
magnification) 
 






AutoMACS depletion of 
CD45+ fraction 
VHR (% of colonies) (n=4) 3.12% (n=5) 1.24% (n=5) 4.58% 
LR (% of colonies)   (n=3) 0.346%   
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  CD4 2.92 2.63 0.29 0.29 .001 
TNFRSF
13B 
7.63 7.44 0.19 0.19 .033 PRTN
3 
5.04 4.84 0.21 0.21 .010 
    
  TNFR
SF10A 
2.39 2.10 0.29 0.29 .000 





2.85 2.65 0.20 0.20 .005 
    
  CD16
3 
6.16 5.88 0.28 0.28 .015 
IL_4RA 1.87 1.69 0.18 0.18 .007 IGFBP
_1 
2.97 3.17 -0.20 0.20 .037 
    
  CTSD 4.72 4.44 0.28 0.28 .005 
SPON1 0.64 0.46 0.17 0.17 .011 MARC
O 
5.05 4.89 0.16 0.16 .010 
    
  SRC 7.02 7.30 -
0.28 
0.28 .036 
SCF 8.61 8.77 -
0.16 
0.16 .015 PRELP 6.33 6.18 0.15 0.15 .024 
    







0.13 0.13 .030 LEP 5.18 5.32 -0.14 0.14 .049 
    
  MCP_
1 
2.63 2.37 0.27 0.27 .016 
CXCL16 4.54 4.41 0.13 0.13 .052 IL_17
RA 
2.32 2.19 0.13 0.13 .027 
    
  Gal_9 7.80 7.54 0.26 0.26 .041 
IL1RL2 3.15 3.03 0.12 0.12 .039 Notch
_3 
2.45 2.34 0.12 0.12 .001 
    




AXL 6.53 6.62 -
0.09 
0.09 .061 CD84 5.00 4.93 0.07 0.07 .068 
    
  LPL 9.41 9.64 -
0.23 
0.23 .007 
PCSK9 0.92 0.82 0.09 0.09 .009 MEPE 2.06 2.12 -0.07 0.07 .001 
    
  JAM_
A 
4.86 4.63 0.23 0.23 .022 
MMP_2 3.57 3.63 -
0.06 
0.06 .040 AXL 6.53 6.48 0.06 0.06 .051 







0.22 0.22 .000 
PRELP 6.33 6.35 -
0.02 
0.02 .010 TIE2 7.05 7.00 0.04 0.04 .048 
    
  IDUA 6.06 5.84 0.21 0.21 .008 
      MMP
_2 
3.57 3.61 -0.04 0.04 .000 
    
  IL_4R
A 
1.87 1.66 0.21 0.21 .002 
      ADA
M_TS
13 
5.33 5.31 0.02 0.02 .039 






     
  SCF 8.61 8.61 0.00 0.00 .046 
    
  SPON
1 
0.64 0.43 0.21 0.21 .012 
     
        
    
  EGFR 2.16 2.36 -
0.21 
0.21 .012 
     
        
    
  PRTN
3 
5.04 4.83 0.21 0.21 .001 
     
  
     
  
    
  ICAM
_2 
4.03 3.85 0.18 0.18 .051 
     
  
     
  








   
  
     
  







0.17 0.17 .012 
 
  
   
  
     
  
    
  Gal_3 5.00 4.83 0.17 0.17 .007  
  
   
  
     
  
    





   
  
     
  
    
  IL1RL
2 
3.15 3.00 0.15 0.15 .011 
 
  
   
  
     
  
    
  MPO 3.22 3.08 0.14 0.14 .057  
  
   
  
     
  
    
  PD_L2 2.57 2.45 0.12 0.12 .043  
  
   
  
     
  
    






   
  
     
  
    
  CD84 5.00 4.91 0.09 0.09 .028      
  
     
  
    
  SCF 8.61 8.69 -
0.08 
0.08 .009 
     
  
     
  
    
  Notch
_3 
2.45 2.37 0.08 0.08 .012 
     
  
     
  




2.85 2.77 0.08 0.08 .008 
     
  
     
  
    
  LEP 5.18 5.25 -
0.07 
0.07 .055 
     
  
     
  
    
  PRELP 6.33 6.27 0.07 0.07 .001      
  
     
  










     
  
     
  






     
  
     
  
    
  AXL 6.53 6.55 -
0.02 
0.02 .030 
Proteins were ranked according to the difference between the NPX means of the compared cohorts. LR: low risk; MR: moderate risk; non-VHR: non-very high 






















Gene Ontology Biological 
processes 2017 
Reactome pathway 2016 Jensen DISEASES 
 





1.Positive regulation of cell 
proliferation  
2.Neutrophil degranulation  
3.Regulation of stem cell 
proliferation  
4.Regulation of osteoblast 
proliferation 
5.Regulation of cell 
proliferation involved in 
compound eye morphogenesis 
6.Regulation of leukocyte 
proliferation 
7.Regulation of cell 
proliferation in bone marrow 
8.Regulation of cell 
proliferation involved in 
imaginal disc derived wing 
morphogenesis 
9.Regulation of synoviocyte 
proliferation 




1. Cytokine signalling in 
immune system 
2. Signalling by interleukins 
3.GRB2: SOS provides linkage to 
MAPK signaling for integrins 
4.p130Cas linkage to MAPK 
signalling for integrins 
5.GP1b.IX-V activation signalling 
6. Integrin alphaIIb beta3 
signalling 
7.MAP2K and MAPK activation 




10. L1CAM interactions 








7. Factor XI 
deficiency 
8. Hyperglycaemia 










1. Regulation of store-operated 
calcium entry 
2. Neutrophil degranulation 
3. Acute inflammatory response 
4. Inflammatory response 
5. Inflammatory response to 
wounding 
6. Chronic inflammatory 
response 
7. Cellular response to 
lipopolysaccharide 
8. Membrane fusion involved in 
viral entry into host cell 
9. Viral entry into host cell via 
pilus retraction 
10. Viral entry into host cell 
1. TP53 regulates transcription 
of death receptors and ligands 
2. CS.DS degradation 
3. Peptide hormone 
metabolism 
4. Metabolism of 
angiotensinogen to 
angiotensins 






8. TP53 regulates transcription 
of cell death genes 
9. Heparan sulfate/heparin (HS-
GAG) metabolism 
10. Transcriptional regulation of 
white adipocyte differentiation 
















 1. Cellular protein catabolic 
process 
2. Osteoclast differentiation 
3. Multinuclear osteoclast 
differentiation 
4. Osteoclast development 
5. Positive regulation of fever 
generation by positive 
regulation of prostaglandin 
secretion 
6. response to granulocyte 
macrophage colony stimulating 
factor 
7. Response to interleukin-21 
1. TNF receptor superfamily 
(TNFSF) members mediating 
non-canonical NF-kB pathway  
2. Regulation of insulin like 
growth factor (IGF) transport 
and uptake by insulin like 
growth factor binding protein 
3. Metabolism of 
angiotensinogen to 
angiotensins 
4. Collagen degradation  




3. Tricuspid valve 
insuffiency 














8. Response to erythropoietin 
9. Response to interleukin- 13 
10. Response to interleukin 17 
6. Peptide hormone 
metabolism 
7. Degradation of the 
extracellular matrix 
8. MHC class II antigen 
presentation 
9. Metabolism of proteins 








1. Neutrophil degranulation 
2. Positive regulation of protein 
kinase B signalling 
3. Negative regulation of 
apoptotic process 
4. Acute inflammatory response 
5. Inflammatory response to 
wounding 
6. Chronic inflammatory 
response  
7. Inflammatory response 
8. Osteoclast development 
9. Negative regulation of 
neuron apoptotic process 





 1. Metabolism of 
angiotensinogen to 
angiotensins 
2. peptide hormone 
metabolism 
3. Cell surface interactions at 
the vascular wall 
4. Signalling by interleukins 
5. GRB2: SOS provides linkage 
to MAPK signalling for 
intergrins 
6. p130Cas linkage to MAPK 
signalling for integrins 
7. GP1b-IX-V activation 
signalling 
8. Hemostatis signalling in 
immune system 
9. Cytokine signalling in 
immune system 
10. Transcriptional regulation of 
white adipocyte differentiation 













This table represents the Gene Ontology Biological processes 2017, the Reactome pathway 2016 and the Jensesn diseases pathways that are relative to 
each set of proteins that were able to differentiate between each compared risk groups. The biological pathways are ranked according to their p value and 




the coloured nodes represent a first shell of interaction whereas white nodes represent a second shell of interaction. Empty nodes are proteins of unknown 
3D structure whereas filled nodes are known or predicted 3D structures. Blue lines represent a known interaction from curated databases whereas a purple 
line represents an experimentally determined known interaction. Green lines represent predicted interactions based on gene neighbourhood, red lines 
represent predicted interactions based on gene fusions and blue lines represent predicted interactions based o gene co-occurrence. Light green lines 
represent textmining, black lines represent co-expression and light blue lines represent protein homology. Szklarczyk et al. Nucleic Acids Res. 2015 

















 Table 3: An example of the inter-correlation (Pearson correlation) analysis within measured proteins 
  
Highlighted cells show a significant correlation
TR_AP MMP_7 PTX3 HOSCAR TRAIL_R2 CEACAM8 U_PAR MMP_12 REN
TNFRSF10












































































































































































































































































































































































































































































































































































































































































































































* -.090 -.058 1 .172
** -.105 -.244
** .084































































































Table 4: Significant proteins specific to the category of VHR participants within each group. 





















































































































































































































































 EGFR SLAMF7 
.007 













 PAR_1 TGM2 
.016 













 CHIT1 AP_N 
.017 












 CD163 GRN 
.018 















 SPON2 XCL1 
.020 












 FAS IL_17RA 
.026 












 TLT_2 VEGF_D 
.030 












   PSGL_1 
.038 












   CPB1 
.040 












   STK4 
.043 












   IDUA 
.048 












   CPA1 
.055 












   HO_1 
.067 












   IL1RL2 
.068 












   TFPI 
.068 
























































PRSS8 .049            FABP4 
.002 BMP_6 .003 SHPS_1 .039 
CTSL1 .001 
RAGE 0.007 
TM .055            TNFRSF10C 
.003 CCL16 .004 KLK6 .045 
PRELP .001 
TM 0.010 
CD163 .055            ICAM_2 
.004 PSP_D .004 PI3 .046 
ST2 .001 
MPO 0.011 
MMP_12 .056            PI3 






TF .058            ST2 
.011 t_PA .005 VSIG2 .051 
t_PA .001 
Notch_3 0.012 
SPON2 .059            IL_6 
.013 SRC .007 PIgR .053 
AGRP .001 
IL16 0.013 
CDH5 .063            t_PA 
.019 FABP2 .009 PLC .053 
DCN .002 
AMBP 0.015 
FAS .064            PRTN3 
.033 G_T .009 U_PAR .055 
GDF_15 .002 
PCSK9 0.015 
LTBR .064            AGRP 
.035 MMP_3 .009 IL1RL2 .061 
TR_AP .002 
MARCO 0.016 
PlGF .065            FGF_21 
.044 PGLYRP1 .010 PAR_1 .069 
TIE2 .003 
TF 0.017 
PD_L2 .066            HSP_27 
.047 PRSS8 .010 CXCL16 .005 
BMP_6 .003 
TNF_R1 0.018 
TLT_2 .069            CCL24 
.050 IL_1ra .011 TR .014 
RARRES2 .003 
CTSD 0.018     
           RARRES2 
.051 TIE2 .013 ADAM_TS13 .016 
CCL17 .004 
PRTN3 0.020     
           MEPE 
.055 CTSZ .013 IL_1RT2 .025 
AZU1 .005 
MMP_12 0.020     
           PSP_D 
.056 U_PAR .014 CCL22 .034 
RETN .006 
GDF_15 0.024     
           GIF 
.062 MPO .017 AGRP .043 
CTSZ .008 
FABP2 0.024     
             
 
RARRES2 .018 CD93 .060 
CD93 .010 
SERPINA12 0.025     





CTRC 0.025     
              PlGF 
.019 
   
CXCL16 .012 
CHI3L1 0.028     
              TFF3 
.020 
   
GRN .013 
HBEGF 0.029     
              TIMP4 
.021 
   
PRTN3 .017 
APN 0.029     
              TNFRSF14 
.026 
   
EPHB4 .017 
PGLYRP1 0.029     
              IL_4RA 
.029 
   
CTSD .018 
SLAMF7 0.029     
              PI3 
.030 
   
TFF3 .018 
RETN 0.033     
              PON3 
.031 
   
GLO1 .021 
CNTN1 0.035     
              SPON1 
.031 
   
uPA .021 
AP_N 0.035     
              IL16 
.032 







GLO1 0.036     
              EPHB4 
.036 
   
TNFRSF14 .025 
t_PA 0.036     
              TNFRSF13B 
.038 
   
SCF .026 
NT_pro_BNP 0.038     
              TM 
.039 
   
MPO .026 
HB_EGF 0.038     
              TF 
.040 
   
IL_1RT1 .028 
MMP_9 0.040     
              GDF_2 
.040 
   
Notch_3 .029 
DCN 0.042     
              LTBR 
.040 
   
GIF .029 
IL_17D 0.043     
              hOSCAR 
.042 
   
COL1A1 .030 
GRN 0.044     
              Gal_9 
.046 
   
LTBR .034 
COL1A1 0.045     
              PRELP 
.048 
   
TM .035 
CTSZ 0.046     
              COL1A1 
.052 
   
SOD2 .037 
TIE2 0.049     
              PAR_1 
.060 
   
MMP_12 
.037 
HAOX1 0.050     
              ADAM_TS13 
<0.0
01    
BNP .038 
TGM2 0.050     
              HB_EGF 
.001 
   
PGLYRP1 .040 
Gal_9 0.051     
              TFPI 
.001 
   
ANG_1 .040 
TGM2 0.052     
              XCL1 
.005 
   
PLC .043 
THBS2 0.057     
              Ep_CAM 
.006 
   
THPO .046 
MMP_2 0.057     
              PSGL_1 
.008 
   
GDF_2 .046 
FGF_23 0.057     
              CD93 
.010 
   
TIMP4 .048 
U_PAR 0.059     
              CXCL16 
.011 
   
Dkk_1 .049 
IL_1ra 0.060     
              CD84 
.013 
   
AP_N .049 
XCL1 0.067     
              AGRP 
.027 
   
RAGE .050 
SCF 0.070     
              IL_17RA 
.029 
   
PlGF .051                       Dkk_1 
.030 











   
THBS2 .060                       TGM2 
.046 
   
G_T .063                       SCF 
.054 
   
PRSS27 .063                       MMP_2 
.061 
   
IGFBP_2 .064                       RAGE 
.069 
   
SERPINA12 .065                         
  
   
PTX3 .066                                 
Group 5: Medical Therapy 
Group 6: 
Angiogram 

































































       
COL1A1 .020 OPG <0.001 CCL24 .049 SOD2 .004 TR .001 
GIF .008 
       
JAM_A .020 CHI3L1 <0.001     ITGB1BP2 .009 FGF_21 .003 
LEP .009 
       
PAR_1 .066 PlGF <0.001     STK4 .017 CD93 .004 
Log_IL1RT2 .019 
       
    LDL_receptor <0.001     DECR1 .020 vWF .007 
Log_CCL22 .020 
       
    IL2_RA <0.001     SLAMF7 .032 PRTN3 .025 
IL_4RA .020 
       
    FAS .001     XCL1 .036 GH .032 
THBS2 .022 
       
    GLO1 .003     TGM2 .049 PON3 .044 
Log_PARP1 .024 
       
    TNFRSF10C .004     PARP_1 .054 CTSD .063 
ACE2 .034 
       
    ST2 .006         AZU1 .068 
Log_APN .037 








       




       




       




       
                   
log_IL16 .050 
       
                   
CCL3 .052 
       
                   
SPON2 .052 
       
                   
ALCAM .056 
       
                   
MERTK .062 
       
                   
CD84 .063 
       
Group 7: Cardiovascular disease and comorbidities 




























































   
GIF .001 EGFR .006 AP_N .007 G_T .013 PAPPA .016 Ep_CAM .013 THPO .032 TLT_2 .000    
















   
TIE2 .012     ITGB1BP2 .062     FABP2 .024 ANG_1 .064            
LDL_recept
or 
.018             
CPA1 
.031             
   
MARCO .023             Protein_BOC .038                
PECAM_1 .034             BMP_6 .048                
PSP_D .037             SELE .056                




Proteins ranked according to the p value. CABG: Coronary artery bypass grafting; CV: Cardiovascular; GFR: Glomerular filtration rate in ml/min; MACE: major 




Table 5: Levels of proteins associated with MACE in cluster 1 and cluster 2 subgroups within the 
VHR cohort.  
Average of the proteins that were higher in 
Cluster 1 
Average of the proteins that were higher in 
Cluster 2 
Protein 
Cluster 1 (n=149) Cluster 2 (n=59) 
Protein 
Cluster 1 Cluster 2 
Mean  
Std 
deviation Mean  
Std 
deviation Mean  
Std 
deviation Mean  
Std 
deviation 
ADAM_TS13 5.355168 .1996098 5.252542 .2314690 PGLYRP1 6.721879 .4237260 7.233559 .5548711 
ANG_1 8.541879 1.1283547 8.267458 .9941043 PRELP 6.256846 .2184128 6.517458 .2775794 
CCL17 8.023356 1.0281449 7.970339 1.0271722 Protein BOC 4.088121 .3245504 4.213559 .3113196 
CCL22 2.617763 1.1051860 2.546429 1.2423693 PRSS27 8.818523 .4414478 8.976271 .5430720 
GLO1 6.609732 .6977405 6.410000 .6791678 PRSS8 9.541611 .3822446 9.858475 .3817736 
IDUA 6.062752 .4735588 6.040169 .5031230 PRTN3 4.940987 0.4228972 5.314107 0.7100468 
LDL receptor 2.905034 .5280326 2.705254 .6276650 PARP1 1.774803 0.7571636 1.851071 0.5703992 
PDGF subunit 
B 
9.494295 1.1110558 9.286949 1.0418787 
PAPPA 
2.302237 0.5138456 2.569643 1.0384568 
PSGL1 4.521946 .2610418 4.458814 .2698409 PSP_D 1.618859 .7432566 1.876441 .6744596 
SERPINA12 4.528456 1.0904715 4.430508 1.1329203 PTX3 3.158859 .4856293 3.560169 .4933191 
CTRC 9.784765 .7089768 9.556271 1.0638024 RAGE 5.163154 .3790602 5.571864 .4983852 
EGFR 2.197047 .1969823 2.051525 .2038070 RARRES2 10.455503 .2858237 10.754915 .3207070 
GDF_2 3.507315 .5217158 3.370847 .5186132 REN 7.665906 .9468183 8.430339 1.0026911 
TGM2 8.210987 0.6676426 7.840714 0.9638651 RETN 5.742829 0.4316355 6.426429 0.7207482 
TIE2 7.048591 .2471459 7.042373 .3046555 COL1A1 2.835302 .3659171 3.097119 .5005516 
SCF 8.632368 0.4681056 8.560714 0.6714621 CPB1 3.495235 .5806760 3.875593 .9335772 
HBEGF 4.994605 0.7470240 4.864643 0.6468777 CSTB 4.869664 .5657755 5.587119 .6883264 
Average of the proteins that were higher in 
Cluster 2 CTSD 
4.658792 .3619745 4.883220 .4769857 
Protein 
Cluster 1 Cluster 2 CTSL1 4.881382 0.4138465 5.273750 0.4137701 
Mean  
Std 
deviation Mean  
Std 
deviation CTSZ 
4.588054 .3830314 5.112373 .4131266 
ACE2 4.026913 .6270328 4.286610 .8369271 CXCL16 4.433758 .2687018 4.810000 .3841246 
ADM 6.838993 .3558047 7.643390 .4509515 DCN 5.166184 0.3057267 5.639107 0.5482046 
AGRP 3.961711 0.3151532 4.398036 0.5890467 EPHB4 1.032500 0.2054530 1.491964 0.3178531 
AMBP 5.969463 .1836705 6.185254 .2183587 FAS 3.998947 0.4333317 4.443929 0.4693852 
APN 4.262632 0.2658380 4.396250 0.5151189 Dkk_1 9.186174 .7108128 9.318136 .5625633 
AZU1 3.009408 0.6371379 3.233929 0.8160764 FABP2 8.562550 .9754979 8.753729 .8697560 
BMP6 4.513947 0.4551779 4.671071 0.6070965 FGF_23 2.728322 .6505272 3.526271 1.3485981 
BNP 2.379933 1.3444121 4.417288 2.0913631 GT 2.042483 .6847587 2.210000 .9489722 
CCL15 5.803893 .4723113 6.464915 .6229058 Gal_3 4.957114 .3450329 5.113051 .3239799 
CCL16 5.802081 .4779210 6.329661 .3981161 Gal_4 2.767987 .5927740 3.271017 .5694695 
CCL3 3.513423 .4633876 4.040508 .5545655 Gal_9 7.681879 .3554277 8.108814 .3907335 
CD163 6.072819 .4606768 6.374237 .5835805 GDF_15 4.439128 .4951657 5.623898 .6443629 
CD93 8.374698 .3143581 8.885932 .3052366 SHPS_1 2.651745 .3502021 3.088814 .4220806 
CDH5 1.990067 .2980488 2.168644 .2981174 SLAMF7 1.435000 0.3717170 1.663393 0.5681014 
CEACAM8 3.577181 .5398562 4.068814 .7484791 SOD2 9.248523 .2511390 9.285763 .2608620 
CHIT1 5.337315 1.2879974 5.732034 1.7317450 SPON2 10.040537 .1952953 10.318644 .1539084 
CNTN1 1.705235 .2308433 1.749661 .3457125 ST2 3.138926 .6300130 3.752203 .9017934 
GIF 6.483691 1.2045221 6.546610 1.2630022 t_PA 5.572886 .7192886 5.894576 .5872505 
GRN 5.749732 .2876676 6.003559 .3237590 TF 5.524295 .2533779 5.895085 .3872020 
HOSCAR 10.382483 .2335100 10.570847 .2062580 TFF3 4.842105 0.3516068 5.922857 0.7566739 
IGFBP_2 6.698389 .6738765 7.740847 .6441602 TFPI 7.994698 .3658950 8.186441 .3521352 
IGFBP_7 3.283154 .2979527 3.878475 .5175433 THPO 2.517651 .3643977 2.542881 .2968458 
IL_18BP 4.698322 .3142395 5.377627 .4812424 TIMP4 3.536779 .4419678 4.167458 .6095351 
IL_1RT1 5.451275 .2467198 5.791356 .3247251 TLT_2 3.884430 .4188101 4.249831 .4746632 
IL_1RT2 4.311812 .3012004 4.388983 .4735074 TM 8.181275 .3051435 8.587458 .3654501 
IL4RA 1.768618 0.2535184 2.142500 0.3932256 TNFR1 5.516776 0.2876454 6.539286 0.7024033 
KLK6 5.884013 0.2966597 6.228929 0.4223470 TNFR2 3.815395 0.3069458 4.704464 0.5448333 
IL17D 2.150987 0.2974812 2.398214 0.6137192 TNFRSF10A 2.249262 .2560962 2.733220 .4853276 




LTBR 2.430263 0.2840762 3.129643 0.5416136 TNFRSF13B 7.528389 .3672967 7.888814 .3728737 
MARCO 5.033490 .2542874 5.096271 .2738103 TNFRSF14 3.458523 .2703561 4.271525 .6062912 
MB 6.340592 0.7588107 7.088571 1.0745679 TNFSF13B 7.556447 0.3559474 7.831964 0.4529235 
MCP1 2.549276 0.4454035 2.850714 0.4448283 VISG2 2.608816 0.5683704 3.368571 0.9106490 
MEPE 1.985000 0.3295070 2.254643 0.6331910 TR 3.669396 .5695496 3.959492 .7039529 
MMP_12 7.653289 .7574820 8.238136 .7491961 TR_AP 4.414430 .3341496 4.610339 .3934111 
MMP_2 3.460537 .2909067 3.841017 .4264638 TRAIL_R2 5.293490 .3653486 6.144237 .5981241 
MMP_3 5.412953 .6303876 6.055424 .8914930 U_PAR 4.278322 .2870903 4.954068 .4477612 
MPO 3.190872 .3631114 3.284407 .4951463 uPA 4.026316 0.3766596 4.221250 0.4264955 
Notch_3 2.316443 .3441619 2.796441 .4712740 VEGF_D 7.126913 .4907480 7.324915 .5534107 
NT_proBNP 1.181645 0.8249314 3.020536 1.7459672 XCL1 4.648456 .6113042 5.039831 .5090542 
OPG 2.493487 0.3483590 3.038393 0.4779037 PI3 4.550268 .5245796 5.296271 .8310004 
OPN 3.874362 .5524140 4.724407 .6137288 PIgR 7.257114 .1622823 7.369153 .1513080 
PAR_1 8.105503 .3933732 8.498475 .3130375 PLC 5.517987 .2911301 6.328983 .4699072 























































1 .076 .214** -.306** .075 .124* .151** .105 .061 .196** -.074 .456** .368** .101 
Sig. (2-
tailed) 
 .172 .000 .000 .167 .022 .006 .117 .525 .001 .347 .000 .000 .084 
N 344 320 296 318 339 339 332 225 110 308 163 343 343 294 
BMI Pearson 
Correlation 
.076 1 .145* -.036 .018 .033 -.090 .034 .122 -.045 .039 .225** .089 .073 
Sig. (2-
tailed) 
.172  .016 .540 .748 .563 .112 .629 .223 .447 .630 .000 .114 .229 
N 320 320 279 296 315 315 311 208 102 285 159 319 319 272 
Systolic BP Pearson 
Correlation 
.214** .145* 1 .072 .064 -.035 .077 .121 .157 .061 .007 .020 .122* -.111 
Sig. (2-
tailed) 
.000 .016  .237 .276 .557 .198 .093 .120 .323 .934 .737 .037 .079 







-.036 .072 1 -.105 -.154** -.089 -.140* -.195* -.127* -.020 -.200** -.234** -.115 
Sig. (2-
tailed) 
.000 .540 .237  .064 .006 .120 .043 .050 .033 .807 .000 .000 .059 





.075 .018 .064 -.105 1 .284** .166** -.010 .233* .176** .214** .048 .120* .046 
Sig. (2-
tailed) 
.167 .748 .276 .064  .000 .003 .880 .016 .002 .006 .382 .027 .435 








.124* .033 -.035 -.154** .284** 1 .143** .006 .169 .208** .134 .173** .122* .107 
Sig. (2-
tailed) 
.022 .563 .557 .006 .000  .010 .926 .080 .000 .089 .001 .024 .069 






.151** -.090 .077 -.089 .166** .143** 1 .281** .134 .221** .054 .013 .199** .064 
Sig. (2-
tailed) 
.006 .112 .198 .120 .003 .010  .000 .176 .000 .497 .817 .000 .283 





.105 .034 .121 -.140* -.010 .006 .281** 1 .292* .160* .073 .062 .322** .141 
Sig. (2-
tailed) 
.117 .629 .093 .043 .880 .926 .000  .010 .023 .464 .358 .000 .053 





.061 .122 .157 -.195* .233* .169 .134 .292* 1 .222* .177 .220* .275** .333** 
Sig. (2-
tailed) 
.525 .223 .120 .050 .016 .080 .176 .010  .025 .204 .021 .004 .002 





.196** -.045 .061 -.127* .176** .208** .221** .160* .222* 1 .126 .073 .162** .012 
Sig. (2-
tailed) 
.001 .447 .323 .033 .002 .000 .000 .023 .025  .130 .204 .004 .850 





-.074 .039 .007 -.020 .214** .134 .054 .073 .177 .126 1 .018 .011 -.027 
Sig. (2-
tailed) 
.347 .630 .934 .807 .006 .089 .497 .464 .204 .130  .821 .888 .741 
N 163 159 141 151 163 163 162 102 53 145 163 163 163 152 
Pearson 
Correlation 








.000 .000 .737 .000 .382 .001 .817 .358 .021 .204 .821  .000 .000 





.368** .089 .122* -.234** .120* .122* .199** .322** .275** .162** .011 .264** 1 .298** 
Sig. (2-
tailed) 
.000 .114 .037 .000 .027 .024 .000 .000 .004 .004 .888 .000  .000 





.101 .073 -.111 -.115 .046 .107 .064 .141 .333** .012 -.027 .372** .298** 1 
Sig. (2-
tailed) 
.084 .229 .079 .059 .435 .069 .283 .053 .002 .850 .741 .000 .000  
N 294 272 251 271 289 290 286 190 86 264 152 293 293 294 
BMI: body mass index, BP: blood pressure, IFN-γ: interferon gamma, IL-10: interleukin 10, IL-12p70: interleukin 12p70; IL-13: interleukin 13; IL-1β: interleukin 
1 beta; IL-2: interleukin 2; IL-4: interleukin 4; IL-6: interleukin6; IL-8: interleukin 8; CRP: C reactive protein. 
** Correlation is significant at the 0.01 level (2-tailed). 











Table 7: Biomarker levels associated with MACE within one year of admission. 
Protein Protein name No MACE (n=213) MACE (n=16) 
p value 
MACE within 6 
months (n=5) 
MACE after 6 
months (n=11) p value 




Tumour necrosis factor alpha converting 




   
   
TACE  
Tumour necrosis factor alpha converting 
enzyme 684.73 ± 2413.31 
1472.15 ± 5574.62 
0.525 
99.68 ± 161.66 2096.00 ± 6725.63 0.801 
TNFα  Tumour necrosis factor alpha  4.661 ± 2.483 6.364 ± 1.943 0.559 6.118 ± 0.716 5.022 ± 2.246 0.292 
TNFR1   Tumour necrosis factor alpha receptor 1 1237.65 ± 1121.52 2003.62 ± 142.50 0.018 1708.04 ± 930.91 2137.97 ± 1618.90 0.061 
TNFR2 Tumour necrosis factor alpha receptor 2 2929.10 ± 2219.55 3525.37 ± 1879.69 0.348 3847.00 ± 1939.68 3379.18 ± 1928.64 0.453 
TIMP3   Metalloproteinase inhibitor 3 3420.52 ± 2702.14 3085.77 ± 2214.90 0.589 3842.40 ± 3333.99 2741.85 ± 1579.92 0.624 
IFN-γ  Interferon gamma 9.61 ± 41.23 7.22 ± 7.50 0.942 5.00 ± 2.37 8.22 ± 8.86 0.852 
IL-10  Interleukin 10 0.37 ± 0.60 0.42 ± 0.63 0.631 0.28 ± 0.10  0.48 ± 0.75 0.886 
IL-12p70  Interleukin 12 p70 0.31 ± 0.35 0.22 ± 0.14 0.148 0.21 ± 0.13 0.22 ± 0.16 0.351 
IL-13  Interleukin 13 0.79 ± 0.63 0.64 ± 0.25 0.775 0.65 ± 0.38 0.63 ± 0.21 0.949 
IL-1β  Interleukin 1 beta 0.41 ± 1.09 0.35 ± 0.13 0.323 0.26 ± 0.09 0.41 ± 0.13 0.543 
IL-2  Interleukin 2 0.27 ± 0.28 0.26 ± 0.15 0.938 0.24 ± 0.16 0.28 ± 0.16 0.836 
IL-4  Interleukin 4 0.03 ± 0.15 0.02 ± 0.01  0.74 0.02 ± 0.01 0.01 ± 0.01 0.763 
IL-6  Interleukin 6 1.99 ± 2.80 3.06 ± 2.67  0.021 4.66 ± 3.78 2.33 ± 1.77 0.023 












MACE within 6 
months (n=5) 





















Retinoic acid receptor 
responder protein 2 
10.517448 0.3209137 10.816250 0.2389386 0.000 10.730000 0.1862794 10.855455 0.2575796 .001 
CCL16 
C-C motif chemokine 
16 




5.522917 0.3008937 5.845625 0.2807364 0.001 5.822000 0.1693222 5.856364 0.3261065 .005 
TNF_R1 
Tumour necrosis 
factor alpha receptor 1 
5.741771 0.5985637 6.395625 0.7150661 0.001 6.242000 0.6036307 6.465455 0.7772176 .005 
TFF3 Trefoil factor 3 5.076510 0.6515530 5.811875 0.7697291 0.002 5.512000 0.5859778 5.948182 0.8282369 .004 
ADM Adrenomedullin 7.023385 0.5045712 7.592500 0.5457533 0.003 7.386000 0.5586412 7.686364 0.5393751 .006 
CXCL16 
C-X-C chemokine motif 
16 




3.716042 0.5969126 4.179375 0.7781642 0.004 4.284000 0.5000300 4.131818 0.8946152 .014 
ADAM_TS13 
































death 1 ligand 2 




4.718125 0.7409981 5.460000 0.6679820 0.010 5.490000 0.7614132 5.446364 0.6608672 .035 
EPHB4 
Ephrin type-B receptor 
4 










2.754375 0.4158793 3.031875 0.3988019 0.011 3.016000 0.4170492 3.039091 0.4108638 
.039 
IDUA Alpha-L-iduronidase 6.080729 0.4762775 5.763750 0.4533560 0.011 5.892000 0.2622403 5.705455 0.5184856 .030 
AGRP Agouti related protein 4.057344 0.4433638 4.341250 0.4572800 0.013 4.386000 0.4132554 4.320909 0.4938513 .043 
IL_1RT2 
Interleukin 1 receptor 
2 
4.319896 0.3453036 4.499375 0.4784066 0.013 4.350000 0.2610555 4.567273 0.5475599 .025 
CCL22 
C-C motif chemokine 
22 
2.633125 1.1412919 2.183750 1.0883497 0.013 2.292000 0.9146420 2.134545 1.1973334 .034 
KLK6 Kallikrein-6 5.955260 0.3643569 6.236250 0.3104593 0.013 6.184000 0.2272224 6.260000 0.3491991 .045 




1.848542 0.3232329 2.118125 0.4397760 0.014 2.060000 0.3672874 2.144545 0.4834121 .047 
PI3 Elafin 4.721250 0.7060045 5.249375 0.5761304 0.016 5.396000 0.5717342 5.182727 0.5928759 .046 
PLC Perlecan 5.714219 0.4971557 6.153750 0.4536941 0.016 6.078000 0.3624500 6.188182 0.5020322 .053 
REN Renin 7.823073 0.9995300 8.598750 1.0321555 0.021 8.030000 1.0926802 8.857273 0.9408410 .023 






























6.017760 0.2140722 6.185625 0.1927336 0.030 5.978000 0.1728294 6.280000 0.1114451 
.003 
CTSD Cathepsin D 4.717344 0.4094073 4.783750 0.4192831 0.033 4.900000 0.5829666 4.730909 0.3434081 0.617 
RAGE 
Receptor for advanced 
glycosylation end 
products 
5.253073 0.4411164 5.591250 0.5084339 0.033 5.564000 0.2802320 5.603636 0.5964943 0.104 
TNF_R2 
Tumour necrosis 
factor alpha receptor 2 
4.019948 0.5368265 4.472500 0.5676090 0.034 4.328000 0.5289329 4.538182 0.5968051 0.089 










8.195365 0.4114206 8.476250 0.3283266 0.036 8.614000 0.2005742 8.413636 0.3630502 .069 








6.477656 1.6182280 7.473750 1.2729801 0.042 6.888000 1.6344479 7.740000 1.0548080 0.080 
CPA1 Carboxypeptidase 1 4.556667 0.7487577 4.952500 0.8252555 0.045 4.990000 0.6685806 4.935455 0.9174679 0.134 
CCL15 
C-C motif chemokine 
15 
5.960052 0.5879759 6.367500 0.6057557 0.045 6.140000 0.5639592 6.470909 0.6209260 0.083 
IGFBP_7 
Insulin like growth 
factor binding protein 
7 
3.425990 0.4556648 3.764375 0.3919518 0.048 3.790000 0.1959592 3.752727 0.4632514 0.137 
IL1RL2 
Interleukin 1 receptor 
like 2 
3.163802 0.3820825 2.960625 0.5209155 0.049 3.152000 0.3006160 2.873636 0.5867243 .061 




Table 8: Sensitivity and specificity of the measured biomarkers in differentiating between 
VHR and non-VHR individuals 


















































































































































4.06 0.75 0.69 0.804 0.024 <0.0001 0.756 0.851 
Number of 
patients 



































Levels expressed in NPX values 
(means) 
         
GDF_15 4.78 3.87 0.002 4.07 0.85 0.81 0.883 0.022 <0.0001 0.841 0.926 
TRAIL_R2 5.53 4.9 <0.0001 5.09 0.80 0.78 0.868 0.022 <0.0001 0.824 0.911 
MMP_7 9.57 8.72 <0.0001 8.98 0.85 0.71 0.865 0.024 <0.0001 0.818 0.911 
MMP_12 7.82 6.95 <0.0001 7.14 0.80 0.66 0.825 0.024 <0.0001 0.778 0.873 
U_PAR 4.47 4.05 <0.0001 4.15 0.76 0.71 0.814 0.026 <0.0001 0.764 0.865 
REN 7.88 6.87 0.001 7.12 0.81 0.72 0.809 0.026 <0.0001 0.758 0.859 




CEACAM8 3.72 3.16 <0.0001 3.36 0.73 0.72 0.796 0.027 <0.0001 0.744 0.848 
ACE2 4.1 3.5 <0.0001 3.59 0.76 0.70 0.795 0.030 <0.0001 0.735 0.855 
PTX3 3.27 2.77 <0.0001 3.01 0.74 0.71 0.785 0.027 <0.0001 0.732 0.838 
TNF_R1 5.79 5.34 0.05 5.42 0.75 0.71 0.778 0.029 <0.0001 0.721 0.836 
EGFR 2.16 2.36 0.012 2.29 0.65 0.71 0.773 0.030 <0.0001 0.715 0.831 
TR_AP 4.47 4.08 <0.0001 4.29 0.71 0.69 0.770 0.030 <0.0001 0.711 0.829 
SPON1 0.64 0.43 0.012 0.48 0.69 0.72 0.764 0.028 <0.0001 0.709 0.818 
t_PA 5.66 5.14 0.067 5.37 0.70 0.69 0.761 0.029 <0.0001 0.705 0.816 
CSTB 5.07 4.6 0.034 4.74 0.68 0.71 0.755 0.030 <0.0001 0.697 0.813 
TIM 7.39 6.68 0.067 6.82 0.71 0.66 0.752 0.032 <0.0001 0.689 0.815 
CTSD 4.72 4.44 0.005 4.49 0.71 0.70 0.751 0.033 <0.0001 0.686 0.816 
PSP_D 1.69 1.1 0.003 1.26 0.71 0.66 0.750 0.031 <0.0001 0.690 0.809 
CCL3 3.66 3.3 0.062 3.41 0.66 0.66 0.746 0.032 <0.0001 0.683 0.808 
OPN 4.12 3.59 0.015 3.70 0.70 0.64 0.745 0.029 <0.0001 0.689 0.801 
hOSCAR 10.44 10.21 <0.0001 10.35 0.69 0.72 0.745 0.031 <0.0001 0.684 0.805 
IL2_RA 3.62 3.24 0.005 3.41 0.63 0.72 0.741 0.029 <0.0001 0.683 0.798 
TNFRSF10A 2.39 2.1 <0.0001 2.19 0.69 0.71 0.738 0.032 <0.0001 0.676 0.799 
CD4 2.92 2.63 0.001 2.71 0.67 0.66 0.737 0.031 <0.0001 0.676 0.798 
MMP_9 3.78 3.3 <0.0001 3.59 0.63 0.71 0.736 0.029 <0.0001 0.680 0.792 
CHIT1 5.45 4.63 0.054 5.08 0.70 0.70 0.735 0.031 <0.0001 0.674 0.795 
TNFRSF11A 5.01 4.59 0.023 4.68 0.65 0.65 0.734 0.031 <0.0001 0.674 0.794 
PON3 5.04 5.53 0.011 5.34 0.66 0.70 0.725 0.034 <0.0001 0.658 0.792 
LOX_1 6.2 5.83 <0.0001 5.94 0.66 0.65 0.724 0.030 <0.0001 0.665 0.784 
MCP_1 2.63 2.37 0.016 2.41 0.71 0.64 0.723 0.031 <0.0001 0.663 0.784 
CNTN1 1.72 1.93 <0.0001 1.83 0.67 0.64 0.723 0.031 <0.0001 0.663 0.783 
Gal_9 7.8 7.54 0.041 7.59 0.66 0.65 0.723 0.032 <0.0001 0.659 0.787 
CTSZ 4.74 4.43 0.041 4.60 0.62 0.71 0.722 0.032 <0.0001 0.660 0.785 
PlGF 7.76 7.35 0.003 7.20 0.70 0.65 0.722 0.032 <0.0001 0.660 0.785 
IL_4RA 1.87 1.66 0.002 1.74 0.62 0.72 0.718 0.032 <0.0001 0.655 0.781 
AZU1 3.07 2.65 <0.0001 2.76 0.68 0.65 0.709 0.032 <0.0001 0.646 0.772 
Gal_4 2.91 2.52 0.032 2.62 0.65 0.64 0.706 0.032 <0.0001 0.644 0.769 
CD163 6.16 5.88 0.015 5.95 0.65 0.64 0.685 0.034 <0.0001 0.617 0.752 
Gal_3 5.00 4.83 0.007 4.85 0.66 0.58 0.671 0.033 <0.0001 0.606 0.737 
GLO1 6.55 6.23 <0.0001 6.33 0.63 0.62 0.664 0.034 <0.0001 0.597 0.730 
vWF 5.34 4.87 0.005 4.98 0.61 0.63 0.660 0.032 <0.0001 0.597 0.723 
FABP4 5.07 4.6 0.006 4.69 0.63 0.61 0.656 0.034 <0.0001 0.589 0.723 
RARRES2 10.54 10.37 0.012 10.44 0.65 0.56 0.652 0.035 <0.0001 0.584 0.720 
LPL 9.41 9.64 0.007 9.59 0.66 0.63 0.647 0.033 <0.0001 0.582 0.713 
ICAM_2 4.03 3.85 0.051 3.88 0.68 0.51 0.640 0.034 <0.0001 0.573 0.706 
MMP_3 5.6 5.26 0.033 5.29 0.62 0.56 0.639 0.037 <0.0001 0.567 0.712 
IDUA 6.06 5.84 0.008 5.86 0.68 0.51 0.638 0.034 <0.0001 0.572 0.705 
RETN 5.93 5.65 0.052 5.68 0.65 0.51 0.637 0.034 <0.0001 0.571 0.703 
FGF_21 6.55 5.79 0.004 6.10 0.61 0.57 0.631 0.036 <0.0001 0.561 0.701 
HAOX1 4.31 3.79 0.008 3.69 0.61 0.60 0.631 0.035 <0.0001 0.562 0.700 
MPO 3.22 3.08 0.057 3.12 0.65 0.63 0.623 0.035 0.001 0.554 0.691 
PRTN3 5.04 4.83 0.001 4.81 0.66 0.51 0.621 0.034 0.001 0.554 0.688 
ITGB2 4.14 4.29 0.043 4.18 0.63 0.60 0.619 0.035 0.001 0.550 0.689 
PD_L2 2.57 2.45 0.043 2.48 0.63 0.56 0.616 0.035 0.002 0.547 0.685 
PRELP 6.33 6.27 0.001 6.24 0.66 0.51 0.610 0.034 0.003 0.543 0.678 
IL_1ra 6.92 6.66 0.009 6.65 0.56 0.52 0.609 0.037 0.003 0.535 0.682 
PCSK9 0.92 0.82 0.003 0.81 0.65 0.53 0.605 0.036 0.004 0.534 0.676 
IL1RL2 3.15 3 0.011 3.04 0.62 0.51 0.603 0.036 0.005 0.533 0.672 
SRC 7.02 7.3 0.036 7.32 0.55 0.55 0.602 0.035 0.005 0.532 0.671 
DECR1 5.9 5.55 0.037 5.77 0.54 0.65 0.601 0.034 0.006 0.534 0.667 
JAM_A 4.86 4.63 0.022 4.56 0.62 0.52 0.594 0.035 0.010 0.525 0.664 
LEP 5.18 5.25 0.055 5.26 0.62 0.51 0.572 0.038 0.050 0.497 0.647 
MMP_2 3.57 3.62 <0.0001 3.54 0.65 0.52 0.562 0.035 0.093 0.492 0.631 




LDL receptor 2.85 2.77 0.008 2.71 0.60 0.51 0.560 0.039 0.103 0.484 0.635 
Notch_3 2.45 2.37 0.012 2.39 0.57 0.51 0.559 0.035 0.107 0.491 0.627 
IGFBP_1 2.97 3.15 0.011 3.05 0.56 0.53 0.558 0.035 0.115 0.489 0.627 
CD84 5.00 4.91 0.028 4.91 0.55 0.51 0.547 0.035 0.199 0.479 0.615 
SCF 8.61 8.69 0.009 8.74 0.52 0.51 0.528 0.036 0.449 0.458 0.598 
AXL 6.53 6.55 0.03 6.48 0.51 0.48 0.496 0.038 0.911 0.421 0.571 
Receiver operating curves (ROC) were calculated for proteins that were able to differentiate 
between VHR and non-VHR patients. Proteins were then ranked according to the AUC value. 
Cut off values refer to the protein level threshold for differentiating between VHR and the 
non-VHR cohort. Sensitivity refers to the true positive participants which is the probability of 
a VHR participant to have high levels of the protein in question. Specificity refers to the false 
positive participants which is the proportion of non-VHR participants who have a low level of 
the protein in question. Sensitivity and specificity are expressed in ratios. The Area Under the 
Curve (AUC) is the test’s ability to reliably distinguish between VHR and non-VHR patients. An 
AUC equal to 1 represents a test with an excellent sensitivity and specificity. Values in bold 
and italic refer to the proteins which levels were higher in non-VHR patients. The confidence 
interval represents the AUC interval of 95% of the observations. CI: confidence interval; non-
VHR: non-very high risk; NPX: normalised protein ratio, ROC: receiver operating 
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Summary  Tumour  necrosis  factor  alpha  converting  enzyme  (TACE/ADAM17)  is  a  member  of
the A  disintegrin  and  metalloproteinase  (ADAM)  family  of  ectodomain  shedding  proteinases.  It
regulates  many  inflammatory  processes  by  cleaving  several  transmembrane  proteins,  including
tumour necrosis  factor  alpha  (TNF)  and  its  receptors  tumour  necrosis  factor  alpha  receptor  1
and tumour  necrosis  factor  alpha  receptor  2.  There  is  evidence  that  TACE  is  involved  in  several
Abbreviations: ACS, Acute coronary syndrome; AMI, Acute myocardial infarction; CAD, Coronary artery disease; MACE, Major adverse
cardiac events; MAPK, Mitogen-activated protein kinases; TACE (CD156b), Tumour necrosis factor alpha converting enzyme or A disintegrin
and metalloproteinase 17 (ADAM17); TIMP3, Tissue inhibitor of metalloproteinase 3; TNF, Tumour necrosis factor alpha; TNFR, TNF receptor.
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Biomarker;
TACE
inflammatory  diseases,  such  as  ischaemia,  heart  failure,  arthritis,  atherosclerosis,  diabetes
and cancer  as  well  as  neurological  and  immune  diseases.  This  review  summarizes  the  latest
discoveries  regarding  the  mechanism  of  action  and  regulation  of  TACE.  It  also  focuses  on  the
role of  TACE  in  atherosclerosis  and  coronary  artery  disease  (CAD),  highlighting  clinical  studies
that have  investigated  its  expression  and  protein  activity.  The  multitude  of  substrates  cleaved
by TACE  make  this  enzyme  an  attractive  target  for  therapy  and  a  candidate  for  biomarker
research and  development  in  CAD.








Résumé  L’enzyme  de  conversion  du  facteur  alpha  de  nécrose  tumorale  (TACE/ADAM17),
membre de  la  famille  des  A  désintégrines  et  métalloprotéinases  (ADAM)  qui  sont  des  protéi-
nases clivant  l’ectodomaine  des  protéines  transmembrannaires,  régule  différents  processus
inflammatoires  en  clivant  des  protéines  transmembrannaires,  y  comrpis  le  facteur  alpha  de
nécrose  tumorale  (TNF)  et  ses  récepteurs  1  et  2.  Différentes  études  ont  montré  l’association  de
TACE avec  des  maladies  inflammatoires  tel  que  l’ischémie,  l’insuffisance  cardiaque,  l’arthrite,
l’athérosclérose,  le  diabète,  le  cancer  ainsi  que  des  maladies  neurologiques  et  immunologiques.
Cette revue  résume  les  dernières  découvertes  concernant  le  mécanisme  d’action  et  de  régula-
tion de  TACE  ainsi  que  son  rôle  dans  l’athérosclerose  et  les  maladies  coronariennes  en  mettant
en évidence  les  études  cliniques  les  plus  récentes  en  relation  avec  son  expression  et  son  activ-
ité. La  multitude  des  substrats  clivés  par  TACE  rendent  cette  enzyme  une  cible  thérapeutique
intéressante  surtout  dans  le  domaine  du  développement  des  biomarqueurs  pour  les  maladies
coronariennes.
Crown Copyright  ©  2017  Publié  par  Elsevier  Masson  SAS.  Tous  droits  réservés.
Background
Tumour  necrosis  factor  alpha  converting  enzyme  (TACE),
also  known  as  A  disintegrin  and  metalloproteinase  17
(ADAM17),  is  a  membrane-anchored  protein  responsible
for  the  ectodomain  shedding  of  a  variety  of  transmem-
brane  proteins,  such  as  cytokines,  chemokines,  and
growth  factors  and  their  receptors.  Shedding  results  in
the  initiation  or  inhibition  of  downstream  signalling  and
cellular  responses,  and  is  associated  with  several  major
acute  and  chronic  inflammatory  diseases.  Recent  studies
have  reported  overexpression  of  TACE  in  patients  with
coronary  artery  disease  (CAD)  as  well  as  after  acute
myocardial  infarction  (AMI),  indicating  that  TACE  may  be
a  useful  cardiac  prognostic  biomarker  of  cardiac  events.
This  review  summarizes  recent  findings  on  TACE  activity
and  regulation,  with  an  emphasis  on  the  role  of  TACE  in
CAD.
Structure
Black  et  al.  first  described  TACE  in  1997  when  working  with
mammalian  THP1  cells,  as  the  enzyme  that  cleaves  tumour
necrosis  factor  alpha  (TNF), and  reported  purification  and
cloning  of  the  protein  [1].  Subsequently,  different  forms  of
TACE  have  been  described  including  the  full-length  protein
(∼110  KDa  under  non-reducing  conditions),  a  mature  form
of  TACE  lacking  the  prodomain  (80  KDa),  and  a  third  form
detected  in  cell  lysates,  which  lacks  the  cytoplasmic  domain
(60  KDa)  [2]  (Fig.  1).
Localization
Immunohistochemical  studies  suggest  that  most  of  the
active  form  of  TACE  is  localized  in  the  cellular  perinuclear
region,  with  a  small  amount  present  on  the  plasma  mem-
brane  surface  [2]. Tellier  et  al.  further  reported  that  TACE
is  sequestered  into  lipid  rafts  (Fig.  2).  This  spatial  distribu-
tion  has  a  role  in  the  regulation  of  TACE  activity  by  keeping
the  enzyme  separate  from  its  substrates  [3].
Lipid  rafts  are  known  to  have  high  concentrations  of
cholesterol,  and  interestingly,  the  shedding  of  TACE  sub-
strates,  such  as  CD30  [4], interleukin-6  receptor  (IL-6R)  [5]
and  L-selectin  (CD62L)  [6],  can  be  increased  by  cholesterol-
lowering  drugs.  The  increase  in  TACE  shedding  was  also
observed  with  TNF, TNF  receptor  1  (TNFR1)  and  TNF  recep-
tor  2  (TNFR2)  after  membrane  cholesterol  depletion  [3].
Disruption  of  the  lipid  rafts  may  displace  the  mature  form  of
TACE  in  the  non-raft  region  of  the  membrane  that  contains
the  major  part  of  TACE  substrates,  and  increase  their  shed-
ding.  Therefore,  under  normal  conditions,  the  sequestration
of  the  mature  form  of  TACE  in  lipid  rafts  can  be  considered
as  the  rate-limiting  process  of  its  shedding  activity  [7].
Activation and regulation
Tissue  inhibitor  of  metalloproteinase  3  (TIMP3)  is  the  only
known  endogenous  inhibitor  of  TACE  [8].
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Figure 1. TACE domains. Signal peptide (1-17 aa); pro-domain (18-214 aa) acting as an inactivator and a chaperone domain; extracellular
domain (215-671 aa) comprising: 1. A metalloprotease domain/catalytic domain (215-473 aa) responsible for an ectodomain shedding; 2. A
disintegrin domain (474-572 aa); 3. An EGF-like/cysteine rich domain (573-671 aa) responsible for substrate recognition and activation;
transmembrane domain (672-694 aa) necessary for effective cleavage of substrates; cytoplasmic domain (695-824 aa) binding to many
proteins that regulate TACE activity. aa: amino acid; EGF: endothelial growth factor; TACE: tumour necrosis factor alpha converting enzyme.
TIMP3  is  downregulated  in  circulating  human  monocytes
in  people  at  high  risk  of  diabetes  and  atherosclerosis  [9].
Stöhr  et  al.  demonstrated  that  TIMP3  also  regulates  lipid
metabolism  as  well  as  the  oxidative  stress  response,  main-
taining  metabolic  flexibility  in  the  heart,  particularly  during
episodes  of  increased  cardiac  stress  [10].  TIMP3  over  expres-
sion  has  been  shown  to  improve  post-myocardial  infarction
cardiac  remodelling  related  to  lower  extracellular  matrix
disruption  in  animal  models  [11,12].
Regarding  TIMP3  activation,  Cesaro  et  al.  showed  that
strong  TACE  expression  was  associated  with  early  acute
phase  inflammation  in  Crohn’s  disease,  whereas  TIMP3  was
upregulated  during  the  quiescent  phase  of  the  disease  [13].
TIMP3  may  therefore  be  involved  in  a  delayed  regulatory
mechanism  following  an  increased  TACE  expression,  and  its
role  in  inflammation  and  heart  related  diseases  should  be
studied  further.
Studies  have  shown  that  only  the  monomeric  form  of
TACE  is  active  and  can  effectively  cleave  its  substrates.  How-
ever,  TACE  appears  to  be  predominantly  present  as  dimers
at  the  cell  surface,  which  enables  its  efficient  association
with  TIMP3  and  silences  its  activity.  Hence,  TIMP3  inhibits
TACE  only  when  it  is  in  its  dimer  form.  Upon  activation  of
the  p38  mitogen-activated  protein  kinase  pathway,  the  bal-
ance  can  shift  from  TACE  dimers  to  monomers,  and  this  shift
is  associated  with  an  increase  in  cell  surface  presentation  of
TACE  and  a  reduction  in  TIMP3  association  [14].
Substrates and shedding process
TACE  mediates  cell-cell  interactions  with  a  wide  range  of
identified  substrates,  although  the  mechanisms  and  con-
sequences  of  this  binding  are  not  yet  fully  understood.
As  the  sequences  cleaved  in  various  substrates  are  highly
variable,  there  is  no  apparent  consensus  for  the  TACE  cleav-
age  sequence.  New  evidence  suggests  that  TACE  activity  is
regulated  by  its  non-catalytic  domains  and  the  secondary
structure  of  its  substrates  [15].
Cleavage  of  TACE  substrates  occurs  at  extracellular  sites
proximal  to  the  cell  membrane,  thereby  releasing  the
soluble  ectodomain  from  the  cell  surface.  The  cleaved
molecules  can  then  bind  to  their  receptor  on  the  same
cell  (autocrine  effect)  or  to  receptors  on  neighbouring  cells
(paracrine  effect)  or  even  enter  the  bloodstream  (endocrine
effect).  When  the  substrate  is  cleaved  and  bound  to  its
receptor,  it  can  initiate  downstream  signalling  events.  Alter-
natively,  the  receptor  can  also  be  cleaved  from  the  cell
surface;  thus,  ectodomain  shedding  can  actually  stop  the
ligand-initiated  signalling.
Because  of  its  many  functional  properties,  TACE  plays  a
major  role  in  inflammation  through  its  shedding  of  a  vari-
ety  of  inflammatory  substrates.  Studies  have  shown  that
TACE  is  implicated  in  platelet  function  through  its  cleavage
of  the  von  Willebrand  factor  (CD42b)  receptor  [16].  TACE
is  also  responsible  for  the  cleavage  of  L-selectin  (CD62L),
intracellular  adhesion  molecule  1  (ICAM-1)  and  vascular  cell
adhesion  protein  1  (VCAM-1)  [17].  Many  TACE  substrates
have  been  extensively  investigated  in  atherosclerosis,  and
all  are  known  to  participate  in  the  inflammatory  process
accompanying  the  formation  and  progression  of  plaque
(Fig.  3).  The  consequences  of  TACE  shedding  on  these  fac-
tors  needs  to  be  closely  investigated,  as  their  soluble  forms
may  hold  different  properties  compared  to  their  membrane
forms.  For  example,  the  cleavage  of  TNFR1  by  TACE  sheds  a
soluble  form  of  TNFR1  that  binds  to  free  TNF, dampening
the  inflammatory  response  [18].  In  addition,  TACE  activates
ligands  (such  as  neuregulin)  that  bind  to  the  ERbB  tyrosine
kinase  family  of  receptors.  The  resulting  signalling  pathways
have  been  involved  in  the  growth  of  many  tumour  types  as
well  as  the  maintenance  of  cardiac  function  [19,20].
The fate of TACE after its activation
There  appears  to  be  contradiction  in  the  understanding  what
happens  to  TACE  after  it  has  been  activated,  and  many  pos-
tulations  have  been  made.
Please  cite  this  article  in  press  as:  Chemaly  M,  et  al.  Role  of  tumour  necrosis  factor  alpha  converting  enzyme
(TACE/ADAM17)  and  associated  proteins  in  coronary  artery  disease  and  cardiac  events.  Arch  Cardiovasc  Dis  (2017),
https://doi.org/10.1016/j.acvd.2017.08.002
ARTICLE IN PRESS+ModelACVD-1047; No. of Pages 12
4  M.  Chemaly  et  al.
Figure 2. TACE activation and regulation. 1. Once synthesized, iRhom bind to TACE and promotes maturation, its exit from the endoplasmic
reticulum and its migration to the Golgi. 2. TACE prodomain is cleaved by furin in the trans-Golgi network. 3. During maturation, ERK-
dependent threonine 735 phosphorylation is necessary for TACE to reach the secretory pathway. 4. TACE is packaged into lipid rafts during
its transport and maturation through the Golgi. 5. Most of the active form of TACE is localized in the cellular perinuclear region, with a
small amount present in the plasma membrane. 6. TACE has an increased shedding rate when exposed to cell activators, such as phorbol
esters, including PMA. Other activators include lipopolysaccharide, which is dependent on ROS and the p38 MAPK pathway. 7. TACE is
present in dimers on the cell surface and binds to its inhibitor TIMP3. 8. Activation of the ERK or p38 MAPK pathway transforms TACE
from a dimer structure into a monomer structure and releases it from TIMP3. 9. TACE is regulated by FHL2 and SAP97. 10. TACE cleaves
transmembrane TNF and releases soluble TNF. ER: endoplasmic reticulum; ERK: extracellular signal-regulated kinases; FHL2: four and a
half LIM domains 2; LPS: lipopolysaccharide; iRhom2: rhomboid family member 2; MAPK: mitogen-activated protein kinases; PKC: protein
kinase C; PMA: phorbol myristate acetate; PTPH1: protein-tyrosine phosphatase; ROS: reactive oxygen species; SAP97: synapse-associated
protein 97; sTNF: soluble TNF; TACE: tumour necrosis factor alpha converting enzyme; TIMP3: tissue inhibitor of metalloproteinases 3;
tmTNF: transmembrane TNF; TNF: tumour necrosis factor alpha.
ADAM10,  another  member  of  the  ADAM  family,  is  known  to
undergo  regulated  intramembrane  proteolysis  by  presenilin
after  its  ectodomain  is  shed  by  ADAM-9  or  ADAM-15  [21].  In
the  intramembrane  proteolysis  process,  a  membrane  pro-
tein  typically  undergoes  two  consecutive  cleavages.  The
first  results  in  the  shedding  of  its  ectodomain;  the  second
one  occurs  within  its  transmembrane  domain,  resulting  in
secretion  of  a  small  peptide  and  the  release  of  the
intracellular  domain  into  the  cytosol.  After  intramem-
brane  proteolysis, the  cytoplasmic  domain  of  ADAM10  can
translocate  to  the  nucleus  to  bind  to  gene  loci  under-
going  transcription.  Since  ADAM10  is  the  closest  relative
of  TACE,  there  is  a  high  possibility  that  the  cytoplas-
mic  domain  of  TACE  itself  can  undergo  intramembrane
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Figure 3. Possible role of TACE in cardiac events. This diagram shows the different proteins cleaved by TACE that are involved in chronic
arterial wall inflammation occurring in atherosclerosis. As an example, TACE cleaves transmembrane TNF, TNFR1 and TNFR2 releasing their
soluble forms, sTNF, sTNFR1 and sTNFR2, respectively. The transmembrane ectodomain shedding combined with a premature endothelial
cell senescence due to TACE, leads to amplification of inflammation as well as reduction in endothelial health. This results in an increased
risk of plaque rupture and thrombosis, and an overall increased risk of developing cardiovascular events. sTNF: soluble tumour necrosis
factor alfa; sTNFR1: soluble tumour necrosis factor alfa receptor 1; sTNFR2: soluble tumour necrosis factor alfa receptor 2; TACE: tumour
necrosis factor alpha converting enzyme; tmTNF:  transmembrane TNF; TNF: tumour necrosis factor alfa; TNFR1: tumour necrosis factor
alfa receptor 1; TNFR2: tumour necrosis factor alfa receptor 2.
proteolysis  and  participate  in  gene  transcription  regula-
tion.  A  recent  study  reported  that  TACE  can  play  a role
in  post-myocardial  infarction  recovery  by  regulating  vascu-
lar  endothelial  growth  factor  receptor-2  transcription  and
angiogenesis  in  cardiomyocytes  [22].  Whether  TACE  is  inter-
nalized  and  downregulated  after  activation  is  still  unclear.
However,  recent  studies  have  reported  that  soluble  TACE  can
be  detected  in  the  plasma  [23,24],  which  is  suggestive  of  a
particular  mechanism  behind  its  own  shedding,  a  process
that  remains  unknown.
TACE and cardiovascular disease
TACE in heart diseases
Several  studies  have  investigated  the  role  of  TACE  in
heart  diseases.  Investigators  found  that  TACE  expression
was  increased  in  endomyocardial  tissues  in  myocarditis,
as  well  as  in  the  peripheral  blood  in  advanced  stages  of
heart  failure.  TACE  was  upregulated  together  with  TNF
in  myocarditis  and  negatively  correlated  with  left  ventricu-
lar  systolic  function  [25].  Patients  with  advanced  congestive
heart  failure  also  had  an  increased  expression  of  TACE  and
TNF compared  to  controls  [26]. The  role  of  TACE  has  been
highlighted  in  aortic  aneurysm  [27]  and  in  heart  develop-
ment  [28]. Interestingly,  Takayanagi  et  al.  recently  reported
that  TACE  may  be  a  novel  therapeutic  target  for  the  preven-
tion  of  hypertensive  complications  [29].
TACE and CAD
The  underlying  pathological  process  behind  the  develop-
ment  and  progression  of  CAD  is  atherosclerosis,  which  results
from  an  imbalance  in  lipid  metabolism  and  a  maladaptive
immune  response  leading  to  chronic  inflammation  in  the
arterial  wall.  Major  adverse  cardiac  events  (MACE)  often
occur  suddenly  in  patients  with  CAD  after  a  revascularization
strategy,  resulting  in  high  mortality  and  morbidity.  These
events  include  death,  stroke,  myocardial  infarction,  heart
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failure  and  repeat  coronary  revascularization  of  the  tar-
get  lesion  [30].  Many  studies  are  currently  investigating  the
association  between  different  cardiovascular  markers  and
MACE  with  a  recent  interest  in  multiple  marker  models  ver-
sus  a  single  marker  model  [31].  However,  the  investigation
of  TACE  and  associated  proteins  as  a  multiple  marker  model
for  MACE  prediction  has  not  yet  been  evaluated.
Clinical studies of TACE and associated
proteins in CAD and AMI
Several  studies  have  demonstrated  that  TACE  plays  a role
in  CAD  initiation  and  progression  to  an  acute  coronary  syn-
drome  (ACS).  Clinical  studies  have  shown  elevated  plasma
levels  of  TNF in  patients  with  AMI,  suggesting  that  TNF
maturation,  which  relies  on  TACE,  may  activate  systemic
inflammation  and  contribute  to  plaque  rupture  [32].  Sub-
sequent  studies  have  found  a  positive  association  between
TACE  in  AMI,  as  summarized  in  Table  1.  Increased  levels  of
gene  expression  of  TNF  ̨ and  TACE  were  found  in  circulating
leucocytes  of  patients  with  myocardial  infarction,  obtained
within  24  hours  of  onset  [33].  The  Killip-Kamball  classifica-
tion  system  is  used  in  patients  with  an  ACS  to  stratify  their
risk  of  mortality  regarding  the  development  of  heart  fail-
ure.  Expression  of  TACE  and  TNF  ̨ was  significantly  higher
in  patients  with  Killip-Kamball  class  III  or  IV  AMI  than  in
those  with  class  I  or  II  AMI  or  in  controls  [34].  This  finding
demonstrates  that  higher  levels  of  TACE-associated  inflam-
mation  correlate  with  an  increased  risk  of  developing  severe
heart  failure  after  an  ACS.  Shimoda  et  al.  [35]  reported
that  TACE  gene  expression  levels  in  peripheral  blood  cells
were  higher  in  patients  with  AMI  compared  to  healthy  sub-
jects,  and  particularly  in  those  who  had  complications,  such
as  malignant  recurrent  ventricular  arrhythmia  or  pump  fail-
ure.  Both  spontaneous  and  phorbol  12-myristate  13-acetate
(PMA)-stimulated  levels  of  TACE  gene  expression  as  well  as
TNF  gene  and  protein  expression  levels  were  found  to  be
higher  in  patients  with  AMI  compared  to  healthy  subjects.
Sustained  increases  in  TACE  and  TNF levels  were  reported
14  days  after  the  onset  of  AMI  and  levels  correlated  posi-
tively  with  peak  creatinine  kinase  levels.
Systemic  gene  expression  levels  of  TACE  and  TNF  ̨ were
documented  to  be  higher  in  patients  with  AMI  compared  to
patients  with  stable  angina  [36].  Interestingly,  TACE  lev-
els  were  higher  in  local  samples,  near  areas  of  ruptured
coronary  plaques,  than  in  systemic  samples  obtained  from
patients  with  AMI.  TACE  and  TNF immunostaining  showed
that  they  were  localized  in  infiltrating  macrophages  in  rup-
tured  coronary  plaque/thrombus  materials  occluding  the
culprit  coronary  artery.  In  addition,  increased  levels  of  TACE
in  culprit  coronary  samples  were  the  strongest  independent
predictor  of  adverse  cardiac  events  (6  months  after  the
onset  of  AMI)  after  adjustment  for  various  clinical  variables.
The  authors  suggested  that  local  expression  of  TACE  in  the
culprit  coronary  artery  leads  to  arterial  remodelling  and  rup-
ture  or  erosion  of  weakened  coronary  plaque,  leading  to  the
exacerbation  of  cardiac  events  [36].
Rizza  et  al.  [37]  recently  measured  TACE  activity  by
evaluating  the  levels  of  its  main  four  substrates  (soluble
VCAM-1,  soluble  ICAM,  soluble  IL6R  and  soluble  TNFR1)  in
subjects  with  established  vascular  atherosclerosis  who  were
followed  for  secondary  MACE.  They  identified  three  homo-
geneous  subgroups  of  patients,  in  terms  of  event  risk,  and
an  increased  risk  for  incident  events  was  observed  among
individuals  with  a  high  TACE  score.  Looking  closely  at  TNF
receptors,  soluble  TNFR2  levels  were  found  to  be  increased
in  heart  failure,  and  other  studies  have  shown  higher  circu-
lating  levels  of  soluble  TNFR1  and  soluble  TNFR2  associated
with  nephropathy,  cardiovascular  events,  and  total  mortal-
ity  in  type  2  diabetes  [38].  Canault  et  al.  demonstrated  that
TACE-containing  microparticles  of  atherosclerotic  plaques
are  partly  of  endothelial  origin  and  that  TACE  on  the  sur-
face  of  microparticles  was  still  active  [39].  A  more  recent
study  showed  TACE  activity  in  the  plasma  of  patients
with  anti-neutrophil  cytoplasmic  autoantibodies  vasculi-
tis  and  indicated  that  TACE  was  also  present  on  plasma
microparticles  derived  mainly  from  platelets  but  also  from
endothelial  cells.  The  authors  reported  that  it  is  the  active
form  of  TACE  that  is  detectable  in  plasma  samples  and  that
it  is  found  on  the  surface  of  microparticles  originating  from
platelets  as  well  as  endothelial  cells  [24].
Other  studies  have  investigated  the  role  of  TACE  poly-
morphisms  in  relation  to  cardiovascular  disease.  In  the
Atherogene  study,  TNF, soluble  TNFR1,  and  soluble  TNFR2
concentrations  were  all  significantly  elevated  in  patients
with  future  cardiovascular  death.  Moreover,  individuals  car-
rying  the  747Leu  allele  in  TACE  displayed  a  borderline
increased  risk  of  future  cardiovascular  death.  This  study  also
suggests  a role  of  TACE  in  the  regulation  of  TNF plasma  lev-
els  and  identified  the  TACE  gene  as  a  candidate  for  CAD  risk
[40].
TACE activation in CAD
The  association  of  TACE  with  CAD  is  due  first,  to  its  role  in
shedding  a variety  of  inflammatory  molecules  (Fig.  3)  and
second,  to  some  of  its  activators  that  have  been  shown  to
be  associated  with  atherosclerosis  and  pathophysiological
functions  in  CAD.
TACE  has  an  increased  shedding  rate  when  exposed  to  cell
activators,  such  as  phorbol  esters  (e.g.  PMA)  [41],  the  p38
MAPK  pathway  and  lipopolysaccharide,  which  is  dependent
on  reactive  oxygen  species  stimulation  [42].  Oxidative  stress
generating  reactive  oxygen  species  is  known  to  be  involved
in  the  progression  of  atherosclerosis,  disturbed  blood  flow
and  arterial  wall  remodelling  [43].  When  reactive  oxygen
species  are  generated,  TACE  activation  is  increased  as  a
result  local  and  systemic  inflammation.  Moreover,  it  is  known
that  nitric  oxide  can  activate  TACE  [44].  Nitric  oxide  is
involved  in  the  physiological  regulation  of  blood  flow  and
has  pathophysiological  functions  in  CAD  [44].  On  the  other
hand,  C-reactive  protein  is  also  known  to  activate  TACE
and  the  release  of  soluble  lectin-like  oxidized  low-density
lipoprotein  receptor-1,  which  plays  an  important  role  in  the
development  and  progression  of  atherosclerosis  [45].  There-
fore,  TACE  is  not  one  inflammatory  factor  among  many,  but  is
a  key  enzyme.  Its  activators  and  subsequently  shed  proteins
are  essential  mediators  in  the  development  and  progression
of  CAD  (Fig.  3).
TACE, associated proteins and endothelial
dysfunction in CAD
TNF is  a major  contributor  to  inflammatory  processes















































































Table  1 Summary  of  studies  of  TACE  and  associated  proteins,  and  their  clinical  implications  in  cardiovascular  disease.
Model/disease  Site  of  TACE
measurement
Methods  Animals  Results  summary  Reference









Five-week-old  apoE−/− male
mice  examined  at  5,  10,  15
and  25  weeks  of  age  (14  in
each  group)  and  wild-type
mice  (n  =  6)  were  fed  a
high-fat  diet
Strong  expression  of  TACE  in
atherosclerosis-prone  sites  (aortic  sinus  and
arch)
Plasma  levels  of  sTNFR1  and  sTNFR2  correlated
with  atherosclerotic  severity







TIMP3-deficient  mice  (n  =  11)
Age-matched  wild-type
littermates  (n  =  9)
Loss  of  TIMP3  function  triggered  spontaneous
left  ventricular  dilatation,  cardiomyocyte
hypertrophy,  and  contractile  dysfunction  at
21  months  of  age
Fedak  et  al.,  2004  [33]
Rabbit  Sections  from
abdominal  aorta
Macrophages





55  adult  male  New  Zealand
white  rabbits  and  were  then
divided  into  3  groups
TACE  gene  silencing  reduced  remodelling  index
and  plaque  burden  and  diminished  the  content
of  macrophages  and  lipids  while  increased  that
of  smooth  muscle  cells  and  collagen  in  the
aortic  plaques
The  expression  levels  of  TACE  in  unstable
plaques  were  significantly  higher  than  in  stable
plaques  (42.6  ±  7.6  vs  25.2  ±  6.5%,  P  <  0.01)
Zhao  et  al.,  2015  [64]







25  patients  (symptomatic,
n  =  10;  asymptomatic,  n  =  15)
undergoing  carotid
endarterectomy  3  controls
Human  plaque  microparticles  carried
catalytically  active  TACE  and  significantly
enhanced  the  cell  surface  processing  of  the
TACE  substrates  TNF, TNFR1  and  endothelial
protein  C  receptor







TNF and  TACE  expression  was  significantly
greater  in  the  myocarditis  group  than  in  the
control  group  (P  <  0.05)
Satoh  et  al.,  2000  [25]




TACE  and  TNF gene  expression,  intracellular
TACE  and  TNF flow  cytometry  staining,  and
supernatant  TNF were  higher  in  CHF  patients
than  in  controls  (P  <  0.001)
Satoh et  al.,  2004  [26]
AAA  Aortic  sample IHC  39  patients
8 controls
TACE  gene  expression  was  increased  in  human
AAA  samples  compared  with  normal  aorta









































































Table  1  (Continued)
Model/disease  Site  of  TACE
measurement
Methods  Animals  Results  summary  Reference
AMI  within
24  h  of  onset
Circulating
leukocytes
qPCR  37  patients
8  controls
TACE.  TNF gene  expression  was  higher  in
circulating  leucocytes  in  AMI  patients
compared  with  controls  (P  <  0.01)
Akatsu  et  al.,  2003  [34]
AMI  (blood
samples  on
day  1  and








TACE  and  TNF gene  expression  levels  were
higher  in  AMI  patients  than  in  healthy  controls
(P  <  0.001)
Levels  of  TACE  and  TNF decreased  14  days
after  the  onset  of  AMI
The  percentage  of  TACE  and  TNF cells  with
positive  staining  was  higher  in  AMI  patients
compared  with  healthy  controls  (P  <  0.001)
Shimoda  et  al.,  2005  [35]
AMI  Local  samples
from  the  plaque
site
Systemic  samples






60  AMI  patients
21  stable  angina  patients
TACE  and  TNF gene  expression  and  protein
levels  in  both  local  and  systemic  samples
obtained  from  AMI  patients  were  higher  than
those  levels  in  systemic  samples  obtained  from
stable  angina  patients  (P  <  0.001)
In  AMI  patients,  these  levels  were  higher  in
local  samples  than  in  systemic  samples
(P  <  0.001)
By  the  6-month  follow-up  study,  local  TACE
levels  remained  the  only  significant
independent  predictor  of  adverse  cardiac
events  in  AMI










WB  306  patients
230  controls
Plasma  TACE  levels  in  the  atherosclerotic
ischaemic  stroke  group  were  higher  than  those
in  the  control  group  (P  =  0.70,  P  =  0.000)









IHC  4  human  atherosclerotic
plaques
TACE  gene  expression  was  observed  in  human
atherosclerotic  plaques










the  beginning  of
sternal  wiring,
48  h  after  the
first  sample
ELISA  25  patients  Analysis  of  TACE  activity  did  not  show
significant  differences  between  the  different
time  points  (P  =  0.40),  but  a  trend  of  the
medians  was  apparent  towards  higher  values
postoperatively  and  after  48  hours















































































Table  1  (Continued)
Model/disease  Site  of  TACE
measurement
Methods  Animals  Results  summary Reference
Other  diseases:  human  studies
MCI  and  AD Cerebrospinal




64  patients  with  AD,
88  subjects  with  MCI,  and
50  age-matched  healthy
controls
Plasma  TACE  protein  levels  did  not  differ
significantly  in  the  three  study  groups.
However,  plasma  TACE  activity  in  subjects  with
MCI  and  AD  patients  was  significantly  higher
than  that  in  HC  (P  <  0.001)
TACE  enzymatic  activity  may  increase
progressively  over  the  clinical  course  of  AD
Sun  et  al.,  2014  [23]




PR3-AAV  active  (n  =  47)
PR3-AAV  remission  (n  =  45)
Disease  control  (n  =  14)
TACE  protein  levels  were  significantly  increased
in  plasma  samples  from  patients  with  active
PR3-AAV  compared  with  samples  from  patients
in  remission  or  from  other  controls  with  renal
nonvascular  diseases
Plasma  TACE  retained  its  specific  proteolytic
activity  and  was  partly  located  on  extracellular
microparticles
Transcript  levels  of  TACE  were  increased  in
blood  samples  of  patients  with  active  AAV
Bertram  et  al.,  2015  [24]
Clinical
malaria
Plasma  samples ELISA  Village  infections  (n  =  6),
uncomplicated  malaria
(n  =  39),  severe  malaria
(n  =  123),  non-malaria
hospitalized  (n  =  32),  Acute
severe  malaria/convalescent
(n  =  19)
Plasma  levels  of  TACE  were  increased  in
Tanzanian  children  hospitalized  with  a  malaria
infection  compared  with  asymptomatic
children,  but  were  similar  to  children
hospitalized  with  other  infectious  diseases
Plasma  levels  of  TACE  decreased  during
recovery  after  an  acute  malaria  episode
Petersen  et  al.,  2016  [67]
AAA: abdominal aortic aneurysm; AAV: active proteinase-3 (PR3)-positive ANCA-associated vasculitis; AD: Alzheimer’s disease; AMI: acute myocardial infarction; ANCA: antineutrophil
cytoplasmic autoantibodies; CHF: congestive heart failure; ELISA: enzyme-linked immunosorbent assay; FC: flow cytometry; FRET: fluorescent resonance energy transfer; IF:
immunofluorescence; IHC: immunohistochemistry assay; MIC: mild cognitive impairment; PBMC: peripheral blood mononuclear cells; qPCR: real time polymerase chain reaction; TIMP3:
metalloproteinase inhibitor 3; TNF: tumour necrosis factor alpha; TNFR1: TNF receptor type 1; TNFR2: TNF receptor type 2; sTNFR1: soluble TNFR1; sTNFR2: soluble TNFR2; WB:
western blot.
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upregulation  of  TNF can  promote  premature  endothe-
lial  cell  senescence  and  can  participate  in  the  ageing
process  of  coronary  arteries  [46].  Recently,  endogenous
transmembrane  TNF was  shown  to  protect  against  prema-
ture  senescence  in  endothelial  colony  forming  cells  [47].
This  is  supported  by  a  murine  study  in  which  transgenic
mice  that  only  express  an  uncleavable  version  of  transmem-
brane  TNF developed  fewer  inflammatory  atherosclerotic
plaques  than  the  wild-type  mice  [48].
It  has  been  also  reported  that  TNFR1  activates  multi-
ple  signalling  pathways  that  have  been  linked  to  apoptosis,
endothelial  cell  dysfunction  and  inflammation,  whereas
TNFR2  signalling  has  been  proven  to  be  beneficial  to  the
cardiovascular  system  by  activating  angiogenic  and  survival
pathways  [49].  Transmembrane  TNF has  a  higher  affinity  for
TNFR2,  which  confers  a  survival  signal,  mediating  angiogenic
and  blood  vessel  repair  activities  [50].  This  suggests  that
transmembrane  TNF cleavage  by  TACE  can  have  a  deleteri-
ous  effect  on  the  protective  and  repair  function  properties
provided  by  transmembrane  TNF. The  role  of  TACE  in  vas-
cular  dysfunction  was  also  highlighted  in  patients  and  mice,
where  ageing  and  obesity  cooperatively  reduced  caveolin-1
expression  and  increased  vascular  endothelial  TACE  activ-
ity  and  soluble  TNF release  in  adipose  tissue.  This  was
believed  to  contribute  to  the  development  of  remote  coro-
nary  microvascular  dysfunction  in  older  obese  patients  [46].
TACE inhibition
As  TACE  seems  to  be  implicated  in  many  physiologi-
cal  processes,  it  is  important  to  consider  its  inhibition
and  the  potential  consequences.  Interestingly,  a  patient
with  homozygous  TACE  deficiency  was  identified  [52]  who,
despite  repeated  skin  infections  and  episodes  of  bowel  dis-
ease,  led  a  relatively  normal  life,  indicating  that  loss  of
TACE  in  humans  might  have  less  severe  consequences  than
in  rodents  [53].  The  most  promising  TACE  inhibition  (with-
out  any  major  physiological  consequences)  seems  to  lie  in
the  inhibition  of  its  regulators.  iRhom1  and  2  are  needed
for  TACE  transport  to  the  cell  surface  (Fig.  2)  and  it  is
well  established  that  iRhom2  is  predominantly  expressed  in
immune  cells,  such  as  neutrophils  and  macrophages  [54],
whereas  iRhom1  is  mostly  expressed  on  non-immune  cells
[55].  Therefore,  it  is  tempting  to  speculate  that  inhibition  of
iRhom2  would  lead  to  a  selective  deficiency  of  TACE  in  neu-
trophils  and  macrophages  with  no  effects  on  keratinocytes
or  intestinal  epithelial  cells  where,  in  these  cell  types,
iRhom1  would  compensate  for  the  blockade  of  iRhom2.
Recently,  it  was  found  that  reducing  the  release  of  TNF in
cardiomyocytes  by  pharmacologically  attenuating  the  phos-
phorylation  of  TACE,  reduced  TNF shedding  activity  by
TACE  [56].  It  was  also  proven  possible  to  inhibit  specifi-
cally  TACE  activity  by  using  its  natural  inhibitory  domain
and  consequently  modulating  TNF secretion  in  cells  [57].
Another  strategy  of  inhibiting  TACE  could  be  an  injection  of
its  inhibitor  TIMP3  in  the  heart,  which  has  been  shown  to  pre-
vent  heart  failure  post-myocardial  infarction  [58].  However,
since  TACE  inhibition  will  reduce  TNF activity,  it  is  impor-
tant  to  consider  the  complex  cardiac  effects  observed  after
TNF inhibition  as  it  is  becoming  increasingly  clear  that  a
minimum  level  of  TNF is  important  for  the  normal  function
of  the  heart  [59,60].
Future work and conclusions
TACE  plays  a  major  role  in  controlling  inflammatory  pro-
cesses  and  is  involved  in  several  chronic  diseases.  The
number  of  known  TACE  substrates  continues  to  increase,
with  mounting  evidence  that  TACE  is  implicated  in  many  cel-
lular  functions.  Recent  research  indicates  a  particular  role
for  TACE  and  the  TNF  family  members  in  CAD  and  cardiovas-
cular  events,  but  none  have  really  looked  at  this  panel  from
a  biomarker  development  point  of  view.  Further  investiga-
tions  are,  however,  required  to  ascertain  the  exact  role  and
mechanism  of  action  of  TACE  in  this  disease  area.
Future  prospective  studies  in  clinical  cohorts  at  vary-
ing  degrees  of  cardiovascular  risk  stratification  are  needed
to  fully  assess  TACE  as  a potential  biomarker  for  CAD  and
MACE  risk.  This  will  be  crucial  for  the  future  development
of  new  personalized  predictive  tests  and  therapeutics  that
can  improve  patient  clinical  care  pathways  and  prevent  the
high  mortality  rates  associated  with  CAD.
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